[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fSzX0cn5Dt7N6ZDxoKL8eHxqvaqxMqqvwq9FftvFHHBA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Genentech, Inc.",[4],509,false,45,71,437494,83,28,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Healthy Volunteer",35,{"name":18,"count":19},"Breast Cancer",27,{"name":21,"count":22},"Rheumatoid Arthritis",21,{"name":24,"count":25},"Solid Cancers",18,{"name":27,"count":25},"Non-Small Cell Lung Cancer",{"name":29,"count":25},"Colorectal Cancer",{"name":31,"count":32},"Asthma",17,{"name":34,"count":35},"Healthy Volunteers",15,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05306340","A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","2025-07-16","Giredestrant",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06693908","A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis","2026-06-09","Vixarelimab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04250155","An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","2026-06-15","XmAb24306",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05867121","A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","2026-06-30","RO7496353",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07214766","A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants","2026-07-03","Trastuzumab",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07144111","A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib","2026-09-05","Inavolisib",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06524375","A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","2026-10-31","Venetoclax",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06847854","A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)","2026-11-16","RO7497372",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT05646836","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed\u002FRefractory Multiple Myeloma","2026-11-18","Cevostamab",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT04302025","A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","2026-11-30","Alectinib",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,146,172,198,232,303,367,404,432,450,468,486,800,919,1026,1424,1542,1629,1675,1701,1868,1914,1967,2020,2065,2096,2118,2140,2162,2180,2198,2216,2241,2266,2291,2309,2327,2351,2369,2395,2413,2431,2449,2482,2514,2544,2629,2655,2685,2711,2733,2755,2793,2838,2872,2915,2963,2999,3025,3051,3073,3095,3117,3143,3168,3186,3204,3222,3240,3260,3278,3296,3314,3332,3350,3368,3386,3408,3426,3444,3462,3480,3503,3521,3672,3789,3861,3926,3979,4036,4058,4087,4105,4129,4147,4165,4188,4210,4280,4361,4425,4484,4546,4597,4654,4688,4726,4760,4794,4828,4865,4895,4936,4974,5000,5026,5052,5074,5096,5118,5141,5159,5184,5202,5220,5246,5264,5282,5300,5328,5346,5364,5382,5400,5418,5436,5460,5478,5496,5572,5638,5709,5810,5871,5916,5950,5991,6033,6067,6135,6183,6213,6268,6298,6334,6368,6406,6446,6476,6513,6546,6590,6620,6646,6683,6709,6745,6778,6808,6830,6863,6890,6917,6939,6961,6983,7017,7044,7078,7112,7140,7162,7184,7211,7233,7255,7277,7299,7332,7354,7382,7409,7430,7448,7466,7484,7502,7520,7545,7563,7581,7599,7617,7639,7657,7675,7693,7718,7739,7757,7775,7793,7811,7835,7853,7871,7889,7907,7925,7943,7961,7979,7997,8015,8037,8063,8081,8099,8121,8139,8157,8175,8198,8216,8234,8252,8270,8288,8316,8340,8364,8382,8404,8422,8440,8463,8488,8506,8581,8621,8662,8692,8739,8765,8798,8822,8849,8879,8901,8925,8947,8969,8996,9020,9045,9063,9081,9099,9120,9138,9162,9187,9205,9223,9244,9265,9286,9309,9327,9345,9363,9381,9399,9417,9438,9462,9480,9502,9525,9551,9569,9587,9605,9627,9649,9667,9691,9709,9734,9752,9770,9794,9812,9830,9853,9871,9895,9913,9935,9956,9977,9999,10022,10047,10068,10086,10110,10132,10157,10175,10198,10220,10241,10262,10285,10303,10321,10344,10365,10389,10407,10428,10446,10464,10482,10500,10518,10540,10558,10576,10594,10616,10634,10655,10677,10695,10718,10736,10759,10777,10800,10823,10841,10863,10886,10909,10933,10958,10976,10994,11020,11038,11056,11074,11092,11110,11128,11146,11167,11301,11384,11451,11499,11549,11587,11617,11646,11675,11702,11720,11742,11764,11782],{"intervention":96,"totalTrials":97,"cells":98},"Faricimab",3,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":117,"PHASE3":131,"PHASE4":133,"NA":144},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":116,"soonestReadout":109},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT07425522","A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)","RECRUITING",[89],"2028-11-17","2026-04-21",93,[113],"Diabetic Macular Edema",[115,96],"RO7823653",1,{"trials":118,"activeCount":116,"soonestReadout":124},[119],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":128},"NCT06850922","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema","ACTIVE_NOT_RECRUITING",[89,90],"2027-04-30","2022-06-22",546,[113],[129,130,96],"RO7446603","Aflibercept",{"trials":132,"activeCount":101},[],{"trials":134,"activeCount":116,"soonestReadout":139},[135],{"nctId":136,"briefTitle":137,"status":122,"phases":138,"primaryCompletion":139,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":143},"NCT05224102","A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema",[92],"2027-01-26","2022-02-28",218,[113],[96],{"trials":145,"activeCount":101},[],{"intervention":147,"totalTrials":116,"cells":148},"OCR SC",{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":170},{"trials":150,"activeCount":101},[],{"trials":152,"activeCount":101},[],{"trials":154,"activeCount":101},[],{"trials":156,"activeCount":101},[],{"trials":158,"activeCount":116,"soonestReadout":164},[159],{"nctId":160,"briefTitle":161,"status":162,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":169},"NCT07609719","A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy","NOT_YET_RECRUITING",[92],"2029-02-28","2026-07-15",100,[168],"Multiple Sclerosis",[147],{"trials":171,"activeCount":101},[],{"intervention":173,"totalTrials":116,"cells":174},"LUCENTIS",{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":196},{"trials":176,"activeCount":101},[],{"trials":178,"activeCount":101},[],{"trials":180,"activeCount":101},[],{"trials":182,"activeCount":101},[],{"trials":184,"activeCount":116,"soonestReadout":189},[185],{"nctId":186,"briefTitle":187,"status":107,"phases":188,"primaryCompletion":189,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":195},"NCT04853251","A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)",[92],"2027-09-30","2027-10-29","2021-12-14",188,[194],"Neovascular Age-related Macular Degeneration",[173],{"trials":197,"activeCount":101},[],{"intervention":199,"totalTrials":200,"cells":201},"Risdiplam",2,{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":208,"PHASE4":210,"NA":222},{"trials":203,"activeCount":101},[],{"trials":205,"activeCount":101},[],{"trials":207,"activeCount":101},[],{"trials":209,"activeCount":101},[],{"trials":211,"activeCount":116,"soonestReadout":216},[212],{"nctId":213,"briefTitle":214,"status":122,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":221},"NCT05232929","Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)",[92],"2026-12-31","2022-03-29",403,[220],"Spinal Muscular Atrophy",[199],{"trials":223,"activeCount":101},[224],{"nctId":225,"briefTitle":226,"status":227,"phases":228,"conditions":229,"interventions":231},"NCT04256265","An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA)","APPROVED_FOR_MARKETING",[],[230],"Muscular Atrophy, Spinal",[199],{"intervention":41,"totalTrials":233,"cells":234},5,{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":260,"PHASE3":273,"PHASE4":299,"NA":301},{"trials":236,"activeCount":101},[],{"trials":238,"activeCount":116,"soonestReadout":253},[239,249],{"nctId":240,"briefTitle":241,"status":242,"phases":243,"primaryCompletion":244,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":248},"NCT03916744","A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer","COMPLETED",[89],"2021-05-25","2019-07-26",75,[18],[41],{"nctId":250,"briefTitle":251,"status":107,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":257},"NCT07214662","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+\u002FHER2-) Breast Cancer",[89],"2030-06-01","2026-01-13",136,[18],[258,41,259],"GDC-0587","Omeprazole",{"trials":261,"activeCount":116,"soonestReadout":266},[262],{"nctId":263,"briefTitle":264,"status":107,"phases":265,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":270},"NCT07100106","A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer",[89,90],"2028-08-31","2025-10-07",285,[18],[271,41,272],"GDC-4198","Abemaciclib",{"trials":274,"activeCount":200,"soonestReadout":40},[275,289],{"nctId":38,"briefTitle":39,"status":122,"phases":276,"primaryCompletion":40,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":282},[91],"2026-10-15","2022-08-03",373,[281],"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer",[41,283,284,285,286,287,288],"Exemestane","Fulvestrant","Tamoxifen","Everolimus","LHRH Agonist","Dexamethasone Mouth Rinse",{"nctId":290,"briefTitle":291,"status":162,"phases":292,"primaryCompletion":293,"completion":294,"start":55,"enrollment":295,"conditions":296,"interventions":298},"NCT07541079","A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+\u002FHER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)",[91],"2032-06-30","2034-06-30",300,[297],"Early Breast Cancer",[41],{"trials":300,"activeCount":101},[],{"trials":302,"activeCount":101},[],{"intervention":284,"totalTrials":233,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":335,"PHASE3":357,"PHASE4":363,"NA":365},{"trials":306,"activeCount":101},[],{"trials":308,"activeCount":116,"soonestReadout":216},[309,322],{"nctId":310,"briefTitle":311,"status":122,"phases":312,"primaryCompletion":216,"completion":216,"start":313,"enrollment":314,"conditions":315,"interventions":317},"NCT03006172","To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",[89],"2016-12-13",200,[18,316],"Solid Tumor",[66,284,318,319,320,61,321],"Letrozole","Palbociclib","Metformin","Pertuzumab",{"nctId":323,"briefTitle":324,"status":325,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":332},"NCT01296555","A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer","TERMINATED",[89],"2021-06-25","2011-03-16",674,[24,331],"Non-Hodgkin's Lymphoma",[284,333,318,334],"GDC-0032","Midazolam",{"trials":336,"activeCount":101},[337,348],{"nctId":338,"briefTitle":339,"status":242,"phases":340,"primaryCompletion":341,"completion":341,"start":342,"enrollment":343,"conditions":344,"interventions":345},"NCT01437566","Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy",[90],"2016-04","2011-10",318,[18],[284,346,347],"GDC-0941","GDC-0980",{"nctId":349,"briefTitle":350,"status":325,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":9,"conditions":354,"interventions":355},"NCT02569801","A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy",[90],"2020-02-28","2015-12-04",[18],[284,356],"GDC-0810",{"trials":358,"activeCount":116,"soonestReadout":40},[359],{"nctId":38,"briefTitle":39,"status":122,"phases":360,"primaryCompletion":40,"completion":277,"start":278,"enrollment":279,"conditions":361,"interventions":362},[91],[281],[41,283,284,285,286,287,288],{"trials":364,"activeCount":101},[],{"trials":366,"activeCount":101},[],{"intervention":287,"totalTrials":97,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":383,"PHASE3":394,"PHASE4":400,"NA":402},{"trials":370,"activeCount":101},[],{"trials":372,"activeCount":116,"soonestReadout":377},[373],{"nctId":374,"briefTitle":375,"status":122,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT03332797","A Study of GDC-9545 Alone or in Combination With Palbociclib and\u002For Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer",[89],"2027-07-31","2017-11-24",181,[18],[382,319,287],"GDC-9545",{"trials":384,"activeCount":101},[385],{"nctId":386,"briefTitle":387,"status":325,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":393},"NCT01823835","A Study of GDC-0810 Single Agent or in Combination With Palbociclib and\u002For a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer",[89,90],"2020-03-13","2014-12-29",152,[18],[356,287,319],{"trials":395,"activeCount":116,"soonestReadout":40},[396],{"nctId":38,"briefTitle":39,"status":122,"phases":397,"primaryCompletion":40,"completion":277,"start":278,"enrollment":279,"conditions":398,"interventions":399},[91],[281],[41,283,284,285,286,287,288],{"trials":401,"activeCount":101},[],{"trials":403,"activeCount":101},[],{"intervention":286,"totalTrials":200,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":422,"PHASE4":428,"NA":430},{"trials":407,"activeCount":101},[],{"trials":409,"activeCount":101},[],{"trials":411,"activeCount":101},[412],{"nctId":413,"briefTitle":414,"status":242,"phases":415,"primaryCompletion":416,"completion":417,"start":342,"enrollment":418,"conditions":419,"interventions":421},"NCT01442090","Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy",[90],"2013-05","2015-07",85,[420],"Renal Cell Carcinoma",[286,347],{"trials":423,"activeCount":116,"soonestReadout":40},[424],{"nctId":38,"briefTitle":39,"status":122,"phases":425,"primaryCompletion":40,"completion":277,"start":278,"enrollment":279,"conditions":426,"interventions":427},[91],[281],[41,283,284,285,286,287,288],{"trials":429,"activeCount":101},[],{"trials":431,"activeCount":101},[],{"intervention":283,"totalTrials":116,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":446,"NA":448},{"trials":435,"activeCount":101},[],{"trials":437,"activeCount":101},[],{"trials":439,"activeCount":101},[],{"trials":441,"activeCount":116,"soonestReadout":40},[442],{"nctId":38,"briefTitle":39,"status":122,"phases":443,"primaryCompletion":40,"completion":277,"start":278,"enrollment":279,"conditions":444,"interventions":445},[91],[281],[41,283,284,285,286,287,288],{"trials":447,"activeCount":101},[],{"trials":449,"activeCount":101},[],{"intervention":285,"totalTrials":116,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":464,"NA":466},{"trials":453,"activeCount":101},[],{"trials":455,"activeCount":101},[],{"trials":457,"activeCount":101},[],{"trials":459,"activeCount":116,"soonestReadout":40},[460],{"nctId":38,"briefTitle":39,"status":122,"phases":461,"primaryCompletion":40,"completion":277,"start":278,"enrollment":279,"conditions":462,"interventions":463},[91],[281],[41,283,284,285,286,287,288],{"trials":465,"activeCount":101},[],{"trials":467,"activeCount":101},[],{"intervention":288,"totalTrials":116,"cells":469},{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":482,"NA":484},{"trials":471,"activeCount":101},[],{"trials":473,"activeCount":101},[],{"trials":475,"activeCount":101},[],{"trials":477,"activeCount":116,"soonestReadout":40},[478],{"nctId":38,"briefTitle":39,"status":122,"phases":479,"primaryCompletion":40,"completion":277,"start":278,"enrollment":279,"conditions":480,"interventions":481},[91],[281],[41,283,284,285,286,287,288],{"trials":483,"activeCount":101},[],{"trials":485,"activeCount":101},[],{"intervention":487,"totalTrials":488,"cells":489},"Atezolizumab",24,{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":674,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":491,"activeCount":101},[],{"trials":493,"activeCount":233,"soonestReadout":50},[494,509,527,538,551,565,578,588,609,616,628,637,648,659],{"nctId":495,"briefTitle":496,"status":325,"phases":497,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":501,"interventions":505},"NCT04045028","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",[89],"2023-03-28","2019-07-22",41,[502,503,504],"Multiple Myeloma","Non-Hodgkin Lymphoma","B-Cell Lymphoma",[506,507,508,487],"Tiragolumab","Daratumumab\u002FrHuPH20","Rituximab",{"nctId":510,"briefTitle":511,"status":242,"phases":512,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NCT01633970","A Study of Atezolizumab Administered in Combination With Bevacizumab and\u002For With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2020-02-26","2012-07-11",240,[517],"Cancer",[519,487,520,521,522,523,524,525,526],"5-FU","Bevacizumab","Carboplatin","Leucovorin","Nab-paclitaxel","Oxaliplatin","Paclitaxel","Pemetrexed",{"nctId":528,"briefTitle":529,"status":242,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":537},"NCT01375842","A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2018-09-30","2011-06-21",661,[535,536],"Tumors","Hematologic Malignancies",[487],{"nctId":539,"briefTitle":540,"status":107,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":549},"NCT06031441","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2027-12-31","2023-11-27",250,[546,547,548],"Locally Advanced Solid Tumors","Recurrent Solid Tumors","Metastatic Solid Tumors",[550,487],"RO7566802",{"nctId":552,"briefTitle":553,"status":242,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":560},"NCT02794571","Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and\u002For Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors",[89],"2024-11-13","2016-05-23",518,[559],"Advanced\u002FMetastatic Tumors",[487,506,521,561,526,525,562,563,520,564],"Cisplatin","Etoposide","Capecitabine","Pembrolizumab",{"nctId":566,"briefTitle":567,"status":122,"phases":568,"primaryCompletion":542,"completion":542,"start":569,"enrollment":570,"conditions":571,"interventions":573},"NCT04449874","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",[89],"2020-07-29",498,[27,29,572],"Advanced Solid Tumors",[574,487,575,520,576,577,66],"GDC-6036","Cetuximab","Erlotinib","GDC-1971",{"nctId":579,"briefTitle":580,"status":242,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":586},"NCT02471846","A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2019-10-02","2015-07-28",158,[316],[487,587],"GDC-0919",{"nctId":589,"briefTitle":590,"status":107,"phases":591,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":595,"interventions":607},"NCT05581004","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2028-07-31","2022-10-20",450,[596,597,598,599,600,601,602,603,29,604,605,606],"Locally Advanced or Metastatic Solid Tumors","NSCLC","HNSCC","Melanoma","TNBC","Esophageal Cancer","Gastric Cancer","Cervical Cancer","Urothelial Carcinoma","Clear Cell RCC","HCC",[608,487,564],"Enzelkitug",{"nctId":48,"briefTitle":49,"status":122,"phases":610,"primaryCompletion":50,"completion":50,"start":611,"enrollment":612,"conditions":613,"interventions":615},[89],"2020-03-09",195,[614],"Solid Tumors",[51,487,51],{"nctId":617,"briefTitle":618,"status":242,"phases":619,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT01656642","A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma",[89],"2020-03-25","2012-08-13",67,[624],"Malignant Melanoma",[487,626,627],"Cobimetinib","Vemurafenib",{"nctId":629,"briefTitle":630,"status":242,"phases":631,"primaryCompletion":632,"completion":632,"start":633,"enrollment":634,"conditions":635,"interventions":636},"NCT05487235","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2025-06-23","2022-08-17",57,[572,548],[577,487,259],{"nctId":53,"briefTitle":54,"status":122,"phases":638,"primaryCompletion":55,"completion":55,"start":639,"enrollment":640,"conditions":641,"interventions":644},[89],"2023-10-02",102,[642,602,643],"Non-small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma",[56,487,563,645,646,524,523,647],"S-1","Nivolumab","Gemcitabine",{"nctId":649,"briefTitle":650,"status":325,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":657},"NCT06488716","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",[89],"2025-11-05","2024-12-16",12,[656],"Solid Tumour",[658,487],"RO7759065",{"nctId":660,"briefTitle":661,"status":242,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":672},"NCT03289962","A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",[89],"2025-07-01","2017-12-20",273,[599,27,667,29,668,669,670,671],"Bladder Cancer","Triple Negative Breast Cancer","Renal Cancer","Head and Neck Cancer","Other Solid Cancers",[673,487],"Autogene cevumeran",{"trials":675,"activeCount":793,"soonestReadout":85},[676,687,700,713,722,736,753,763,774,784],{"nctId":677,"briefTitle":678,"status":107,"phases":679,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":683,"interventions":685},"NCT05968326","A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC",[90],"2031-01-01","2023-10-18",260,[684],"Adenocarcinoma, Pancreatic Ductal",[673,487,686],"mFOLFIRINOX",{"nctId":688,"briefTitle":689,"status":242,"phases":690,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":698},"NCT02091141","My Pathway: A Study Evaluating Herceptin\u002FPerjeta, Tarceva, Zelboraf\u002FCotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",[90],"2023-05-24","2014-04-14",673,[695,614,696,697,667],"Neoplasms","Biliary Cancer","Salivary Cancer",[61,321,576,627,626,699,86,487],"Vismodegib",{"nctId":701,"briefTitle":702,"status":122,"phases":703,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":710},"NCT00781612","A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies",[90],"2029-09-30","2030-04-30","2008-10-16",720,[709],"Neoplasm Metastasis",[711,525,321,61,712,487],"Docetaxel","Trastuzumab Emtansine",{"nctId":714,"briefTitle":715,"status":242,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":721},"NCT02848651","A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer",[90],"2019-05-14","2016-09-23",153,[27],[487],{"nctId":723,"briefTitle":724,"status":242,"phases":725,"primaryCompletion":726,"completion":727,"start":728,"enrollment":729,"conditions":730,"interventions":733},"NCT02500407","A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",[89,90],"2024-05-21","2025-09-01","2015-09-15",713,[731,732],"Lymphocytic Leukemia, Chronic","Lymphoma, Non Hodgkin",[734,487,735],"BTCT4465A (Mosunetuzumab) IV","BTCT4465A (Mosunetuzumab) SC",{"nctId":737,"briefTitle":738,"status":242,"phases":739,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":746},"NCT04632992","A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response",[90],"2023-12-04","2024-02-27","2021-01-13",252,[745],"Advanced Unresectable or Metastatic Solid Malignancy",[747,66,86,748,487,712,749,750,751,525,506,752],"Entrectinib","Ipatasertib","Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf","Tucatinib","Investigator's Choice of Chemotherapy","Pralsetinib",{"nctId":754,"briefTitle":755,"status":242,"phases":756,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":761,"interventions":762},"NCT03563716","A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[90],"2019-06-30","2025-11-14","2018-08-10",135,[642],[487,506],{"nctId":764,"briefTitle":765,"status":107,"phases":766,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":773},"NCT06096779","A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis",[90],"2027-07-30","2027-12-30","2024-07-15",30,[772],"Hepatocellular Carcinoma",[487,520],{"nctId":83,"briefTitle":84,"status":107,"phases":775,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":780},[90],"2030-05-30","2020-11-06",99,[642],[86,747,627,626,752,487,781,782,783],"SBRT","Chemotherapy","Divarasib",{"nctId":785,"briefTitle":786,"status":325,"phases":787,"primaryCompletion":788,"completion":788,"start":789,"enrollment":233,"conditions":790,"interventions":791},"NCT03029832","A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy",[90],"2018-04-25","2017-04-27",[604],[792,487],"MOXR0916",4,{"trials":795,"activeCount":101},[],{"trials":797,"activeCount":101},[],{"trials":799,"activeCount":101},[],{"intervention":801,"totalTrials":802,"cells":803},"Tocilizumab",10,{"EARLY_PHASE1":804,"PHASE1":806,"PHASE2":868,"PHASE3":879,"PHASE4":901,"NA":917},{"trials":805,"activeCount":101},[],{"trials":807,"activeCount":793,"soonestReadout":80},[808,814,823,836,848,858],{"nctId":78,"briefTitle":79,"status":122,"phases":809,"primaryCompletion":80,"completion":80,"start":810,"enrollment":811,"conditions":812,"interventions":813},[89],"2023-03-21",90,[502],[81,51,801],{"nctId":815,"briefTitle":816,"status":242,"phases":817,"primaryCompletion":818,"completion":818,"start":819,"enrollment":820,"conditions":821,"interventions":822},"NCT03275103","Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R\u002FR MM)",[89],"2026-01-07","2017-09-19",355,[502],[81,801],{"nctId":824,"briefTitle":825,"status":826,"phases":827,"primaryCompletion":828,"completion":828,"start":829,"enrollment":101,"conditions":830,"interventions":834},"NCT06372574","A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors","WITHDRAWN",[89],"2028-02-01","2024-09-30",[831,832,833],"Refractory Cancer","Recurrent Cancer","Solid Tumor, Adult",[835,801],"RO7617991",{"nctId":837,"briefTitle":838,"status":122,"phases":839,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":843,"interventions":844},"NCT04910568","A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma",[89],"2029-12-10","2021-07-26",126,[502],[81,801,845,846,847],"Pomalidomide","Daratumumab","Dexamethasone",{"nctId":849,"briefTitle":850,"status":122,"phases":851,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":855,"interventions":856},"NCT03448042","A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers",[89],"2027-11-30","2018-06-06",123,[614],[857,61,801],"Runimotamab",{"nctId":859,"briefTitle":860,"status":107,"phases":861,"primaryCompletion":377,"completion":377,"start":862,"enrollment":863,"conditions":864,"interventions":866},"NCT05927571","A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R\u002FR MM)",[89],"2023-08-10",120,[865],"Relapsed or Refractory Multiple Myeloma",[81,867,801],"Elranatamab",{"trials":869,"activeCount":116,"soonestReadout":592},[870],{"nctId":871,"briefTitle":872,"status":122,"phases":873,"primaryCompletion":592,"completion":592,"start":874,"enrollment":875,"conditions":876,"interventions":877},"NCT05207670","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies",[90],"2022-02-01",320,[503],[878,878,801],"Mosunetuzumab",{"trials":880,"activeCount":101},[881,892],{"nctId":882,"briefTitle":883,"status":242,"phases":884,"primaryCompletion":885,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":891},"NCT04372186","A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia",[91],"2020-08-18","2020-09-22","2020-05-14",377,[890],"COVID-19 Pneumonia",[801],{"nctId":893,"briefTitle":894,"status":242,"phases":895,"primaryCompletion":896,"completion":897,"start":898,"enrollment":141,"conditions":899,"interventions":900},"NCT01662063","A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)",[91],"2014-04","2014-06","2012-08",[21],[801],{"trials":902,"activeCount":101},[903],{"nctId":904,"briefTitle":905,"status":242,"phases":906,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":911,"interventions":912},"NCT01163747","A Study of the Effects of RoActemra\u002FActemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)",[92],"2011-12","2012-06","2010-09",91,[21],[913,914,915,916],"tocilizumab","methotrexate","23-Valent Pneumococcal Polysaccharide Vaccine","Tetanus Toxoid Adsorbed Vaccine",{"trials":918,"activeCount":101},[],{"intervention":61,"totalTrials":654,"cells":920},{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":970,"PHASE3":999,"PHASE4":1011,"NA":1013},{"trials":922,"activeCount":101},[],{"trials":924,"activeCount":97,"soonestReadout":60},[925,929,933,943,952,963],{"nctId":310,"briefTitle":311,"status":122,"phases":926,"primaryCompletion":216,"completion":216,"start":313,"enrollment":314,"conditions":927,"interventions":928},[89],[18,316],[66,284,318,319,320,61,321],{"nctId":849,"briefTitle":850,"status":122,"phases":930,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":931,"interventions":932},[89],[614],[857,61,801],{"nctId":934,"briefTitle":935,"status":242,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":634,"conditions":939,"interventions":941},"NCT00928330","Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy",[89],"2014-01","2009-07",[940],"Metastatic Breast Cancer",[346,61,942],"trastuzumab-MCC-DM1",{"nctId":944,"briefTitle":945,"status":242,"phases":946,"primaryCompletion":947,"completion":947,"start":948,"enrollment":9,"conditions":949,"interventions":950},"NCT00960960","A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer",[89],"2015-12","2009-08",[18],[520,951,318,525,61],"Pictilisib",{"nctId":953,"briefTitle":954,"status":242,"phases":955,"primaryCompletion":956,"completion":956,"start":938,"enrollment":957,"conditions":958,"interventions":959},"NCT00927589","A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer",[89],"2013-02",59,[24],[960,961,962],"carboplatin","docetaxel","trastuzumab",{"nctId":58,"briefTitle":59,"status":122,"phases":964,"primaryCompletion":60,"completion":60,"start":965,"enrollment":966,"conditions":967,"interventions":969},[89],"2025-10-17",312,[968],"Healthy Participants",[61],{"trials":971,"activeCount":116,"soonestReadout":704},[972,982,986,990],{"nctId":973,"briefTitle":974,"status":242,"phases":975,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":981},"NCT02536339","A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy",[90],"2019-05-01","2020-12-29","2015-12-16",40,[940],[321,61],{"nctId":688,"briefTitle":689,"status":242,"phases":983,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":984,"interventions":985},[90],[695,614,696,697,667],[61,321,576,627,626,699,86,487],{"nctId":701,"briefTitle":702,"status":122,"phases":987,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":988,"interventions":989},[90],[709],[711,525,321,61,712,487],{"nctId":991,"briefTitle":992,"status":242,"phases":993,"primaryCompletion":994,"start":995,"conditions":996,"interventions":997},"NCT00005635","Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2",[90],"2001-11","2000-01",[18],[962,998],"paclitaxel",{"trials":1000,"activeCount":101},[1001],{"nctId":1002,"briefTitle":1003,"status":242,"phases":1004,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1009,"interventions":1010},"NCT00567190","A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer",[91],"2011-05-13","2018-11-23","2008-02-12",808,[940],[321,61,711],{"trials":1012,"activeCount":101},[],{"trials":1014,"activeCount":101},[1015],{"nctId":1016,"briefTitle":1017,"status":242,"phases":1018,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1024},"NCT00833963","A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine",[],"2017-04-13","2009-01-14",20,[18,1023],"Pregnancy",[61,321,1025],"Ado-Trastuzumab Emtansine",{"intervention":1027,"totalTrials":1028,"cells":1029},"bevacizumab",43,{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1181,"PHASE3":1357,"PHASE4":1420,"NA":1422},{"trials":1031,"activeCount":101},[],{"trials":1033,"activeCount":116,"soonestReadout":542},[1034,1038,1042,1054,1058,1065,1075,1084,1094,1107,1114,1122,1126,1136,1145,1155,1164,1174],{"nctId":510,"briefTitle":511,"status":242,"phases":1035,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":1036,"interventions":1037},[89],[517],[519,487,520,521,522,523,524,525,526],{"nctId":552,"briefTitle":553,"status":242,"phases":1039,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":1040,"interventions":1041},[89],[559],[487,506,521,561,526,525,562,563,520,564],{"nctId":1043,"briefTitle":1044,"status":242,"phases":1045,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":1049,"interventions":1051},"NCT00974584","A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer",[89],"2015-03","2009-10",65,[1050],"Non-Squamous Non-Small Cell Lung Cancer",[346,1027,960,1052,998,1053],"cisplatin","pemetrexed",{"nctId":566,"briefTitle":567,"status":122,"phases":1055,"primaryCompletion":542,"completion":542,"start":569,"enrollment":570,"conditions":1056,"interventions":1057},[89],[27,29,572],[574,487,575,520,576,577,66],{"nctId":1059,"briefTitle":1060,"status":242,"phases":1061,"start":1062,"conditions":1063,"interventions":1064},"NCT00047762","Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer",[89],"2002-10",[29],[576,520],{"nctId":1066,"briefTitle":1067,"status":242,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":1071,"conditions":1072,"interventions":1073},"NCT01139723","A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors",[89],"2014-08","2010-06",54,[24],[1074,1027],"MINT1526A",{"nctId":1076,"briefTitle":1077,"status":242,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":500,"conditions":1081,"interventions":1082},"NCT01995188","A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer",[89],"2016-11-09","2013-12-16",[1050],[520,521,1083],"DNIB0600A",{"nctId":1085,"briefTitle":1086,"status":242,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1092},"NCT01068977","A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors",[89],"2010-01","2007-08",44,[24],[1027,1093,1093],"MetMAb",{"nctId":1095,"briefTitle":1096,"status":242,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1102},"NCT00671372","A Study of Dulanermin Administered in Combination With Camptosar®\u002FErbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer",[89],"2012-03","2006-07",42,[29],[1103,1027,1104,1105,1106],"FOLFIRI regimen","cetuximab","dulanermin","irinotecan",{"nctId":1108,"briefTitle":1109,"status":242,"phases":1110,"primaryCompletion":907,"completion":907,"start":948,"enrollment":488,"conditions":1111,"interventions":1112},"NCT00954642","A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors",[89],[24],[1027,1113,998],"MNRP1685A",{"nctId":1115,"briefTitle":1116,"status":242,"phases":1117,"primaryCompletion":909,"completion":909,"start":1118,"enrollment":1021,"conditions":1119,"interventions":1120},"NCT00497497","A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)",[89],"2007-10",[29],[1027,1104,1103,1106,1121],"PRO95780",{"nctId":944,"briefTitle":945,"status":242,"phases":1123,"primaryCompletion":947,"completion":947,"start":948,"enrollment":9,"conditions":1124,"interventions":1125},[89],[18],[520,951,318,525,61],{"nctId":1127,"briefTitle":1128,"status":242,"phases":1129,"primaryCompletion":1070,"completion":1070,"start":1130,"enrollment":1131,"conditions":1132,"interventions":1134},"NCT00851136","A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)",[89],"2009-05",9,[1133],"Metastatic Colorectal Cancer",[1027,1135,1121],"FOLFOX",{"nctId":1137,"briefTitle":1138,"status":242,"phases":1139,"primaryCompletion":1140,"completion":896,"start":1130,"enrollment":1141,"conditions":1142,"interventions":1143},"NCT00873756","A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer",[89],"2014-03",23,[1133],[1144,1027,1105],"FOLFOX regimen",{"nctId":1146,"briefTitle":1147,"status":242,"phases":1148,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":1152,"interventions":1153},"NCT01075464","A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors",[89],"2013-04","2010-02",64,[24],[1154,1027,998],"MEGF0444A",{"nctId":1156,"briefTitle":1157,"status":242,"phases":1158,"primaryCompletion":1159,"completion":1149,"start":1160,"enrollment":1161,"conditions":1162,"interventions":1163},"NCT01254526","Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer",[89],"2012-07","2010-12",52,[18],[347,1027,998],{"nctId":1165,"briefTitle":1166,"status":242,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":500,"conditions":1170,"interventions":1171},"NCT01332604","GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors",[89],"2015-06","2011-07",[24],[347,1027,1172,1173],"capecitabine","mFOLFOX6",{"nctId":1175,"briefTitle":1176,"status":242,"phases":1177,"primaryCompletion":1069,"completion":1069,"start":1178,"enrollment":246,"conditions":1179,"interventions":1180},"NCT01301716","A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors",[89],"2011-09",[24],[347,1027,960,1052,998,1053],{"trials":1182,"activeCount":116,"soonestReadout":767},[1183,1191,1203,1212,1223,1232,1241,1250,1258,1267,1276,1286,1296,1306,1314,1318,1329,1340,1348],{"nctId":1184,"briefTitle":1185,"status":242,"phases":1186,"primaryCompletion":938,"completion":938,"start":1187,"enrollment":1188,"conditions":1189,"interventions":1190},"NCT00318136","A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)",[90],"2005-09",47,[642],[520,521,525],{"nctId":1192,"briefTitle":1193,"status":242,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT01186991","Study Evaluating the Safety and Efficacy of Onartuzumab And\u002For Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer",[90],"2016-03","2011-03",185,[18],[1200,520,525,1201,1202],"Onartuzumab","Bevacizumab Placebo","Onartuzumab Placebo",{"nctId":1204,"briefTitle":1205,"status":242,"phases":1206,"primaryCompletion":1207,"completion":1207,"start":1208,"enrollment":640,"conditions":1209,"interventions":1210},"NCT00473590","A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)",[90],"2009-11","2007-06",[502],[520,1211],"Bortezomib",{"nctId":1213,"briefTitle":1214,"status":242,"phases":1215,"primaryCompletion":1216,"completion":417,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1220},"NCT01374425","Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)",[90],"2015-05","2011-08",376,[29],[1221,520,1222,522,524,563],"5-Fluorouracil","Irinotecan",{"nctId":1224,"briefTitle":1225,"status":325,"phases":1226,"primaryCompletion":1227,"start":1089,"enrollment":1228,"conditions":1229,"interventions":1230},"NCT00491738","A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)",[90],"2008-01",16,[420],[1027,1231],"sunitinib",{"nctId":1233,"briefTitle":1234,"status":325,"phases":1235,"primaryCompletion":1236,"start":1237,"enrollment":1238,"conditions":1239,"interventions":1240},"NCT00434226","A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)",[90],"2008-04","2007-03",56,[27],[1027,1231,960,998],{"nctId":1242,"briefTitle":1243,"status":242,"phases":1244,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1249},"NCT00434252","A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma",[90],"2009-04","2007-02",214,[599],[1027,960,998],{"nctId":1251,"briefTitle":1252,"status":242,"phases":1253,"primaryCompletion":1254,"completion":1254,"start":1208,"enrollment":1255,"conditions":1256,"interventions":1257},"NCT00480831","A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)",[90],"2010-08",128,[27],[1027,960,998,1121],{"nctId":1259,"briefTitle":1260,"status":242,"phases":1261,"primaryCompletion":1262,"completion":1262,"start":1099,"enrollment":1263,"conditions":1264,"interventions":1266},"NCT00345163","A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)",[90],"2007-09",167,[1265],"Glioblastoma",[1027,1106],{"nctId":1268,"briefTitle":1269,"status":242,"phases":1270,"primaryCompletion":1271,"completion":1272,"start":1237,"enrollment":640,"conditions":1273,"interventions":1275},"NCT00403403","A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)",[90],"2009-02","2009-06",[1274],"Small Cell Lung Cancer",[520,782],{"nctId":1277,"briefTitle":1278,"status":242,"phases":1279,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1285},"NCT00097019","A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed",[90],"2006-05","2005-02",53,[1284],"Ovarian Cancer",[1027],{"nctId":1287,"briefTitle":1288,"status":242,"phases":1289,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1293,"interventions":1294},"NCT01399684","A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer",[90],"2014-02","2011-11",127,[1133],[1221,520,1295,1154,524],"Folinic acid",{"nctId":1297,"briefTitle":1298,"status":242,"phases":1299,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":1302,"conditions":1303,"interventions":1304},"NCT01493843","Safety and Efficacy of Carboplatin\u002FPaclitaxel and Carboplatin\u002FPaclitaxel\u002FBevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer",[90],"2016-03-30","2012-01-20",501,[27],[1305,1027,960,998],"pictilisib",{"nctId":1307,"briefTitle":1308,"status":325,"phases":1309,"primaryCompletion":1310,"start":1237,"enrollment":1311,"conditions":1312,"interventions":1313},"NCT00434356","A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)",[90],"2008-05",46,[940],[1027,1231,998],{"nctId":764,"briefTitle":765,"status":107,"phases":1315,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":1316,"interventions":1317},[90],[772],[487,520],{"nctId":1319,"briefTitle":1320,"status":242,"phases":1321,"primaryCompletion":1272,"completion":1272,"start":1322,"enrollment":1323,"conditions":1324,"interventions":1326},"NCT00312728","A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)",[90],"2006-03",115,[27,1325],"Brain Neoplasms",[1027,1327,1328],"First-Line Chemotherapy Agents","Second-Line Chemotherapy Agents",{"nctId":1330,"briefTitle":1331,"status":242,"phases":1332,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1338},"NCT00959647","A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study",[90],"2014-01-09","2009-09-03",19,[1284,1337,1133],"Basal Cell Carcinoma",[699,1135,1339,520],"FOLFIRI",{"nctId":1341,"briefTitle":1342,"status":242,"phases":1343,"primaryCompletion":956,"start":1344,"enrollment":1345,"conditions":1346,"interventions":1347},"NCT01366131","Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)",[90],"2011-06",104,[1050],[1154,1027,960,998],{"nctId":1349,"briefTitle":1350,"status":242,"phases":1351,"primaryCompletion":1160,"completion":1160,"start":1310,"enrollment":1352,"conditions":1353,"interventions":1354},"NCT00636610","A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer",[90],199,[1133],[1355,520,1356,1339],"Vismodegib 150 mg","Modified FOLFOX",{"trials":1358,"activeCount":101},[1359,1369,1380,1391,1401,1411],{"nctId":1360,"briefTitle":1361,"status":242,"phases":1362,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1367},"NCT00257608","A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)",[91],"2014-11","2006-01",1145,[27],[1027,1368],"erlotinib HCl",{"nctId":1370,"briefTitle":1371,"status":242,"phases":1372,"primaryCompletion":1373,"completion":1374,"start":1375,"enrollment":1376,"conditions":1377,"interventions":1378},"NCT00281697","A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)",[91],"2009-03","2012-09","2006-02",684,[940],[520,1379],"Standard chemotherapy",{"nctId":1381,"briefTitle":1382,"status":1383,"phases":1384,"primaryCompletion":1385,"completion":1386,"start":1387,"enrollment":1388,"conditions":1389,"interventions":1390},"NCT00262067","A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","UNKNOWN",[91],"2008-07","2013-12","2005-12",1237,[940],[520,782],{"nctId":1392,"briefTitle":1393,"status":242,"phases":1394,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":1398,"conditions":1399,"interventions":1400},"NCT00130728","A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer",[91],"2008-07-15","2019-12-23","2005-06-08",636,[27],[1027,1368],{"nctId":1402,"briefTitle":1403,"status":242,"phases":1404,"primaryCompletion":1207,"completion":1405,"start":1262,"enrollment":1406,"conditions":1407,"interventions":1409},"NCT00548548","A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer",[91],"2013-11",774,[1408],"Adenocarcinoma",[520,563,561,1410],"5-fluorouracil",{"nctId":1412,"briefTitle":1413,"status":242,"phases":1414,"primaryCompletion":909,"completion":1415,"start":1416,"enrollment":1417,"conditions":1418,"interventions":1419},"NCT00434642","A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma",[91],"2013-07","2007-04",484,[1284],[521,647,520],{"trials":1421,"activeCount":101},[],{"trials":1423,"activeCount":101},[],{"intervention":626,"totalTrials":1425,"cells":1426},14,{"EARLY_PHASE1":1427,"PHASE1":1429,"PHASE2":1526,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1428,"activeCount":101},[],{"trials":1430,"activeCount":116,"soonestReadout":1470},[1431,1439,1447,1457,1466,1475,1479,1486,1493,1501,1511,1518],{"nctId":1432,"briefTitle":1433,"status":242,"phases":1434,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":1021,"conditions":1437,"interventions":1438},"NCT01249131","A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants",[89],"2011-01-10","2010-12-01",[34],[626],{"nctId":1440,"briefTitle":1441,"status":242,"phases":1442,"primaryCompletion":1443,"completion":1443,"start":1069,"enrollment":12,"conditions":1444,"interventions":1445},"NCT02300025","A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage",[89],"2015-01",[15],[1446],"cobimetinib",{"nctId":1448,"briefTitle":1449,"status":242,"phases":1450,"primaryCompletion":896,"completion":896,"start":1451,"enrollment":1452,"conditions":1453,"interventions":1454},"NCT00467779","Study of Cobimetinib in Participants With Solid Tumors",[89],"2007-05",119,[316],[1446,1455,1456],"dextromethorphan","midazolam",{"nctId":1458,"briefTitle":1459,"status":242,"phases":1460,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":1021,"conditions":1463,"interventions":1464},"NCT01277718","A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants",[89],"2011-02","2011-01",[15],[626,1465],"Rabeprazole",{"nctId":1467,"briefTitle":1468,"status":122,"phases":1469,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1048,"conditions":1472,"interventions":1473},"NCT04835805","A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.",[89],"2027-06-30","2021-05-13",[599],[1474,626,646],"Belvarafenib",{"nctId":617,"briefTitle":618,"status":242,"phases":1476,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":1477,"interventions":1478},[89],[624],[487,626,627],{"nctId":1480,"briefTitle":1481,"status":242,"phases":1482,"primaryCompletion":1483,"completion":1483,"start":896,"enrollment":12,"conditions":1484,"interventions":1485},"NCT02136524","A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation",[89],"2014-05",[15],[1446,1446],{"nctId":1487,"briefTitle":1488,"status":325,"phases":1489,"primaryCompletion":1140,"completion":1140,"start":1207,"enrollment":1490,"conditions":1491,"interventions":1492},"NCT00996892","Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors",[89],178,[614],[626,951],{"nctId":1494,"briefTitle":1495,"status":242,"phases":1496,"primaryCompletion":1497,"completion":1497,"start":1415,"enrollment":1228,"conditions":1498,"interventions":1499},"NCT01929876","A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants",[89],"2013-10",[968],[626,1500],"Itraconazole",{"nctId":1502,"briefTitle":1503,"status":242,"phases":1504,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":488,"conditions":1507,"interventions":1509},"NCT02457793","A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",[89],"2016-12-05","2015-06-16",[1508],"Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma",[626,1510],"GDC-0994",{"nctId":1512,"briefTitle":1513,"status":242,"phases":1514,"primaryCompletion":1443,"completion":1443,"start":1515,"enrollment":622,"conditions":1516,"interventions":1517},"NCT01562275","A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2012-04",[695],[748,626],{"nctId":1519,"briefTitle":1520,"status":242,"phases":1521,"primaryCompletion":1522,"completion":1522,"start":1405,"enrollment":1141,"conditions":1523,"interventions":1524},"NCT01986166","A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS",[89],"2016-01",[695],[626,1525],"MEHD7945A",{"trials":1527,"activeCount":116,"soonestReadout":85},[1528,1532],{"nctId":688,"briefTitle":689,"status":242,"phases":1529,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":1530,"interventions":1531},[90],[695,614,696,697,667],[61,321,576,627,626,699,86,487],{"nctId":83,"briefTitle":84,"status":107,"phases":1533,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":1534,"interventions":1535},[90],[642],[86,747,627,626,752,487,781,782,783],{"trials":1537,"activeCount":101},[],{"trials":1539,"activeCount":101},[],{"trials":1541,"activeCount":101},[],{"intervention":321,"totalTrials":654,"cells":1543},{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1552,"PHASE3":1615,"PHASE4":1621,"NA":1623},{"trials":1545,"activeCount":101},[],{"trials":1547,"activeCount":116,"soonestReadout":216},[1548],{"nctId":310,"briefTitle":311,"status":122,"phases":1549,"primaryCompletion":216,"completion":216,"start":313,"enrollment":314,"conditions":1550,"interventions":1551},[89],[18,316],[66,284,318,319,320,61,321],{"trials":1553,"activeCount":116,"soonestReadout":704},[1554,1558,1562,1566,1576,1582,1591,1599,1608],{"nctId":973,"briefTitle":974,"status":242,"phases":1555,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":1556,"interventions":1557},[90],[940],[321,61],{"nctId":688,"briefTitle":689,"status":242,"phases":1559,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":1560,"interventions":1561},[90],[695,614,696,697,667],[61,321,576,627,626,699,86,487],{"nctId":701,"briefTitle":702,"status":122,"phases":1563,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":1564,"interventions":1565},[90],[709],[711,525,321,61,712,487],{"nctId":1567,"briefTitle":1568,"status":242,"phases":1569,"primaryCompletion":1262,"completion":1262,"start":1570,"enrollment":1571,"conditions":1572,"interventions":1575},"NCT00096993","A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[90],"2005-01",131,[1284,1573,1574],"Peritoneal Cancer","Fallopian Tube Cancer",[647,321],{"nctId":1577,"briefTitle":1578,"status":242,"phases":1579,"primaryCompletion":1098,"completion":1098,"start":1373,"enrollment":500,"conditions":1580,"interventions":1581},"NCT00855894","A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer",[90],[27],[321,576],{"nctId":1583,"briefTitle":1584,"status":242,"phases":1585,"primaryCompletion":1586,"completion":1586,"start":1587,"enrollment":1588,"conditions":1589,"interventions":1590},"NCT00063154","Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy",[90],"2005-04","2003-07",51,[642],[321],{"nctId":1592,"briefTitle":1593,"status":242,"phases":1594,"primaryCompletion":1160,"completion":1217,"start":938,"enrollment":1588,"conditions":1595,"interventions":1596},"NCT00943670","Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression",[90],[940],[1597,1598],"pertuzumab","Trastuzumab emtansine [Kadcyla]",{"nctId":1600,"briefTitle":1601,"status":242,"phases":1602,"primaryCompletion":1603,"completion":1603,"start":1604,"enrollment":1605,"conditions":1606,"interventions":1607},"NCT00058552","A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer",[90],"2004-07","2003-05",129,[1284],[321],{"nctId":1609,"briefTitle":1610,"status":242,"phases":1611,"primaryCompletion":1118,"completion":1118,"start":1612,"enrollment":97,"conditions":1613,"interventions":1614},"NCT00096941","A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study",[90],"2005-05",[24],[321],{"trials":1616,"activeCount":101},[1617],{"nctId":1002,"briefTitle":1003,"status":242,"phases":1618,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1619,"interventions":1620},[91],[940],[321,61,711],{"trials":1622,"activeCount":101},[],{"trials":1624,"activeCount":101},[1625],{"nctId":1016,"briefTitle":1017,"status":242,"phases":1626,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":1021,"conditions":1627,"interventions":1628},[],[18,1023],[61,321,1025],{"intervention":711,"totalTrials":233,"cells":1630},{"EARLY_PHASE1":1631,"PHASE1":1633,"PHASE2":1659,"PHASE3":1665,"PHASE4":1671,"NA":1673},{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[1635,1645,1655],{"nctId":1636,"briefTitle":1637,"status":242,"phases":1638,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1643},"NCT01362374","Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors",[89],"2020-10-16","2011-07-11",122,[695],[519,711,1644,748,522,524,525],"Enzalutamide",{"nctId":1646,"briefTitle":1647,"status":242,"phases":1648,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":1651,"conditions":1652,"interventions":1654},"NCT01862081","A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer",[89],"2017-06-09","2013-07-16",80,[1653],"Breast Cancer, Non-small Lung Cancer",[711,333,525],{"nctId":953,"briefTitle":954,"status":242,"phases":1656,"primaryCompletion":956,"completion":956,"start":938,"enrollment":957,"conditions":1657,"interventions":1658},[89],[24],[960,961,962],{"trials":1660,"activeCount":116,"soonestReadout":704},[1661],{"nctId":701,"briefTitle":702,"status":122,"phases":1662,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":1663,"interventions":1664},[90],[709],[711,525,321,61,712,487],{"trials":1666,"activeCount":101},[1667],{"nctId":1002,"briefTitle":1003,"status":242,"phases":1668,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1669,"interventions":1670},[91],[940],[321,61,711],{"trials":1672,"activeCount":101},[],{"trials":1674,"activeCount":101},[],{"intervention":782,"totalTrials":97,"cells":1676},{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1691,"PHASE4":1697,"NA":1699},{"trials":1678,"activeCount":101},[],{"trials":1680,"activeCount":101},[],{"trials":1682,"activeCount":116,"soonestReadout":85},[1683,1687],{"nctId":1268,"briefTitle":1269,"status":242,"phases":1684,"primaryCompletion":1271,"completion":1272,"start":1237,"enrollment":640,"conditions":1685,"interventions":1686},[90],[1274],[520,782],{"nctId":83,"briefTitle":84,"status":107,"phases":1688,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":1689,"interventions":1690},[90],[642],[86,747,627,626,752,487,781,782,783],{"trials":1692,"activeCount":101},[1693],{"nctId":1381,"briefTitle":1382,"status":1383,"phases":1694,"primaryCompletion":1385,"completion":1386,"start":1387,"enrollment":1388,"conditions":1695,"interventions":1696},[91],[940],[520,782],{"trials":1698,"activeCount":101},[],{"trials":1700,"activeCount":101},[],{"intervention":998,"totalTrials":12,"cells":1702},{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1755,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1704,"activeCount":101},[],{"trials":1706,"activeCount":101},[1707,1711,1715,1719,1723,1727,1731,1735,1743,1747,1751],{"nctId":510,"briefTitle":511,"status":242,"phases":1708,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":1709,"interventions":1710},[89],[517],[519,487,520,521,522,523,524,525,526],{"nctId":1636,"briefTitle":1637,"status":242,"phases":1712,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":1713,"interventions":1714},[89],[695],[519,711,1644,748,522,524,525],{"nctId":1646,"briefTitle":1647,"status":242,"phases":1716,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":1651,"conditions":1717,"interventions":1718},[89],[1653],[711,333,525],{"nctId":552,"briefTitle":553,"status":242,"phases":1720,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":1721,"interventions":1722},[89],[559],[487,506,521,561,526,525,562,563,520,564],{"nctId":1043,"briefTitle":1044,"status":242,"phases":1724,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":1725,"interventions":1726},[89],[1050],[346,1027,960,1052,998,1053],{"nctId":1108,"briefTitle":1109,"status":242,"phases":1728,"primaryCompletion":907,"completion":907,"start":948,"enrollment":488,"conditions":1729,"interventions":1730},[89],[24],[1027,1113,998],{"nctId":944,"briefTitle":945,"status":242,"phases":1732,"primaryCompletion":947,"completion":947,"start":948,"enrollment":9,"conditions":1733,"interventions":1734},[89],[18],[520,951,318,525,61],{"nctId":1736,"briefTitle":1737,"status":242,"phases":1738,"primaryCompletion":1739,"completion":1739,"start":1740,"enrollment":488,"conditions":1741,"interventions":1742},"NCT01911598","A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent\u002FMetastatic Squamous Cell Carcinoma of the Head and Neck (R\u002FM SCCHN)",[89],"2017-06-22","2013-09-19",[670],[519,521,561,1525,525],{"nctId":1146,"briefTitle":1147,"status":242,"phases":1744,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":1745,"interventions":1746},[89],[24],[1154,1027,998],{"nctId":1156,"briefTitle":1157,"status":242,"phases":1748,"primaryCompletion":1159,"completion":1149,"start":1160,"enrollment":1161,"conditions":1749,"interventions":1750},[89],[18],[347,1027,998],{"nctId":1175,"briefTitle":1176,"status":242,"phases":1752,"primaryCompletion":1069,"completion":1069,"start":1178,"enrollment":246,"conditions":1753,"interventions":1754},[89],[24],[347,1027,960,1052,998,1053],{"trials":1756,"activeCount":116,"soonestReadout":704},[1757,1768,1772,1776,1780,1784,1788,1792,1803,1807,1818,1822,1826,1835,1845,1849,1853],{"nctId":1758,"briefTitle":1759,"status":242,"phases":1760,"primaryCompletion":1761,"completion":1762,"start":1763,"enrollment":1764,"conditions":1765,"interventions":1767},"NCT02162719","A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors",[90],"2016-06-07","2019-08-31","2014-08-19",124,[1766],"Breast Neoplasms",[748,525],{"nctId":1184,"briefTitle":1185,"status":242,"phases":1769,"primaryCompletion":938,"completion":938,"start":1187,"enrollment":1188,"conditions":1770,"interventions":1771},[90],[642],[520,521,525],{"nctId":701,"briefTitle":702,"status":122,"phases":1773,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":1774,"interventions":1775},[90],[709],[711,525,321,61,712,487],{"nctId":1192,"briefTitle":1193,"status":242,"phases":1777,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":1778,"interventions":1779},[90],[18],[1200,520,525,1201,1202],{"nctId":737,"briefTitle":738,"status":242,"phases":1781,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":1782,"interventions":1783},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"nctId":1233,"briefTitle":1234,"status":325,"phases":1785,"primaryCompletion":1236,"start":1237,"enrollment":1238,"conditions":1786,"interventions":1787},[90],[27],[1027,1231,960,998],{"nctId":1242,"briefTitle":1243,"status":242,"phases":1789,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":1790,"interventions":1791},[90],[599],[1027,960,998],{"nctId":1793,"briefTitle":1794,"status":242,"phases":1795,"primaryCompletion":1796,"completion":1796,"start":1515,"enrollment":1797,"conditions":1798,"interventions":1799},"NCT01496742","A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer",[90],"2015-11",259,[1050],[1800,1801,1802,998,1053],"RO5490258","bevacizumab [Avastin]","cisplatin\u002Fcarboplatin",{"nctId":1251,"briefTitle":1252,"status":242,"phases":1804,"primaryCompletion":1254,"completion":1254,"start":1208,"enrollment":1255,"conditions":1805,"interventions":1806},[90],[27],[1027,960,998,1121],{"nctId":1808,"briefTitle":1809,"status":242,"phases":1810,"primaryCompletion":1811,"completion":1812,"start":948,"enrollment":1813,"conditions":1814,"interventions":1815},"NCT00951665","A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer",[89,90],"2012-02","2013-06",107,[940],[998,1816,1817,998,1817],"pertuzumab [Perjeta]","trastuzumab emtansine [Kadcyla]",{"nctId":1297,"briefTitle":1298,"status":242,"phases":1819,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":1302,"conditions":1820,"interventions":1821},[90],[27],[1305,1027,960,998],{"nctId":1307,"briefTitle":1308,"status":325,"phases":1823,"primaryCompletion":1310,"start":1237,"enrollment":1311,"conditions":1824,"interventions":1825},[90],[940],[1027,1231,998],{"nctId":1827,"briefTitle":1828,"status":242,"phases":1829,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1832,"conditions":1833,"interventions":1834},"NCT02301988","A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer",[90],"2017-08-02","2015-02-17",151,[18],[748,525],{"nctId":1836,"briefTitle":1837,"status":242,"phases":1838,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1842,"conditions":1843,"interventions":1844},"NCT01740336","A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer",[90],"2015-10-20","2015-12-10","2013-02-06",183,[18],[346,525],{"nctId":991,"briefTitle":992,"status":242,"phases":1846,"primaryCompletion":994,"start":995,"conditions":1847,"interventions":1848},[90],[18],[962,998],{"nctId":1341,"briefTitle":1342,"status":242,"phases":1850,"primaryCompletion":956,"start":1344,"enrollment":1345,"conditions":1851,"interventions":1852},[90],[1050],[1154,1027,960,998],{"nctId":1854,"briefTitle":1855,"status":242,"phases":1856,"primaryCompletion":937,"completion":1857,"start":1515,"enrollment":1858,"conditions":1859,"interventions":1860},"NCT01519804","A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer",[90],"2015-09",108,[1050],[1802,1861,998],"onartuzumab",{"trials":1863,"activeCount":101},[],{"trials":1865,"activeCount":101},[],{"trials":1867,"activeCount":101},[],{"intervention":627,"totalTrials":233,"cells":1869},{"EARLY_PHASE1":1870,"PHASE1":1872,"PHASE2":1889,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1871,"activeCount":101},[],{"trials":1873,"activeCount":101},[1874,1878],{"nctId":617,"briefTitle":618,"status":242,"phases":1875,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":1876,"interventions":1877},[89],[624],[487,626,627],{"nctId":1879,"briefTitle":1880,"status":242,"phases":1881,"primaryCompletion":1882,"completion":1882,"start":1883,"enrollment":1884,"conditions":1885,"interventions":1887},"NCT02608034","A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State",[89],"2018-09-10","2016-05-26",32,[1886],"Metastatic Melanoma, BRAF V600 Mutation Positive",[1500,1888,627],"Rifampin",{"trials":1890,"activeCount":116,"soonestReadout":85},[1891,1895,1904],{"nctId":688,"briefTitle":689,"status":242,"phases":1892,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":1893,"interventions":1894},[90],[695,614,696,697,667],[61,321,576,627,626,699,86,487],{"nctId":1896,"briefTitle":1897,"status":325,"phases":1898,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1903},"NCT01586195","Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",[90],"2015-04-30","2011-10-31",31,[624],[627],{"nctId":83,"briefTitle":84,"status":107,"phases":1905,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":1906,"interventions":1907},[90],[642],[86,747,627,626,752,487,781,782,783],{"trials":1909,"activeCount":101},[],{"trials":1911,"activeCount":101},[],{"trials":1913,"activeCount":101},[],{"intervention":783,"totalTrials":233,"cells":1915},{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1955,"PHASE3":1961,"PHASE4":1963,"NA":1965},{"trials":1917,"activeCount":101},[],{"trials":1919,"activeCount":101},[1920,1929,1937,1947],{"nctId":1921,"briefTitle":1922,"status":242,"phases":1923,"primaryCompletion":1924,"completion":1924,"start":1925,"enrollment":1901,"conditions":1926,"interventions":1928},"NCT06734208","A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function",[89],"2025-11-27","2025-01-31",[1927],"Hepatic Impairment",[783],{"nctId":1930,"briefTitle":1931,"status":242,"phases":1932,"primaryCompletion":1933,"completion":1933,"start":1934,"enrollment":25,"conditions":1935,"interventions":1936},"NCT06690138","A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants",[89],"2025-02-11","2024-11-15",[968],[783,1500],{"nctId":1938,"briefTitle":1939,"status":242,"phases":1940,"primaryCompletion":1941,"completion":1941,"start":1942,"enrollment":1335,"conditions":1943,"interventions":1944},"NCT06677957","A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants",[89],"2024-12-30","2024-11-06",[968],[1945,783,1946],"Digoxin","Rosuvastatin",{"nctId":1948,"briefTitle":1949,"status":242,"phases":1950,"primaryCompletion":1951,"completion":1951,"start":1952,"enrollment":25,"conditions":1953,"interventions":1954},"NCT06835465","A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants",[89],"2025-05-06","2025-02-21",[968],[783,1888],{"trials":1956,"activeCount":116,"soonestReadout":85},[1957],{"nctId":83,"briefTitle":84,"status":107,"phases":1958,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":1959,"interventions":1960},[90],[642],[86,747,627,626,752,487,781,782,783],{"trials":1962,"activeCount":101},[],{"trials":1964,"activeCount":101},[],{"trials":1966,"activeCount":101},[],{"intervention":46,"totalTrials":793,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":1970,"activeCount":101},[],{"trials":1972,"activeCount":101},[],{"trials":1974,"activeCount":116,"soonestReadout":45},[1975,1982,1993,2003],{"nctId":43,"briefTitle":44,"status":107,"phases":1976,"primaryCompletion":45,"completion":1977,"start":1978,"enrollment":488,"conditions":1979,"interventions":1981},[89,90],"2026-08-16","2025-03-31",[1980],"Moderate to Severe Ulcerative Colitis",[46],{"nctId":1983,"briefTitle":1984,"status":242,"phases":1985,"primaryCompletion":1986,"completion":1987,"start":1988,"enrollment":515,"conditions":1989,"interventions":1992},"NCT03816891","Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis",[90],"2022-12-28","2023-08-24","2019-03-11",[1990,1991],"Prurigo Nodularis","Pruritis",[46],{"nctId":1994,"briefTitle":1995,"status":325,"phases":1996,"primaryCompletion":1997,"completion":1997,"start":1998,"enrollment":1999,"conditions":2000,"interventions":2002},"NCT06137183","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)",[90],"2025-06-16","2024-05-01",79,[2001],"Ulcerative Colitis",[46],{"nctId":2004,"briefTitle":2005,"status":325,"phases":2006,"primaryCompletion":2007,"completion":2007,"start":2008,"enrollment":2009,"conditions":2010,"interventions":2013},"NCT05785624","A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease",[90],"2026-01-12","2023-05-26",286,[2011,2012],"Idiopathic Pulmonary Fibrosis","Systemic Sclerosis With Lung Involvement",[46],{"trials":2015,"activeCount":101},[],{"trials":2017,"activeCount":101},[],{"trials":2019,"activeCount":101},[],{"intervention":71,"totalTrials":97,"cells":2021},{"EARLY_PHASE1":2022,"PHASE1":2024,"PHASE2":2049,"PHASE3":2059,"PHASE4":2061,"NA":2063},{"trials":2023,"activeCount":101},[],{"trials":2025,"activeCount":101},[2026,2037],{"nctId":2027,"briefTitle":2028,"status":242,"phases":2029,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":2034,"interventions":2035},"NCT01685892","A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia",[89],"2018-05-21","2019-08-23","2012-11-29",82,[731],[2036,71],"Obinutuzumab",{"nctId":2038,"briefTitle":2039,"status":242,"phases":2040,"primaryCompletion":2041,"completion":2042,"start":2043,"enrollment":2044,"conditions":2045,"interventions":2047},"NCT01671904","A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed\u002FRefractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)",[89],"2018-08-17","2020-08-11","2014-01-13",84,[2046],"Chronic Lymphocytic Leukemia",[2048,2036,508,71],"Bendamustine",{"trials":2050,"activeCount":116,"soonestReadout":70},[2051],{"nctId":68,"briefTitle":69,"status":122,"phases":2052,"primaryCompletion":70,"completion":2053,"start":2054,"enrollment":2055,"conditions":2056,"interventions":2057},[90],"2030-01-31","2024-08-09",118,[2046],[71,2058],"cBTKi Monotherapy",{"trials":2060,"activeCount":101},[],{"trials":2062,"activeCount":101},[],{"trials":2064,"activeCount":101},[],{"intervention":673,"totalTrials":97,"cells":2066},{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2075,"PHASE3":2090,"PHASE4":2092,"NA":2094},{"trials":2068,"activeCount":101},[],{"trials":2070,"activeCount":101},[2071],{"nctId":660,"briefTitle":661,"status":242,"phases":2072,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":2073,"interventions":2074},[89],[599,27,667,29,668,669,670,671],[673,487],{"trials":2076,"activeCount":116,"soonestReadout":680},[2077,2081],{"nctId":677,"briefTitle":678,"status":107,"phases":2078,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":2079,"interventions":2080},[90],[684],[673,487,686],{"nctId":2082,"briefTitle":2083,"status":242,"phases":2084,"primaryCompletion":2085,"completion":2085,"start":2086,"enrollment":1571,"conditions":2087,"interventions":2089},"NCT03815058","A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.",[90],"2025-01-21","2018-12-21",[2088],"Advanced Melanoma",[673,564],{"trials":2091,"activeCount":101},[],{"trials":2093,"activeCount":101},[],{"trials":2095,"activeCount":101},[],{"intervention":712,"totalTrials":200,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2112,"PHASE4":2114,"NA":2116},{"trials":2099,"activeCount":101},[],{"trials":2101,"activeCount":101},[],{"trials":2103,"activeCount":116,"soonestReadout":704},[2104,2108],{"nctId":701,"briefTitle":702,"status":122,"phases":2105,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":2106,"interventions":2107},[90],[709],[711,525,321,61,712,487],{"nctId":737,"briefTitle":738,"status":242,"phases":2109,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":2110,"interventions":2111},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"trials":2113,"activeCount":101},[],{"trials":2115,"activeCount":101},[],{"trials":2117,"activeCount":101},[],{"intervention":747,"totalTrials":200,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2134,"PHASE4":2136,"NA":2138},{"trials":2121,"activeCount":101},[],{"trials":2123,"activeCount":101},[],{"trials":2125,"activeCount":116,"soonestReadout":85},[2126,2130],{"nctId":737,"briefTitle":738,"status":242,"phases":2127,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":2128,"interventions":2129},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"nctId":83,"briefTitle":84,"status":107,"phases":2131,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":2132,"interventions":2133},[90],[642],[86,747,627,626,752,487,781,782,783],{"trials":2135,"activeCount":101},[],{"trials":2137,"activeCount":101},[],{"trials":2139,"activeCount":101},[],{"intervention":752,"totalTrials":200,"cells":2141},{"EARLY_PHASE1":2142,"PHASE1":2144,"PHASE2":2146,"PHASE3":2156,"PHASE4":2158,"NA":2160},{"trials":2143,"activeCount":101},[],{"trials":2145,"activeCount":101},[],{"trials":2147,"activeCount":116,"soonestReadout":85},[2148,2152],{"nctId":737,"briefTitle":738,"status":242,"phases":2149,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":2150,"interventions":2151},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"nctId":83,"briefTitle":84,"status":107,"phases":2153,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":2154,"interventions":2155},[90],[642],[86,747,627,626,752,487,781,782,783],{"trials":2157,"activeCount":101},[],{"trials":2159,"activeCount":101},[],{"trials":2161,"activeCount":101},[],{"intervention":686,"totalTrials":116,"cells":2163},{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2174,"PHASE4":2176,"NA":2178},{"trials":2165,"activeCount":101},[],{"trials":2167,"activeCount":101},[],{"trials":2169,"activeCount":116,"soonestReadout":680},[2170],{"nctId":677,"briefTitle":678,"status":107,"phases":2171,"primaryCompletion":680,"completion":680,"start":681,"enrollment":682,"conditions":2172,"interventions":2173},[90],[684],[673,487,686],{"trials":2175,"activeCount":101},[],{"trials":2177,"activeCount":101},[],{"trials":2179,"activeCount":101},[],{"intervention":271,"totalTrials":116,"cells":2181},{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2183,"activeCount":101},[],{"trials":2185,"activeCount":101},[],{"trials":2187,"activeCount":116,"soonestReadout":266},[2188],{"nctId":263,"briefTitle":264,"status":107,"phases":2189,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":2190,"interventions":2191},[89,90],[18],[271,41,272],{"trials":2193,"activeCount":101},[],{"trials":2195,"activeCount":101},[],{"trials":2197,"activeCount":101},[],{"intervention":272,"totalTrials":116,"cells":2199},{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2210,"PHASE4":2212,"NA":2214},{"trials":2201,"activeCount":101},[],{"trials":2203,"activeCount":101},[],{"trials":2205,"activeCount":116,"soonestReadout":266},[2206],{"nctId":263,"briefTitle":264,"status":107,"phases":2207,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":2208,"interventions":2209},[89,90],[18],[271,41,272],{"trials":2211,"activeCount":101},[],{"trials":2213,"activeCount":101},[],{"trials":2215,"activeCount":101},[],{"intervention":2217,"totalTrials":116,"cells":2218},"OpRegen",{"EARLY_PHASE1":2219,"PHASE1":2221,"PHASE2":2223,"PHASE3":2235,"PHASE4":2237,"NA":2239},{"trials":2220,"activeCount":101},[],{"trials":2222,"activeCount":101},[],{"trials":2224,"activeCount":116,"soonestReadout":2229},[2225],{"nctId":2226,"briefTitle":2227,"status":107,"phases":2228,"primaryCompletion":2229,"completion":2229,"start":2230,"enrollment":2231,"conditions":2232,"interventions":2234},"NCT05626114","A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251",[90],"2031-03-01","2023-03-23",60,[2233],"Geographic Atrophy",[2217],{"trials":2236,"activeCount":101},[],{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":101},[],{"intervention":2242,"totalTrials":116,"cells":2243},"Selnoflast",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2260,"PHASE4":2262,"NA":2264},{"trials":2245,"activeCount":101},[],{"trials":2247,"activeCount":101},[],{"trials":2249,"activeCount":116,"soonestReadout":2254},[2250],{"nctId":2251,"briefTitle":2252,"status":107,"phases":2253,"primaryCompletion":2254,"completion":2255,"start":50,"enrollment":2256,"conditions":2257,"interventions":2259},"NCT07448038","A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events",[90],"2028-01-31","2028-02-28",162,[2258],"Atherosclerosis",[2242],{"trials":2261,"activeCount":101},[],{"trials":2263,"activeCount":101},[],{"trials":2265,"activeCount":101},[],{"intervention":2267,"totalTrials":116,"cells":2268},"GDC-6988",{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2285,"PHASE4":2287,"NA":2289},{"trials":2270,"activeCount":101},[],{"trials":2272,"activeCount":101},[],{"trials":2274,"activeCount":116,"soonestReadout":2279},[2275],{"nctId":2276,"briefTitle":2277,"status":107,"phases":2278,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":1255,"conditions":2281,"interventions":2284},"NCT06603246","A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease",[89,90],"2027-11-15","2024-11-18",[2282,2283],"Non-cystic Fibrosis Bronchiectasis","Chronic Obstructive Pulmonary Disease",[2267],{"trials":2286,"activeCount":101},[],{"trials":2288,"activeCount":101},[],{"trials":2290,"activeCount":101},[],{"intervention":129,"totalTrials":116,"cells":2292},{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2303,"PHASE4":2305,"NA":2307},{"trials":2294,"activeCount":101},[],{"trials":2296,"activeCount":101},[],{"trials":2298,"activeCount":116,"soonestReadout":124},[2299],{"nctId":120,"briefTitle":121,"status":122,"phases":2300,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":2301,"interventions":2302},[89,90],[113],[129,130,96],{"trials":2304,"activeCount":101},[],{"trials":2306,"activeCount":101},[],{"trials":2308,"activeCount":101},[],{"intervention":130,"totalTrials":116,"cells":2310},{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2315,"PHASE3":2321,"PHASE4":2323,"NA":2325},{"trials":2312,"activeCount":101},[],{"trials":2314,"activeCount":101},[],{"trials":2316,"activeCount":116,"soonestReadout":124},[2317],{"nctId":120,"briefTitle":121,"status":122,"phases":2318,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":2319,"interventions":2320},[89,90],[113],[129,130,96],{"trials":2322,"activeCount":101},[],{"trials":2324,"activeCount":101},[],{"trials":2326,"activeCount":101},[],{"intervention":2328,"totalTrials":116,"cells":2329},"GDC-1261",{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2334,"PHASE3":2345,"PHASE4":2347,"NA":2349},{"trials":2331,"activeCount":101},[],{"trials":2333,"activeCount":101},[],{"trials":2335,"activeCount":116,"soonestReadout":852},[2336],{"nctId":2337,"briefTitle":2338,"status":162,"phases":2339,"primaryCompletion":852,"completion":768,"start":2340,"enrollment":682,"conditions":2341,"interventions":2344},"NCT07567846","A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer",[89,90],"2026-04-30",[2342,2343],"Advanced Prostate Cancer","Metastatic Prostate Cancer",[2328],{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":101},[],{"trials":2350,"activeCount":101},[],{"intervention":2058,"totalTrials":116,"cells":2352},{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2363,"PHASE4":2365,"NA":2367},{"trials":2354,"activeCount":101},[],{"trials":2356,"activeCount":101},[],{"trials":2358,"activeCount":116,"soonestReadout":70},[2359],{"nctId":68,"briefTitle":69,"status":122,"phases":2360,"primaryCompletion":70,"completion":2053,"start":2054,"enrollment":2055,"conditions":2361,"interventions":2362},[90],[2046],[71,2058],{"trials":2364,"activeCount":101},[],{"trials":2366,"activeCount":101},[],{"trials":2368,"activeCount":101},[],{"intervention":2370,"totalTrials":116,"cells":2371},"RO7837195",{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2389,"PHASE4":2391,"NA":2393},{"trials":2373,"activeCount":101},[],{"trials":2375,"activeCount":101},[],{"trials":2377,"activeCount":116,"soonestReadout":2382},[2378],{"nctId":2379,"briefTitle":2380,"status":107,"phases":2381,"primaryCompletion":2382,"completion":2383,"start":2384,"enrollment":2385,"conditions":2386,"interventions":2387},"NCT06979336","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)",[90],"2027-08-25","2028-10-31","2025-09-29",224,[2001],[2370,2388],"RO7837195 Matched Placebo",{"trials":2390,"activeCount":101},[],{"trials":2392,"activeCount":101},[],{"trials":2394,"activeCount":101},[],{"intervention":2388,"totalTrials":116,"cells":2396},{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2401,"PHASE3":2407,"PHASE4":2409,"NA":2411},{"trials":2398,"activeCount":101},[],{"trials":2400,"activeCount":101},[],{"trials":2402,"activeCount":116,"soonestReadout":2382},[2403],{"nctId":2379,"briefTitle":2380,"status":107,"phases":2404,"primaryCompletion":2382,"completion":2383,"start":2384,"enrollment":2385,"conditions":2405,"interventions":2406},[90],[2001],[2370,2388],{"trials":2408,"activeCount":101},[],{"trials":2410,"activeCount":101},[],{"trials":2412,"activeCount":101},[],{"intervention":878,"totalTrials":116,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2419,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2416,"activeCount":101},[],{"trials":2418,"activeCount":101},[],{"trials":2420,"activeCount":116,"soonestReadout":592},[2421],{"nctId":871,"briefTitle":872,"status":122,"phases":2422,"primaryCompletion":592,"completion":592,"start":874,"enrollment":875,"conditions":2423,"interventions":2424},[90],[503],[878,878,801],{"trials":2426,"activeCount":101},[],{"trials":2428,"activeCount":101},[],{"trials":2430,"activeCount":101},[],{"intervention":781,"totalTrials":116,"cells":2432},{"EARLY_PHASE1":2433,"PHASE1":2435,"PHASE2":2437,"PHASE3":2443,"PHASE4":2445,"NA":2447},{"trials":2434,"activeCount":101},[],{"trials":2436,"activeCount":101},[],{"trials":2438,"activeCount":116,"soonestReadout":85},[2439],{"nctId":83,"briefTitle":84,"status":107,"phases":2440,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":2441,"interventions":2442},[90],[642],[86,747,627,626,752,487,781,782,783],{"trials":2444,"activeCount":101},[],{"trials":2446,"activeCount":101},[],{"trials":2448,"activeCount":101},[],{"intervention":86,"totalTrials":793,"cells":2450},{"EARLY_PHASE1":2451,"PHASE1":2453,"PHASE2":2455,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2452,"activeCount":101},[],{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":116,"soonestReadout":85},[2457,2461,2465],{"nctId":688,"briefTitle":689,"status":242,"phases":2458,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":2459,"interventions":2460},[90],[695,614,696,697,667],[61,321,576,627,626,699,86,487],{"nctId":737,"briefTitle":738,"status":242,"phases":2462,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":2463,"interventions":2464},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"nctId":83,"briefTitle":84,"status":107,"phases":2466,"primaryCompletion":85,"completion":776,"start":777,"enrollment":778,"conditions":2467,"interventions":2468},[90],[642],[86,747,627,626,752,487,781,782,783],{"trials":2470,"activeCount":101},[],{"trials":2472,"activeCount":101},[],{"trials":2474,"activeCount":101},[2475],{"nctId":2476,"briefTitle":2477,"status":2478,"phases":2479,"conditions":2480,"interventions":2481},"NCT02271139","Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy","NO_LONGER_AVAILABLE",[],[27],[86],{"intervention":66,"totalTrials":793,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2502,"PHASE3":2508,"PHASE4":2510,"NA":2512},{"trials":2485,"activeCount":101},[],{"trials":2487,"activeCount":97,"soonestReadout":65},[2488,2494,2498],{"nctId":63,"briefTitle":64,"status":107,"phases":2489,"primaryCompletion":65,"completion":2490,"start":2491,"enrollment":1884,"conditions":2492,"interventions":2493},[89],"2026-09-09","2025-08-21",[1927],[66],{"nctId":310,"briefTitle":311,"status":122,"phases":2495,"primaryCompletion":216,"completion":216,"start":313,"enrollment":314,"conditions":2496,"interventions":2497},[89],[18,316],[66,284,318,319,320,61,321],{"nctId":566,"briefTitle":567,"status":122,"phases":2499,"primaryCompletion":542,"completion":542,"start":569,"enrollment":570,"conditions":2500,"interventions":2501},[89],[27,29,572],[574,487,575,520,576,577,66],{"trials":2503,"activeCount":101},[2504],{"nctId":737,"briefTitle":738,"status":242,"phases":2505,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":2506,"interventions":2507},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"trials":2509,"activeCount":101},[],{"trials":2511,"activeCount":101},[],{"trials":2513,"activeCount":101},[],{"intervention":81,"totalTrials":793,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2536,"PHASE3":2538,"PHASE4":2540,"NA":2542},{"trials":2517,"activeCount":101},[],{"trials":2519,"activeCount":97,"soonestReadout":80},[2520,2524,2528,2532],{"nctId":78,"briefTitle":79,"status":122,"phases":2521,"primaryCompletion":80,"completion":80,"start":810,"enrollment":811,"conditions":2522,"interventions":2523},[89],[502],[81,51,801],{"nctId":815,"briefTitle":816,"status":242,"phases":2525,"primaryCompletion":818,"completion":818,"start":819,"enrollment":820,"conditions":2526,"interventions":2527},[89],[502],[81,801],{"nctId":837,"briefTitle":838,"status":122,"phases":2529,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":2530,"interventions":2531},[89],[502],[81,801,845,846,847],{"nctId":859,"briefTitle":860,"status":107,"phases":2533,"primaryCompletion":377,"completion":377,"start":862,"enrollment":863,"conditions":2534,"interventions":2535},[89],[865],[81,867,801],{"trials":2537,"activeCount":101},[],{"trials":2539,"activeCount":101},[],{"trials":2541,"activeCount":101},[],{"trials":2543,"activeCount":101},[],{"intervention":2545,"totalTrials":2546,"cells":2547},"Cyclophosphamide",6,{"EARLY_PHASE1":2548,"PHASE1":2550,"PHASE2":2579,"PHASE3":2608,"PHASE4":2625,"NA":2627},{"trials":2549,"activeCount":101},[],{"trials":2551,"activeCount":200,"soonestReadout":2556},[2552,2562,2571],{"nctId":2553,"briefTitle":2554,"status":122,"phases":2555,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":2231,"conditions":2558,"interventions":2559},"NCT07008378","A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis",[89],"2032-08-31","2025-10-15",[168],[2560,2545,2561],"P-CD19CD20-ALLO1 Cells","Fludarabine",{"nctId":2563,"briefTitle":2564,"status":162,"phases":2565,"primaryCompletion":2566,"completion":2566,"start":55,"enrollment":2256,"conditions":2567,"interventions":2569},"NCT06984341","A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)",[89],"2033-11-01",[2568],"Systemic Lupus Erythematosus",[2560,2545,2561,2570],"Rimiducid",{"nctId":2572,"briefTitle":2573,"status":242,"phases":2574,"primaryCompletion":2575,"completion":947,"start":2576,"enrollment":500,"conditions":2577,"interventions":2578},"NCT01300247","A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)",[89],"2013-01","2011-05",[731],[2561,2036,2048,2545],{"trials":2580,"activeCount":101},[2581,2593],{"nctId":2582,"briefTitle":2583,"status":242,"phases":2584,"primaryCompletion":2585,"completion":2585,"start":2586,"enrollment":418,"conditions":2587,"interventions":2588},"NCT01992653","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",[89,90],"2018-12-19","2013-11-29",[732],[2545,2589,2036,2590,2591,2592,508],"Doxorubicin","Polatuzumab Vedotin","Prednisolone","Prednisone",{"nctId":2594,"briefTitle":2595,"status":242,"phases":2596,"primaryCompletion":2597,"completion":2598,"start":2599,"enrollment":166,"conditions":2600,"interventions":2602},"NCT01414855","A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)",[90],"2013-12-31","2016-12-23","2011-08-31",[2601],"Lymphoma, B-Cell",[2603,2604,2605,2606,2607],"obinutuzumab","cyclophosphamide","doxorubicin","prednisone","vincristine",{"trials":2609,"activeCount":101},[2610],{"nctId":2611,"briefTitle":2612,"status":325,"phases":2613,"primaryCompletion":2614,"completion":2615,"start":2616,"enrollment":2617,"conditions":2618,"interventions":2620},"NCT00626197","A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)",[91],"2009-10-19","2013-10-28","2008-02-15",381,[2619,2568],"Lupus Nephritis",[2621,2545,2622,2623,2624],"Corticosteroids","Mycophenolate Mofetil","Ocrelizumab","Azathioprine",{"trials":2626,"activeCount":101},[],{"trials":2628,"activeCount":101},[],{"intervention":319,"totalTrials":97,"cells":2630},{"EARLY_PHASE1":2631,"PHASE1":2633,"PHASE2":2643,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2632,"activeCount":101},[],{"trials":2634,"activeCount":200,"soonestReadout":216},[2635,2639],{"nctId":310,"briefTitle":311,"status":122,"phases":2636,"primaryCompletion":216,"completion":216,"start":313,"enrollment":314,"conditions":2637,"interventions":2638},[89],[18,316],[66,284,318,319,320,61,321],{"nctId":374,"briefTitle":375,"status":122,"phases":2640,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":2641,"interventions":2642},[89],[18],[382,319,287],{"trials":2644,"activeCount":101},[2645],{"nctId":386,"briefTitle":387,"status":325,"phases":2646,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":2647,"interventions":2648},[89,90],[18],[356,287,319],{"trials":2650,"activeCount":101},[],{"trials":2652,"activeCount":101},[],{"trials":2654,"activeCount":101},[],{"intervention":51,"totalTrials":97,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2677,"PHASE3":2679,"PHASE4":2681,"NA":2683},{"trials":2658,"activeCount":101},[],{"trials":2660,"activeCount":200,"soonestReadout":50},[2661,2665,2673],{"nctId":78,"briefTitle":79,"status":122,"phases":2662,"primaryCompletion":80,"completion":80,"start":810,"enrollment":811,"conditions":2663,"interventions":2664},[89],[502],[81,51,801],{"nctId":2666,"briefTitle":2667,"status":242,"phases":2668,"primaryCompletion":2669,"completion":2669,"start":2670,"enrollment":25,"conditions":2671,"interventions":2672},"NCT05243342","A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed\u002FRefractory Multiple Myeloma",[89],"2024-07-10","2022-04-28",[502],[51,846],{"nctId":48,"briefTitle":49,"status":122,"phases":2674,"primaryCompletion":50,"completion":50,"start":611,"enrollment":612,"conditions":2675,"interventions":2676},[89],[614],[51,487,51],{"trials":2678,"activeCount":101},[],{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":101},[],{"trials":2684,"activeCount":101},[],{"intervention":2561,"totalTrials":97,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2703,"PHASE3":2705,"PHASE4":2707,"NA":2709},{"trials":2688,"activeCount":101},[],{"trials":2690,"activeCount":200,"soonestReadout":2556},[2691,2695,2699],{"nctId":2553,"briefTitle":2554,"status":122,"phases":2692,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":2231,"conditions":2693,"interventions":2694},[89],[168],[2560,2545,2561],{"nctId":2563,"briefTitle":2564,"status":162,"phases":2696,"primaryCompletion":2566,"completion":2566,"start":55,"enrollment":2256,"conditions":2697,"interventions":2698},[89],[2568],[2560,2545,2561,2570],{"nctId":2572,"briefTitle":2573,"status":242,"phases":2700,"primaryCompletion":2575,"completion":947,"start":2576,"enrollment":500,"conditions":2701,"interventions":2702},[89],[731],[2561,2036,2048,2545],{"trials":2704,"activeCount":101},[],{"trials":2706,"activeCount":101},[],{"trials":2708,"activeCount":101},[],{"trials":2710,"activeCount":101},[],{"intervention":646,"totalTrials":200,"cells":2712},{"EARLY_PHASE1":2713,"PHASE1":2715,"PHASE2":2725,"PHASE3":2727,"PHASE4":2729,"NA":2731},{"trials":2714,"activeCount":101},[],{"trials":2716,"activeCount":200,"soonestReadout":55},[2717,2721],{"nctId":1467,"briefTitle":1468,"status":122,"phases":2718,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1048,"conditions":2719,"interventions":2720},[89],[599],[1474,626,646],{"nctId":53,"briefTitle":54,"status":122,"phases":2722,"primaryCompletion":55,"completion":55,"start":639,"enrollment":640,"conditions":2723,"interventions":2724},[89],[642,602,643],[56,487,563,645,646,524,523,647],{"trials":2726,"activeCount":101},[],{"trials":2728,"activeCount":101},[],{"trials":2730,"activeCount":101},[],{"trials":2732,"activeCount":101},[],{"intervention":2560,"totalTrials":200,"cells":2734},{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2747,"PHASE3":2749,"PHASE4":2751,"NA":2753},{"trials":2736,"activeCount":101},[],{"trials":2738,"activeCount":200,"soonestReadout":2556},[2739,2743],{"nctId":2553,"briefTitle":2554,"status":122,"phases":2740,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":2231,"conditions":2741,"interventions":2742},[89],[168],[2560,2545,2561],{"nctId":2563,"briefTitle":2564,"status":162,"phases":2744,"primaryCompletion":2566,"completion":2566,"start":55,"enrollment":2256,"conditions":2745,"interventions":2746},[89],[2568],[2560,2545,2561,2570],{"trials":2748,"activeCount":101},[],{"trials":2750,"activeCount":101},[],{"trials":2752,"activeCount":101},[],{"trials":2754,"activeCount":101},[],{"intervention":576,"totalTrials":233,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2769,"PHASE3":2779,"PHASE4":2789,"NA":2791},{"trials":2758,"activeCount":101},[],{"trials":2760,"activeCount":116,"soonestReadout":542},[2761,2765],{"nctId":566,"briefTitle":567,"status":122,"phases":2762,"primaryCompletion":542,"completion":542,"start":569,"enrollment":570,"conditions":2763,"interventions":2764},[89],[27,29,572],[574,487,575,520,576,577,66],{"nctId":1059,"briefTitle":1060,"status":242,"phases":2766,"start":1062,"conditions":2767,"interventions":2768},[89],[29],[576,520],{"trials":2770,"activeCount":101},[2771,2775],{"nctId":688,"briefTitle":689,"status":242,"phases":2772,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":2773,"interventions":2774},[90],[695,614,696,697,667],[61,321,576,627,626,699,86,487],{"nctId":1577,"briefTitle":1578,"status":242,"phases":2776,"primaryCompletion":1098,"completion":1098,"start":1373,"enrollment":500,"conditions":2777,"interventions":2778},[90],[27],[321,576],{"trials":2780,"activeCount":101},[2781],{"nctId":2782,"briefTitle":2783,"status":242,"phases":2784,"primaryCompletion":1522,"completion":1522,"start":2785,"enrollment":2786,"conditions":2787,"interventions":2788},"NCT01456325","A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)",[91],"2012-01",494,[1050],[576,1200],{"trials":2790,"activeCount":101},[],{"trials":2792,"activeCount":101},[],{"intervention":647,"totalTrials":233,"cells":2794},{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2822,"PHASE3":2828,"PHASE4":2834,"NA":2836},{"trials":2796,"activeCount":101},[],{"trials":2798,"activeCount":116,"soonestReadout":55},[2799,2809,2813],{"nctId":2800,"briefTitle":2801,"status":242,"phases":2802,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":1345,"conditions":2805,"interventions":2807},"NCT01564251","A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma",[89],"2018-01-11","2012-03-23",[2806],"Lymphoma, Solid Tumor",[2808,647],"GDC-0575",{"nctId":53,"briefTitle":54,"status":122,"phases":2810,"primaryCompletion":55,"completion":55,"start":639,"enrollment":640,"conditions":2811,"interventions":2812},[89],[642,602,643],[56,487,563,645,646,524,523,647],{"nctId":2814,"briefTitle":2815,"status":242,"phases":2816,"primaryCompletion":2817,"completion":2817,"start":1640,"enrollment":979,"conditions":2818,"interventions":2819},"NCT01359696","A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma",[89],"2014-05-29",[316],[2820,2821],"GDC-0425","gemcitabine",{"trials":2823,"activeCount":101},[2824],{"nctId":1567,"briefTitle":1568,"status":242,"phases":2825,"primaryCompletion":1262,"completion":1262,"start":1570,"enrollment":1571,"conditions":2826,"interventions":2827},[90],[1284,1573,1574],[647,321],{"trials":2829,"activeCount":101},[2830],{"nctId":1412,"briefTitle":1413,"status":242,"phases":2831,"primaryCompletion":909,"completion":1415,"start":1416,"enrollment":1417,"conditions":2832,"interventions":2833},[91],[1284],[521,647,520],{"trials":2835,"activeCount":101},[],{"trials":2837,"activeCount":101},[],{"intervention":563,"totalTrials":233,"cells":2839},{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2856,"PHASE3":2862,"PHASE4":2868,"NA":2870},{"trials":2841,"activeCount":101},[],{"trials":2843,"activeCount":116,"soonestReadout":55},[2844,2848,2852],{"nctId":552,"briefTitle":553,"status":242,"phases":2845,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":2846,"interventions":2847},[89],[559],[487,506,521,561,526,525,562,563,520,564],{"nctId":53,"briefTitle":54,"status":122,"phases":2849,"primaryCompletion":55,"completion":55,"start":639,"enrollment":640,"conditions":2850,"interventions":2851},[89],[642,602,643],[56,487,563,645,646,524,523,647],{"nctId":1165,"briefTitle":1166,"status":242,"phases":2853,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":500,"conditions":2854,"interventions":2855},[89],[24],[347,1027,1172,1173],{"trials":2857,"activeCount":101},[2858],{"nctId":1213,"briefTitle":1214,"status":242,"phases":2859,"primaryCompletion":1216,"completion":417,"start":1217,"enrollment":1218,"conditions":2860,"interventions":2861},[90],[29],[1221,520,1222,522,524,563],{"trials":2863,"activeCount":101},[2864],{"nctId":1402,"briefTitle":1403,"status":242,"phases":2865,"primaryCompletion":1207,"completion":1405,"start":1262,"enrollment":1406,"conditions":2866,"interventions":2867},[91],[1408],[520,563,561,1410],{"trials":2869,"activeCount":101},[],{"trials":2871,"activeCount":101},[],{"intervention":524,"totalTrials":2546,"cells":2873},{"EARLY_PHASE1":2874,"PHASE1":2876,"PHASE2":2890,"PHASE3":2909,"PHASE4":2911,"NA":2913},{"trials":2875,"activeCount":101},[],{"trials":2877,"activeCount":116,"soonestReadout":55},[2878,2882,2886],{"nctId":510,"briefTitle":511,"status":242,"phases":2879,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":2880,"interventions":2881},[89],[517],[519,487,520,521,522,523,524,525,526],{"nctId":1636,"briefTitle":1637,"status":242,"phases":2883,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":2884,"interventions":2885},[89],[695],[519,711,1644,748,522,524,525],{"nctId":53,"briefTitle":54,"status":122,"phases":2887,"primaryCompletion":55,"completion":55,"start":639,"enrollment":640,"conditions":2888,"interventions":2889},[89],[642,602,643],[56,487,563,645,646,524,523,647],{"trials":2891,"activeCount":101},[2892,2896,2900],{"nctId":1213,"briefTitle":1214,"status":242,"phases":2893,"primaryCompletion":1216,"completion":417,"start":1217,"enrollment":1218,"conditions":2894,"interventions":2895},[90],[29],[1221,520,1222,522,524,563],{"nctId":1287,"briefTitle":1288,"status":242,"phases":2897,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":2898,"interventions":2899},[90],[1133],[1221,520,1295,1154,524],{"nctId":2901,"briefTitle":2902,"status":242,"phases":2903,"primaryCompletion":2904,"completion":2905,"start":2906,"enrollment":719,"conditions":2907,"interventions":2908},"NCT01896531","A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer",[90],"2015-06-03","2021-01-26","2013-08-14",[602],[1221,748,522,524],{"trials":2910,"activeCount":101},[],{"trials":2912,"activeCount":101},[],{"trials":2914,"activeCount":101},[],{"intervention":1104,"totalTrials":2546,"cells":2916},{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2942,"PHASE3":2957,"PHASE4":2959,"NA":2961},{"trials":2918,"activeCount":101},[],{"trials":2920,"activeCount":116,"soonestReadout":542},[2921,2925,2929,2933],{"nctId":566,"briefTitle":567,"status":122,"phases":2922,"primaryCompletion":542,"completion":542,"start":569,"enrollment":570,"conditions":2923,"interventions":2924},[89],[27,29,572],[574,487,575,520,576,577,66],{"nctId":1095,"briefTitle":1096,"status":242,"phases":2926,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":2927,"interventions":2928},[89],[29],[1103,1027,1104,1105,1106],{"nctId":1115,"briefTitle":1116,"status":242,"phases":2930,"primaryCompletion":909,"completion":909,"start":1118,"enrollment":1021,"conditions":2931,"interventions":2932},[89],[29],[1027,1104,1103,1106,1121],{"nctId":2934,"briefTitle":2935,"status":242,"phases":2936,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":802,"conditions":2939,"interventions":2940},"NCT05954871","Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer",[89],"2025-09-16","2024-01-08",[29,27],[577,2941,575],"Osimertinib",{"trials":2943,"activeCount":101},[2944,2950],{"nctId":2945,"briefTitle":2946,"status":242,"phases":2947,"primaryCompletion":1168,"completion":1168,"start":1159,"enrollment":1641,"conditions":2948,"interventions":2949},"NCT01577173","A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent\u002FMetastatic Squamous Cell Carcinoma of The Head And Neck",[90],[670],[1525,1104],{"nctId":2951,"briefTitle":2952,"status":242,"phases":2953,"primaryCompletion":1363,"completion":1363,"start":2954,"enrollment":760,"conditions":2955,"interventions":2956},"NCT01652482","Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)",[90],"2012-10",[29],[1410,575,1222,522,1525],{"trials":2958,"activeCount":101},[],{"trials":2960,"activeCount":101},[],{"trials":2962,"activeCount":101},[],{"intervention":318,"totalTrials":793,"cells":2964},{"EARLY_PHASE1":2965,"PHASE1":2967,"PHASE2":2981,"PHASE3":2993,"PHASE4":2995,"NA":2997},{"trials":2966,"activeCount":101},[],{"trials":2968,"activeCount":116,"soonestReadout":216},[2969,2973,2977],{"nctId":310,"briefTitle":311,"status":122,"phases":2970,"primaryCompletion":216,"completion":216,"start":313,"enrollment":314,"conditions":2971,"interventions":2972},[89],[18,316],[66,284,318,319,320,61,321],{"nctId":944,"briefTitle":945,"status":242,"phases":2974,"primaryCompletion":947,"completion":947,"start":948,"enrollment":9,"conditions":2975,"interventions":2976},[89],[18],[520,951,318,525,61],{"nctId":323,"briefTitle":324,"status":325,"phases":2978,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":2979,"interventions":2980},[89],[24,331],[284,333,318,334],{"trials":2982,"activeCount":101},[2983],{"nctId":2984,"briefTitle":2985,"status":242,"phases":2986,"primaryCompletion":2987,"completion":2987,"start":2988,"enrollment":2989,"conditions":2990,"interventions":2991},"NCT02273973","A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)",[90],"2017-03-13","2014-11-12",334,[18],[318,2992],"Taselisib",{"trials":2994,"activeCount":101},[],{"trials":2996,"activeCount":101},[],{"trials":2998,"activeCount":101},[],{"intervention":564,"totalTrials":97,"cells":3000},{"EARLY_PHASE1":3001,"PHASE1":3003,"PHASE2":3013,"PHASE3":3019,"PHASE4":3021,"NA":3023},{"trials":3002,"activeCount":101},[],{"trials":3004,"activeCount":116,"soonestReadout":592},[3005,3009],{"nctId":552,"briefTitle":553,"status":242,"phases":3006,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":3007,"interventions":3008},[89],[559],[487,506,521,561,526,525,562,563,520,564],{"nctId":589,"briefTitle":590,"status":107,"phases":3010,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":3011,"interventions":3012},[89],[596,597,598,599,600,601,602,603,29,604,605,606],[608,487,564],{"trials":3014,"activeCount":101},[3015],{"nctId":2082,"briefTitle":2083,"status":242,"phases":3016,"primaryCompletion":2085,"completion":2085,"start":2086,"enrollment":1571,"conditions":3017,"interventions":3018},[90],[2088],[673,564],{"trials":3020,"activeCount":101},[],{"trials":3022,"activeCount":101},[],{"trials":3024,"activeCount":101},[],{"intervention":577,"totalTrials":97,"cells":3026},{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3043,"PHASE3":3045,"PHASE4":3047,"NA":3049},{"trials":3028,"activeCount":101},[],{"trials":3030,"activeCount":116,"soonestReadout":542},[3031,3035,3039],{"nctId":566,"briefTitle":567,"status":122,"phases":3032,"primaryCompletion":542,"completion":542,"start":569,"enrollment":570,"conditions":3033,"interventions":3034},[89],[27,29,572],[574,487,575,520,576,577,66],{"nctId":629,"briefTitle":630,"status":242,"phases":3036,"primaryCompletion":632,"completion":632,"start":633,"enrollment":634,"conditions":3037,"interventions":3038},[89],[572,548],[577,487,259],{"nctId":2934,"briefTitle":2935,"status":242,"phases":3040,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":802,"conditions":3041,"interventions":3042},[89],[29,27],[577,2941,575],{"trials":3044,"activeCount":101},[],{"trials":3046,"activeCount":101},[],{"trials":3048,"activeCount":101},[],{"trials":3050,"activeCount":101},[],{"intervention":523,"totalTrials":200,"cells":3052},{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3065,"PHASE3":3067,"PHASE4":3069,"NA":3071},{"trials":3054,"activeCount":101},[],{"trials":3056,"activeCount":116,"soonestReadout":55},[3057,3061],{"nctId":510,"briefTitle":511,"status":242,"phases":3058,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":3059,"interventions":3060},[89],[517],[519,487,520,521,522,523,524,525,526],{"nctId":53,"briefTitle":54,"status":122,"phases":3062,"primaryCompletion":55,"completion":55,"start":639,"enrollment":640,"conditions":3063,"interventions":3064},[89],[642,602,643],[56,487,563,645,646,524,523,647],{"trials":3066,"activeCount":101},[],{"trials":3068,"activeCount":101},[],{"trials":3070,"activeCount":101},[],{"trials":3072,"activeCount":101},[],{"intervention":846,"totalTrials":200,"cells":3074},{"EARLY_PHASE1":3075,"PHASE1":3077,"PHASE2":3087,"PHASE3":3089,"PHASE4":3091,"NA":3093},{"trials":3076,"activeCount":101},[],{"trials":3078,"activeCount":116,"soonestReadout":840},[3079,3083],{"nctId":837,"briefTitle":838,"status":122,"phases":3080,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":3081,"interventions":3082},[89],[502],[81,801,845,846,847],{"nctId":2666,"briefTitle":2667,"status":242,"phases":3084,"primaryCompletion":2669,"completion":2669,"start":2670,"enrollment":25,"conditions":3085,"interventions":3086},[89],[502],[51,846],{"trials":3088,"activeCount":101},[],{"trials":3090,"activeCount":101},[],{"trials":3092,"activeCount":101},[],{"trials":3094,"activeCount":101},[],{"intervention":259,"totalTrials":200,"cells":3096},{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3109,"PHASE3":3111,"PHASE4":3113,"NA":3115},{"trials":3098,"activeCount":101},[],{"trials":3100,"activeCount":116,"soonestReadout":253},[3101,3105],{"nctId":629,"briefTitle":630,"status":242,"phases":3102,"primaryCompletion":632,"completion":632,"start":633,"enrollment":634,"conditions":3103,"interventions":3104},[89],[572,548],[577,487,259],{"nctId":250,"briefTitle":251,"status":107,"phases":3106,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":3107,"interventions":3108},[89],[18],[258,41,259],{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"trials":3116,"activeCount":101},[],{"intervention":3118,"totalTrials":116,"cells":3119},"RO7851624",{"EARLY_PHASE1":3120,"PHASE1":3122,"PHASE2":3135,"PHASE3":3137,"PHASE4":3139,"NA":3141},{"trials":3121,"activeCount":101},[],{"trials":3123,"activeCount":116,"soonestReadout":3128},[3124],{"nctId":3125,"briefTitle":3126,"status":162,"phases":3127,"primaryCompletion":3128,"completion":3129,"start":3130,"enrollment":3131,"conditions":3132,"interventions":3134},"NCT07558915","A Study to Evaluate RO7851624 in Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM)",[89],"2030-07-01","2031-10-01","2026-06-01",160,[3133],"Relapsed\u002FRefractory Multiple Myeloma",[3118],{"trials":3136,"activeCount":101},[],{"trials":3138,"activeCount":101},[],{"trials":3140,"activeCount":101},[],{"trials":3142,"activeCount":101},[],{"intervention":3144,"totalTrials":116,"cells":3145},"Phase I Arm A",{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3160,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3147,"activeCount":101},[],{"trials":3149,"activeCount":116,"soonestReadout":3154},[3150],{"nctId":3151,"briefTitle":3152,"status":107,"phases":3153,"primaryCompletion":3154,"completion":3154,"start":3155,"enrollment":3156,"conditions":3157,"interventions":3158},"NCT06619587","A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors",[89],"2028-05-31","2024-11-14",410,[316],[3144,3159],"Phase I Arm B",{"trials":3161,"activeCount":101},[],{"trials":3163,"activeCount":101},[],{"trials":3165,"activeCount":101},[],{"trials":3167,"activeCount":101},[],{"intervention":3159,"totalTrials":116,"cells":3169},{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3178,"PHASE3":3180,"PHASE4":3182,"NA":3184},{"trials":3171,"activeCount":101},[],{"trials":3173,"activeCount":116,"soonestReadout":3154},[3174],{"nctId":3151,"briefTitle":3152,"status":107,"phases":3175,"primaryCompletion":3154,"completion":3154,"start":3155,"enrollment":3156,"conditions":3176,"interventions":3177},[89],[316],[3144,3159],{"trials":3179,"activeCount":101},[],{"trials":3181,"activeCount":101},[],{"trials":3183,"activeCount":101},[],{"trials":3185,"activeCount":101},[],{"intervention":550,"totalTrials":116,"cells":3187},{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3196,"PHASE3":3198,"PHASE4":3200,"NA":3202},{"trials":3189,"activeCount":101},[],{"trials":3191,"activeCount":116,"soonestReadout":542},[3192],{"nctId":539,"briefTitle":540,"status":107,"phases":3193,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":3194,"interventions":3195},[89],[546,547,548],[550,487],{"trials":3197,"activeCount":101},[],{"trials":3199,"activeCount":101},[],{"trials":3201,"activeCount":101},[],{"trials":3203,"activeCount":101},[],{"intervention":320,"totalTrials":116,"cells":3205},{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3214,"PHASE3":3216,"PHASE4":3218,"NA":3220},{"trials":3207,"activeCount":101},[],{"trials":3209,"activeCount":116,"soonestReadout":216},[3210],{"nctId":310,"briefTitle":311,"status":122,"phases":3211,"primaryCompletion":216,"completion":216,"start":313,"enrollment":314,"conditions":3212,"interventions":3213},[89],[18,316],[66,284,318,319,320,61,321],{"trials":3215,"activeCount":101},[],{"trials":3217,"activeCount":101},[],{"trials":3219,"activeCount":101},[],{"trials":3221,"activeCount":101},[],{"intervention":574,"totalTrials":116,"cells":3223},{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3232,"PHASE3":3234,"PHASE4":3236,"NA":3238},{"trials":3225,"activeCount":101},[],{"trials":3227,"activeCount":116,"soonestReadout":542},[3228],{"nctId":566,"briefTitle":567,"status":122,"phases":3229,"primaryCompletion":542,"completion":542,"start":569,"enrollment":570,"conditions":3230,"interventions":3231},[89],[27,29,572],[574,487,575,520,576,577,66],{"trials":3233,"activeCount":101},[],{"trials":3235,"activeCount":101},[],{"trials":3237,"activeCount":101},[],{"trials":3239,"activeCount":101},[],{"intervention":76,"totalTrials":116,"cells":3241},{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3252,"PHASE3":3254,"PHASE4":3256,"NA":3258},{"trials":3243,"activeCount":101},[],{"trials":3245,"activeCount":116,"soonestReadout":75},[3246],{"nctId":73,"briefTitle":74,"status":122,"phases":3247,"primaryCompletion":75,"completion":3248,"start":3249,"enrollment":1832,"conditions":3250,"interventions":3251},[89],"2027-01-12","2022-12-08",[113],[76],{"trials":3253,"activeCount":101},[],{"trials":3255,"activeCount":101},[],{"trials":3257,"activeCount":101},[],{"trials":3259,"activeCount":101},[],{"intervention":115,"totalTrials":116,"cells":3261},{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3270,"PHASE3":3272,"PHASE4":3274,"NA":3276},{"trials":3263,"activeCount":101},[],{"trials":3265,"activeCount":116,"soonestReadout":109},[3266],{"nctId":105,"briefTitle":106,"status":107,"phases":3267,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":3268,"interventions":3269},[89],[113],[115,96],{"trials":3271,"activeCount":101},[],{"trials":3273,"activeCount":101},[],{"trials":3275,"activeCount":101},[],{"trials":3277,"activeCount":101},[],{"intervention":845,"totalTrials":116,"cells":3279},{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3288,"PHASE3":3290,"PHASE4":3292,"NA":3294},{"trials":3281,"activeCount":101},[],{"trials":3283,"activeCount":116,"soonestReadout":840},[3284],{"nctId":837,"briefTitle":838,"status":122,"phases":3285,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":3286,"interventions":3287},[89],[502],[81,801,845,846,847],{"trials":3289,"activeCount":101},[],{"trials":3291,"activeCount":101},[],{"trials":3293,"activeCount":101},[],{"trials":3295,"activeCount":101},[],{"intervention":847,"totalTrials":116,"cells":3297},{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3306,"PHASE3":3308,"PHASE4":3310,"NA":3312},{"trials":3299,"activeCount":101},[],{"trials":3301,"activeCount":116,"soonestReadout":840},[3302],{"nctId":837,"briefTitle":838,"status":122,"phases":3303,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":3304,"interventions":3305},[89],[502],[81,801,845,846,847],{"trials":3307,"activeCount":101},[],{"trials":3309,"activeCount":101},[],{"trials":3311,"activeCount":101},[],{"trials":3313,"activeCount":101},[],{"intervention":857,"totalTrials":116,"cells":3315},{"EARLY_PHASE1":3316,"PHASE1":3318,"PHASE2":3324,"PHASE3":3326,"PHASE4":3328,"NA":3330},{"trials":3317,"activeCount":101},[],{"trials":3319,"activeCount":116,"soonestReadout":852},[3320],{"nctId":849,"briefTitle":850,"status":122,"phases":3321,"primaryCompletion":852,"completion":852,"start":853,"enrollment":854,"conditions":3322,"interventions":3323},[89],[614],[857,61,801],{"trials":3325,"activeCount":101},[],{"trials":3327,"activeCount":101},[],{"trials":3329,"activeCount":101},[],{"trials":3331,"activeCount":101},[],{"intervention":867,"totalTrials":116,"cells":3333},{"EARLY_PHASE1":3334,"PHASE1":3336,"PHASE2":3342,"PHASE3":3344,"PHASE4":3346,"NA":3348},{"trials":3335,"activeCount":101},[],{"trials":3337,"activeCount":116,"soonestReadout":377},[3338],{"nctId":859,"briefTitle":860,"status":107,"phases":3339,"primaryCompletion":377,"completion":377,"start":862,"enrollment":863,"conditions":3340,"interventions":3341},[89],[865],[81,867,801],{"trials":3343,"activeCount":101},[],{"trials":3345,"activeCount":101},[],{"trials":3347,"activeCount":101},[],{"trials":3349,"activeCount":101},[],{"intervention":608,"totalTrials":116,"cells":3351},{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3360,"PHASE3":3362,"PHASE4":3364,"NA":3366},{"trials":3353,"activeCount":101},[],{"trials":3355,"activeCount":116,"soonestReadout":592},[3356],{"nctId":589,"briefTitle":590,"status":107,"phases":3357,"primaryCompletion":592,"completion":592,"start":593,"enrollment":594,"conditions":3358,"interventions":3359},[89],[596,597,598,599,600,601,602,603,29,604,605,606],[608,487,564],{"trials":3361,"activeCount":101},[],{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":101},[],{"trials":3367,"activeCount":101},[],{"intervention":1474,"totalTrials":116,"cells":3369},{"EARLY_PHASE1":3370,"PHASE1":3372,"PHASE2":3378,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3371,"activeCount":101},[],{"trials":3373,"activeCount":116,"soonestReadout":1470},[3374],{"nctId":1467,"briefTitle":1468,"status":122,"phases":3375,"primaryCompletion":1470,"completion":1470,"start":1471,"enrollment":1048,"conditions":3376,"interventions":3377},[89],[599],[1474,626,646],{"trials":3379,"activeCount":101},[],{"trials":3381,"activeCount":101},[],{"trials":3383,"activeCount":101},[],{"trials":3385,"activeCount":101},[],{"intervention":3387,"totalTrials":116,"cells":3388},"RO7875913",{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3400,"PHASE3":3402,"PHASE4":3404,"NA":3406},{"trials":3390,"activeCount":101},[],{"trials":3392,"activeCount":116,"soonestReadout":216},[3393],{"nctId":3394,"briefTitle":3395,"status":107,"phases":3396,"primaryCompletion":216,"completion":216,"start":3397,"enrollment":979,"conditions":3398,"interventions":3399},"NCT07342114","A Dose-Escalation Study of RO7875913 in Healthy Participants",[89],"2026-03-11",[34],[3387],{"trials":3401,"activeCount":101},[],{"trials":3403,"activeCount":101},[],{"trials":3405,"activeCount":101},[],{"trials":3407,"activeCount":101},[],{"intervention":2570,"totalTrials":116,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3418,"PHASE3":3420,"PHASE4":3422,"NA":3424},{"trials":3411,"activeCount":101},[],{"trials":3413,"activeCount":116,"soonestReadout":2566},[3414],{"nctId":2563,"briefTitle":2564,"status":162,"phases":3415,"primaryCompletion":2566,"completion":2566,"start":55,"enrollment":2256,"conditions":3416,"interventions":3417},[89],[2568],[2560,2545,2561,2570],{"trials":3419,"activeCount":101},[],{"trials":3421,"activeCount":101},[],{"trials":3423,"activeCount":101},[],{"trials":3425,"activeCount":101},[],{"intervention":56,"totalTrials":116,"cells":3427},{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3436,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3429,"activeCount":101},[],{"trials":3431,"activeCount":116,"soonestReadout":55},[3432],{"nctId":53,"briefTitle":54,"status":122,"phases":3433,"primaryCompletion":55,"completion":55,"start":639,"enrollment":640,"conditions":3434,"interventions":3435},[89],[642,602,643],[56,487,563,645,646,524,523,647],{"trials":3437,"activeCount":101},[],{"trials":3439,"activeCount":101},[],{"trials":3441,"activeCount":101},[],{"trials":3443,"activeCount":101},[],{"intervention":645,"totalTrials":116,"cells":3445},{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3454,"PHASE3":3456,"PHASE4":3458,"NA":3460},{"trials":3447,"activeCount":101},[],{"trials":3449,"activeCount":116,"soonestReadout":55},[3450],{"nctId":53,"briefTitle":54,"status":122,"phases":3451,"primaryCompletion":55,"completion":55,"start":639,"enrollment":640,"conditions":3452,"interventions":3453},[89],[642,602,643],[56,487,563,645,646,524,523,647],{"trials":3455,"activeCount":101},[],{"trials":3457,"activeCount":101},[],{"trials":3459,"activeCount":101},[],{"trials":3461,"activeCount":101},[],{"intervention":258,"totalTrials":116,"cells":3463},{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3472,"PHASE3":3474,"PHASE4":3476,"NA":3478},{"trials":3465,"activeCount":101},[],{"trials":3467,"activeCount":116,"soonestReadout":253},[3468],{"nctId":250,"briefTitle":251,"status":107,"phases":3469,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":3470,"interventions":3471},[89],[18],[258,41,259],{"trials":3473,"activeCount":101},[],{"trials":3475,"activeCount":101},[],{"trials":3477,"activeCount":101},[],{"trials":3479,"activeCount":101},[],{"intervention":3481,"totalTrials":116,"cells":3482},"RO7656594",{"EARLY_PHASE1":3483,"PHASE1":3485,"PHASE2":3495,"PHASE3":3497,"PHASE4":3499,"NA":3501},{"trials":3484,"activeCount":101},[],{"trials":3486,"activeCount":116,"soonestReadout":1470},[3487],{"nctId":3488,"briefTitle":3489,"status":107,"phases":3490,"primaryCompletion":1470,"completion":1470,"start":3491,"enrollment":3492,"conditions":3493,"interventions":3494},"NCT05800665","A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer",[89],"2023-05-02",210,[2342,2343],[3481],{"trials":3496,"activeCount":101},[],{"trials":3498,"activeCount":101},[],{"trials":3500,"activeCount":101},[],{"trials":3502,"activeCount":101},[],{"intervention":382,"totalTrials":116,"cells":3504},{"EARLY_PHASE1":3505,"PHASE1":3507,"PHASE2":3513,"PHASE3":3515,"PHASE4":3517,"NA":3519},{"trials":3506,"activeCount":101},[],{"trials":3508,"activeCount":116,"soonestReadout":377},[3509],{"nctId":374,"briefTitle":375,"status":122,"phases":3510,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":3511,"interventions":3512},[89],[18],[382,319,287],{"trials":3514,"activeCount":101},[],{"trials":3516,"activeCount":101},[],{"trials":3518,"activeCount":101},[],{"trials":3520,"activeCount":101},[],{"intervention":3522,"totalTrials":1425,"cells":3523},"Methotrexate",{"EARLY_PHASE1":3524,"PHASE1":3526,"PHASE2":3538,"PHASE3":3596,"PHASE4":3664,"NA":3670},{"trials":3525,"activeCount":101},[],{"trials":3527,"activeCount":101},[3528],{"nctId":3529,"briefTitle":3530,"status":242,"phases":3531,"primaryCompletion":1883,"completion":1883,"start":3532,"enrollment":3533,"conditions":3534,"interventions":3535},"NCT02699710","Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects",[89],"2015-09-03",50,[15],[3536,3537,3522,1465],"Folic Acid","GDC-0853",{"trials":3539,"activeCount":101},[3540,3555,3566,3576,3585],{"nctId":3541,"briefTitle":3542,"status":242,"phases":3543,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":3548,"interventions":3549},"NCT00282308","A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate",[90],"2008-01-31","2012-05-28","2006-01-23",103,[21],[508,3522,3550,3551,3552,3553,3554],"Methylprednisone","C. albicans","Tetanus toxoid adsorbed booster vaccine","23-valent pneumococcal polysaccharide vaccine","Keyhole limpet hemocyanin",{"nctId":3556,"briefTitle":3557,"status":242,"phases":3558,"primaryCompletion":1159,"start":3559,"enrollment":3560,"conditions":3561,"interventions":3562},"NCT01225393","A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis",[90],"2010-11",211,[21],[3563,3564,3565,914],"MLTA3698A","adalimumab","leflunomide",{"nctId":3567,"briefTitle":3568,"status":325,"phases":3569,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":12,"conditions":3572,"interventions":3573},"NCT00808210","A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab",[90],"2012-11-14","2009-03-05",[21],[3574,3522,3575,2623],"Infliximab","Methylprednisolone",{"nctId":3577,"briefTitle":3578,"status":242,"phases":3579,"primaryCompletion":1271,"completion":1271,"start":3580,"enrollment":1100,"conditions":3581,"interventions":3582},"NCT00243412","A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate",[90],"2005-08",[21],[3583,914,3584,508],"folate","methylprednisolone",{"nctId":3586,"briefTitle":3587,"status":242,"phases":3588,"primaryCompletion":3589,"completion":1169,"start":3590,"enrollment":3591,"conditions":3592,"interventions":3593},"NCT00074438","Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis",[90],"2004-09","2003-06",465,[21],[914,3594,3595],"rituximab","corticosteroids",{"trials":3597,"activeCount":101},[3598,3608,3617,3624,3632,3643,3653],{"nctId":3599,"briefTitle":3600,"status":325,"phases":3601,"primaryCompletion":3602,"completion":3603,"start":3604,"enrollment":3605,"conditions":3606,"interventions":3607},"NCT00485589","A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)",[91],"2010-01-29","2013-08-29","2007-06-11",613,[21],[3522,2623],{"nctId":3609,"briefTitle":3610,"status":325,"phases":3611,"primaryCompletion":3612,"completion":3612,"start":3613,"enrollment":3614,"conditions":3615,"interventions":3616},"NCT00673920","A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy",[91],"2009-10-26","2008-04-24",314,[21],[3522,2623],{"nctId":3618,"briefTitle":3619,"status":242,"phases":3620,"primaryCompletion":1118,"start":1364,"enrollment":3621,"conditions":3622,"interventions":3623},"NCT00266227","A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate",[91],559,[21],[3594,914,3583],{"nctId":3625,"briefTitle":3626,"status":242,"phases":3627,"primaryCompletion":3628,"completion":1415,"start":1364,"enrollment":3629,"conditions":3630,"interventions":3631},"NCT00299104","A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis",[91],"2008-09",755,[21],[3583,914,3584,3594],{"nctId":3633,"briefTitle":3634,"status":325,"phases":3635,"primaryCompletion":3636,"completion":3637,"start":3638,"enrollment":3639,"conditions":3640,"interventions":3641},"NCT00476996","A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)",[91],"2010-01-21","2018-05-14","2007-05-15",836,[21],[3642,3522,2623,2623],"Leflunomide",{"nctId":3644,"briefTitle":3645,"status":242,"phases":3646,"primaryCompletion":3647,"completion":1415,"start":3648,"enrollment":3649,"conditions":3650,"interventions":3651},"NCT00299130","A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis",[91],"2008-06","2005-10",511,[21],[3652,3522,3575,508],"Folate",{"nctId":3654,"briefTitle":3655,"status":325,"phases":3656,"primaryCompletion":3657,"completion":3658,"start":3659,"enrollment":3660,"conditions":3661,"interventions":3662},"NCT00406419","A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)",[91],"2009-10-06","2015-04-22","2006-12-27",1015,[21],[3522,3663],"ocrelizumab",{"trials":3665,"activeCount":101},[3666],{"nctId":904,"briefTitle":905,"status":242,"phases":3667,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":3668,"interventions":3669},[92],[21],[913,914,915,916],{"trials":3671,"activeCount":101},[],{"intervention":3673,"totalTrials":654,"cells":3674},"Omalizumab",{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3709,"PHASE4":3742,"NA":3787},{"trials":3676,"activeCount":101},[],{"trials":3678,"activeCount":101},[],{"trials":3680,"activeCount":101},[3681,3692,3700],{"nctId":3682,"briefTitle":3683,"status":242,"phases":3684,"primaryCompletion":3685,"completion":3685,"start":3686,"enrollment":3687,"conditions":3688,"interventions":3690},"NCT00382148","A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g",[90],"2008-06-28","2006-11",11,[3689],"Peanut Hypersensitivity",[3691],"omalizumab",{"nctId":3693,"briefTitle":3694,"status":242,"phases":3695,"primaryCompletion":1271,"completion":1272,"start":1118,"enrollment":3696,"conditions":3697,"interventions":3699},"NCT00434434","A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma",[90],61,[3698],"Allergic Asthma",[3691,3691],{"nctId":3701,"briefTitle":3702,"status":242,"phases":3703,"primaryCompletion":1088,"completion":1088,"start":1373,"enrollment":811,"conditions":3704,"interventions":3706},"NCT00866788","A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)",[90],[3705],"Chronic Idiopathic Urticaria",[3691,3707,3708],"H1 antihistamines","Diphenhydramine",{"trials":3710,"activeCount":101},[3711,3720,3727,3734],{"nctId":3712,"briefTitle":3713,"status":242,"phases":3714,"primaryCompletion":3715,"completion":3715,"start":1461,"enrollment":3716,"conditions":3717,"interventions":3718},"NCT01264939","A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and\u002For Leukotriene Receptor Antagonists",[91],"2012-11",336,[3705],[3673,3719,3708],"H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist",{"nctId":3721,"briefTitle":3722,"status":242,"phases":3723,"primaryCompletion":908,"completion":908,"start":1196,"enrollment":3724,"conditions":3725,"interventions":3726},"NCT01292473","A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)\u002FChronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)",[91],323,[3705],[3673],{"nctId":3728,"briefTitle":3729,"status":242,"phases":3730,"primaryCompletion":2954,"completion":2954,"start":1461,"enrollment":3731,"conditions":3732,"interventions":3733},"NCT01287117","A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)\u002FChronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment",[91],319,[3705],[3673],{"nctId":3735,"briefTitle":3736,"status":242,"phases":3737,"primaryCompletion":1207,"completion":1207,"start":1387,"enrollment":3738,"conditions":3739,"interventions":3740},"NCT00314574","A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)",[91],850,[31],[3691,3595,3741],"long-acting beta-agonists",{"trials":3743,"activeCount":101},[3744,3754,3761,3771,3778],{"nctId":3745,"briefTitle":3746,"status":242,"phases":3747,"primaryCompletion":3748,"completion":3748,"start":3749,"enrollment":3750,"conditions":3751,"interventions":3752},"NCT01125748","A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy",[92],"2013-08","2010-05",176,[3698],[3673,3753],"Asthma therapies",{"nctId":3755,"briefTitle":3756,"status":242,"phases":3757,"primaryCompletion":909,"completion":909,"start":1375,"enrollment":3758,"conditions":3759,"interventions":3760},"NCT00096954","A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)",[92],333,[31],[3691],{"nctId":3762,"briefTitle":3763,"status":242,"phases":3764,"primaryCompletion":3765,"completion":3765,"start":3766,"enrollment":3767,"conditions":3768,"interventions":3770},"NCT02392624","A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria",[92],"2017-03-09","2015-05-18",206,[3769],"Urticaria",[3673],{"nctId":3772,"briefTitle":3773,"status":242,"phases":3774,"primaryCompletion":1272,"completion":1272,"start":1262,"enrollment":3775,"conditions":3776,"interventions":3777},"NCT00495612","A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma",[92],69,[31],[3673],{"nctId":3779,"briefTitle":3780,"status":325,"phases":3781,"primaryCompletion":3782,"completion":3782,"start":3783,"enrollment":97,"conditions":3784,"interventions":3786},"NCT04195958","A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma",[92],"2021-10-18","2020-11-30",[3785],"Moderate-to-severe Allergic Asthma",[3673],{"trials":3788,"activeCount":101},[],{"intervention":3790,"totalTrials":3791,"cells":3792},"Avastin",7,{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3797,"PHASE3":3833,"PHASE4":3849,"NA":3859},{"trials":3794,"activeCount":101},[],{"trials":3796,"activeCount":101},[],{"trials":3798,"activeCount":101},[3799,3808,3817,3825],{"nctId":3800,"briefTitle":3801,"status":242,"phases":3802,"completion":3686,"start":1603,"enrollment":1641,"conditions":3803,"interventions":3806},"NCT00095225","A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)",[90],[3804,3805],"Non-Small-Cell Lung Carcinoma","Neoplasm Recurrence, Local",[3790,3807],"Tarceva",{"nctId":3809,"briefTitle":3810,"status":242,"phases":3811,"completion":3812,"start":3813,"enrollment":166,"conditions":3814,"interventions":3816},"NCT00081614","A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma",[90],"2005-07","2004-03",[420,3815],"Metastases",[3790,3807],{"nctId":3818,"briefTitle":3819,"status":242,"phases":3820,"completion":3821,"start":3822,"conditions":3823,"interventions":3824},"NCT00109226","A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer",[90],"2003-09","2000-08",[29],[3790],{"nctId":3826,"briefTitle":3827,"status":242,"phases":3828,"completion":3829,"start":3830,"enrollment":1238,"conditions":3831,"interventions":3832},"NCT00109057","An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study",[90],"2004-02","1998-02",[517],[3790],{"trials":3834,"activeCount":101},[3835,3843],{"nctId":3836,"briefTitle":3837,"status":242,"phases":3838,"completion":3839,"start":3840,"conditions":3841,"interventions":3842},"NCT00109070","A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer",[91],"2003-04","2000-09",[29],[3790],{"nctId":3844,"briefTitle":3845,"status":242,"phases":3846,"completion":1603,"start":1062,"enrollment":166,"conditions":3847,"interventions":3848},"NCT00096967","A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study",[91],[18,29,3815],[3790],{"trials":3850,"activeCount":101},[3851],{"nctId":3852,"briefTitle":3853,"status":325,"phases":3854,"completion":3855,"start":1612,"enrollment":3856,"conditions":3857,"interventions":3858},"NCT00114946","A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer",[92],"2007-12",800,[29],[3790],{"trials":3860,"activeCount":101},[],{"intervention":3862,"totalTrials":2546,"cells":3863},"Ranibizumab",{"EARLY_PHASE1":3864,"PHASE1":3866,"PHASE2":3868,"PHASE3":3881,"PHASE4":3915,"NA":3924},{"trials":3865,"activeCount":101},[],{"trials":3867,"activeCount":101},[],{"trials":3869,"activeCount":101},[3870],{"nctId":3871,"briefTitle":3872,"status":242,"phases":3873,"primaryCompletion":3874,"completion":3875,"start":3876,"enrollment":3877,"conditions":3878,"interventions":3880},"NCT02510794","Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration",[90],"2018-04-10","2019-03-28","2015-09-28",225,[3879],"Macular Degeneration",[3862],{"trials":3882,"activeCount":101},[3883,3891,3900,3908],{"nctId":3884,"briefTitle":3885,"status":242,"phases":3886,"primaryCompletion":1217,"completion":898,"start":938,"enrollment":3887,"conditions":3888,"interventions":3890},"NCT00891735","A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)",[91],1097,[3889],"Age-related Macular Degeneration",[3862],{"nctId":3892,"briefTitle":3893,"status":242,"phases":3894,"primaryCompletion":3895,"completion":3895,"start":3896,"enrollment":16,"conditions":3897,"interventions":3899},"NCT02698566","A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)",[91],"2016-04-05","2016-03-21",[3898],"Macular Edema",[3862],{"nctId":3901,"briefTitle":3902,"status":242,"phases":3903,"primaryCompletion":3559,"completion":3715,"start":1208,"enrollment":888,"conditions":3904,"interventions":3906},"NCT00473330","A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)",[91],[3905,3898],"Diabetes Mellitus",[3862,3907],"Sham",{"nctId":3909,"briefTitle":3910,"status":242,"phases":3911,"primaryCompletion":1462,"completion":1374,"start":1208,"enrollment":3912,"conditions":3913,"interventions":3914},"NCT00473382","A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)",[91],382,[3905,3898],[3862,3907],{"trials":3916,"activeCount":101},[3917],{"nctId":3918,"briefTitle":3919,"status":242,"phases":3920,"primaryCompletion":2954,"completion":2954,"start":1461,"enrollment":3921,"conditions":3922,"interventions":3923},"NCT01277302","A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion",[92],202,[3898],[3862],{"trials":3925,"activeCount":101},[],{"intervention":3927,"totalTrials":233,"cells":3928},"Raptiva",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3940,"PHASE3":3942,"PHASE4":3967,"NA":3977},{"trials":3930,"activeCount":101},[],{"trials":3932,"activeCount":101},[3933],{"nctId":3934,"briefTitle":3935,"status":242,"phases":3936,"start":1604,"enrollment":2231,"conditions":3937,"interventions":3939},"NCT00382512","A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis",[89],[3938],"Plaque Psoriasis",[3927],{"trials":3941,"activeCount":101},[],{"trials":3943,"activeCount":101},[3944,3952,3961],{"nctId":3945,"briefTitle":3946,"status":242,"phases":3947,"completion":3839,"start":3948,"enrollment":101,"conditions":3949,"interventions":3951},"NCT00109252","A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g",[91],"2002-01",[3950],"Psoriasis",[3927],{"nctId":3953,"briefTitle":3954,"status":242,"phases":3955,"completion":3956,"start":3957,"enrollment":3958,"conditions":3959,"interventions":3960},"NCT00109317","A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy",[91],"2003-02","2002-09",686,[3950],[3927],{"nctId":3962,"briefTitle":3963,"status":242,"phases":3964,"completion":1603,"start":1062,"enrollment":594,"conditions":3965,"interventions":3966},"NCT00096603","A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g",[91],[3950],[3927],{"trials":3968,"activeCount":101},[3969],{"nctId":3970,"briefTitle":3971,"status":242,"phases":3972,"completion":3973,"start":3974,"enrollment":295,"conditions":3975,"interventions":3976},"NCT00096980","A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies",[92],"2004-05","2001-02",[3950],[3927],{"trials":3978,"activeCount":101},[],{"intervention":3980,"totalTrials":233,"cells":3981},"efalizumab",{"EARLY_PHASE1":3982,"PHASE1":3984,"PHASE2":3986,"PHASE3":3988,"PHASE4":4008,"NA":4034},{"trials":3983,"activeCount":101},[],{"trials":3985,"activeCount":101},[],{"trials":3987,"activeCount":101},[],{"trials":3989,"activeCount":101},[3990,3998],{"nctId":3991,"briefTitle":3992,"status":242,"phases":3993,"completion":3973,"start":3994,"enrollment":3995,"conditions":3996,"interventions":3997},"NCT00338143","A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies",[91],"2003-10",1200,[3950],[3980],{"nctId":3999,"briefTitle":4000,"status":826,"phases":4001,"enrollment":101,"conditions":4002,"interventions":4004},"NCT00729768","A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation",[90,91],[4003],"Kidney Transplantation",[4005,3980,4006,3595,4007],"basiliximab","mycophenolate mofetil","cyclosporine",{"trials":4009,"activeCount":101},[4010,4018,4027],{"nctId":4011,"briefTitle":4012,"status":242,"phases":4013,"primaryCompletion":4014,"completion":4014,"start":4015,"enrollment":246,"conditions":4016,"interventions":4017},"NCT00312026","A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and\u002For Feet",[92],"2006-11-28","2006-03-30",[3950],[3980],{"nctId":4019,"briefTitle":4020,"status":242,"phases":4021,"primaryCompletion":4022,"completion":4022,"start":4023,"enrollment":4024,"conditions":4025,"interventions":4026},"NCT00669214","A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp",[92],"2009-01","2008-02",89,[3950],[3980],{"nctId":4028,"briefTitle":4029,"status":242,"phases":4030,"primaryCompletion":4023,"start":1280,"enrollment":4031,"conditions":4032,"interventions":4033},"NCT00336973","A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent",[92],73,[3950],[3980],{"trials":4035,"activeCount":101},[],{"intervention":3553,"totalTrials":200,"cells":4037},{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4048,"PHASE4":4050,"NA":4056},{"trials":4039,"activeCount":101},[],{"trials":4041,"activeCount":101},[],{"trials":4043,"activeCount":101},[4044],{"nctId":3541,"briefTitle":3542,"status":242,"phases":4045,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":4046,"interventions":4047},[90],[21],[508,3522,3550,3551,3552,3553,3554],{"trials":4049,"activeCount":101},[],{"trials":4051,"activeCount":101},[4052],{"nctId":904,"briefTitle":905,"status":242,"phases":4053,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":4054,"interventions":4055},[92],[21],[913,914,915,916],{"trials":4057,"activeCount":101},[],{"intervention":4059,"totalTrials":200,"cells":4060},"Dornase alfa",{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4067,"PHASE4":4069,"NA":4085},{"trials":4062,"activeCount":101},[],{"trials":4064,"activeCount":101},[],{"trials":4066,"activeCount":101},[],{"trials":4068,"activeCount":101},[],{"trials":4070,"activeCount":101},[4071,4078],{"nctId":4072,"briefTitle":4073,"status":325,"phases":4074,"primaryCompletion":1130,"completion":1130,"start":3647,"enrollment":97,"conditions":4075,"interventions":4077},"NCT00680316","A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis",[92],[4076],"Cystic Fibrosis",[4059],{"nctId":4079,"briefTitle":4080,"status":325,"phases":4081,"primaryCompletion":4082,"completion":4082,"start":1237,"enrollment":19,"conditions":4083,"interventions":4084},"NCT00434278","A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)",[92],"2008-11",[4076],[4059],{"trials":4086,"activeCount":101},[],{"intervention":3753,"totalTrials":116,"cells":4088},{"EARLY_PHASE1":4089,"PHASE1":4091,"PHASE2":4093,"PHASE3":4095,"PHASE4":4097,"NA":4103},{"trials":4090,"activeCount":101},[],{"trials":4092,"activeCount":101},[],{"trials":4094,"activeCount":101},[],{"trials":4096,"activeCount":101},[],{"trials":4098,"activeCount":101},[4099],{"nctId":3745,"briefTitle":3746,"status":242,"phases":4100,"primaryCompletion":3748,"completion":3748,"start":3749,"enrollment":3750,"conditions":4101,"interventions":4102},[92],[3698],[3673,3753],{"trials":4104,"activeCount":101},[],{"intervention":4106,"totalTrials":116,"cells":4107},"Cohort I",{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4112,"PHASE3":4114,"PHASE4":4116,"NA":4127},{"trials":4109,"activeCount":101},[],{"trials":4111,"activeCount":101},[],{"trials":4113,"activeCount":101},[],{"trials":4115,"activeCount":101},[],{"trials":4117,"activeCount":101},[4118],{"nctId":4119,"briefTitle":4120,"status":242,"phases":4121,"primaryCompletion":1245,"completion":1245,"start":4122,"enrollment":2231,"conditions":4123,"interventions":4125},"NCT00777764","The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)",[92],"2008-08",[4124,31],"Healthy",[4106,4126],"Cohort 2",{"trials":4128,"activeCount":101},[],{"intervention":4126,"totalTrials":116,"cells":4130},{"EARLY_PHASE1":4131,"PHASE1":4133,"PHASE2":4135,"PHASE3":4137,"PHASE4":4139,"NA":4145},{"trials":4132,"activeCount":101},[],{"trials":4134,"activeCount":101},[],{"trials":4136,"activeCount":101},[],{"trials":4138,"activeCount":101},[],{"trials":4140,"activeCount":101},[4141],{"nctId":4119,"briefTitle":4120,"status":242,"phases":4142,"primaryCompletion":1245,"completion":1245,"start":4122,"enrollment":2231,"conditions":4143,"interventions":4144},[92],[4124,31],[4106,4126],{"trials":4146,"activeCount":101},[],{"intervention":916,"totalTrials":116,"cells":4148},{"EARLY_PHASE1":4149,"PHASE1":4151,"PHASE2":4153,"PHASE3":4155,"PHASE4":4157,"NA":4163},{"trials":4150,"activeCount":101},[],{"trials":4152,"activeCount":101},[],{"trials":4154,"activeCount":101},[],{"trials":4156,"activeCount":101},[],{"trials":4158,"activeCount":101},[4159],{"nctId":904,"briefTitle":905,"status":242,"phases":4160,"primaryCompletion":907,"completion":908,"start":909,"enrollment":910,"conditions":4161,"interventions":4162},[92],[21],[913,914,915,916],{"trials":4164,"activeCount":101},[],{"intervention":4166,"totalTrials":116,"cells":4167},"Cathflo Activase",{"EARLY_PHASE1":4168,"PHASE1":4170,"PHASE2":4172,"PHASE3":4174,"PHASE4":4176,"NA":4186},{"trials":4169,"activeCount":101},[],{"trials":4171,"activeCount":101},[],{"trials":4173,"activeCount":101},[],{"trials":4175,"activeCount":101},[],{"trials":4177,"activeCount":101},[4178],{"nctId":4179,"briefTitle":4180,"status":242,"phases":4181,"completion":1604,"start":4182,"enrollment":295,"conditions":4183,"interventions":4185},"NCT00307580","Cathflo Activase Pediatric Study",[92],"2002-04",[4184],"Dysfunctional Central Venous Access Devices (CVADS)",[4166],{"trials":4187,"activeCount":101},[],{"intervention":4189,"totalTrials":116,"cells":4190},"dornase alfa [Pulmozyme®]",{"EARLY_PHASE1":4191,"PHASE1":4193,"PHASE2":4195,"PHASE3":4197,"PHASE4":4199,"NA":4208},{"trials":4192,"activeCount":101},[],{"trials":4194,"activeCount":101},[],{"trials":4196,"activeCount":101},[],{"trials":4198,"activeCount":101},[],{"trials":4200,"activeCount":101},[4201],{"nctId":4202,"briefTitle":4203,"status":242,"phases":4204,"primaryCompletion":1812,"completion":1812,"start":4205,"enrollment":778,"conditions":4206,"interventions":4207},"NCT01712334","A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis",[92],"2012-12",[4076],[4189,4189],{"trials":4209,"activeCount":101},[],{"intervention":960,"totalTrials":1425,"cells":4211},{"EARLY_PHASE1":4212,"PHASE1":4214,"PHASE2":4244,"PHASE3":4270,"PHASE4":4276,"NA":4278},{"trials":4213,"activeCount":101},[],{"trials":4215,"activeCount":101},[4216,4220,4224,4228,4232,4236,4240],{"nctId":510,"briefTitle":511,"status":242,"phases":4217,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":4218,"interventions":4219},[89],[517],[519,487,520,521,522,523,524,525,526],{"nctId":552,"briefTitle":553,"status":242,"phases":4221,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":4222,"interventions":4223},[89],[559],[487,506,521,561,526,525,562,563,520,564],{"nctId":1043,"briefTitle":1044,"status":242,"phases":4225,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":4226,"interventions":4227},[89],[1050],[346,1027,960,1052,998,1053],{"nctId":1076,"briefTitle":1077,"status":242,"phases":4229,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":500,"conditions":4230,"interventions":4231},[89],[1050],[520,521,1083],{"nctId":1736,"briefTitle":1737,"status":242,"phases":4233,"primaryCompletion":1739,"completion":1739,"start":1740,"enrollment":488,"conditions":4234,"interventions":4235},[89],[670],[519,521,561,1525,525],{"nctId":953,"briefTitle":954,"status":242,"phases":4237,"primaryCompletion":956,"completion":956,"start":938,"enrollment":957,"conditions":4238,"interventions":4239},[89],[24],[960,961,962],{"nctId":1175,"briefTitle":1176,"status":242,"phases":4241,"primaryCompletion":1069,"completion":1069,"start":1178,"enrollment":246,"conditions":4242,"interventions":4243},[89],[24],[347,1027,960,1052,998,1053],{"trials":4245,"activeCount":101},[4246,4250,4254,4258,4262,4266],{"nctId":1184,"briefTitle":1185,"status":242,"phases":4247,"primaryCompletion":938,"completion":938,"start":1187,"enrollment":1188,"conditions":4248,"interventions":4249},[90],[642],[520,521,525],{"nctId":1233,"briefTitle":1234,"status":325,"phases":4251,"primaryCompletion":1236,"start":1237,"enrollment":1238,"conditions":4252,"interventions":4253},[90],[27],[1027,1231,960,998],{"nctId":1242,"briefTitle":1243,"status":242,"phases":4255,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":1247,"conditions":4256,"interventions":4257},[90],[599],[1027,960,998],{"nctId":1251,"briefTitle":1252,"status":242,"phases":4259,"primaryCompletion":1254,"completion":1254,"start":1208,"enrollment":1255,"conditions":4260,"interventions":4261},[90],[27],[1027,960,998,1121],{"nctId":1297,"briefTitle":1298,"status":242,"phases":4263,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":1302,"conditions":4264,"interventions":4265},[90],[27],[1305,1027,960,998],{"nctId":1341,"briefTitle":1342,"status":242,"phases":4267,"primaryCompletion":956,"start":1344,"enrollment":1345,"conditions":4268,"interventions":4269},[90],[1050],[1154,1027,960,998],{"trials":4271,"activeCount":101},[4272],{"nctId":1412,"briefTitle":1413,"status":242,"phases":4273,"primaryCompletion":909,"completion":1415,"start":1416,"enrollment":1417,"conditions":4274,"interventions":4275},[91],[1284],[521,647,520],{"trials":4277,"activeCount":101},[],{"trials":4279,"activeCount":101},[],{"intervention":2036,"totalTrials":802,"cells":4281},{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4298,"PHASE3":4345,"PHASE4":4357,"NA":4359},{"trials":4283,"activeCount":101},[],{"trials":4285,"activeCount":101},[4286,4290,4294],{"nctId":2027,"briefTitle":2028,"status":242,"phases":4287,"primaryCompletion":2030,"completion":2031,"start":2032,"enrollment":2033,"conditions":4288,"interventions":4289},[89],[731],[2036,71],{"nctId":2038,"briefTitle":2039,"status":242,"phases":4291,"primaryCompletion":2041,"completion":2042,"start":2043,"enrollment":2044,"conditions":4292,"interventions":4293},[89],[2046],[2048,2036,508,71],{"nctId":2572,"briefTitle":2573,"status":242,"phases":4295,"primaryCompletion":2575,"completion":947,"start":2576,"enrollment":500,"conditions":4296,"interventions":4297},[89],[731],[2561,2036,2048,2545],{"trials":4299,"activeCount":101},[4300,4304,4317,4324,4328,4336],{"nctId":2582,"briefTitle":2583,"status":242,"phases":4301,"primaryCompletion":2585,"completion":2585,"start":2586,"enrollment":418,"conditions":4302,"interventions":4303},[89,90],[732],[2545,2589,2036,2590,2591,2592,508],{"nctId":4305,"briefTitle":4306,"status":242,"phases":4307,"primaryCompletion":4308,"completion":4309,"start":4310,"enrollment":4311,"conditions":4312,"interventions":4315},"NCT01691898","A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)",[89,90],"2017-03-08","2019-02-07","2012-09-27",231,[4313,4314],"Follicular Lymphoma","Diffuse Large B-Cell Lymphoma",[2036,4316,2590,508],"Pinatuzumab Vedotin",{"nctId":4318,"briefTitle":4319,"status":242,"phases":4320,"primaryCompletion":937,"completion":937,"start":3748,"enrollment":1021,"conditions":4321,"interventions":4322},"NCT01868893","An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia",[90],[2046],[2036,4323],"Chlorambucil",{"nctId":2594,"briefTitle":2595,"status":242,"phases":4325,"primaryCompletion":2597,"completion":2598,"start":2599,"enrollment":166,"conditions":4326,"interventions":4327},[90],[2601],[2603,2604,2605,2606,2607],{"nctId":4329,"briefTitle":4330,"status":242,"phases":4331,"primaryCompletion":4332,"completion":4333,"start":1900,"enrollment":1651,"conditions":4334,"interventions":4335},"NCT01414205","A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)",[90],"2013-03-31","2016-03-31",[731],[2036,2621],{"nctId":4337,"briefTitle":4338,"status":242,"phases":4339,"primaryCompletion":4340,"completion":4341,"start":4342,"enrollment":640,"conditions":4343,"interventions":4344},"NCT02320487","A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)",[90],"2016-11-07","2019-02-06","2015-03-31",[2046],[2048,2036],{"trials":4346,"activeCount":101},[4347],{"nctId":4348,"briefTitle":4349,"status":242,"phases":4350,"primaryCompletion":4351,"completion":4352,"start":4353,"enrollment":4354,"conditions":4355,"interventions":4356},"NCT01059630","A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)",[91],"2014-09-30","2018-11-30","2010-04-30",413,[331],[2036,2048],{"trials":4358,"activeCount":101},[],{"trials":4360,"activeCount":101},[],{"intervention":1368,"totalTrials":3791,"cells":4362},{"EARLY_PHASE1":4363,"PHASE1":4365,"PHASE2":4377,"PHASE3":4411,"PHASE4":4421,"NA":4423},{"trials":4364,"activeCount":101},[],{"trials":4366,"activeCount":101},[4367],{"nctId":4368,"briefTitle":4369,"status":242,"phases":4370,"primaryCompletion":4371,"completion":4371,"start":4372,"enrollment":4373,"conditions":4374,"interventions":4376},"NCT00975182","A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors",[89],"2014-09","2009-09",58,[4375],"Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers",[346,1368],{"trials":4378,"activeCount":101},[4379,4387,4394,4404],{"nctId":4380,"briefTitle":4381,"status":242,"phases":4382,"completion":1062,"start":4383,"conditions":4384,"interventions":4385},"NCT00109265","A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy",[90],"2001-05",[18],[4386],"Erlotinib HCl",{"nctId":4388,"briefTitle":4389,"status":242,"phases":4390,"completion":3648,"start":1587,"enrollment":4391,"conditions":4392,"interventions":4393},"NCT00337883","A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)",[90],110,[1265],[4386],{"nctId":4395,"briefTitle":4396,"status":242,"phases":4397,"primaryCompletion":4398,"completion":4399,"start":4400,"enrollment":4401,"conditions":4402,"interventions":4403},"NCT00453362","A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib",[89,90],"2010-04","2010-04-23","2006-12",88,[27],[1368],{"nctId":4405,"briefTitle":4406,"status":242,"phases":4407,"primaryCompletion":3559,"completion":2785,"start":1245,"enrollment":4408,"conditions":4409,"interventions":4410},"NCT00854308","A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)",[90],137,[27],[4386,1093],{"trials":4412,"activeCount":101},[4413,4417],{"nctId":1360,"briefTitle":1361,"status":242,"phases":4414,"primaryCompletion":1363,"completion":1363,"start":1364,"enrollment":1365,"conditions":4415,"interventions":4416},[91],[27],[1027,1368],{"nctId":1392,"briefTitle":1393,"status":242,"phases":4418,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":1398,"conditions":4419,"interventions":4420},[91],[27],[1027,1368],{"trials":4422,"activeCount":101},[],{"trials":4424,"activeCount":101},[],{"intervention":3575,"totalTrials":3791,"cells":4426},{"EARLY_PHASE1":4427,"PHASE1":4429,"PHASE2":4431,"PHASE3":4441,"PHASE4":4480,"NA":4482},{"trials":4428,"activeCount":101},[],{"trials":4430,"activeCount":101},[],{"trials":4432,"activeCount":101},[4433,4437],{"nctId":3567,"briefTitle":3568,"status":325,"phases":4434,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":12,"conditions":4435,"interventions":4436},[90],[21],[3574,3522,3575,2623],{"nctId":3577,"briefTitle":3578,"status":242,"phases":4438,"primaryCompletion":1271,"completion":1271,"start":3580,"enrollment":1100,"conditions":4439,"interventions":4440},[90],[21],[3583,914,3584,508],{"trials":4442,"activeCount":101},[4443,4454,4464,4472,4476],{"nctId":4444,"briefTitle":4445,"status":325,"phases":4446,"primaryCompletion":4447,"completion":4448,"start":4449,"enrollment":1901,"conditions":4450,"interventions":4452},"NCT00381810","A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus",[91],"2008-07-31","2012-02-29","2006-06-22",[4451],"Lupus Erythematosus, Systemic",[508,3575,4453,3708],"Acetaminophen",{"nctId":4455,"briefTitle":4456,"status":325,"phases":4457,"primaryCompletion":4458,"completion":4458,"start":4459,"enrollment":4460,"conditions":4461,"interventions":4462},"NCT00539838","A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)",[91],"2011-07-12","2007-12-19",33,[2568],[2592,4463,3575,2623],"Immunosuppressive regime",{"nctId":4465,"briefTitle":4466,"status":242,"phases":4467,"primaryCompletion":4022,"completion":2575,"start":1364,"enrollment":4468,"conditions":4469,"interventions":4470},"NCT00282347","A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology\u002FRenal Pathology Society (ISN\u002FRPS) 2003 Class III or IV Lupus Nephritis",[91],144,[2619],[508,4471,3575,3708,4453,2592],"Mycophenolate mofetil",{"nctId":3625,"briefTitle":3626,"status":242,"phases":4473,"primaryCompletion":3628,"completion":1415,"start":1364,"enrollment":3629,"conditions":4474,"interventions":4475},[91],[21],[3583,914,3584,3594],{"nctId":3644,"briefTitle":3645,"status":242,"phases":4477,"primaryCompletion":3647,"completion":1415,"start":3648,"enrollment":3649,"conditions":4478,"interventions":4479},[91],[21],[3652,3522,3575,508],{"trials":4481,"activeCount":101},[],{"trials":4483,"activeCount":101},[],{"intervention":4485,"totalTrials":2546,"cells":4486},"rhuFab V2",{"EARLY_PHASE1":4487,"PHASE1":4489,"PHASE2":4491,"PHASE3":4502,"PHASE4":4542,"NA":4544},{"trials":4488,"activeCount":101},[],{"trials":4490,"activeCount":101},[],{"trials":4492,"activeCount":101},[4493],{"nctId":4494,"briefTitle":4495,"status":242,"phases":4496,"completion":1387,"start":4497,"enrollment":4498,"conditions":4499,"interventions":4501},"NCT00056823","Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)",[89,90],"2003-03",168,[4500],"Age-Related Maculopathy",[4485],{"trials":4503,"activeCount":101},[4504,4510,4518,4525,4534],{"nctId":4505,"briefTitle":4506,"status":242,"phases":4507,"completion":1387,"start":4497,"enrollment":707,"conditions":4508,"interventions":4509},"NCT00056836","A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration",[91],[3879],[4485],{"nctId":4511,"briefTitle":4512,"status":242,"phases":4513,"completion":1237,"start":4514,"enrollment":4515,"conditions":4516,"interventions":4517},"NCT00090623","A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)",[91],"2004-08",180,[3879],[4485],{"nctId":4519,"briefTitle":4520,"status":242,"phases":4521,"primaryCompletion":4522,"completion":4522,"start":3957,"enrollment":166,"conditions":4523,"interventions":4524},"NCT00095433","Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)",[91],"2006-08",[3879],[4485],{"nctId":4526,"briefTitle":4527,"status":242,"phases":4528,"completion":1262,"start":4529,"enrollment":4530,"conditions":4531,"interventions":4533},"NCT00251459","A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)",[91],"2005-11",5000,[4532,3889],"Choroidal Neovascularization",[4485],{"nctId":4535,"briefTitle":4536,"status":242,"phases":4537,"completion":4538,"start":1604,"enrollment":4539,"conditions":4540,"interventions":4541},"NCT00061594","A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration",[91],"2006-09",426,[3879],[4485],{"trials":4543,"activeCount":101},[],{"trials":4545,"activeCount":101},[],{"intervention":2592,"totalTrials":2546,"cells":4547},{"EARLY_PHASE1":4548,"PHASE1":4550,"PHASE2":4552,"PHASE3":4575,"PHASE4":4593,"NA":4595},{"trials":4549,"activeCount":101},[],{"trials":4551,"activeCount":101},[],{"trials":4553,"activeCount":101},[4554,4558,4571],{"nctId":2582,"briefTitle":2583,"status":242,"phases":4555,"primaryCompletion":2585,"completion":2585,"start":2586,"enrollment":418,"conditions":4556,"interventions":4557},[89,90],[732],[2545,2589,2036,2590,2591,2592,508],{"nctId":4559,"briefTitle":4560,"status":242,"phases":4561,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":4566,"interventions":4568},"NCT01485861","Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy",[89,90],"2015-09-01","2022-08-31","2012-01-11",298,[4567],"Prostate Cancer",[4569,4570,748,2592,2591],"Abiraterone","Apitolisib",{"nctId":2594,"briefTitle":2595,"status":242,"phases":4572,"primaryCompletion":2597,"completion":2598,"start":2599,"enrollment":166,"conditions":4573,"interventions":4574},[90],[2601],[2603,2604,2605,2606,2607],{"trials":4576,"activeCount":101},[4577,4585,4589],{"nctId":4578,"briefTitle":4445,"status":242,"phases":4579,"primaryCompletion":4580,"completion":4580,"start":4581,"enrollment":4582,"conditions":4583,"interventions":4584},"NCT00137969",[90,91],"2008-08-25","2005-05-10",262,[4451],[508,2592,4453,3708],{"nctId":4455,"briefTitle":4456,"status":325,"phases":4586,"primaryCompletion":4458,"completion":4458,"start":4459,"enrollment":4460,"conditions":4587,"interventions":4588},[91],[2568],[2592,4463,3575,2623],{"nctId":4465,"briefTitle":4466,"status":242,"phases":4590,"primaryCompletion":4022,"completion":2575,"start":1364,"enrollment":4468,"conditions":4591,"interventions":4592},[91],[2619],[508,4471,3575,3708,4453,2592],{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"intervention":4598,"totalTrials":233,"cells":4599},"tenecteplase",{"EARLY_PHASE1":4600,"PHASE1":4602,"PHASE2":4604,"PHASE3":4606,"PHASE4":4650,"NA":4652},{"trials":4601,"activeCount":101},[],{"trials":4603,"activeCount":101},[],{"trials":4605,"activeCount":101},[],{"trials":4607,"activeCount":101},[4608,4618,4626,4635,4645],{"nctId":4609,"briefTitle":4610,"status":242,"phases":4611,"primaryCompletion":4612,"start":4613,"enrollment":4614,"conditions":4615,"interventions":4617},"NCT00396032","A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters",[91],"2008-12","2006-10",150,[4616],"Dysfunctional Hemodialysis Catheters",[4598],{"nctId":4619,"briefTitle":4620,"status":242,"phases":4621,"primaryCompletion":3647,"start":4400,"enrollment":4622,"conditions":4623,"interventions":4625},"NCT00396318","A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters",[91],251,[4624],"Dysfunctional Central Venous Access Catheters",[4598],{"nctId":4627,"briefTitle":4628,"status":242,"phases":4629,"primaryCompletion":4630,"completion":4630,"start":3686,"enrollment":4631,"conditions":4632,"interventions":4633},"NCT00396253","A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters",[91],"2008-10",223,[4616],[4634],"Tenecteplase",{"nctId":4636,"briefTitle":4637,"status":242,"phases":4638,"primaryCompletion":4639,"completion":4639,"start":4640,"enrollment":4641,"conditions":4642,"interventions":4644},"NCT03785678","Tenecteplase in Stroke Patients Between 4.5 and 24 Hours",[91],"2023-02-28","2019-03-02",458,[4643],"THROMBOLYSIS",[4634],{"nctId":4646,"briefTitle":4620,"status":242,"phases":4647,"primaryCompletion":3647,"start":3686,"enrollment":166,"conditions":4648,"interventions":4649},"NCT00395876",[91],[4624],[4598],{"trials":4651,"activeCount":101},[],{"trials":4653,"activeCount":101},[],{"intervention":3708,"totalTrials":233,"cells":4655},{"EARLY_PHASE1":4656,"PHASE1":4658,"PHASE2":4660,"PHASE3":4666,"PHASE4":4684,"NA":4686},{"trials":4657,"activeCount":101},[],{"trials":4659,"activeCount":101},[],{"trials":4661,"activeCount":101},[4662],{"nctId":3701,"briefTitle":3702,"status":242,"phases":4663,"primaryCompletion":1088,"completion":1088,"start":1373,"enrollment":811,"conditions":4664,"interventions":4665},[90],[3705],[3691,3707,3708],{"trials":4667,"activeCount":101},[4668,4672,4676,4680],{"nctId":3712,"briefTitle":3713,"status":242,"phases":4669,"primaryCompletion":3715,"completion":3715,"start":1461,"enrollment":3716,"conditions":4670,"interventions":4671},[91],[3705],[3673,3719,3708],{"nctId":4578,"briefTitle":4445,"status":242,"phases":4673,"primaryCompletion":4580,"completion":4580,"start":4581,"enrollment":4582,"conditions":4674,"interventions":4675},[90,91],[4451],[508,2592,4453,3708],{"nctId":4444,"briefTitle":4445,"status":325,"phases":4677,"primaryCompletion":4447,"completion":4448,"start":4449,"enrollment":1901,"conditions":4678,"interventions":4679},[91],[4451],[508,3575,4453,3708],{"nctId":4465,"briefTitle":4466,"status":242,"phases":4681,"primaryCompletion":4022,"completion":2575,"start":1364,"enrollment":4468,"conditions":4682,"interventions":4683},[91],[2619],[508,4471,3575,3708,4453,2592],{"trials":4685,"activeCount":101},[],{"trials":4687,"activeCount":101},[],{"intervention":2048,"totalTrials":233,"cells":4689},{"EARLY_PHASE1":4690,"PHASE1":4692,"PHASE2":4702,"PHASE3":4716,"PHASE4":4722,"NA":4724},{"trials":4691,"activeCount":101},[],{"trials":4693,"activeCount":101},[4694,4698],{"nctId":2038,"briefTitle":2039,"status":242,"phases":4695,"primaryCompletion":2041,"completion":2042,"start":2043,"enrollment":2044,"conditions":4696,"interventions":4697},[89],[2046],[2048,2036,508,71],{"nctId":2572,"briefTitle":2573,"status":242,"phases":4699,"primaryCompletion":2575,"completion":947,"start":2576,"enrollment":500,"conditions":4700,"interventions":4701},[89],[731],[2561,2036,2048,2545],{"trials":4703,"activeCount":101},[4704,4712],{"nctId":4705,"briefTitle":4706,"status":826,"phases":4707,"primaryCompletion":1290,"completion":1290,"start":342,"enrollment":101,"conditions":4708,"interventions":4709},"NCT01423539","A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)",[90],[4314],[4710,4711,3594],"bendamustine","navitoclax",{"nctId":4337,"briefTitle":4338,"status":242,"phases":4713,"primaryCompletion":4340,"completion":4341,"start":4342,"enrollment":640,"conditions":4714,"interventions":4715},[90],[2046],[2048,2036],{"trials":4717,"activeCount":101},[4718],{"nctId":4348,"briefTitle":4349,"status":242,"phases":4719,"primaryCompletion":4351,"completion":4352,"start":4353,"enrollment":4354,"conditions":4720,"interventions":4721},[91],[331],[2036,2048],{"trials":4723,"activeCount":101},[],{"trials":4725,"activeCount":101},[],{"intervention":561,"totalTrials":233,"cells":4727},{"EARLY_PHASE1":4728,"PHASE1":4730,"PHASE2":4748,"PHASE3":4750,"PHASE4":4756,"NA":4758},{"trials":4729,"activeCount":101},[],{"trials":4731,"activeCount":101},[4732,4736,4740,4744],{"nctId":552,"briefTitle":553,"status":242,"phases":4733,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":4734,"interventions":4735},[89],[559],[487,506,521,561,526,525,562,563,520,564],{"nctId":1043,"briefTitle":1044,"status":242,"phases":4737,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":4738,"interventions":4739},[89],[1050],[346,1027,960,1052,998,1053],{"nctId":1736,"briefTitle":1737,"status":242,"phases":4741,"primaryCompletion":1739,"completion":1739,"start":1740,"enrollment":488,"conditions":4742,"interventions":4743},[89],[670],[519,521,561,1525,525],{"nctId":1175,"briefTitle":1176,"status":242,"phases":4745,"primaryCompletion":1069,"completion":1069,"start":1178,"enrollment":246,"conditions":4746,"interventions":4747},[89],[24],[347,1027,960,1052,998,1053],{"trials":4749,"activeCount":101},[],{"trials":4751,"activeCount":101},[4752],{"nctId":1402,"briefTitle":1403,"status":242,"phases":4753,"primaryCompletion":1207,"completion":1405,"start":1262,"enrollment":1406,"conditions":4754,"interventions":4755},[91],[1408],[520,563,561,1410],{"trials":4757,"activeCount":101},[],{"trials":4759,"activeCount":101},[],{"intervention":1221,"totalTrials":233,"cells":4761},{"EARLY_PHASE1":4762,"PHASE1":4764,"PHASE2":4766,"PHASE3":4784,"PHASE4":4790,"NA":4792},{"trials":4763,"activeCount":101},[],{"trials":4765,"activeCount":101},[],{"trials":4767,"activeCount":101},[4768,4772,4776,4780],{"nctId":1213,"briefTitle":1214,"status":242,"phases":4769,"primaryCompletion":1216,"completion":417,"start":1217,"enrollment":1218,"conditions":4770,"interventions":4771},[90],[29],[1221,520,1222,522,524,563],{"nctId":1287,"briefTitle":1288,"status":242,"phases":4773,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":4774,"interventions":4775},[90],[1133],[1221,520,1295,1154,524],{"nctId":2901,"briefTitle":2902,"status":242,"phases":4777,"primaryCompletion":2904,"completion":2905,"start":2906,"enrollment":719,"conditions":4778,"interventions":4779},[90],[602],[1221,748,522,524],{"nctId":2951,"briefTitle":2952,"status":242,"phases":4781,"primaryCompletion":1363,"completion":1363,"start":2954,"enrollment":760,"conditions":4782,"interventions":4783},[90],[29],[1410,575,1222,522,1525],{"trials":4785,"activeCount":101},[4786],{"nctId":1402,"briefTitle":1403,"status":242,"phases":4787,"primaryCompletion":1207,"completion":1405,"start":1262,"enrollment":1406,"conditions":4788,"interventions":4789},[91],[1408],[520,563,561,1410],{"trials":4791,"activeCount":101},[],{"trials":4793,"activeCount":101},[],{"intervention":3595,"totalTrials":233,"cells":4795},{"EARLY_PHASE1":4796,"PHASE1":4798,"PHASE2":4800,"PHASE3":4810,"PHASE4":4824,"NA":4826},{"trials":4797,"activeCount":101},[],{"trials":4799,"activeCount":101},[],{"trials":4801,"activeCount":101},[4802,4806],{"nctId":3586,"briefTitle":3587,"status":242,"phases":4803,"primaryCompletion":3589,"completion":1169,"start":3590,"enrollment":3591,"conditions":4804,"interventions":4805},[90],[21],[914,3594,3595],{"nctId":4329,"briefTitle":4330,"status":242,"phases":4807,"primaryCompletion":4332,"completion":4333,"start":1900,"enrollment":1651,"conditions":4808,"interventions":4809},[90],[731],[2036,2621],{"trials":4811,"activeCount":101},[4812,4816,4820],{"nctId":3735,"briefTitle":3736,"status":242,"phases":4813,"primaryCompletion":1207,"completion":1207,"start":1387,"enrollment":3738,"conditions":4814,"interventions":4815},[91],[31],[3691,3595,3741],{"nctId":3999,"briefTitle":4000,"status":826,"phases":4817,"enrollment":101,"conditions":4818,"interventions":4819},[90,91],[4003],[4005,3980,4006,3595,4007],{"nctId":2611,"briefTitle":2612,"status":325,"phases":4821,"primaryCompletion":2614,"completion":2615,"start":2616,"enrollment":2617,"conditions":4822,"interventions":4823},[91],[2619,2568],[2621,2545,2622,2623,2624],{"trials":4825,"activeCount":101},[],{"trials":4827,"activeCount":101},[],{"intervention":3807,"totalTrials":793,"cells":4829},{"EARLY_PHASE1":4830,"PHASE1":4832,"PHASE2":4834,"PHASE3":4844,"PHASE4":4861,"NA":4863},{"trials":4831,"activeCount":101},[],{"trials":4833,"activeCount":101},[],{"trials":4835,"activeCount":101},[4836,4840],{"nctId":3800,"briefTitle":3801,"status":242,"phases":4837,"completion":3686,"start":1603,"enrollment":1641,"conditions":4838,"interventions":4839},[90],[3804,3805],[3790,3807],{"nctId":3809,"briefTitle":3810,"status":242,"phases":4841,"completion":3812,"start":3813,"enrollment":166,"conditions":4842,"interventions":4843},[90],[420,3815],[3790,3807],{"trials":4845,"activeCount":101},[4846,4854],{"nctId":4847,"briefTitle":4848,"status":242,"phases":4849,"completion":1587,"start":4850,"conditions":4851,"interventions":4853},"NCT00047736","A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer",[91],"2001-07",[4852],"Lung Cancer",[3807],{"nctId":4855,"briefTitle":4856,"status":242,"phases":4857,"completion":3580,"start":4514,"enrollment":4530,"conditions":4858,"interventions":4860},"NCT00091663","A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",[91],[4852,4859],"Non-small-cell Lung Carcinoma",[3807],{"trials":4862,"activeCount":101},[],{"trials":4864,"activeCount":101},[],{"intervention":3583,"totalTrials":793,"cells":4866},{"EARLY_PHASE1":4867,"PHASE1":4869,"PHASE2":4871,"PHASE3":4877,"PHASE4":4891,"NA":4893},{"trials":4868,"activeCount":101},[],{"trials":4870,"activeCount":101},[],{"trials":4872,"activeCount":101},[4873],{"nctId":3577,"briefTitle":3578,"status":242,"phases":4874,"primaryCompletion":1271,"completion":1271,"start":3580,"enrollment":1100,"conditions":4875,"interventions":4876},[90],[21],[3583,914,3584,508],{"trials":4878,"activeCount":101},[4879,4883,4887],{"nctId":3618,"briefTitle":3619,"status":242,"phases":4880,"primaryCompletion":1118,"start":1364,"enrollment":3621,"conditions":4881,"interventions":4882},[91],[21],[3594,914,3583],{"nctId":3625,"briefTitle":3626,"status":242,"phases":4884,"primaryCompletion":3628,"completion":1415,"start":1364,"enrollment":3629,"conditions":4885,"interventions":4886},[91],[21],[3583,914,3584,3594],{"nctId":3644,"briefTitle":3645,"status":242,"phases":4888,"primaryCompletion":3647,"completion":1415,"start":3648,"enrollment":3649,"conditions":4889,"interventions":4890},[91],[21],[3652,3522,3575,508],{"trials":4892,"activeCount":101},[],{"trials":4894,"activeCount":101},[],{"intervention":3907,"totalTrials":793,"cells":4896},{"EARLY_PHASE1":4897,"PHASE1":4899,"PHASE2":4901,"PHASE3":4903,"PHASE4":4932,"NA":4934},{"trials":4898,"activeCount":101},[],{"trials":4900,"activeCount":101},[],{"trials":4902,"activeCount":101},[],{"trials":4904,"activeCount":101},[4905,4916,4920,4924],{"nctId":4906,"briefTitle":4907,"status":242,"phases":4908,"primaryCompletion":1130,"completion":1207,"start":4909,"enrollment":4910,"conditions":4911,"interventions":4913},"NCT00486018","A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)",[91],"2007-07",397,[3898,4912],"Retinal Vein Occlusion",[4914,4915,3907],"Ranibizumab injection 0.3 mg","Ranibizumab injection 0.5 mg",{"nctId":3901,"briefTitle":3902,"status":242,"phases":4917,"primaryCompletion":3559,"completion":3715,"start":1208,"enrollment":888,"conditions":4918,"interventions":4919},[91],[3905,3898],[3862,3907],{"nctId":3909,"briefTitle":3910,"status":242,"phases":4921,"primaryCompletion":1462,"completion":1374,"start":1208,"enrollment":3912,"conditions":4922,"interventions":4923},[91],[3905,3898],[3862,3907],{"nctId":4925,"briefTitle":4926,"status":242,"phases":4927,"primaryCompletion":1272,"completion":4928,"start":4909,"enrollment":4929,"conditions":4930,"interventions":4931},"NCT00485836","A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)",[91],"2009-12",392,[3898,4912],[3907,4914,4915],{"trials":4933,"activeCount":101},[],{"trials":4935,"activeCount":101},[],{"intervention":4937,"totalTrials":97,"cells":4938},"rhuMAb VEGF",{"EARLY_PHASE1":4939,"PHASE1":4941,"PHASE2":4952,"PHASE3":4954,"PHASE4":4970,"NA":4972},{"trials":4940,"activeCount":101},[],{"trials":4942,"activeCount":101},[4943],{"nctId":4944,"briefTitle":4945,"status":242,"phases":4946,"primaryCompletion":4947,"completion":4947,"start":4948,"enrollment":3533,"conditions":4949,"interventions":4951},"NCT00069446","A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers",[89],"2004-10","2003-08",[4950],"Foot Ulcer",[4937],{"trials":4953,"activeCount":101},[],{"trials":4955,"activeCount":101},[4956,4963],{"nctId":4957,"briefTitle":4958,"status":242,"phases":4959,"completion":3957,"start":4960,"conditions":4961,"interventions":4962},"NCT00109239","A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer",[91],"2000-11",[18],[4937],{"nctId":4964,"briefTitle":4965,"status":826,"phases":4966,"enrollment":101,"conditions":4967,"interventions":4969},"NCT00061178","Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma",[91],[4968],"Renal Cell Cancer",[4937],{"trials":4971,"activeCount":101},[],{"trials":4973,"activeCount":101},[],{"intervention":4453,"totalTrials":97,"cells":4975},{"EARLY_PHASE1":4976,"PHASE1":4978,"PHASE2":4980,"PHASE3":4982,"PHASE4":4996,"NA":4998},{"trials":4977,"activeCount":101},[],{"trials":4979,"activeCount":101},[],{"trials":4981,"activeCount":101},[],{"trials":4983,"activeCount":101},[4984,4988,4992],{"nctId":4578,"briefTitle":4445,"status":242,"phases":4985,"primaryCompletion":4580,"completion":4580,"start":4581,"enrollment":4582,"conditions":4986,"interventions":4987},[90,91],[4451],[508,2592,4453,3708],{"nctId":4444,"briefTitle":4445,"status":325,"phases":4989,"primaryCompletion":4447,"completion":4448,"start":4449,"enrollment":1901,"conditions":4990,"interventions":4991},[91],[4451],[508,3575,4453,3708],{"nctId":4465,"briefTitle":4466,"status":242,"phases":4993,"primaryCompletion":4022,"completion":2575,"start":1364,"enrollment":4468,"conditions":4994,"interventions":4995},[91],[2619],[508,4471,3575,3708,4453,2592],{"trials":4997,"activeCount":101},[],{"trials":4999,"activeCount":101},[],{"intervention":1200,"totalTrials":97,"cells":5001},{"EARLY_PHASE1":5002,"PHASE1":5004,"PHASE2":5006,"PHASE3":5016,"PHASE4":5022,"NA":5024},{"trials":5003,"activeCount":101},[],{"trials":5005,"activeCount":101},[],{"trials":5007,"activeCount":101},[5008,5012],{"nctId":1192,"briefTitle":1193,"status":242,"phases":5009,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":5010,"interventions":5011},[90],[18],[1200,520,525,1201,1202],{"nctId":1854,"briefTitle":1855,"status":242,"phases":5013,"primaryCompletion":937,"completion":1857,"start":1515,"enrollment":1858,"conditions":5014,"interventions":5015},[90],[1050],[1802,1861,998],{"trials":5017,"activeCount":101},[5018],{"nctId":2782,"briefTitle":2783,"status":242,"phases":5019,"primaryCompletion":1522,"completion":1522,"start":2785,"enrollment":2786,"conditions":5020,"interventions":5021},[91],[1050],[576,1200],{"trials":5023,"activeCount":101},[],{"trials":5025,"activeCount":101},[],{"intervention":4471,"totalTrials":97,"cells":5027},{"EARLY_PHASE1":5028,"PHASE1":5030,"PHASE2":5032,"PHASE3":5034,"PHASE4":5048,"NA":5050},{"trials":5029,"activeCount":101},[],{"trials":5031,"activeCount":101},[],{"trials":5033,"activeCount":101},[],{"trials":5035,"activeCount":101},[5036,5040,5044],{"nctId":4465,"briefTitle":4466,"status":242,"phases":5037,"primaryCompletion":4022,"completion":2575,"start":1364,"enrollment":4468,"conditions":5038,"interventions":5039},[91],[2619],[508,4471,3575,3708,4453,2592],{"nctId":3999,"briefTitle":4000,"status":826,"phases":5041,"enrollment":101,"conditions":5042,"interventions":5043},[90,91],[4003],[4005,3980,4006,3595,4007],{"nctId":2611,"briefTitle":2612,"status":325,"phases":5045,"primaryCompletion":2614,"completion":2615,"start":2616,"enrollment":2617,"conditions":5046,"interventions":5047},[91],[2619,2568],[2621,2545,2622,2623,2624],{"trials":5049,"activeCount":101},[],{"trials":5051,"activeCount":101},[],{"intervention":3565,"totalTrials":200,"cells":5053},{"EARLY_PHASE1":5054,"PHASE1":5056,"PHASE2":5058,"PHASE3":5064,"PHASE4":5070,"NA":5072},{"trials":5055,"activeCount":101},[],{"trials":5057,"activeCount":101},[],{"trials":5059,"activeCount":101},[5060],{"nctId":3556,"briefTitle":3557,"status":242,"phases":5061,"primaryCompletion":1159,"start":3559,"enrollment":3560,"conditions":5062,"interventions":5063},[90],[21],[3563,3564,3565,914],{"trials":5065,"activeCount":101},[5066],{"nctId":3633,"briefTitle":3634,"status":325,"phases":5067,"primaryCompletion":3636,"completion":3637,"start":3638,"enrollment":3639,"conditions":5068,"interventions":5069},[91],[21],[3642,3522,2623,2623],{"trials":5071,"activeCount":101},[],{"trials":5073,"activeCount":101},[],{"intervention":4914,"totalTrials":200,"cells":5075},{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5080,"PHASE3":5082,"PHASE4":5092,"NA":5094},{"trials":5077,"activeCount":101},[],{"trials":5079,"activeCount":101},[],{"trials":5081,"activeCount":101},[],{"trials":5083,"activeCount":101},[5084,5088],{"nctId":4906,"briefTitle":4907,"status":242,"phases":5085,"primaryCompletion":1130,"completion":1207,"start":4909,"enrollment":4910,"conditions":5086,"interventions":5087},[91],[3898,4912],[4914,4915,3907],{"nctId":4925,"briefTitle":4926,"status":242,"phases":5089,"primaryCompletion":1272,"completion":4928,"start":4909,"enrollment":4929,"conditions":5090,"interventions":5091},[91],[3898,4912],[3907,4914,4915],{"trials":5093,"activeCount":101},[],{"trials":5095,"activeCount":101},[],{"intervention":4915,"totalTrials":200,"cells":5097},{"EARLY_PHASE1":5098,"PHASE1":5100,"PHASE2":5102,"PHASE3":5104,"PHASE4":5114,"NA":5116},{"trials":5099,"activeCount":101},[],{"trials":5101,"activeCount":101},[],{"trials":5103,"activeCount":101},[],{"trials":5105,"activeCount":101},[5106,5110],{"nctId":4906,"briefTitle":4907,"status":242,"phases":5107,"primaryCompletion":1130,"completion":1207,"start":4909,"enrollment":4910,"conditions":5108,"interventions":5109},[91],[3898,4912],[4914,4915,3907],{"nctId":4925,"briefTitle":4926,"status":242,"phases":5111,"primaryCompletion":1272,"completion":4928,"start":4909,"enrollment":4929,"conditions":5112,"interventions":5113},[91],[3898,4912],[3907,4914,4915],{"trials":5115,"activeCount":101},[],{"trials":5117,"activeCount":101},[],{"intervention":5119,"totalTrials":116,"cells":5120},"Anti-inflammatory drugs",{"EARLY_PHASE1":5121,"PHASE1":5123,"PHASE2":5125,"PHASE3":5127,"PHASE4":5137,"NA":5139},{"trials":5122,"activeCount":101},[],{"trials":5124,"activeCount":101},[],{"trials":5126,"activeCount":101},[],{"trials":5128,"activeCount":101},[5129],{"nctId":5130,"briefTitle":5131,"status":242,"phases":5132,"primaryCompletion":2576,"completion":956,"start":5133,"enrollment":5134,"conditions":5135,"interventions":5136},"NCT00443651","A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis",[91],"2007-01",578,[21],[508,5119],{"trials":5138,"activeCount":101},[],{"trials":5140,"activeCount":101},[],{"intervention":3719,"totalTrials":116,"cells":5142},{"EARLY_PHASE1":5143,"PHASE1":5145,"PHASE2":5147,"PHASE3":5149,"PHASE4":5155,"NA":5157},{"trials":5144,"activeCount":101},[],{"trials":5146,"activeCount":101},[],{"trials":5148,"activeCount":101},[],{"trials":5150,"activeCount":101},[5151],{"nctId":3712,"briefTitle":3713,"status":242,"phases":5152,"primaryCompletion":3715,"completion":3715,"start":1461,"enrollment":3716,"conditions":5153,"interventions":5154},[91],[3705],[3673,3719,3708],{"trials":5156,"activeCount":101},[],{"trials":5158,"activeCount":101},[],{"intervention":5160,"totalTrials":116,"cells":5161},"Ocrelizumab Dose 1",{"EARLY_PHASE1":5162,"PHASE1":5164,"PHASE2":5166,"PHASE3":5168,"PHASE4":5180,"NA":5182},{"trials":5163,"activeCount":101},[],{"trials":5165,"activeCount":101},[],{"trials":5167,"activeCount":101},[],{"trials":5169,"activeCount":101},[5170],{"nctId":5171,"briefTitle":5172,"status":242,"phases":5173,"primaryCompletion":5174,"completion":5174,"start":5175,"enrollment":5176,"conditions":5177,"interventions":5178},"NCT03606460","A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)",[91],"2019-05-31","2018-09-14",141,[168],[5160,5179],"Ocrelizumab Dose 2 and Dose 3",{"trials":5181,"activeCount":101},[],{"trials":5183,"activeCount":101},[],{"intervention":5179,"totalTrials":116,"cells":5185},{"EARLY_PHASE1":5186,"PHASE1":5188,"PHASE2":5190,"PHASE3":5192,"PHASE4":5198,"NA":5200},{"trials":5187,"activeCount":101},[],{"trials":5189,"activeCount":101},[],{"trials":5191,"activeCount":101},[],{"trials":5193,"activeCount":101},[5194],{"nctId":5171,"briefTitle":5172,"status":242,"phases":5195,"primaryCompletion":5174,"completion":5174,"start":5175,"enrollment":5176,"conditions":5196,"interventions":5197},[91],[168],[5160,5179],{"trials":5199,"activeCount":101},[],{"trials":5201,"activeCount":101},[],{"intervention":1379,"totalTrials":116,"cells":5203},{"EARLY_PHASE1":5204,"PHASE1":5206,"PHASE2":5208,"PHASE3":5210,"PHASE4":5216,"NA":5218},{"trials":5205,"activeCount":101},[],{"trials":5207,"activeCount":101},[],{"trials":5209,"activeCount":101},[],{"trials":5211,"activeCount":101},[5212],{"nctId":1370,"briefTitle":1371,"status":242,"phases":5213,"primaryCompletion":1373,"completion":1374,"start":1375,"enrollment":1376,"conditions":5214,"interventions":5215},[91],[940],[520,1379],{"trials":5217,"activeCount":101},[],{"trials":5219,"activeCount":101},[],{"intervention":5221,"totalTrials":116,"cells":5222},"Methyloprednisolone",{"EARLY_PHASE1":5223,"PHASE1":5225,"PHASE2":5227,"PHASE3":5229,"PHASE4":5242,"NA":5244},{"trials":5224,"activeCount":101},[],{"trials":5226,"activeCount":101},[],{"trials":5228,"activeCount":101},[],{"trials":5230,"activeCount":101},[5231],{"nctId":5232,"briefTitle":5233,"status":242,"phases":5234,"primaryCompletion":5235,"completion":5235,"start":5236,"enrollment":1571,"conditions":5237,"interventions":5240},"NCT02688985","Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)",[91],"2023-04-11","2016-04-29",[5238,5239],"Relapsing Multiple Sclerorsis","Multiple Sclerosis, Primary Progressive",[2623,5221,5241],"Antihistamine",{"trials":5243,"activeCount":101},[],{"trials":5245,"activeCount":101},[],{"intervention":5241,"totalTrials":116,"cells":5247},{"EARLY_PHASE1":5248,"PHASE1":5250,"PHASE2":5252,"PHASE3":5254,"PHASE4":5260,"NA":5262},{"trials":5249,"activeCount":101},[],{"trials":5251,"activeCount":101},[],{"trials":5253,"activeCount":101},[],{"trials":5255,"activeCount":101},[5256],{"nctId":5232,"briefTitle":5233,"status":242,"phases":5257,"primaryCompletion":5235,"completion":5235,"start":5236,"enrollment":1571,"conditions":5258,"interventions":5259},[91],[5238,5239],[2623,5221,5241],{"trials":5261,"activeCount":101},[],{"trials":5263,"activeCount":101},[],{"intervention":3741,"totalTrials":116,"cells":5265},{"EARLY_PHASE1":5266,"PHASE1":5268,"PHASE2":5270,"PHASE3":5272,"PHASE4":5278,"NA":5280},{"trials":5267,"activeCount":101},[],{"trials":5269,"activeCount":101},[],{"trials":5271,"activeCount":101},[],{"trials":5273,"activeCount":101},[5274],{"nctId":3735,"briefTitle":3736,"status":242,"phases":5275,"primaryCompletion":1207,"completion":1207,"start":1387,"enrollment":3738,"conditions":5276,"interventions":5277},[91],[31],[3691,3595,3741],{"trials":5279,"activeCount":101},[],{"trials":5281,"activeCount":101},[],{"intervention":4463,"totalTrials":116,"cells":5283},{"EARLY_PHASE1":5284,"PHASE1":5286,"PHASE2":5288,"PHASE3":5290,"PHASE4":5296,"NA":5298},{"trials":5285,"activeCount":101},[],{"trials":5287,"activeCount":101},[],{"trials":5289,"activeCount":101},[],{"trials":5291,"activeCount":101},[5292],{"nctId":4455,"briefTitle":4456,"status":325,"phases":5293,"primaryCompletion":4458,"completion":4458,"start":4459,"enrollment":4460,"conditions":5294,"interventions":5295},[91],[2568],[2592,4463,3575,2623],{"trials":5297,"activeCount":101},[],{"trials":5299,"activeCount":101},[],{"intervention":5301,"totalTrials":116,"cells":5302},"Alteplase",{"EARLY_PHASE1":5303,"PHASE1":5305,"PHASE2":5307,"PHASE3":5309,"PHASE4":5324,"NA":5326},{"trials":5304,"activeCount":101},[],{"trials":5306,"activeCount":101},[],{"trials":5308,"activeCount":101},[],{"trials":5310,"activeCount":101},[5311],{"nctId":5312,"briefTitle":5313,"status":325,"phases":5314,"primaryCompletion":5315,"completion":5315,"start":5316,"enrollment":5317,"conditions":5318,"interventions":5320},"NCT02072226","A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke",[91],"2017-03-22","2014-05-31",313,[5319],"Stroke",[5301,5321,5322,5323],"Alteplase Placebo","Aspirin","Aspirin Placebo",{"trials":5325,"activeCount":101},[],{"trials":5327,"activeCount":101},[],{"intervention":5321,"totalTrials":116,"cells":5329},{"EARLY_PHASE1":5330,"PHASE1":5332,"PHASE2":5334,"PHASE3":5336,"PHASE4":5342,"NA":5344},{"trials":5331,"activeCount":101},[],{"trials":5333,"activeCount":101},[],{"trials":5335,"activeCount":101},[],{"trials":5337,"activeCount":101},[5338],{"nctId":5312,"briefTitle":5313,"status":325,"phases":5339,"primaryCompletion":5315,"completion":5315,"start":5316,"enrollment":5317,"conditions":5340,"interventions":5341},[91],[5319],[5301,5321,5322,5323],{"trials":5343,"activeCount":101},[],{"trials":5345,"activeCount":101},[],{"intervention":5322,"totalTrials":116,"cells":5347},{"EARLY_PHASE1":5348,"PHASE1":5350,"PHASE2":5352,"PHASE3":5354,"PHASE4":5360,"NA":5362},{"trials":5349,"activeCount":101},[],{"trials":5351,"activeCount":101},[],{"trials":5353,"activeCount":101},[],{"trials":5355,"activeCount":101},[5356],{"nctId":5312,"briefTitle":5313,"status":325,"phases":5357,"primaryCompletion":5315,"completion":5315,"start":5316,"enrollment":5317,"conditions":5358,"interventions":5359},[91],[5319],[5301,5321,5322,5323],{"trials":5361,"activeCount":101},[],{"trials":5363,"activeCount":101},[],{"intervention":5323,"totalTrials":116,"cells":5365},{"EARLY_PHASE1":5366,"PHASE1":5368,"PHASE2":5370,"PHASE3":5372,"PHASE4":5378,"NA":5380},{"trials":5367,"activeCount":101},[],{"trials":5369,"activeCount":101},[],{"trials":5371,"activeCount":101},[],{"trials":5373,"activeCount":101},[5374],{"nctId":5312,"briefTitle":5313,"status":325,"phases":5375,"primaryCompletion":5315,"completion":5315,"start":5316,"enrollment":5317,"conditions":5376,"interventions":5377},[91],[5319],[5301,5321,5322,5323],{"trials":5379,"activeCount":101},[],{"trials":5381,"activeCount":101},[],{"intervention":4005,"totalTrials":116,"cells":5383},{"EARLY_PHASE1":5384,"PHASE1":5386,"PHASE2":5388,"PHASE3":5390,"PHASE4":5396,"NA":5398},{"trials":5385,"activeCount":101},[],{"trials":5387,"activeCount":101},[],{"trials":5389,"activeCount":101},[],{"trials":5391,"activeCount":101},[5392],{"nctId":3999,"briefTitle":4000,"status":826,"phases":5393,"enrollment":101,"conditions":5394,"interventions":5395},[90,91],[4003],[4005,3980,4006,3595,4007],{"trials":5397,"activeCount":101},[],{"trials":5399,"activeCount":101},[],{"intervention":4007,"totalTrials":116,"cells":5401},{"EARLY_PHASE1":5402,"PHASE1":5404,"PHASE2":5406,"PHASE3":5408,"PHASE4":5414,"NA":5416},{"trials":5403,"activeCount":101},[],{"trials":5405,"activeCount":101},[],{"trials":5407,"activeCount":101},[],{"trials":5409,"activeCount":101},[5410],{"nctId":3999,"briefTitle":4000,"status":826,"phases":5411,"enrollment":101,"conditions":5412,"interventions":5413},[90,91],[4003],[4005,3980,4006,3595,4007],{"trials":5415,"activeCount":101},[],{"trials":5417,"activeCount":101},[],{"intervention":2624,"totalTrials":116,"cells":5419},{"EARLY_PHASE1":5420,"PHASE1":5422,"PHASE2":5424,"PHASE3":5426,"PHASE4":5432,"NA":5434},{"trials":5421,"activeCount":101},[],{"trials":5423,"activeCount":101},[],{"trials":5425,"activeCount":101},[],{"trials":5427,"activeCount":101},[5428],{"nctId":2611,"briefTitle":2612,"status":325,"phases":5429,"primaryCompletion":2614,"completion":2615,"start":2616,"enrollment":2617,"conditions":5430,"interventions":5431},[91],[2619,2568],[2621,2545,2622,2623,2624],{"trials":5433,"activeCount":101},[],{"trials":5435,"activeCount":101},[],{"intervention":5437,"totalTrials":116,"cells":5438},"CHOP",{"EARLY_PHASE1":5439,"PHASE1":5441,"PHASE2":5443,"PHASE3":5445,"PHASE4":5456,"NA":5458},{"trials":5440,"activeCount":101},[],{"trials":5442,"activeCount":101},[],{"trials":5444,"activeCount":101},[],{"trials":5446,"activeCount":101},[5447],{"nctId":5448,"briefTitle":5449,"status":242,"phases":5450,"primaryCompletion":2576,"completion":2576,"start":1385,"enrollment":5451,"conditions":5452,"interventions":5453},"NCT00719472","A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)",[91],451,[331],[508,5437,5454,5455],"CVP","Analgesic\u002Fantipyretic and antihistamine drugs",{"trials":5457,"activeCount":101},[],{"trials":5459,"activeCount":101},[],{"intervention":5454,"totalTrials":116,"cells":5461},{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5466,"PHASE3":5468,"PHASE4":5474,"NA":5476},{"trials":5463,"activeCount":101},[],{"trials":5465,"activeCount":101},[],{"trials":5467,"activeCount":101},[],{"trials":5469,"activeCount":101},[5470],{"nctId":5448,"briefTitle":5449,"status":242,"phases":5471,"primaryCompletion":2576,"completion":2576,"start":1385,"enrollment":5451,"conditions":5472,"interventions":5473},[91],[331],[508,5437,5454,5455],{"trials":5475,"activeCount":101},[],{"trials":5477,"activeCount":101},[],{"intervention":5455,"totalTrials":116,"cells":5479},{"EARLY_PHASE1":5480,"PHASE1":5482,"PHASE2":5484,"PHASE3":5486,"PHASE4":5492,"NA":5494},{"trials":5481,"activeCount":101},[],{"trials":5483,"activeCount":101},[],{"trials":5485,"activeCount":101},[],{"trials":5487,"activeCount":101},[5488],{"nctId":5448,"briefTitle":5449,"status":242,"phases":5489,"primaryCompletion":2576,"completion":2576,"start":1385,"enrollment":5451,"conditions":5490,"interventions":5491},[91],[331],[508,5437,5454,5455],{"trials":5493,"activeCount":101},[],{"trials":5495,"activeCount":101},[],{"intervention":346,"totalTrials":3687,"cells":5497},{"EARLY_PHASE1":5498,"PHASE1":5500,"PHASE2":5556,"PHASE3":5566,"PHASE4":5568,"NA":5570},{"trials":5499,"activeCount":101},[],{"trials":5501,"activeCount":101},[5502,5510,5516,5522,5526,5534,5538,5542,5550],{"nctId":5503,"briefTitle":5504,"status":242,"phases":5505,"primaryCompletion":908,"completion":1159,"start":5506,"enrollment":2231,"conditions":5507,"interventions":5509},"NCT00876122","A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable",[89],"2008-03",[5508],"Non-Hodgkin's Lymphoma, Solid Cancers",[346],{"nctId":5511,"briefTitle":5512,"status":242,"phases":5513,"primaryCompletion":1483,"completion":1483,"start":896,"enrollment":488,"conditions":5514,"interventions":5515},"NCT02092831","A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers",[89],[15],[346,346,346,346],{"nctId":5517,"briefTitle":5518,"status":242,"phases":5519,"primaryCompletion":342,"completion":342,"start":342,"enrollment":233,"conditions":5520,"interventions":5521},"NCT01474668","Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects",[89],[15],[346],{"nctId":1043,"briefTitle":1044,"status":242,"phases":5523,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":5524,"interventions":5525},[89],[1050],[346,1027,960,1052,998,1053],{"nctId":5527,"briefTitle":5528,"status":242,"phases":5529,"primaryCompletion":1160,"completion":1160,"start":3559,"enrollment":5530,"conditions":5531,"interventions":5532},"NCT01240226","A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet",[89],22,[15],[346,346,5533],"ketoconazole",{"nctId":934,"briefTitle":935,"status":242,"phases":5535,"primaryCompletion":937,"completion":937,"start":938,"enrollment":634,"conditions":5536,"interventions":5537},[89],[940],[346,61,942],{"nctId":4368,"briefTitle":4369,"status":242,"phases":5539,"primaryCompletion":4371,"completion":4371,"start":4372,"enrollment":4373,"conditions":5540,"interventions":5541},[89],[4375],[346,1368],{"nctId":5543,"briefTitle":5544,"status":242,"phases":5545,"primaryCompletion":5546,"completion":5546,"start":3612,"enrollment":3533,"conditions":5547,"interventions":5548},"NCT00999128","A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers",[89],"2010-02-26",[34],[346,5549],"rabeprazole",{"nctId":5551,"briefTitle":5552,"status":242,"phases":5553,"primaryCompletion":908,"completion":1405,"start":1118,"enrollment":1858,"conditions":5554,"interventions":5555},"NCT00876109","A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable",[89],[24],[346],{"trials":5557,"activeCount":101},[5558,5562],{"nctId":338,"briefTitle":339,"status":242,"phases":5559,"primaryCompletion":341,"completion":341,"start":342,"enrollment":343,"conditions":5560,"interventions":5561},[90],[18],[284,346,347],{"nctId":1836,"briefTitle":1837,"status":242,"phases":5563,"primaryCompletion":1839,"completion":1840,"start":1841,"enrollment":1842,"conditions":5564,"interventions":5565},[90],[18],[346,525],{"trials":5567,"activeCount":101},[],{"trials":5569,"activeCount":101},[],{"trials":5571,"activeCount":101},[],{"intervention":748,"totalTrials":802,"cells":5573},{"EARLY_PHASE1":5574,"PHASE1":5576,"PHASE2":5610,"PHASE3":5632,"PHASE4":5634,"NA":5636},{"trials":5575,"activeCount":101},[],{"trials":5577,"activeCount":101},[5578,5582,5592,5599,5606],{"nctId":1636,"briefTitle":1637,"status":242,"phases":5579,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":5580,"interventions":5581},[89],[695],[519,711,1644,748,522,524,525],{"nctId":5583,"briefTitle":5584,"status":242,"phases":5585,"primaryCompletion":5586,"completion":5586,"start":5587,"enrollment":5588,"conditions":5589,"interventions":5591},"NCT03341884","A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants",[89],"2018-06-26","2017-11-09",29,[5590],"Hepatic Insufficiency",[748],{"nctId":5593,"briefTitle":5594,"status":242,"phases":5595,"primaryCompletion":1796,"completion":1796,"start":5596,"enrollment":25,"conditions":5597,"interventions":5598},"NCT02536391","Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects",[89],"2015-10",[517],[748,748],{"nctId":5600,"briefTitle":5601,"status":242,"phases":5602,"primaryCompletion":1140,"completion":1140,"start":1290,"enrollment":1228,"conditions":5603,"interventions":5604},"NCT02063581","A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy Volunteers",[89],[15],[5605,5605],"ipatasertib",{"nctId":1512,"briefTitle":1513,"status":242,"phases":5607,"primaryCompletion":1443,"completion":1443,"start":1515,"enrollment":622,"conditions":5608,"interventions":5609},[89],[695],[748,626],{"trials":5611,"activeCount":101},[5612,5616,5620,5624,5628],{"nctId":1758,"briefTitle":1759,"status":242,"phases":5613,"primaryCompletion":1761,"completion":1762,"start":1763,"enrollment":1764,"conditions":5614,"interventions":5615},[90],[1766],[748,525],{"nctId":737,"briefTitle":738,"status":242,"phases":5617,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":5618,"interventions":5619},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"nctId":2901,"briefTitle":2902,"status":242,"phases":5621,"primaryCompletion":2904,"completion":2905,"start":2906,"enrollment":719,"conditions":5622,"interventions":5623},[90],[602],[1221,748,522,524],{"nctId":4559,"briefTitle":4560,"status":242,"phases":5625,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":5626,"interventions":5627},[89,90],[4567],[4569,4570,748,2592,2591],{"nctId":1827,"briefTitle":1828,"status":242,"phases":5629,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1832,"conditions":5630,"interventions":5631},[90],[18],[748,525],{"trials":5633,"activeCount":101},[],{"trials":5635,"activeCount":101},[],{"trials":5637,"activeCount":101},[],{"intervention":347,"totalTrials":802,"cells":5639},{"EARLY_PHASE1":5640,"PHASE1":5642,"PHASE2":5685,"PHASE3":5703,"PHASE4":5705,"NA":5707},{"trials":5641,"activeCount":101},[],{"trials":5643,"activeCount":101},[5644,5651,5658,5666,5670,5674,5678],{"nctId":5645,"briefTitle":5646,"status":242,"phases":5647,"primaryCompletion":1159,"completion":1159,"start":1130,"enrollment":5648,"conditions":5649,"interventions":5650},"NCT00854126","A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma",[89],38,[5508],[347],{"nctId":5652,"briefTitle":5653,"status":242,"phases":5654,"primaryCompletion":1363,"completion":1363,"start":1373,"enrollment":5655,"conditions":5656,"interventions":5657},"NCT00854152","A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma",[89],121,[5508],[347],{"nctId":5659,"briefTitle":5660,"status":242,"phases":5661,"primaryCompletion":5662,"completion":5662,"start":5663,"enrollment":1311,"conditions":5664,"interventions":5665},"NCT01287091","A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet",[89],"2011-02-03","2010-10-14",[15],[347,347,347,347,347,347,5549],{"nctId":1156,"briefTitle":1157,"status":242,"phases":5667,"primaryCompletion":1159,"completion":1149,"start":1160,"enrollment":1161,"conditions":5668,"interventions":5669},[89],[18],[347,1027,998],{"nctId":1165,"briefTitle":1166,"status":242,"phases":5671,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":500,"conditions":5672,"interventions":5673},[89],[24],[347,1027,1172,1173],{"nctId":1175,"briefTitle":1176,"status":242,"phases":5675,"primaryCompletion":1069,"completion":1069,"start":1178,"enrollment":246,"conditions":5676,"interventions":5677},[89],[24],[347,1027,960,1052,998,1053],{"nctId":5679,"briefTitle":5680,"status":242,"phases":5681,"primaryCompletion":907,"completion":907,"start":1291,"enrollment":5530,"conditions":5682,"interventions":5683},"NCT01473316","Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980",[89],[15],[347,5684],"Ketoconazole",{"trials":5686,"activeCount":101},[5687,5695,5699],{"nctId":5688,"briefTitle":5689,"status":242,"phases":5690,"primaryCompletion":5691,"completion":937,"start":907,"enrollment":1238,"conditions":5692,"interventions":5694},"NCT01455493","A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma",[90],"2013-03",[5693],"Endometrial Carcinoma",[347],{"nctId":413,"briefTitle":414,"status":242,"phases":5696,"primaryCompletion":416,"completion":417,"start":342,"enrollment":418,"conditions":5697,"interventions":5698},[90],[420],[286,347],{"nctId":338,"briefTitle":339,"status":242,"phases":5700,"primaryCompletion":341,"completion":341,"start":342,"enrollment":343,"conditions":5701,"interventions":5702},[90],[18],[284,346,347],{"trials":5704,"activeCount":101},[],{"trials":5706,"activeCount":101},[],{"trials":5708,"activeCount":101},[],{"intervention":3537,"totalTrials":802,"cells":5710},{"EARLY_PHASE1":5711,"PHASE1":5713,"PHASE2":5748,"PHASE3":5804,"PHASE4":5806,"NA":5808},{"trials":5712,"activeCount":101},[],{"trials":5714,"activeCount":101},[5715,5719,5728,5736],{"nctId":3529,"briefTitle":3530,"status":242,"phases":5716,"primaryCompletion":1883,"completion":1883,"start":3532,"enrollment":3533,"conditions":5717,"interventions":5718},[89],[15],[3536,3537,3522,1465],{"nctId":5720,"briefTitle":5721,"status":242,"phases":5722,"primaryCompletion":5723,"completion":5723,"start":5724,"enrollment":5725,"conditions":5726,"interventions":5727},"NCT03290703","A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants",[89],"2018-10-25","2017-04-18",63,[34],[3537,1465],{"nctId":5729,"briefTitle":5730,"status":242,"phases":5731,"primaryCompletion":5732,"completion":5732,"start":1080,"enrollment":488,"conditions":5733,"interventions":5735},"NCT01991184","A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.",[89],"2022-03-08",[5734],"Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma",[3537],{"nctId":5737,"briefTitle":5738,"status":242,"phases":5739,"primaryCompletion":5740,"completion":5740,"start":5724,"enrollment":5725,"conditions":5741,"interventions":5742},"NCT03174041","A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin",[89],"2017-06-23",[968],[334,3537,5743,1946,5744,5745,5746,3537,1500,5747],"Midazolam and GDC-0853","Rosuvastatin and GDC-0853","Simvastatin","Simvastatin and GDC-0853","GDC-0853 and itraconazole",{"trials":5749,"activeCount":101},[5750,5758,5767,5777,5785,5795],{"nctId":5751,"briefTitle":5752,"status":325,"phases":5753,"primaryCompletion":5754,"completion":5754,"start":5755,"enrollment":1901,"conditions":5756,"interventions":5757},"NCT03693625","A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study",[90],"2019-10-23","2018-09-27",[3769],[3537],{"nctId":5759,"briefTitle":5760,"status":242,"phases":5761,"primaryCompletion":5762,"completion":5763,"start":5764,"enrollment":682,"conditions":5765,"interventions":5766},"NCT02908100","A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus",[90],"2019-05-28","2019-07-16","2017-01-19",[2568],[3537],{"nctId":5768,"briefTitle":5769,"status":242,"phases":5770,"primaryCompletion":5771,"completion":5772,"start":5773,"enrollment":5774,"conditions":5775,"interventions":5776},"NCT03137069","A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).",[90],"2019-09-27","2019-10-25","2017-05-26",134,[3769],[3537],{"nctId":5778,"briefTitle":5779,"status":325,"phases":5780,"primaryCompletion":5781,"completion":5781,"start":5782,"enrollment":3131,"conditions":5783,"interventions":5784},"NCT03407482","An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus",[90],"2019-11-20","2018-01-09",[4451],[3537],{"nctId":5786,"briefTitle":5787,"status":242,"phases":5788,"primaryCompletion":5789,"completion":5789,"start":5790,"enrollment":5134,"conditions":5791,"interventions":5792},"NCT02833350","Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)",[90],"2018-07-02","2016-09-09",[21],[3537,5793,3536,5794],"Adalimumab","MTX",{"nctId":5796,"briefTitle":5797,"status":242,"phases":5798,"primaryCompletion":5799,"completion":5799,"start":5800,"enrollment":5801,"conditions":5802,"interventions":5803},"NCT02983227","A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350",[90],"2019-07-17","2016-11-30",496,[21],[3537],{"trials":5805,"activeCount":101},[],{"trials":5807,"activeCount":101},[],{"trials":5809,"activeCount":101},[],{"intervention":5811,"totalTrials":3791,"cells":5812},"lebrikizumab",{"EARLY_PHASE1":5813,"PHASE1":5815,"PHASE2":5830,"PHASE3":5865,"PHASE4":5867,"NA":5869},{"trials":5814,"activeCount":101},[],{"trials":5816,"activeCount":101},[5817,5824],{"nctId":5818,"briefTitle":5819,"status":242,"phases":5820,"primaryCompletion":5596,"completion":5596,"start":417,"enrollment":3750,"conditions":5821,"interventions":5822},"NCT02486809","A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)",[89],[15],[5823],"Lebrikizumab",{"nctId":5825,"briefTitle":5826,"status":242,"phases":5827,"primaryCompletion":1811,"completion":1811,"start":1217,"enrollment":2231,"conditions":5828,"interventions":5829},"NCT01423318","A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers",[89],[15],[5811],{"trials":5831,"activeCount":101},[5832,5838,5845,5852,5858],{"nctId":5833,"briefTitle":5834,"status":242,"phases":5835,"primaryCompletion":1207,"start":4612,"enrollment":5588,"conditions":5836,"interventions":5837},"NCT00781443","A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma",[90],[3698],[5811],{"nctId":5839,"briefTitle":5840,"status":242,"phases":5841,"primaryCompletion":5842,"completion":909,"start":938,"enrollment":141,"conditions":5843,"interventions":5844},"NCT00930163","A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids",[90],"2010-07",[31],[5811],{"nctId":5846,"briefTitle":5847,"status":242,"phases":5848,"primaryCompletion":5691,"completion":1415,"start":1098,"enrollment":5849,"conditions":5850,"interventions":5851},"NCT01545440","A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)",[90],258,[31],[5811,5811,5811],{"nctId":5853,"briefTitle":5854,"status":242,"phases":5855,"primaryCompletion":1160,"completion":1461,"start":1207,"enrollment":3492,"conditions":5856,"interventions":5857},"NCT00971035","A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids",[90],[31],[5811,5811,5811],{"nctId":5859,"briefTitle":5860,"status":242,"phases":5861,"primaryCompletion":1415,"completion":1415,"start":1098,"enrollment":5862,"conditions":5863,"interventions":5864},"NCT01545453","A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)",[90],205,[31],[5811,5811,5811],{"trials":5866,"activeCount":101},[],{"trials":5868,"activeCount":101},[],{"trials":5870,"activeCount":101},[],{"intervention":522,"totalTrials":2546,"cells":5872},{"EARLY_PHASE1":5873,"PHASE1":5875,"PHASE2":5885,"PHASE3":5910,"PHASE4":5912,"NA":5914},{"trials":5874,"activeCount":101},[],{"trials":5876,"activeCount":101},[5877,5881],{"nctId":510,"briefTitle":511,"status":242,"phases":5878,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":5879,"interventions":5880},[89],[517],[519,487,520,521,522,523,524,525,526],{"nctId":1636,"briefTitle":1637,"status":242,"phases":5882,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":5883,"interventions":5884},[89],[695],[519,711,1644,748,522,524,525],{"trials":5886,"activeCount":101},[5887,5891,5902,5906],{"nctId":1213,"briefTitle":1214,"status":242,"phases":5888,"primaryCompletion":1216,"completion":417,"start":1217,"enrollment":1218,"conditions":5889,"interventions":5890},[90],[29],[1221,520,1222,522,524,563],{"nctId":5892,"briefTitle":5893,"status":242,"phases":5894,"primaryCompletion":5895,"completion":5895,"start":5896,"enrollment":5897,"conditions":5898,"interventions":5899},"NCT01418222","FOLFOX\u002FBevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer",[90],"2013-03-18","2011-09-14",194,[29],[519,1144,1801,5900,5901],"leucovorin","onartuzumab [MetMAb]",{"nctId":2901,"briefTitle":2902,"status":242,"phases":5903,"primaryCompletion":2904,"completion":2905,"start":2906,"enrollment":719,"conditions":5904,"interventions":5905},[90],[602],[1221,748,522,524],{"nctId":2951,"briefTitle":2952,"status":242,"phases":5907,"primaryCompletion":1363,"completion":1363,"start":2954,"enrollment":760,"conditions":5908,"interventions":5909},[90],[29],[1410,575,1222,522,1525],{"trials":5911,"activeCount":101},[],{"trials":5913,"activeCount":101},[],{"trials":5915,"activeCount":101},[],{"intervention":1053,"totalTrials":233,"cells":5917},{"EARLY_PHASE1":5918,"PHASE1":5920,"PHASE2":5938,"PHASE3":5944,"PHASE4":5946,"NA":5948},{"trials":5919,"activeCount":101},[],{"trials":5921,"activeCount":101},[5922,5926,5930,5934],{"nctId":510,"briefTitle":511,"status":242,"phases":5923,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":5924,"interventions":5925},[89],[517],[519,487,520,521,522,523,524,525,526],{"nctId":552,"briefTitle":553,"status":242,"phases":5927,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":5928,"interventions":5929},[89],[559],[487,506,521,561,526,525,562,563,520,564],{"nctId":1043,"briefTitle":1044,"status":242,"phases":5931,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":1048,"conditions":5932,"interventions":5933},[89],[1050],[346,1027,960,1052,998,1053],{"nctId":1175,"briefTitle":1176,"status":242,"phases":5935,"primaryCompletion":1069,"completion":1069,"start":1178,"enrollment":246,"conditions":5936,"interventions":5937},[89],[24],[347,1027,960,1052,998,1053],{"trials":5939,"activeCount":101},[5940],{"nctId":1793,"briefTitle":1794,"status":242,"phases":5941,"primaryCompletion":1796,"completion":1796,"start":1515,"enrollment":1797,"conditions":5942,"interventions":5943},[90],[1050],[1800,1801,1802,998,1053],{"trials":5945,"activeCount":101},[],{"trials":5947,"activeCount":101},[],{"trials":5949,"activeCount":101},[],{"intervention":1525,"totalTrials":233,"cells":5951},{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5975,"PHASE3":5985,"PHASE4":5987,"NA":5989},{"trials":5953,"activeCount":101},[],{"trials":5955,"activeCount":101},[5956,5960,5971],{"nctId":1736,"briefTitle":1737,"status":242,"phases":5957,"primaryCompletion":1739,"completion":1739,"start":1740,"enrollment":488,"conditions":5958,"interventions":5959},[89],[670],[519,521,561,1525,525],{"nctId":5961,"briefTitle":5962,"status":242,"phases":5963,"primaryCompletion":5964,"completion":5965,"start":5966,"enrollment":5967,"conditions":5968,"interventions":5970},"NCT01207323","A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors",[89],"2013-12-03","2018-04-23","2010-11-09",66,[5969],"Epithelial Tumors, Malignant",[1525],{"nctId":1519,"briefTitle":1520,"status":242,"phases":5972,"primaryCompletion":1522,"completion":1522,"start":1405,"enrollment":1141,"conditions":5973,"interventions":5974},[89],[695],[626,1525],{"trials":5976,"activeCount":101},[5977,5981],{"nctId":2945,"briefTitle":2946,"status":242,"phases":5978,"primaryCompletion":1168,"completion":1168,"start":1159,"enrollment":1641,"conditions":5979,"interventions":5980},[90],[670],[1525,1104],{"nctId":2951,"briefTitle":2952,"status":242,"phases":5982,"primaryCompletion":1363,"completion":1363,"start":2954,"enrollment":760,"conditions":5983,"interventions":5984},[90],[29],[1410,575,1222,522,1525],{"trials":5986,"activeCount":101},[],{"trials":5988,"activeCount":101},[],{"trials":5990,"activeCount":101},[],{"intervention":1121,"totalTrials":233,"cells":5992},{"EARLY_PHASE1":5993,"PHASE1":5995,"PHASE2":6005,"PHASE3":6027,"PHASE4":6029,"NA":6031},{"trials":5994,"activeCount":101},[],{"trials":5996,"activeCount":101},[5997,6001],{"nctId":1115,"briefTitle":1116,"status":242,"phases":5998,"primaryCompletion":909,"completion":909,"start":1118,"enrollment":1021,"conditions":5999,"interventions":6000},[89],[29],[1027,1104,1103,1106,1121],{"nctId":1127,"briefTitle":1128,"status":242,"phases":6002,"primaryCompletion":1070,"completion":1070,"start":1130,"enrollment":1131,"conditions":6003,"interventions":6004},[89],[1133],[1027,1135,1121],{"trials":6006,"activeCount":101},[6007,6014,6018],{"nctId":6008,"briefTitle":6009,"status":242,"phases":6010,"primaryCompletion":4928,"completion":4928,"start":5506,"enrollment":6011,"conditions":6012,"interventions":6013},"NCT00517049","A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)",[90],49,[331],[1121,3594],{"nctId":1251,"briefTitle":1252,"status":242,"phases":6015,"primaryCompletion":1254,"completion":1254,"start":1208,"enrollment":1255,"conditions":6016,"interventions":6017},[90],[27],[1027,960,998,1121],{"nctId":6019,"briefTitle":6020,"status":325,"phases":6021,"primaryCompletion":6022,"completion":6022,"start":6023,"enrollment":35,"conditions":6024,"interventions":6026},"NCT00543712","A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)",[90],"2008-05-05","2007-05-31",[6025],"Chondrosarcoma",[1121],{"trials":6028,"activeCount":101},[],{"trials":6030,"activeCount":101},[],{"trials":6032,"activeCount":101},[],{"intervention":1106,"totalTrials":233,"cells":6034},{"EARLY_PHASE1":6035,"PHASE1":6037,"PHASE2":6047,"PHASE3":6061,"PHASE4":6063,"NA":6065},{"trials":6036,"activeCount":101},[],{"trials":6038,"activeCount":101},[6039,6043],{"nctId":1095,"briefTitle":1096,"status":242,"phases":6040,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":6041,"interventions":6042},[89],[29],[1103,1027,1104,1105,1106],{"nctId":1115,"briefTitle":1116,"status":242,"phases":6044,"primaryCompletion":909,"completion":909,"start":1118,"enrollment":1021,"conditions":6045,"interventions":6046},[89],[29],[1027,1104,1103,1106,1121],{"trials":6048,"activeCount":101},[6049,6053,6057],{"nctId":1213,"briefTitle":1214,"status":242,"phases":6050,"primaryCompletion":1216,"completion":417,"start":1217,"enrollment":1218,"conditions":6051,"interventions":6052},[90],[29],[1221,520,1222,522,524,563],{"nctId":1259,"briefTitle":1260,"status":242,"phases":6054,"primaryCompletion":1262,"completion":1262,"start":1099,"enrollment":1263,"conditions":6055,"interventions":6056},[90],[1265],[1027,1106],{"nctId":2951,"briefTitle":2952,"status":242,"phases":6058,"primaryCompletion":1363,"completion":1363,"start":2954,"enrollment":760,"conditions":6059,"interventions":6060},[90],[29],[1410,575,1222,522,1525],{"trials":6062,"activeCount":101},[],{"trials":6064,"activeCount":101},[],{"trials":6066,"activeCount":101},[],{"intervention":6068,"totalTrials":233,"cells":6069},"UTTR1147A",{"EARLY_PHASE1":6070,"PHASE1":6072,"PHASE2":6094,"PHASE3":6129,"PHASE4":6131,"NA":6133},{"trials":6071,"activeCount":101},[],{"trials":6073,"activeCount":101},[6074,6084],{"nctId":6075,"briefTitle":6076,"status":242,"phases":6077,"primaryCompletion":6078,"completion":6078,"start":6079,"enrollment":6080,"conditions":6081,"interventions":6083},"NCT02833389","The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers",[89],"2018-11-12","2016-11-14",72,[6082],"Neuropathic Diabetic Foot Ulcers",[6068],{"nctId":6085,"briefTitle":6086,"status":242,"phases":6087,"primaryCompletion":6088,"completion":6088,"start":6089,"enrollment":6090,"conditions":6091,"interventions":6093},"NCT02749630","A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)",[89],"2020-02-19","2016-04-11",70,[2001,6092],"Crohn's Disease",[6068],{"trials":6095,"activeCount":101},[6096,6105,6118],{"nctId":6097,"briefTitle":6098,"status":325,"phases":6099,"primaryCompletion":6100,"completion":6100,"start":6101,"enrollment":6102,"conditions":6103,"interventions":6104},"NCT03650413","An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease",[90],"2022-07-12","2019-01-14",143,[2001,6092],[6068],{"nctId":6106,"briefTitle":6107,"status":242,"phases":6108,"primaryCompletion":6109,"completion":6110,"start":6111,"enrollment":6112,"conditions":6113,"interventions":6114},"NCT04386616","A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia",[90],"2021-01-08","2021-02-12","2020-06-02",396,[890],[6115,6116,6068,6117],"MSTT1041A","MSTT1041A-matched Placebo","UTTR1147A-matched Placebo",{"nctId":6119,"briefTitle":6120,"status":242,"phases":6121,"primaryCompletion":6122,"completion":6122,"start":6123,"enrollment":612,"conditions":6124,"interventions":6125},"NCT03558152","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)",[90],"2021-12-15","2018-10-26",[2001],[6068,6126,6127,6128],"UTTR1147A Placebo","Vedolizumab","Vedolizumab Placebo",{"trials":6130,"activeCount":101},[],{"trials":6132,"activeCount":101},[],{"trials":6134,"activeCount":101},[],{"intervention":6136,"totalTrials":793,"cells":6137},"MHAA4549A",{"EARLY_PHASE1":6138,"PHASE1":6140,"PHASE2":6156,"PHASE3":6177,"PHASE4":6179,"NA":6181},{"trials":6139,"activeCount":101},[],{"trials":6141,"activeCount":101},[6142,6148],{"nctId":6143,"briefTitle":6144,"status":242,"phases":6145,"primaryCompletion":1405,"completion":1405,"start":1415,"enrollment":22,"conditions":6146,"interventions":6147},"NCT01877785","A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers",[89],[15],[6136],{"nctId":6149,"briefTitle":6150,"status":242,"phases":6151,"primaryCompletion":6152,"completion":6152,"start":6153,"enrollment":1425,"conditions":6154,"interventions":6155},"NCT02284607","A Study of High Dose MHAA4549A in Healthy Volunteers",[89],"2015-03-13","2014-11-03",[15],[6136,6136],{"trials":6157,"activeCount":101},[6158,6167],{"nctId":6159,"briefTitle":6160,"status":242,"phases":6161,"primaryCompletion":6162,"completion":6162,"start":6163,"enrollment":1764,"conditions":6164,"interventions":6166},"NCT02623322","A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults",[90],"2017-11-13","2016-10-12",[6165],"Influenza A",[6136],{"nctId":6168,"briefTitle":6169,"status":242,"phases":6170,"primaryCompletion":6171,"completion":6171,"start":6172,"enrollment":4498,"conditions":6173,"interventions":6175},"NCT02293863","A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection",[90],"2017-05-23","2015-01-14",[6174],"Influenza",[6136,6176],"Oseltamivir",{"trials":6178,"activeCount":101},[],{"trials":6180,"activeCount":101},[],{"trials":6182,"activeCount":101},[],{"intervention":506,"totalTrials":793,"cells":6184},{"EARLY_PHASE1":6185,"PHASE1":6187,"PHASE2":6197,"PHASE3":6207,"PHASE4":6209,"NA":6211},{"trials":6186,"activeCount":101},[],{"trials":6188,"activeCount":101},[6189,6193],{"nctId":495,"briefTitle":496,"status":325,"phases":6190,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":6191,"interventions":6192},[89],[502,503,504],[506,507,508,487],{"nctId":552,"briefTitle":553,"status":242,"phases":6194,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":6195,"interventions":6196},[89],[559],[487,506,521,561,526,525,562,563,520,564],{"trials":6198,"activeCount":101},[6199,6203],{"nctId":737,"briefTitle":738,"status":242,"phases":6200,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":6201,"interventions":6202},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"nctId":754,"briefTitle":755,"status":242,"phases":6204,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":6205,"interventions":6206},[90],[642],[487,506],{"trials":6208,"activeCount":101},[],{"trials":6210,"activeCount":101},[],{"trials":6212,"activeCount":101},[],{"intervention":6214,"totalTrials":793,"cells":6215},"[18F]GTP1",{"EARLY_PHASE1":6216,"PHASE1":6218,"PHASE2":6240,"PHASE3":6262,"PHASE4":6264,"NA":6266},{"trials":6217,"activeCount":101},[],{"trials":6219,"activeCount":101},[6220,6229],{"nctId":6221,"briefTitle":6222,"status":242,"phases":6223,"primaryCompletion":6224,"completion":6224,"start":6225,"enrollment":6080,"conditions":6226,"interventions":6228},"NCT02640092","Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants",[89],"2019-06-11","2015-12-23",[6227],"Alzheimer's Disease",[6214],{"nctId":6230,"briefTitle":6231,"status":242,"phases":6232,"primaryCompletion":6233,"completion":6233,"start":6234,"enrollment":979,"conditions":6235,"interventions":6237},"NCT04566003","Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease",[89],"2023-06-27","2020-10-26",[6236],"Alzheimer Disease (AD)",[6214,6238,6239],"[18F]PI-2620","[18F]MK-6240",{"trials":6241,"activeCount":101},[6242,6252],{"nctId":6243,"briefTitle":6244,"status":325,"phases":6245,"primaryCompletion":6246,"completion":6246,"start":6247,"enrollment":6248,"conditions":6249,"interventions":6250},"NCT03289143","A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease",[90],"2021-01-15","2017-10-04",457,[6227],[6251,6214],"Semorinemab",{"nctId":6253,"briefTitle":6254,"status":242,"phases":6255,"primaryCompletion":6256,"completion":6257,"start":6258,"enrollment":6259,"conditions":6260,"interventions":6261},"NCT03828747","A Study of Semorinemab in Patients With Moderate Alzheimer's Disease",[90],"2021-07-20","2023-08-30","2019-01-25",272,[6227],[6251,6214],{"trials":6263,"activeCount":101},[],{"trials":6265,"activeCount":101},[],{"trials":6267,"activeCount":101},[],{"intervention":519,"totalTrials":793,"cells":6269},{"EARLY_PHASE1":6270,"PHASE1":6272,"PHASE2":6286,"PHASE3":6292,"PHASE4":6294,"NA":6296},{"trials":6271,"activeCount":101},[],{"trials":6273,"activeCount":101},[6274,6278,6282],{"nctId":510,"briefTitle":511,"status":242,"phases":6275,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":6276,"interventions":6277},[89],[517],[519,487,520,521,522,523,524,525,526],{"nctId":1636,"briefTitle":1637,"status":242,"phases":6279,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":6280,"interventions":6281},[89],[695],[519,711,1644,748,522,524,525],{"nctId":1736,"briefTitle":1737,"status":242,"phases":6283,"primaryCompletion":1739,"completion":1739,"start":1740,"enrollment":488,"conditions":6284,"interventions":6285},[89],[670],[519,521,561,1525,525],{"trials":6287,"activeCount":101},[6288],{"nctId":5892,"briefTitle":5893,"status":242,"phases":6289,"primaryCompletion":5895,"completion":5895,"start":5896,"enrollment":5897,"conditions":6290,"interventions":6291},[90],[29],[519,1144,1801,5900,5901],{"trials":6293,"activeCount":101},[],{"trials":6295,"activeCount":101},[],{"trials":6297,"activeCount":101},[],{"intervention":1598,"totalTrials":793,"cells":6299},{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6304,"PHASE3":6328,"PHASE4":6330,"NA":6332},{"trials":6301,"activeCount":101},[],{"trials":6303,"activeCount":101},[],{"trials":6305,"activeCount":101},[6306,6313,6320,6324],{"nctId":6307,"briefTitle":6308,"status":242,"phases":6309,"primaryCompletion":4372,"completion":6310,"start":4122,"enrollment":4391,"conditions":6311,"interventions":6312},"NCT00679211","A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer",[90],"2011-04",[940],[1598],{"nctId":6314,"briefTitle":6315,"status":242,"phases":6316,"primaryCompletion":4022,"completion":1272,"start":4909,"enrollment":6317,"conditions":6318,"interventions":6319},"NCT00509769","A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer",[90],112,[940],[1598],{"nctId":1808,"briefTitle":1809,"status":242,"phases":6321,"primaryCompletion":1811,"completion":1812,"start":948,"enrollment":1813,"conditions":6322,"interventions":6323},[89,90],[940],[998,1816,1817,998,1817],{"nctId":1592,"briefTitle":1593,"status":242,"phases":6325,"primaryCompletion":1160,"completion":1217,"start":938,"enrollment":1588,"conditions":6326,"interventions":6327},[90],[940],[1597,1598],{"trials":6329,"activeCount":101},[],{"trials":6331,"activeCount":101},[],{"trials":6333,"activeCount":101},[],{"intervention":1154,"totalTrials":793,"cells":6335},{"EARLY_PHASE1":6336,"PHASE1":6338,"PHASE2":6352,"PHASE3":6362,"PHASE4":6364,"NA":6366},{"trials":6337,"activeCount":101},[],{"trials":6339,"activeCount":101},[6340,6348],{"nctId":6341,"briefTitle":6342,"status":242,"phases":6343,"primaryCompletion":6344,"completion":6344,"start":6345,"enrollment":770,"conditions":6346,"interventions":6347},"NCT00909740","A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors",[89],"2011-10-26","2009-05-22",[24],[1154],{"nctId":1146,"briefTitle":1147,"status":242,"phases":6349,"primaryCompletion":1149,"completion":1149,"start":1150,"enrollment":1151,"conditions":6350,"interventions":6351},[89],[24],[1154,1027,998],{"trials":6353,"activeCount":101},[6354,6358],{"nctId":1287,"briefTitle":1288,"status":242,"phases":6355,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":6356,"interventions":6357},[90],[1133],[1221,520,1295,1154,524],{"nctId":1341,"briefTitle":1342,"status":242,"phases":6359,"primaryCompletion":956,"start":1344,"enrollment":1345,"conditions":6360,"interventions":6361},[90],[1050],[1154,1027,960,998],{"trials":6363,"activeCount":101},[],{"trials":6365,"activeCount":101},[],{"trials":6367,"activeCount":101},[],{"intervention":6369,"totalTrials":97,"cells":6370},"Etrolizumab",{"EARLY_PHASE1":6371,"PHASE1":6373,"PHASE2":6390,"PHASE3":6400,"PHASE4":6402,"NA":6404},{"trials":6372,"activeCount":101},[],{"trials":6374,"activeCount":101},[6375,6382],{"nctId":6376,"briefTitle":6377,"status":242,"phases":6378,"primaryCompletion":6379,"completion":6379,"start":947,"enrollment":19,"conditions":6380,"interventions":6381},"NCT02629744","A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants",[89],"2016-06",[15],[6369],{"nctId":6383,"briefTitle":6384,"status":242,"phases":6385,"primaryCompletion":6386,"completion":6386,"start":6387,"enrollment":4515,"conditions":6388,"interventions":6389},"NCT02996019","A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)",[89],"2018-04-09","2016-12-07",[34],[6369],{"trials":6391,"activeCount":101},[6392],{"nctId":6393,"briefTitle":6394,"status":242,"phases":6395,"primaryCompletion":6396,"completion":6396,"start":6397,"enrollment":5655,"conditions":6398,"interventions":6399},"NCT01461317","Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis",[90],"2016-08-07","2011-11-29",[2001],[6369],{"trials":6401,"activeCount":101},[],{"trials":6403,"activeCount":101},[],{"trials":6405,"activeCount":101},[],{"intervention":6407,"totalTrials":97,"cells":6408},"Crenezumab",{"EARLY_PHASE1":6409,"PHASE1":6411,"PHASE2":6420,"PHASE3":6440,"PHASE4":6442,"NA":6444},{"trials":6410,"activeCount":101},[],{"trials":6412,"activeCount":101},[6413],{"nctId":6414,"briefTitle":6415,"status":242,"phases":6416,"primaryCompletion":417,"completion":417,"start":6417,"enrollment":2231,"conditions":6418,"interventions":6419},"NCT02427243","A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose",[89],"2015-04",[15],[6407,6407],{"trials":6421,"activeCount":101},[6422,6431],{"nctId":6423,"briefTitle":6424,"status":242,"phases":6425,"primaryCompletion":6426,"completion":6427,"start":6428,"enrollment":743,"conditions":6429,"interventions":6430},"NCT01998841","A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort",[90],"2022-03-22","2023-08-08","2013-12-20",[6227],[6407],{"nctId":6432,"briefTitle":6433,"status":242,"phases":6434,"primaryCompletion":6435,"completion":6435,"start":6436,"enrollment":6437,"conditions":6438,"interventions":6439},"NCT01723826","A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab",[90],"2017-02-08","2012-12-07",360,[6227],[6407],{"trials":6441,"activeCount":101},[],{"trials":6443,"activeCount":101},[],{"trials":6445,"activeCount":101},[],{"intervention":1105,"totalTrials":97,"cells":6447},{"EARLY_PHASE1":6448,"PHASE1":6450,"PHASE2":6460,"PHASE3":6470,"PHASE4":6472,"NA":6474},{"trials":6449,"activeCount":101},[],{"trials":6451,"activeCount":101},[6452,6456],{"nctId":1095,"briefTitle":1096,"status":242,"phases":6453,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":6454,"interventions":6455},[89],[29],[1103,1027,1104,1105,1106],{"nctId":1137,"briefTitle":1138,"status":242,"phases":6457,"primaryCompletion":1140,"completion":896,"start":1130,"enrollment":1141,"conditions":6458,"interventions":6459},[89],[1133],[1144,1027,1105],{"trials":6461,"activeCount":101},[6462],{"nctId":6463,"briefTitle":6464,"status":325,"phases":6465,"primaryCompletion":3749,"start":6466,"enrollment":6080,"conditions":6467,"interventions":6468},"NCT00400764","A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas",[89,90],"2006-06",[331],[6469,508],"Dulanermin",{"trials":6471,"activeCount":101},[],{"trials":6473,"activeCount":101},[],{"trials":6475,"activeCount":101},[],{"intervention":6477,"totalTrials":97,"cells":6478},"MABT5102A",{"EARLY_PHASE1":6479,"PHASE1":6481,"PHASE2":6489,"PHASE3":6507,"PHASE4":6509,"NA":6511},{"trials":6480,"activeCount":101},[],{"trials":6482,"activeCount":101},[6483],{"nctId":6484,"briefTitle":6485,"status":242,"phases":6486,"primaryCompletion":1150,"completion":1150,"start":1047,"enrollment":5530,"conditions":6487,"interventions":6488},"NCT00997919","A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers",[89],[15],[6477,6477],{"trials":6490,"activeCount":101},[6491,6500],{"nctId":6492,"briefTitle":6493,"status":242,"phases":6494,"primaryCompletion":6495,"completion":6495,"start":6496,"enrollment":6497,"conditions":6498,"interventions":6499},"NCT01343966","A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)",[90],"2014-02-28","2011-04-30",448,[6227],[6477,6477],{"nctId":6501,"briefTitle":6502,"status":242,"phases":6503,"primaryCompletion":6504,"completion":6504,"start":2599,"enrollment":910,"conditions":6505,"interventions":6506},"NCT01397578","A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease",[90],"2014-04-30",[6227],[6477,6477],{"trials":6508,"activeCount":101},[],{"trials":6510,"activeCount":101},[],{"trials":6512,"activeCount":101},[],{"intervention":2590,"totalTrials":97,"cells":6514},{"EARLY_PHASE1":6515,"PHASE1":6517,"PHASE2":6530,"PHASE3":6540,"PHASE4":6542,"NA":6544},{"trials":6516,"activeCount":101},[],{"trials":6518,"activeCount":101},[6519],{"nctId":6520,"briefTitle":6521,"status":242,"phases":6522,"primaryCompletion":6523,"completion":6524,"start":6525,"enrollment":6526,"conditions":6527,"interventions":6529},"NCT01290549","A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma",[89],"2012-06-29","2014-11-18","2011-03-22",95,[6528,2046],"Non-Hodgkins Lymphoma",[2590,508],{"trials":6531,"activeCount":101},[6532,6536],{"nctId":2582,"briefTitle":2583,"status":242,"phases":6533,"primaryCompletion":2585,"completion":2585,"start":2586,"enrollment":418,"conditions":6534,"interventions":6535},[89,90],[732],[2545,2589,2036,2590,2591,2592,508],{"nctId":4305,"briefTitle":4306,"status":242,"phases":6537,"primaryCompletion":4308,"completion":4309,"start":4310,"enrollment":4311,"conditions":6538,"interventions":6539},[89,90],[4313,4314],[2036,4316,2590,508],{"trials":6541,"activeCount":101},[],{"trials":6543,"activeCount":101},[],{"trials":6545,"activeCount":101},[],{"intervention":6547,"totalTrials":97,"cells":6548},"BFKB8488A",{"EARLY_PHASE1":6549,"PHASE1":6551,"PHASE2":6573,"PHASE3":6584,"PHASE4":6586,"NA":6588},{"trials":6550,"activeCount":101},[],{"trials":6552,"activeCount":101},[6553,6564],{"nctId":6554,"briefTitle":6555,"status":242,"phases":6556,"primaryCompletion":6557,"completion":6557,"start":6558,"enrollment":6559,"conditions":6560,"interventions":6563},"NCT03060538","A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease",[89],"2019-12-13","2017-03-05",154,[6561,6562],"Diabetes Mellitus, Type 2","Non-Alcoholic Fatty Liver Disease",[6547],{"nctId":6565,"briefTitle":6566,"status":242,"phases":6567,"primaryCompletion":6568,"completion":6568,"start":6569,"enrollment":1999,"conditions":6570,"interventions":6572},"NCT02593331","Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance",[89],"2017-03-28","2015-10-29",[6571],"Insulin Resistance",[6547],{"trials":6574,"activeCount":101},[6575],{"nctId":6576,"briefTitle":6577,"status":325,"phases":6578,"primaryCompletion":6579,"completion":6579,"start":6580,"enrollment":1311,"conditions":6581,"interventions":6583},"NCT04171765","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis",[90],"2023-01-23","2020-09-30",[6582],"Non-alcoholic Steatohepatitis",[6547],{"trials":6585,"activeCount":101},[],{"trials":6587,"activeCount":101},[],{"trials":6589,"activeCount":101},[],{"intervention":356,"totalTrials":97,"cells":6591},{"EARLY_PHASE1":6592,"PHASE1":6594,"PHASE2":6604,"PHASE3":6614,"PHASE4":6616,"NA":6618},{"trials":6593,"activeCount":101},[],{"trials":6595,"activeCount":101},[6596],{"nctId":6597,"briefTitle":6598,"status":242,"phases":6599,"primaryCompletion":6600,"completion":6600,"start":947,"enrollment":35,"conditions":6601,"interventions":6602},"NCT02621957","Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential",[89],"2016-02",[18],[356,6603],"Pravastatin",{"trials":6605,"activeCount":101},[6606,6610],{"nctId":386,"briefTitle":387,"status":325,"phases":6607,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":6608,"interventions":6609},[89,90],[18],[356,287,319],{"nctId":349,"briefTitle":350,"status":325,"phases":6611,"primaryCompletion":352,"completion":352,"start":353,"enrollment":9,"conditions":6612,"interventions":6613},[90],[18],[284,356],{"trials":6615,"activeCount":101},[],{"trials":6617,"activeCount":101},[],{"trials":6619,"activeCount":101},[],{"intervention":1231,"totalTrials":97,"cells":6621},{"EARLY_PHASE1":6622,"PHASE1":6624,"PHASE2":6626,"PHASE3":6640,"PHASE4":6642,"NA":6644},{"trials":6623,"activeCount":101},[],{"trials":6625,"activeCount":101},[],{"trials":6627,"activeCount":101},[6628,6632,6636],{"nctId":1224,"briefTitle":1225,"status":325,"phases":6629,"primaryCompletion":1227,"start":1089,"enrollment":1228,"conditions":6630,"interventions":6631},[90],[420],[1027,1231],{"nctId":1233,"briefTitle":1234,"status":325,"phases":6633,"primaryCompletion":1236,"start":1237,"enrollment":1238,"conditions":6634,"interventions":6635},[90],[27],[1027,1231,960,998],{"nctId":1307,"briefTitle":1308,"status":325,"phases":6637,"primaryCompletion":1310,"start":1237,"enrollment":1311,"conditions":6638,"interventions":6639},[90],[940],[1027,1231,998],{"trials":6641,"activeCount":101},[],{"trials":6643,"activeCount":101},[],{"trials":6645,"activeCount":101},[],{"intervention":1083,"totalTrials":97,"cells":6647},{"EARLY_PHASE1":6648,"PHASE1":6650,"PHASE2":6666,"PHASE3":6677,"PHASE4":6679,"NA":6681},{"trials":6649,"activeCount":101},[],{"trials":6651,"activeCount":101},[6652,6656],{"nctId":1076,"briefTitle":1077,"status":242,"phases":6653,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":500,"conditions":6654,"interventions":6655},[89],[1050],[520,521,1083],{"nctId":6657,"briefTitle":6658,"status":242,"phases":6659,"primaryCompletion":6660,"completion":6660,"start":6661,"enrollment":6662,"conditions":6663,"interventions":6665},"NCT01363947","Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer",[89],"2016-06-03","2011-06-14",87,[6664],"Non-Small Cell Lung Cancer, Ovarian Cancer",[1083],{"trials":6667,"activeCount":101},[6668],{"nctId":6669,"briefTitle":6670,"status":325,"phases":6671,"primaryCompletion":6672,"completion":6672,"start":6673,"enrollment":6526,"conditions":6674,"interventions":6675},"NCT01991210","A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)",[90],"2016-08-17","2014-02-06",[1284],[1083,6676],"PLD",{"trials":6678,"activeCount":101},[],{"trials":6680,"activeCount":101},[],{"trials":6682,"activeCount":101},[],{"intervention":951,"totalTrials":97,"cells":6684},{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6697,"PHASE3":6703,"PHASE4":6705,"NA":6707},{"trials":6686,"activeCount":101},[],{"trials":6688,"activeCount":101},[6689,6693],{"nctId":944,"briefTitle":945,"status":242,"phases":6690,"primaryCompletion":947,"completion":947,"start":948,"enrollment":9,"conditions":6691,"interventions":6692},[89],[18],[520,951,318,525,61],{"nctId":1487,"briefTitle":1488,"status":325,"phases":6694,"primaryCompletion":1140,"completion":1140,"start":1207,"enrollment":1490,"conditions":6695,"interventions":6696},[89],[614],[626,951],{"trials":6698,"activeCount":101},[6699],{"nctId":1297,"briefTitle":1298,"status":242,"phases":6700,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":1302,"conditions":6701,"interventions":6702},[90],[27],[1305,1027,960,998],{"trials":6704,"activeCount":101},[],{"trials":6706,"activeCount":101},[],{"trials":6708,"activeCount":101},[],{"intervention":6710,"totalTrials":97,"cells":6711},"MEMP1972A",{"EARLY_PHASE1":6712,"PHASE1":6714,"PHASE2":6725,"PHASE3":6739,"PHASE4":6741,"NA":6743},{"trials":6713,"activeCount":101},[],{"trials":6715,"activeCount":101},[6716],{"nctId":6717,"briefTitle":6718,"status":242,"phases":6719,"primaryCompletion":6310,"completion":6310,"start":6720,"enrollment":6721,"conditions":6722,"interventions":6724},"NCT01160861","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis",[89],"2010-07-11",36,[6723],"Allergic Rhinitis",[6710],{"trials":6726,"activeCount":101},[6727,6733],{"nctId":6728,"briefTitle":6729,"status":242,"phases":6730,"primaryCompletion":1483,"completion":1363,"start":1515,"enrollment":5134,"conditions":6731,"interventions":6732},"NCT01582503","A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)",[90],[31],[6710,6710,6710],{"nctId":6734,"briefTitle":6735,"status":242,"phases":6736,"primaryCompletion":1217,"completion":2785,"start":1160,"enrollment":5588,"conditions":6737,"interventions":6738},"NCT01196039","A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)",[90],[31],[6710],{"trials":6740,"activeCount":101},[],{"trials":6742,"activeCount":101},[],{"trials":6744,"activeCount":101},[],{"intervention":1355,"totalTrials":97,"cells":6746},{"EARLY_PHASE1":6747,"PHASE1":6749,"PHASE2":6751,"PHASE3":6772,"PHASE4":6774,"NA":6776},{"trials":6748,"activeCount":101},[],{"trials":6750,"activeCount":101},[],{"trials":6752,"activeCount":101},[6753,6762,6768],{"nctId":6754,"briefTitle":6755,"status":242,"phases":6756,"primaryCompletion":6757,"completion":6758,"start":6759,"enrollment":1345,"conditions":6760,"interventions":6761},"NCT00833417","A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma",[90],"2010-11-26","2014-04-09","2009-02-10",[1337],[1355],{"nctId":6763,"briefTitle":6764,"status":242,"phases":6765,"primaryCompletion":3559,"completion":3559,"start":4612,"enrollment":1345,"conditions":6766,"interventions":6767},"NCT00739661","A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission",[90],[1284],[1355],{"nctId":1349,"briefTitle":1350,"status":242,"phases":6769,"primaryCompletion":1160,"completion":1160,"start":1310,"enrollment":1352,"conditions":6770,"interventions":6771},[90],[1133],[1355,520,1356,1339],{"trials":6773,"activeCount":101},[],{"trials":6775,"activeCount":101},[],{"trials":6777,"activeCount":101},[],{"intervention":6779,"totalTrials":200,"cells":6780},"PRO131921",{"EARLY_PHASE1":6781,"PHASE1":6783,"PHASE2":6785,"PHASE3":6802,"PHASE4":6804,"NA":6806},{"trials":6782,"activeCount":101},[],{"trials":6784,"activeCount":101},[],{"trials":6786,"activeCount":101},[6787,6795],{"nctId":6788,"briefTitle":6789,"status":325,"phases":6790,"primaryCompletion":6791,"completion":6791,"start":6792,"enrollment":1228,"conditions":6793,"interventions":6794},"NCT00496132","A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",[89,90],"2009-06-17","2007-08-27",[2046],[6779],{"nctId":6796,"briefTitle":6797,"status":325,"phases":6798,"primaryCompletion":1130,"start":1451,"enrollment":6799,"conditions":6800,"interventions":6801},"NCT00452127","A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",[89,90],26,[331],[6779],{"trials":6803,"activeCount":101},[],{"trials":6805,"activeCount":101},[],{"trials":6807,"activeCount":101},[],{"intervention":3564,"totalTrials":200,"cells":6809},{"EARLY_PHASE1":6810,"PHASE1":6812,"PHASE2":6814,"PHASE3":6824,"PHASE4":6826,"NA":6828},{"trials":6811,"activeCount":101},[],{"trials":6813,"activeCount":101},[],{"trials":6815,"activeCount":101},[6816,6820],{"nctId":3556,"briefTitle":3557,"status":242,"phases":6817,"primaryCompletion":1159,"start":3559,"enrollment":3560,"conditions":6818,"interventions":6819},[90],[21],[3563,3564,3565,914],{"nctId":5786,"briefTitle":5787,"status":242,"phases":6821,"primaryCompletion":5789,"completion":5789,"start":5790,"enrollment":5134,"conditions":6822,"interventions":6823},[90],[21],[3537,5793,3536,5794],{"trials":6825,"activeCount":101},[],{"trials":6827,"activeCount":101},[],{"trials":6829,"activeCount":101},[],{"intervention":6831,"totalTrials":200,"cells":6832},"MTPS9579A",{"EARLY_PHASE1":6833,"PHASE1":6835,"PHASE2":6837,"PHASE3":6857,"PHASE4":6859,"NA":6861},{"trials":6834,"activeCount":101},[],{"trials":6836,"activeCount":101},[],{"trials":6838,"activeCount":101},[6839,6847],{"nctId":6840,"briefTitle":6841,"status":242,"phases":6842,"primaryCompletion":6843,"completion":6843,"start":6844,"enrollment":760,"conditions":6845,"interventions":6846},"NCT04092582","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller",[90],"2022-05-19","2019-10-31",[31],[6831],{"nctId":6848,"briefTitle":6849,"status":826,"phases":6850,"primaryCompletion":6851,"completion":6852,"start":6853,"enrollment":101,"conditions":6854,"interventions":6856},"NCT05129423","A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria",[90],"2024-07-31","2024-08-31","2022-07-31",[6855],"Chronic Spontaneous Urticaria",[6831],{"trials":6858,"activeCount":101},[],{"trials":6860,"activeCount":101},[],{"trials":6862,"activeCount":101},[],{"intervention":1211,"totalTrials":200,"cells":6864},{"EARLY_PHASE1":6865,"PHASE1":6867,"PHASE2":6878,"PHASE3":6884,"PHASE4":6886,"NA":6888},{"trials":6866,"activeCount":101},[],{"trials":6868,"activeCount":101},[6869],{"nctId":6870,"briefTitle":6871,"status":242,"phases":6872,"primaryCompletion":6873,"completion":6873,"start":1310,"enrollment":25,"conditions":6874,"interventions":6875},"NCT00664898","A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma",[89],"2010-04-08",[502],[6876,6877],"bortezomib","SGN-40",{"trials":6879,"activeCount":101},[6880],{"nctId":1204,"briefTitle":1205,"status":242,"phases":6881,"primaryCompletion":1207,"completion":1207,"start":1208,"enrollment":640,"conditions":6882,"interventions":6883},[90],[502],[520,1211],{"trials":6885,"activeCount":101},[],{"trials":6887,"activeCount":101},[],{"trials":6889,"activeCount":101},[],{"intervention":6115,"totalTrials":200,"cells":6891},{"EARLY_PHASE1":6892,"PHASE1":6894,"PHASE2":6896,"PHASE3":6911,"PHASE4":6913,"NA":6915},{"trials":6893,"activeCount":101},[],{"trials":6895,"activeCount":101},[],{"trials":6897,"activeCount":101},[6898,6907],{"nctId":6899,"briefTitle":6900,"status":242,"phases":6901,"primaryCompletion":6902,"completion":6903,"start":4341,"enrollment":1048,"conditions":6904,"interventions":6906},"NCT03747575","A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis",[90],"2020-03-11","2020-05-05",[6905],"Atopic Dermatitis",[6115],{"nctId":6106,"briefTitle":6107,"status":242,"phases":6908,"primaryCompletion":6109,"completion":6110,"start":6111,"enrollment":6112,"conditions":6909,"interventions":6910},[90],[890],[6115,6116,6068,6117],{"trials":6912,"activeCount":101},[],{"trials":6914,"activeCount":101},[],{"trials":6916,"activeCount":101},[],{"intervention":2589,"totalTrials":200,"cells":6918},{"EARLY_PHASE1":6919,"PHASE1":6921,"PHASE2":6923,"PHASE3":6933,"PHASE4":6935,"NA":6937},{"trials":6920,"activeCount":101},[],{"trials":6922,"activeCount":101},[],{"trials":6924,"activeCount":101},[6925,6929],{"nctId":2582,"briefTitle":2583,"status":242,"phases":6926,"primaryCompletion":2585,"completion":2585,"start":2586,"enrollment":418,"conditions":6927,"interventions":6928},[89,90],[732],[2545,2589,2036,2590,2591,2592,508],{"nctId":2594,"briefTitle":2595,"status":242,"phases":6930,"primaryCompletion":2597,"completion":2598,"start":2599,"enrollment":166,"conditions":6931,"interventions":6932},[90],[2601],[2603,2604,2605,2606,2607],{"trials":6934,"activeCount":101},[],{"trials":6936,"activeCount":101},[],{"trials":6938,"activeCount":101},[],{"intervention":2591,"totalTrials":200,"cells":6940},{"EARLY_PHASE1":6941,"PHASE1":6943,"PHASE2":6945,"PHASE3":6955,"PHASE4":6957,"NA":6959},{"trials":6942,"activeCount":101},[],{"trials":6944,"activeCount":101},[],{"trials":6946,"activeCount":101},[6947,6951],{"nctId":2582,"briefTitle":2583,"status":242,"phases":6948,"primaryCompletion":2585,"completion":2585,"start":2586,"enrollment":418,"conditions":6949,"interventions":6950},[89,90],[732],[2545,2589,2036,2590,2591,2592,508],{"nctId":4559,"briefTitle":4560,"status":242,"phases":6952,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":6953,"interventions":6954},[89,90],[4567],[4569,4570,748,2592,2591],{"trials":6956,"activeCount":101},[],{"trials":6958,"activeCount":101},[],{"trials":6960,"activeCount":101},[],{"intervention":3536,"totalTrials":200,"cells":6962},{"EARLY_PHASE1":6963,"PHASE1":6965,"PHASE2":6971,"PHASE3":6977,"PHASE4":6979,"NA":6981},{"trials":6964,"activeCount":101},[],{"trials":6966,"activeCount":101},[6967],{"nctId":3529,"briefTitle":3530,"status":242,"phases":6968,"primaryCompletion":1883,"completion":1883,"start":3532,"enrollment":3533,"conditions":6969,"interventions":6970},[89],[15],[3536,3537,3522,1465],{"trials":6972,"activeCount":101},[6973],{"nctId":5786,"briefTitle":5787,"status":242,"phases":6974,"primaryCompletion":5789,"completion":5789,"start":5790,"enrollment":5134,"conditions":6975,"interventions":6976},[90],[21],[3537,5793,3536,5794],{"trials":6978,"activeCount":101},[],{"trials":6980,"activeCount":101},[],{"trials":6982,"activeCount":101},[],{"intervention":6984,"totalTrials":200,"cells":6985},"Lampalizumab",{"EARLY_PHASE1":6986,"PHASE1":6988,"PHASE2":6990,"PHASE3":7011,"PHASE4":7013,"NA":7015},{"trials":6987,"activeCount":101},[],{"trials":6989,"activeCount":101},[],{"trials":6991,"activeCount":101},[6992,7002],{"nctId":6993,"briefTitle":6994,"status":325,"phases":6995,"primaryCompletion":6996,"completion":6997,"start":6998,"enrollment":6999,"conditions":7000,"interventions":7001},"NCT01602120","An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy",[90],"2017-11-08","2018-02-09","2012-05-29",159,[2233],[6984],{"nctId":7003,"briefTitle":7004,"status":242,"phases":7005,"primaryCompletion":7006,"completion":7006,"start":7007,"enrollment":7008,"conditions":7009,"interventions":7010},"NCT02288559","A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy",[90],"2017-06-02","2015-03-30",96,[2233],[6984],{"trials":7012,"activeCount":101},[],{"trials":7014,"activeCount":101},[],{"trials":7016,"activeCount":101},[],{"intervention":7018,"totalTrials":200,"cells":7019},"rhuMAb 2C4",{"EARLY_PHASE1":7020,"PHASE1":7022,"PHASE2":7030,"PHASE3":7038,"PHASE4":7040,"NA":7042},{"trials":7021,"activeCount":101},[],{"trials":7023,"activeCount":101},[7024],{"nctId":7025,"briefTitle":7026,"status":242,"phases":7027,"primaryCompletion":4948,"completion":4948,"start":994,"enrollment":22,"conditions":7028,"interventions":7029},"NCT00027027","Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors",[89],[695],[7018],{"trials":7031,"activeCount":101},[7032],{"nctId":7033,"briefTitle":7034,"status":242,"phases":7035,"primaryCompletion":4947,"completion":4947,"start":3839,"enrollment":1100,"conditions":7036,"interventions":7037},"NCT00058539","Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer",[90],[4567],[7018],{"trials":7039,"activeCount":101},[],{"trials":7041,"activeCount":101},[],{"trials":7043,"activeCount":101},[],{"intervention":7045,"totalTrials":200,"cells":7046},"Galegenimab",{"EARLY_PHASE1":7047,"PHASE1":7049,"PHASE2":7051,"PHASE3":7072,"PHASE4":7074,"NA":7076},{"trials":7048,"activeCount":101},[],{"trials":7050,"activeCount":101},[],{"trials":7052,"activeCount":101},[7053,7062],{"nctId":7054,"briefTitle":7055,"status":325,"phases":7056,"primaryCompletion":7057,"completion":7057,"start":7058,"enrollment":4468,"conditions":7059,"interventions":7061},"NCT04607148","A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration",[90],"2022-11-14","2020-11-16",[7060,2233],"Macular Degeneration, Age-Related",[7045],{"nctId":7063,"briefTitle":7064,"status":325,"phases":7065,"primaryCompletion":7066,"completion":7066,"start":7067,"enrollment":7068,"conditions":7069,"interventions":7070},"NCT03972709","A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)",[90],"2022-10-27","2019-06-03",372,[7060,2233],[7045,7071],"Sham Control",{"trials":7073,"activeCount":101},[],{"trials":7075,"activeCount":101},[],{"trials":7077,"activeCount":101},[],{"intervention":7079,"totalTrials":200,"cells":7080},"Astegolimab",{"EARLY_PHASE1":7081,"PHASE1":7083,"PHASE2":7094,"PHASE3":7106,"PHASE4":7108,"NA":7110},{"trials":7082,"activeCount":101},[],{"trials":7084,"activeCount":101},[7085],{"nctId":7086,"briefTitle":7087,"status":242,"phases":7088,"primaryCompletion":7089,"completion":7089,"start":7090,"enrollment":7091,"conditions":7092,"interventions":7093},"NCT06462118","A Study to Evaluate the Effect of Injection Site on PK of Astegolimab in Healthy Subjects",[89],"2024-10-22","2024-06-17",78,[34],[7079],{"trials":7095,"activeCount":101},[7096],{"nctId":7097,"briefTitle":7098,"status":242,"phases":7099,"primaryCompletion":7100,"completion":7101,"start":7102,"enrollment":7103,"conditions":7104,"interventions":7105},"NCT05037929","A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease",[90],"2025-02-24","2025-07-07","2021-10-05",1334,[2283],[7079],{"trials":7107,"activeCount":101},[],{"trials":7109,"activeCount":101},[],{"trials":7111,"activeCount":101},[],{"intervention":792,"totalTrials":200,"cells":7113},{"EARLY_PHASE1":7114,"PHASE1":7116,"PHASE2":7128,"PHASE3":7134,"PHASE4":7136,"NA":7138},{"trials":7115,"activeCount":101},[],{"trials":7117,"activeCount":101},[7118],{"nctId":7119,"briefTitle":7120,"status":242,"phases":7121,"primaryCompletion":7122,"completion":7123,"start":7124,"enrollment":7125,"conditions":7126,"interventions":7127},"NCT02219724","A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2017-07-14","2019-08-18","2014-08-12",174,[695],[792],{"trials":7129,"activeCount":101},[7130],{"nctId":785,"briefTitle":786,"status":325,"phases":7131,"primaryCompletion":788,"completion":788,"start":789,"enrollment":233,"conditions":7132,"interventions":7133},[90],[604],[792,487],{"trials":7135,"activeCount":101},[],{"trials":7137,"activeCount":101},[],{"trials":7139,"activeCount":101},[],{"intervention":1801,"totalTrials":200,"cells":7141},{"EARLY_PHASE1":7142,"PHASE1":7144,"PHASE2":7146,"PHASE3":7156,"PHASE4":7158,"NA":7160},{"trials":7143,"activeCount":101},[],{"trials":7145,"activeCount":101},[],{"trials":7147,"activeCount":101},[7148,7152],{"nctId":1793,"briefTitle":1794,"status":242,"phases":7149,"primaryCompletion":1796,"completion":1796,"start":1515,"enrollment":1797,"conditions":7150,"interventions":7151},[90],[1050],[1800,1801,1802,998,1053],{"nctId":5892,"briefTitle":5893,"status":242,"phases":7153,"primaryCompletion":5895,"completion":5895,"start":5896,"enrollment":5897,"conditions":7154,"interventions":7155},[90],[29],[519,1144,1801,5900,5901],{"trials":7157,"activeCount":101},[],{"trials":7159,"activeCount":101},[],{"trials":7161,"activeCount":101},[],{"intervention":1802,"totalTrials":200,"cells":7163},{"EARLY_PHASE1":7164,"PHASE1":7166,"PHASE2":7168,"PHASE3":7178,"PHASE4":7180,"NA":7182},{"trials":7165,"activeCount":101},[],{"trials":7167,"activeCount":101},[],{"trials":7169,"activeCount":101},[7170,7174],{"nctId":1793,"briefTitle":1794,"status":242,"phases":7171,"primaryCompletion":1796,"completion":1796,"start":1515,"enrollment":1797,"conditions":7172,"interventions":7173},[90],[1050],[1800,1801,1802,998,1053],{"nctId":1854,"briefTitle":1855,"status":242,"phases":7175,"primaryCompletion":937,"completion":1857,"start":1515,"enrollment":1858,"conditions":7176,"interventions":7177},[90],[1050],[1802,1861,998],{"trials":7179,"activeCount":101},[],{"trials":7181,"activeCount":101},[],{"trials":7183,"activeCount":101},[],{"intervention":7185,"totalTrials":200,"cells":7186},"FCFD4514S",{"EARLY_PHASE1":7187,"PHASE1":7189,"PHASE2":7197,"PHASE3":7205,"PHASE4":7207,"NA":7209},{"trials":7188,"activeCount":101},[],{"trials":7190,"activeCount":101},[7191],{"nctId":7192,"briefTitle":7193,"status":242,"phases":7194,"primaryCompletion":5842,"completion":5842,"start":4372,"enrollment":25,"conditions":7195,"interventions":7196},"NCT00973011","A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy",[89],[2233],[7185],{"trials":7198,"activeCount":101},[7199],{"nctId":7200,"briefTitle":7201,"status":242,"phases":7202,"primaryCompletion":1149,"completion":1149,"start":1461,"enrollment":6102,"conditions":7203,"interventions":7204},"NCT01229215","A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy",[90],[2233],[7185],{"trials":7206,"activeCount":101},[],{"trials":7208,"activeCount":101},[],{"trials":7210,"activeCount":101},[],{"intervention":1093,"totalTrials":200,"cells":7212},{"EARLY_PHASE1":7213,"PHASE1":7215,"PHASE2":7221,"PHASE3":7227,"PHASE4":7229,"NA":7231},{"trials":7214,"activeCount":101},[],{"trials":7216,"activeCount":101},[7217],{"nctId":1085,"briefTitle":1086,"status":242,"phases":7218,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":7219,"interventions":7220},[89],[24],[1027,1093,1093],{"trials":7222,"activeCount":101},[7223],{"nctId":4405,"briefTitle":4406,"status":242,"phases":7224,"primaryCompletion":3559,"completion":2785,"start":1245,"enrollment":4408,"conditions":7225,"interventions":7226},[90],[27],[4386,1093],{"trials":7228,"activeCount":101},[],{"trials":7230,"activeCount":101},[],{"trials":7232,"activeCount":101},[],{"intervention":1144,"totalTrials":200,"cells":7234},{"EARLY_PHASE1":7235,"PHASE1":7237,"PHASE2":7243,"PHASE3":7249,"PHASE4":7251,"NA":7253},{"trials":7236,"activeCount":101},[],{"trials":7238,"activeCount":101},[7239],{"nctId":1137,"briefTitle":1138,"status":242,"phases":7240,"primaryCompletion":1140,"completion":896,"start":1130,"enrollment":1141,"conditions":7241,"interventions":7242},[89],[1133],[1144,1027,1105],{"trials":7244,"activeCount":101},[7245],{"nctId":5892,"briefTitle":5893,"status":242,"phases":7246,"primaryCompletion":5895,"completion":5895,"start":5896,"enrollment":5897,"conditions":7247,"interventions":7248},[90],[29],[519,1144,1801,5900,5901],{"trials":7250,"activeCount":101},[],{"trials":7252,"activeCount":101},[],{"trials":7254,"activeCount":101},[],{"intervention":6251,"totalTrials":200,"cells":7256},{"EARLY_PHASE1":7257,"PHASE1":7259,"PHASE2":7261,"PHASE3":7271,"PHASE4":7273,"NA":7275},{"trials":7258,"activeCount":101},[],{"trials":7260,"activeCount":101},[],{"trials":7262,"activeCount":101},[7263,7267],{"nctId":6243,"briefTitle":6244,"status":325,"phases":7264,"primaryCompletion":6246,"completion":6246,"start":6247,"enrollment":6248,"conditions":7265,"interventions":7266},[90],[6227],[6251,6214],{"nctId":6253,"briefTitle":6254,"status":242,"phases":7268,"primaryCompletion":6256,"completion":6257,"start":6258,"enrollment":6259,"conditions":7269,"interventions":7270},[90],[6227],[6251,6214],{"trials":7272,"activeCount":101},[],{"trials":7274,"activeCount":101},[],{"trials":7276,"activeCount":101},[],{"intervention":1135,"totalTrials":200,"cells":7278},{"EARLY_PHASE1":7279,"PHASE1":7281,"PHASE2":7287,"PHASE3":7293,"PHASE4":7295,"NA":7297},{"trials":7280,"activeCount":101},[],{"trials":7282,"activeCount":101},[7283],{"nctId":1127,"briefTitle":1128,"status":242,"phases":7284,"primaryCompletion":1070,"completion":1070,"start":1130,"enrollment":1131,"conditions":7285,"interventions":7286},[89],[1133],[1027,1135,1121],{"trials":7288,"activeCount":101},[7289],{"nctId":1330,"briefTitle":1331,"status":242,"phases":7290,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":7291,"interventions":7292},[90],[1284,1337,1133],[699,1135,1339,520],{"trials":7294,"activeCount":101},[],{"trials":7296,"activeCount":101},[],{"trials":7298,"activeCount":101},[],{"intervention":7300,"totalTrials":200,"cells":7301},"GDC-8264",{"EARLY_PHASE1":7302,"PHASE1":7304,"PHASE2":7315,"PHASE3":7326,"PHASE4":7328,"NA":7330},{"trials":7303,"activeCount":101},[],{"trials":7305,"activeCount":101},[7306],{"nctId":7307,"briefTitle":7308,"status":242,"phases":7309,"primaryCompletion":7310,"completion":7310,"start":7311,"enrollment":3791,"conditions":7312,"interventions":7314},"NCT05673876","A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)",[89],"2024-01-15","2023-04-06",[7313],"Acute Graft-versus-host Disease",[7300],{"trials":7316,"activeCount":101},[7317],{"nctId":7318,"briefTitle":7319,"status":325,"phases":7320,"primaryCompletion":7321,"completion":7321,"start":7322,"enrollment":622,"conditions":7323,"interventions":7325},"NCT06602453","A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)",[90],"2026-03-03","2025-01-17",[7324],"Acute Kidney Injury",[7300],{"trials":7327,"activeCount":101},[],{"trials":7329,"activeCount":101},[],{"trials":7331,"activeCount":101},[],{"intervention":1339,"totalTrials":200,"cells":7333},{"EARLY_PHASE1":7334,"PHASE1":7336,"PHASE2":7338,"PHASE3":7348,"PHASE4":7350,"NA":7352},{"trials":7335,"activeCount":101},[],{"trials":7337,"activeCount":101},[],{"trials":7339,"activeCount":101},[7340,7344],{"nctId":1330,"briefTitle":1331,"status":242,"phases":7341,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":7342,"interventions":7343},[90],[1284,1337,1133],[699,1135,1339,520],{"nctId":1349,"briefTitle":1350,"status":242,"phases":7345,"primaryCompletion":1160,"completion":1160,"start":1310,"enrollment":1352,"conditions":7346,"interventions":7347},[90],[1133],[1355,520,1356,1339],{"trials":7349,"activeCount":101},[],{"trials":7351,"activeCount":101},[],{"trials":7353,"activeCount":101},[],{"intervention":7355,"totalTrials":200,"cells":7356},"rhuMAb Beta7",{"EARLY_PHASE1":7357,"PHASE1":7359,"PHASE2":7368,"PHASE3":7376,"PHASE4":7378,"NA":7380},{"trials":7358,"activeCount":101},[],{"trials":7360,"activeCount":101},[7361],{"nctId":7362,"briefTitle":7363,"status":242,"phases":7364,"primaryCompletion":1178,"completion":1374,"start":3628,"enrollment":7365,"conditions":7366,"interventions":7367},"NCT00694980","A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis",[89],48,[2001],[7355],{"trials":7369,"activeCount":101},[7370],{"nctId":7371,"briefTitle":7372,"status":242,"phases":7373,"primaryCompletion":1374,"completion":1812,"start":1178,"enrollment":1764,"conditions":7374,"interventions":7375},"NCT01336465","Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis",[90],[2001],[7355],{"trials":7377,"activeCount":101},[],{"trials":7379,"activeCount":101},[],{"trials":7381,"activeCount":101},[],{"intervention":7383,"totalTrials":116,"cells":7384},"KPL-716",{"EARLY_PHASE1":7385,"PHASE1":7387,"PHASE2":7389,"PHASE3":7403,"PHASE4":7405,"NA":7407},{"trials":7386,"activeCount":101},[],{"trials":7388,"activeCount":101},[],{"trials":7390,"activeCount":101},[7391],{"nctId":7392,"briefTitle":7393,"status":242,"phases":7394,"primaryCompletion":7395,"completion":7396,"start":7397,"enrollment":4373,"conditions":7398,"interventions":7402},"NCT03858634","A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases",[90],"2020-04-01","2020-06-08","2019-05-29",[3705,7399,7400,7401,3938],"Chronic Idiopathic Pruritus","Lichen Planus","Lichen Simplex Chronicus",[7383],{"trials":7404,"activeCount":101},[],{"trials":7406,"activeCount":101},[],{"trials":7408,"activeCount":101},[],{"intervention":7410,"totalTrials":116,"cells":7411},"ABT-263",{"EARLY_PHASE1":7412,"PHASE1":7414,"PHASE2":7416,"PHASE3":7424,"PHASE4":7426,"NA":7428},{"trials":7413,"activeCount":101},[],{"trials":7415,"activeCount":101},[],{"trials":7417,"activeCount":101},[7418],{"nctId":7419,"briefTitle":7420,"status":242,"phases":7421,"primaryCompletion":908,"completion":908,"start":1254,"enrollment":2055,"conditions":7422,"interventions":7423},"NCT01087151","A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)",[90],[2046],[7410,3594],{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[],{"intervention":3550,"totalTrials":116,"cells":7431},{"EARLY_PHASE1":7432,"PHASE1":7434,"PHASE2":7436,"PHASE3":7442,"PHASE4":7444,"NA":7446},{"trials":7433,"activeCount":101},[],{"trials":7435,"activeCount":101},[],{"trials":7437,"activeCount":101},[7438],{"nctId":3541,"briefTitle":3542,"status":242,"phases":7439,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":7440,"interventions":7441},[90],[21],[508,3522,3550,3551,3552,3553,3554],{"trials":7443,"activeCount":101},[],{"trials":7445,"activeCount":101},[],{"trials":7447,"activeCount":101},[],{"intervention":3551,"totalTrials":116,"cells":7449},{"EARLY_PHASE1":7450,"PHASE1":7452,"PHASE2":7454,"PHASE3":7460,"PHASE4":7462,"NA":7464},{"trials":7451,"activeCount":101},[],{"trials":7453,"activeCount":101},[],{"trials":7455,"activeCount":101},[7456],{"nctId":3541,"briefTitle":3542,"status":242,"phases":7457,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":7458,"interventions":7459},[90],[21],[508,3522,3550,3551,3552,3553,3554],{"trials":7461,"activeCount":101},[],{"trials":7463,"activeCount":101},[],{"trials":7465,"activeCount":101},[],{"intervention":3552,"totalTrials":116,"cells":7467},{"EARLY_PHASE1":7468,"PHASE1":7470,"PHASE2":7472,"PHASE3":7478,"PHASE4":7480,"NA":7482},{"trials":7469,"activeCount":101},[],{"trials":7471,"activeCount":101},[],{"trials":7473,"activeCount":101},[7474],{"nctId":3541,"briefTitle":3542,"status":242,"phases":7475,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":7476,"interventions":7477},[90],[21],[508,3522,3550,3551,3552,3553,3554],{"trials":7479,"activeCount":101},[],{"trials":7481,"activeCount":101},[],{"trials":7483,"activeCount":101},[],{"intervention":3554,"totalTrials":116,"cells":7485},{"EARLY_PHASE1":7486,"PHASE1":7488,"PHASE2":7490,"PHASE3":7496,"PHASE4":7498,"NA":7500},{"trials":7487,"activeCount":101},[],{"trials":7489,"activeCount":101},[],{"trials":7491,"activeCount":101},[7492],{"nctId":3541,"briefTitle":3542,"status":242,"phases":7493,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":7494,"interventions":7495},[90],[21],[508,3522,3550,3551,3552,3553,3554],{"trials":7497,"activeCount":101},[],{"trials":7499,"activeCount":101},[],{"trials":7501,"activeCount":101},[],{"intervention":3563,"totalTrials":116,"cells":7503},{"EARLY_PHASE1":7504,"PHASE1":7506,"PHASE2":7508,"PHASE3":7514,"PHASE4":7516,"NA":7518},{"trials":7505,"activeCount":101},[],{"trials":7507,"activeCount":101},[],{"trials":7509,"activeCount":101},[7510],{"nctId":3556,"briefTitle":3557,"status":242,"phases":7511,"primaryCompletion":1159,"start":3559,"enrollment":3560,"conditions":7512,"interventions":7513},[90],[21],[3563,3564,3565,914],{"trials":7515,"activeCount":101},[],{"trials":7517,"activeCount":101},[],{"trials":7519,"activeCount":101},[],{"intervention":7521,"totalTrials":116,"cells":7522},"MCMV3068A",{"EARLY_PHASE1":7523,"PHASE1":7525,"PHASE2":7527,"PHASE3":7539,"PHASE4":7541,"NA":7543},{"trials":7524,"activeCount":101},[],{"trials":7526,"activeCount":101},[],{"trials":7528,"activeCount":101},[7529],{"nctId":7530,"briefTitle":7531,"status":242,"phases":7532,"primaryCompletion":7533,"completion":7533,"start":7534,"enrollment":1641,"conditions":7535,"interventions":7537},"NCT01753167","A Study of MCMV5322A\u002FMCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients",[90],"2014-10-15","2012-12-14",[7536],"Cytomegalovirus Infections",[7521,7538],"MCMV5322A",{"trials":7540,"activeCount":101},[],{"trials":7542,"activeCount":101},[],{"trials":7544,"activeCount":101},[],{"intervention":7538,"totalTrials":116,"cells":7546},{"EARLY_PHASE1":7547,"PHASE1":7549,"PHASE2":7551,"PHASE3":7557,"PHASE4":7559,"NA":7561},{"trials":7548,"activeCount":101},[],{"trials":7550,"activeCount":101},[],{"trials":7552,"activeCount":101},[7553],{"nctId":7530,"briefTitle":7531,"status":242,"phases":7554,"primaryCompletion":7533,"completion":7533,"start":7534,"enrollment":1641,"conditions":7555,"interventions":7556},[90],[7536],[7521,7538],{"trials":7558,"activeCount":101},[],{"trials":7560,"activeCount":101},[],{"trials":7562,"activeCount":101},[],{"intervention":1201,"totalTrials":116,"cells":7564},{"EARLY_PHASE1":7565,"PHASE1":7567,"PHASE2":7569,"PHASE3":7575,"PHASE4":7577,"NA":7579},{"trials":7566,"activeCount":101},[],{"trials":7568,"activeCount":101},[],{"trials":7570,"activeCount":101},[7571],{"nctId":1192,"briefTitle":1193,"status":242,"phases":7572,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":7573,"interventions":7574},[90],[18],[1200,520,525,1201,1202],{"trials":7576,"activeCount":101},[],{"trials":7578,"activeCount":101},[],{"trials":7580,"activeCount":101},[],{"intervention":1202,"totalTrials":116,"cells":7582},{"EARLY_PHASE1":7583,"PHASE1":7585,"PHASE2":7587,"PHASE3":7593,"PHASE4":7595,"NA":7597},{"trials":7584,"activeCount":101},[],{"trials":7586,"activeCount":101},[],{"trials":7588,"activeCount":101},[7589],{"nctId":1192,"briefTitle":1193,"status":242,"phases":7590,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":7591,"interventions":7592},[90],[18],[1200,520,525,1201,1202],{"trials":7594,"activeCount":101},[],{"trials":7596,"activeCount":101},[],{"trials":7598,"activeCount":101},[],{"intervention":3574,"totalTrials":116,"cells":7600},{"EARLY_PHASE1":7601,"PHASE1":7603,"PHASE2":7605,"PHASE3":7611,"PHASE4":7613,"NA":7615},{"trials":7602,"activeCount":101},[],{"trials":7604,"activeCount":101},[],{"trials":7606,"activeCount":101},[7607],{"nctId":3567,"briefTitle":3568,"status":325,"phases":7608,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":12,"conditions":7609,"interventions":7610},[90],[21],[3574,3522,3575,2623],{"trials":7612,"activeCount":101},[],{"trials":7614,"activeCount":101},[],{"trials":7616,"activeCount":101},[],{"intervention":7618,"totalTrials":116,"cells":7619},"Nutropin AQ [somatropin (DNA origin) injection]",{"EARLY_PHASE1":7620,"PHASE1":7622,"PHASE2":7624,"PHASE3":7633,"PHASE4":7635,"NA":7637},{"trials":7621,"activeCount":101},[],{"trials":7623,"activeCount":101},[],{"trials":7625,"activeCount":101},[7626],{"nctId":7627,"briefTitle":7628,"status":242,"phases":7629,"completion":1451,"start":3821,"enrollment":7630,"conditions":7631,"interventions":7632},"NCT00079742","A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis",[90],68,[4076],[7618],{"trials":7634,"activeCount":101},[],{"trials":7636,"activeCount":101},[],{"trials":7638,"activeCount":101},[],{"intervention":4316,"totalTrials":116,"cells":7640},{"EARLY_PHASE1":7641,"PHASE1":7643,"PHASE2":7645,"PHASE3":7651,"PHASE4":7653,"NA":7655},{"trials":7642,"activeCount":101},[],{"trials":7644,"activeCount":101},[],{"trials":7646,"activeCount":101},[7647],{"nctId":4305,"briefTitle":4306,"status":242,"phases":7648,"primaryCompletion":4308,"completion":4309,"start":4310,"enrollment":4311,"conditions":7649,"interventions":7650},[89,90],[4313,4314],[2036,4316,2590,508],{"trials":7652,"activeCount":101},[],{"trials":7654,"activeCount":101},[],{"trials":7656,"activeCount":101},[],{"intervention":734,"totalTrials":116,"cells":7658},{"EARLY_PHASE1":7659,"PHASE1":7661,"PHASE2":7663,"PHASE3":7669,"PHASE4":7671,"NA":7673},{"trials":7660,"activeCount":101},[],{"trials":7662,"activeCount":101},[],{"trials":7664,"activeCount":101},[7665],{"nctId":723,"briefTitle":724,"status":242,"phases":7666,"primaryCompletion":726,"completion":727,"start":728,"enrollment":729,"conditions":7667,"interventions":7668},[89,90],[731,732],[734,487,735],{"trials":7670,"activeCount":101},[],{"trials":7672,"activeCount":101},[],{"trials":7674,"activeCount":101},[],{"intervention":735,"totalTrials":116,"cells":7676},{"EARLY_PHASE1":7677,"PHASE1":7679,"PHASE2":7681,"PHASE3":7687,"PHASE4":7689,"NA":7691},{"trials":7678,"activeCount":101},[],{"trials":7680,"activeCount":101},[],{"trials":7682,"activeCount":101},[7683],{"nctId":723,"briefTitle":724,"status":242,"phases":7684,"primaryCompletion":726,"completion":727,"start":728,"enrollment":729,"conditions":7685,"interventions":7686},[89,90],[731,732],[734,487,735],{"trials":7688,"activeCount":101},[],{"trials":7690,"activeCount":101},[],{"trials":7692,"activeCount":101},[],{"intervention":7694,"totalTrials":116,"cells":7695},"Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody",{"EARLY_PHASE1":7696,"PHASE1":7698,"PHASE2":7700,"PHASE3":7712,"PHASE4":7714,"NA":7716},{"trials":7697,"activeCount":101},[],{"trials":7699,"activeCount":101},[],{"trials":7701,"activeCount":101},[7702],{"nctId":7703,"briefTitle":7704,"status":242,"phases":7705,"primaryCompletion":7706,"completion":7707,"start":7708,"enrollment":7709,"conditions":7710,"interventions":7711},"NCT01846416","A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]",[90],"2015-01-07","2017-12-18","2013-05-30",138,[27],[7694],{"trials":7713,"activeCount":101},[],{"trials":7715,"activeCount":101},[],{"trials":7717,"activeCount":101},[],{"intervention":7719,"totalTrials":116,"cells":7720},"HAE1",{"EARLY_PHASE1":7721,"PHASE1":7723,"PHASE2":7725,"PHASE3":7733,"PHASE4":7735,"NA":7737},{"trials":7722,"activeCount":101},[],{"trials":7724,"activeCount":101},[],{"trials":7726,"activeCount":101},[7727],{"nctId":7728,"briefTitle":7729,"status":242,"phases":7730,"completion":1262,"start":4400,"enrollment":3533,"conditions":7731,"interventions":7732},"NCT00406965","A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma",[90],[3698],[7719],{"trials":7734,"activeCount":101},[],{"trials":7736,"activeCount":101},[],{"trials":7738,"activeCount":101},[],{"intervention":749,"totalTrials":116,"cells":7740},{"EARLY_PHASE1":7741,"PHASE1":7743,"PHASE2":7745,"PHASE3":7751,"PHASE4":7753,"NA":7755},{"trials":7742,"activeCount":101},[],{"trials":7744,"activeCount":101},[],{"trials":7746,"activeCount":101},[7747],{"nctId":737,"briefTitle":738,"status":242,"phases":7748,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":7749,"interventions":7750},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"trials":7752,"activeCount":101},[],{"trials":7754,"activeCount":101},[],{"trials":7756,"activeCount":101},[],{"intervention":750,"totalTrials":116,"cells":7758},{"EARLY_PHASE1":7759,"PHASE1":7761,"PHASE2":7763,"PHASE3":7769,"PHASE4":7771,"NA":7773},{"trials":7760,"activeCount":101},[],{"trials":7762,"activeCount":101},[],{"trials":7764,"activeCount":101},[7765],{"nctId":737,"briefTitle":738,"status":242,"phases":7766,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":7767,"interventions":7768},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"trials":7770,"activeCount":101},[],{"trials":7772,"activeCount":101},[],{"trials":7774,"activeCount":101},[],{"intervention":751,"totalTrials":116,"cells":7776},{"EARLY_PHASE1":7777,"PHASE1":7779,"PHASE2":7781,"PHASE3":7787,"PHASE4":7789,"NA":7791},{"trials":7778,"activeCount":101},[],{"trials":7780,"activeCount":101},[],{"trials":7782,"activeCount":101},[7783],{"nctId":737,"briefTitle":738,"status":242,"phases":7784,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":7785,"interventions":7786},[90],[745],[747,66,86,748,487,712,749,750,751,525,506,752],{"trials":7788,"activeCount":101},[],{"trials":7790,"activeCount":101},[],{"trials":7792,"activeCount":101},[],{"intervention":4323,"totalTrials":116,"cells":7794},{"EARLY_PHASE1":7795,"PHASE1":7797,"PHASE2":7799,"PHASE3":7805,"PHASE4":7807,"NA":7809},{"trials":7796,"activeCount":101},[],{"trials":7798,"activeCount":101},[],{"trials":7800,"activeCount":101},[7801],{"nctId":4318,"briefTitle":4319,"status":242,"phases":7802,"primaryCompletion":937,"completion":937,"start":3748,"enrollment":1021,"conditions":7803,"interventions":7804},[90],[2046],[2036,4323],{"trials":7806,"activeCount":101},[],{"trials":7808,"activeCount":101},[],{"trials":7810,"activeCount":101},[],{"intervention":7812,"totalTrials":116,"cells":7813},"MLDL1278A",{"EARLY_PHASE1":7814,"PHASE1":7816,"PHASE2":7818,"PHASE3":7829,"PHASE4":7831,"NA":7833},{"trials":7815,"activeCount":101},[],{"trials":7817,"activeCount":101},[],{"trials":7819,"activeCount":101},[7820],{"nctId":7821,"briefTitle":7822,"status":242,"phases":7823,"primaryCompletion":1159,"start":7824,"enrollment":7825,"conditions":7826,"interventions":7827},"NCT01258907","A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)",[90],"2010-03",147,[2258],[7812,7812,7828],"statin, stable dose",{"trials":7830,"activeCount":101},[],{"trials":7832,"activeCount":101},[],{"trials":7834,"activeCount":101},[],{"intervention":7828,"totalTrials":116,"cells":7836},{"EARLY_PHASE1":7837,"PHASE1":7839,"PHASE2":7841,"PHASE3":7847,"PHASE4":7849,"NA":7851},{"trials":7838,"activeCount":101},[],{"trials":7840,"activeCount":101},[],{"trials":7842,"activeCount":101},[7843],{"nctId":7821,"briefTitle":7822,"status":242,"phases":7844,"primaryCompletion":1159,"start":7824,"enrollment":7825,"conditions":7845,"interventions":7846},[90],[2258],[7812,7812,7828],{"trials":7848,"activeCount":101},[],{"trials":7850,"activeCount":101},[],{"trials":7852,"activeCount":101},[],{"intervention":6176,"totalTrials":116,"cells":7854},{"EARLY_PHASE1":7855,"PHASE1":7857,"PHASE2":7859,"PHASE3":7865,"PHASE4":7867,"NA":7869},{"trials":7856,"activeCount":101},[],{"trials":7858,"activeCount":101},[],{"trials":7860,"activeCount":101},[7861],{"nctId":6168,"briefTitle":6169,"status":242,"phases":7862,"primaryCompletion":6171,"completion":6171,"start":6172,"enrollment":4498,"conditions":7863,"interventions":7864},[90],[6174],[6136,6176],{"trials":7866,"activeCount":101},[],{"trials":7868,"activeCount":101},[],{"trials":7870,"activeCount":101},[],{"intervention":1800,"totalTrials":116,"cells":7872},{"EARLY_PHASE1":7873,"PHASE1":7875,"PHASE2":7877,"PHASE3":7883,"PHASE4":7885,"NA":7887},{"trials":7874,"activeCount":101},[],{"trials":7876,"activeCount":101},[],{"trials":7878,"activeCount":101},[7879],{"nctId":1793,"briefTitle":1794,"status":242,"phases":7880,"primaryCompletion":1796,"completion":1796,"start":1515,"enrollment":1797,"conditions":7881,"interventions":7882},[90],[1050],[1800,1801,1802,998,1053],{"trials":7884,"activeCount":101},[],{"trials":7886,"activeCount":101},[],{"trials":7888,"activeCount":101},[],{"intervention":4711,"totalTrials":116,"cells":7890},{"EARLY_PHASE1":7891,"PHASE1":7893,"PHASE2":7895,"PHASE3":7901,"PHASE4":7903,"NA":7905},{"trials":7892,"activeCount":101},[],{"trials":7894,"activeCount":101},[],{"trials":7896,"activeCount":101},[7897],{"nctId":4705,"briefTitle":4706,"status":826,"phases":7898,"primaryCompletion":1290,"completion":1290,"start":342,"enrollment":101,"conditions":7899,"interventions":7900},[90],[4314],[4710,4711,3594],{"trials":7902,"activeCount":101},[],{"trials":7904,"activeCount":101},[],{"trials":7906,"activeCount":101},[],{"intervention":6676,"totalTrials":116,"cells":7908},{"EARLY_PHASE1":7909,"PHASE1":7911,"PHASE2":7913,"PHASE3":7919,"PHASE4":7921,"NA":7923},{"trials":7910,"activeCount":101},[],{"trials":7912,"activeCount":101},[],{"trials":7914,"activeCount":101},[7915],{"nctId":6669,"briefTitle":6670,"status":325,"phases":7916,"primaryCompletion":6672,"completion":6672,"start":6673,"enrollment":6526,"conditions":7917,"interventions":7918},[90],[1284],[1083,6676],{"trials":7920,"activeCount":101},[],{"trials":7922,"activeCount":101},[],{"trials":7924,"activeCount":101},[],{"intervention":1816,"totalTrials":116,"cells":7926},{"EARLY_PHASE1":7927,"PHASE1":7929,"PHASE2":7931,"PHASE3":7937,"PHASE4":7939,"NA":7941},{"trials":7928,"activeCount":101},[],{"trials":7930,"activeCount":101},[],{"trials":7932,"activeCount":101},[7933],{"nctId":1808,"briefTitle":1809,"status":242,"phases":7934,"primaryCompletion":1811,"completion":1812,"start":948,"enrollment":1813,"conditions":7935,"interventions":7936},[89,90],[940],[998,1816,1817,998,1817],{"trials":7938,"activeCount":101},[],{"trials":7940,"activeCount":101},[],{"trials":7942,"activeCount":101},[],{"intervention":1295,"totalTrials":116,"cells":7944},{"EARLY_PHASE1":7945,"PHASE1":7947,"PHASE2":7949,"PHASE3":7955,"PHASE4":7957,"NA":7959},{"trials":7946,"activeCount":101},[],{"trials":7948,"activeCount":101},[],{"trials":7950,"activeCount":101},[7951],{"nctId":1287,"briefTitle":1288,"status":242,"phases":7952,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":7953,"interventions":7954},[90],[1133],[1221,520,1295,1154,524],{"trials":7956,"activeCount":101},[],{"trials":7958,"activeCount":101},[],{"trials":7960,"activeCount":101},[],{"intervention":5901,"totalTrials":116,"cells":7962},{"EARLY_PHASE1":7963,"PHASE1":7965,"PHASE2":7967,"PHASE3":7973,"PHASE4":7975,"NA":7977},{"trials":7964,"activeCount":101},[],{"trials":7966,"activeCount":101},[],{"trials":7968,"activeCount":101},[7969],{"nctId":5892,"briefTitle":5893,"status":242,"phases":7970,"primaryCompletion":5895,"completion":5895,"start":5896,"enrollment":5897,"conditions":7971,"interventions":7972},[90],[29],[519,1144,1801,5900,5901],{"trials":7974,"activeCount":101},[],{"trials":7976,"activeCount":101},[],{"trials":7978,"activeCount":101},[],{"intervention":4569,"totalTrials":116,"cells":7980},{"EARLY_PHASE1":7981,"PHASE1":7983,"PHASE2":7985,"PHASE3":7991,"PHASE4":7993,"NA":7995},{"trials":7982,"activeCount":101},[],{"trials":7984,"activeCount":101},[],{"trials":7986,"activeCount":101},[7987],{"nctId":4559,"briefTitle":4560,"status":242,"phases":7988,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":7989,"interventions":7990},[89,90],[4567],[4569,4570,748,2592,2591],{"trials":7992,"activeCount":101},[],{"trials":7994,"activeCount":101},[],{"trials":7996,"activeCount":101},[],{"intervention":4570,"totalTrials":116,"cells":7998},{"EARLY_PHASE1":7999,"PHASE1":8001,"PHASE2":8003,"PHASE3":8009,"PHASE4":8011,"NA":8013},{"trials":8000,"activeCount":101},[],{"trials":8002,"activeCount":101},[],{"trials":8004,"activeCount":101},[8005],{"nctId":4559,"briefTitle":4560,"status":242,"phases":8006,"primaryCompletion":4562,"completion":4563,"start":4564,"enrollment":4565,"conditions":8007,"interventions":8008},[89,90],[4567],[4569,4570,748,2592,2591],{"trials":8010,"activeCount":101},[],{"trials":8012,"activeCount":101},[],{"trials":8014,"activeCount":101},[],{"intervention":8016,"totalTrials":116,"cells":8017},"Rontalizumab",{"EARLY_PHASE1":8018,"PHASE1":8020,"PHASE2":8022,"PHASE3":8031,"PHASE4":8033,"NA":8035},{"trials":8019,"activeCount":101},[],{"trials":8021,"activeCount":101},[],{"trials":8023,"activeCount":101},[8024],{"nctId":8025,"briefTitle":8026,"status":242,"phases":8027,"primaryCompletion":2785,"completion":3748,"start":4372,"enrollment":8028,"conditions":8029,"interventions":8030},"NCT00962832","A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus",[90],238,[2568],[8016],{"trials":8032,"activeCount":101},[],{"trials":8034,"activeCount":101},[],{"trials":8036,"activeCount":101},[],{"intervention":8038,"totalTrials":116,"cells":8039},"Avonex",{"EARLY_PHASE1":8040,"PHASE1":8042,"PHASE2":8044,"PHASE3":8057,"PHASE4":8059,"NA":8061},{"trials":8041,"activeCount":101},[],{"trials":8043,"activeCount":101},[],{"trials":8045,"activeCount":101},[8046],{"nctId":8047,"briefTitle":8048,"status":242,"phases":8049,"primaryCompletion":8050,"completion":8051,"start":8052,"enrollment":8053,"conditions":8054,"interventions":8056},"NCT00676715","A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis",[90],"2012-03-09","2023-11-08","2008-07-17",220,[8055],"Multiple Sclerosis, Relapsing-Remitting",[2623,8038],{"trials":8058,"activeCount":101},[],{"trials":8060,"activeCount":101},[],{"trials":8062,"activeCount":101},[],{"intervention":5794,"totalTrials":116,"cells":8064},{"EARLY_PHASE1":8065,"PHASE1":8067,"PHASE2":8069,"PHASE3":8075,"PHASE4":8077,"NA":8079},{"trials":8066,"activeCount":101},[],{"trials":8068,"activeCount":101},[],{"trials":8070,"activeCount":101},[8071],{"nctId":5786,"briefTitle":5787,"status":242,"phases":8072,"primaryCompletion":5789,"completion":5789,"start":5790,"enrollment":5134,"conditions":8073,"interventions":8074},[90],[21],[3537,5793,3536,5794],{"trials":8076,"activeCount":101},[],{"trials":8078,"activeCount":101},[],{"trials":8080,"activeCount":101},[],{"intervention":2992,"totalTrials":116,"cells":8082},{"EARLY_PHASE1":8083,"PHASE1":8085,"PHASE2":8087,"PHASE3":8093,"PHASE4":8095,"NA":8097},{"trials":8084,"activeCount":101},[],{"trials":8086,"activeCount":101},[],{"trials":8088,"activeCount":101},[8089],{"nctId":2984,"briefTitle":2985,"status":242,"phases":8090,"primaryCompletion":2987,"completion":2987,"start":2988,"enrollment":2989,"conditions":8091,"interventions":8092},[90],[18],[318,2992],{"trials":8094,"activeCount":101},[],{"trials":8096,"activeCount":101},[],{"trials":8098,"activeCount":101},[],{"intervention":8100,"totalTrials":116,"cells":8101},"Quilizumab",{"EARLY_PHASE1":8102,"PHASE1":8104,"PHASE2":8106,"PHASE3":8115,"PHASE4":8117,"NA":8119},{"trials":8103,"activeCount":101},[],{"trials":8105,"activeCount":101},[],{"trials":8107,"activeCount":101},[8108],{"nctId":8109,"briefTitle":8110,"status":242,"phases":8111,"primaryCompletion":8112,"completion":8112,"start":1386,"enrollment":1884,"conditions":8113,"interventions":8114},"NCT01987947","A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria",[90],"2014-10",[3769],[8100],{"trials":8116,"activeCount":101},[],{"trials":8118,"activeCount":101},[],{"trials":8120,"activeCount":101},[],{"intervention":2607,"totalTrials":116,"cells":8122},{"EARLY_PHASE1":8123,"PHASE1":8125,"PHASE2":8127,"PHASE3":8133,"PHASE4":8135,"NA":8137},{"trials":8124,"activeCount":101},[],{"trials":8126,"activeCount":101},[],{"trials":8128,"activeCount":101},[8129],{"nctId":2594,"briefTitle":2595,"status":242,"phases":8130,"primaryCompletion":2597,"completion":2598,"start":2599,"enrollment":166,"conditions":8131,"interventions":8132},[90],[2601],[2603,2604,2605,2606,2607],{"trials":8134,"activeCount":101},[],{"trials":8136,"activeCount":101},[],{"trials":8138,"activeCount":101},[],{"intervention":1327,"totalTrials":116,"cells":8140},{"EARLY_PHASE1":8141,"PHASE1":8143,"PHASE2":8145,"PHASE3":8151,"PHASE4":8153,"NA":8155},{"trials":8142,"activeCount":101},[],{"trials":8144,"activeCount":101},[],{"trials":8146,"activeCount":101},[8147],{"nctId":1319,"briefTitle":1320,"status":242,"phases":8148,"primaryCompletion":1272,"completion":1272,"start":1322,"enrollment":1323,"conditions":8149,"interventions":8150},[90],[27,1325],[1027,1327,1328],{"trials":8152,"activeCount":101},[],{"trials":8154,"activeCount":101},[],{"trials":8156,"activeCount":101},[],{"intervention":1328,"totalTrials":116,"cells":8158},{"EARLY_PHASE1":8159,"PHASE1":8161,"PHASE2":8163,"PHASE3":8169,"PHASE4":8171,"NA":8173},{"trials":8160,"activeCount":101},[],{"trials":8162,"activeCount":101},[],{"trials":8164,"activeCount":101},[8165],{"nctId":1319,"briefTitle":1320,"status":242,"phases":8166,"primaryCompletion":1272,"completion":1272,"start":1322,"enrollment":1323,"conditions":8167,"interventions":8168},[90],[27,1325],[1027,1327,1328],{"trials":8170,"activeCount":101},[],{"trials":8172,"activeCount":101},[],{"trials":8174,"activeCount":101},[],{"intervention":8176,"totalTrials":116,"cells":8177},"telbermin",{"EARLY_PHASE1":8178,"PHASE1":8180,"PHASE2":8182,"PHASE3":8192,"PHASE4":8194,"NA":8196},{"trials":8179,"activeCount":101},[],{"trials":8181,"activeCount":101},[],{"trials":8183,"activeCount":101},[8184],{"nctId":8185,"briefTitle":8186,"status":242,"phases":8187,"primaryCompletion":1227,"start":1364,"enrollment":8188,"conditions":8189,"interventions":8191},"NCT00351767","A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers",[90],170,[8190],"Foot Ulcer, Diabetic",[8176],{"trials":8193,"activeCount":101},[],{"trials":8195,"activeCount":101},[],{"trials":8197,"activeCount":101},[],{"intervention":6116,"totalTrials":116,"cells":8199},{"EARLY_PHASE1":8200,"PHASE1":8202,"PHASE2":8204,"PHASE3":8210,"PHASE4":8212,"NA":8214},{"trials":8201,"activeCount":101},[],{"trials":8203,"activeCount":101},[],{"trials":8205,"activeCount":101},[8206],{"nctId":6106,"briefTitle":6107,"status":242,"phases":8207,"primaryCompletion":6109,"completion":6110,"start":6111,"enrollment":6112,"conditions":8208,"interventions":8209},[90],[890],[6115,6116,6068,6117],{"trials":8211,"activeCount":101},[],{"trials":8213,"activeCount":101},[],{"trials":8215,"activeCount":101},[],{"intervention":6117,"totalTrials":116,"cells":8217},{"EARLY_PHASE1":8218,"PHASE1":8220,"PHASE2":8222,"PHASE3":8228,"PHASE4":8230,"NA":8232},{"trials":8219,"activeCount":101},[],{"trials":8221,"activeCount":101},[],{"trials":8223,"activeCount":101},[8224],{"nctId":6106,"briefTitle":6107,"status":242,"phases":8225,"primaryCompletion":6109,"completion":6110,"start":6111,"enrollment":6112,"conditions":8226,"interventions":8227},[90],[890],[6115,6116,6068,6117],{"trials":8229,"activeCount":101},[],{"trials":8231,"activeCount":101},[],{"trials":8233,"activeCount":101},[],{"intervention":6126,"totalTrials":116,"cells":8235},{"EARLY_PHASE1":8236,"PHASE1":8238,"PHASE2":8240,"PHASE3":8246,"PHASE4":8248,"NA":8250},{"trials":8237,"activeCount":101},[],{"trials":8239,"activeCount":101},[],{"trials":8241,"activeCount":101},[8242],{"nctId":6119,"briefTitle":6120,"status":242,"phases":8243,"primaryCompletion":6122,"completion":6122,"start":6123,"enrollment":612,"conditions":8244,"interventions":8245},[90],[2001],[6068,6126,6127,6128],{"trials":8247,"activeCount":101},[],{"trials":8249,"activeCount":101},[],{"trials":8251,"activeCount":101},[],{"intervention":6127,"totalTrials":116,"cells":8253},{"EARLY_PHASE1":8254,"PHASE1":8256,"PHASE2":8258,"PHASE3":8264,"PHASE4":8266,"NA":8268},{"trials":8255,"activeCount":101},[],{"trials":8257,"activeCount":101},[],{"trials":8259,"activeCount":101},[8260],{"nctId":6119,"briefTitle":6120,"status":242,"phases":8261,"primaryCompletion":6122,"completion":6122,"start":6123,"enrollment":612,"conditions":8262,"interventions":8263},[90],[2001],[6068,6126,6127,6128],{"trials":8265,"activeCount":101},[],{"trials":8267,"activeCount":101},[],{"trials":8269,"activeCount":101},[],{"intervention":6128,"totalTrials":116,"cells":8271},{"EARLY_PHASE1":8272,"PHASE1":8274,"PHASE2":8276,"PHASE3":8282,"PHASE4":8284,"NA":8286},{"trials":8273,"activeCount":101},[],{"trials":8275,"activeCount":101},[],{"trials":8277,"activeCount":101},[8278],{"nctId":6119,"briefTitle":6120,"status":242,"phases":8279,"primaryCompletion":6122,"completion":6122,"start":6123,"enrollment":612,"conditions":8280,"interventions":8281},[90],[2001],[6068,6126,6127,6128],{"trials":8283,"activeCount":101},[],{"trials":8285,"activeCount":101},[],{"trials":8287,"activeCount":101},[],{"intervention":8289,"totalTrials":116,"cells":8290},"GDC-6599",{"EARLY_PHASE1":8291,"PHASE1":8293,"PHASE2":8295,"PHASE3":8310,"PHASE4":8312,"NA":8314},{"trials":8292,"activeCount":101},[],{"trials":8294,"activeCount":101},[],{"trials":8296,"activeCount":101},[8297],{"nctId":8298,"briefTitle":8299,"status":242,"phases":8300,"primaryCompletion":8301,"completion":8301,"start":8302,"enrollment":6011,"conditions":8303,"interventions":8309},"NCT05660850","A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough",[90],"2024-10-20","2023-03-22",[8304,8305,8306,8307,8308],"Chronic Refractory Cough (CRC) With Non-atopic Asthma","CRC With Atopic Asthma","Unexplained Chronic Cough","CRC With Chronic Obstructive Pulmonary Disease","CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis",[8289],{"trials":8311,"activeCount":101},[],{"trials":8313,"activeCount":101},[],{"trials":8315,"activeCount":101},[],{"intervention":8317,"totalTrials":116,"cells":8318},"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody",{"EARLY_PHASE1":8319,"PHASE1":8321,"PHASE2":8323,"PHASE3":8334,"PHASE4":8336,"NA":8338},{"trials":8320,"activeCount":101},[],{"trials":8322,"activeCount":101},[],{"trials":8324,"activeCount":101},[8325],{"nctId":8326,"briefTitle":8327,"status":242,"phases":8328,"primaryCompletion":8329,"completion":8330,"start":8331,"enrollment":379,"conditions":8332,"interventions":8333},"NCT02927301","A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)",[90],"2020-05-07","2023-09-05","2017-04-20",[27],[8317],{"trials":8335,"activeCount":101},[],{"trials":8337,"activeCount":101},[],{"trials":8339,"activeCount":101},[],{"intervention":8341,"totalTrials":116,"cells":8342},"MPSK3169A",{"EARLY_PHASE1":8343,"PHASE1":8345,"PHASE2":8347,"PHASE3":8358,"PHASE4":8360,"NA":8362},{"trials":8344,"activeCount":101},[],{"trials":8346,"activeCount":101},[],{"trials":8348,"activeCount":101},[8349],{"nctId":8350,"briefTitle":8351,"status":242,"phases":8352,"primaryCompletion":416,"completion":1415,"start":8353,"enrollment":8354,"conditions":8355,"interventions":8357},"NCT01609140","A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease",[90],"2012-05",248,[8356],"Coronary Heart Disease",[8341,8341,8341,8341,8341],{"trials":8359,"activeCount":101},[],{"trials":8361,"activeCount":101},[],{"trials":8363,"activeCount":101},[],{"intervention":7071,"totalTrials":116,"cells":8365},{"EARLY_PHASE1":8366,"PHASE1":8368,"PHASE2":8370,"PHASE3":8376,"PHASE4":8378,"NA":8380},{"trials":8367,"activeCount":101},[],{"trials":8369,"activeCount":101},[],{"trials":8371,"activeCount":101},[8372],{"nctId":7063,"briefTitle":7064,"status":325,"phases":8373,"primaryCompletion":7066,"completion":7066,"start":7067,"enrollment":7068,"conditions":8374,"interventions":8375},[90],[7060,2233],[7045,7071],{"trials":8377,"activeCount":101},[],{"trials":8379,"activeCount":101},[],{"trials":8381,"activeCount":101},[],{"intervention":8383,"totalTrials":116,"cells":8384},"huMAb OX40L",{"EARLY_PHASE1":8385,"PHASE1":8387,"PHASE2":8389,"PHASE3":8398,"PHASE4":8400,"NA":8402},{"trials":8386,"activeCount":101},[],{"trials":8388,"activeCount":101},[],{"trials":8390,"activeCount":101},[8391],{"nctId":8392,"briefTitle":8393,"status":242,"phases":8394,"primaryCompletion":1254,"completion":8395,"start":4372,"enrollment":5588,"conditions":8396,"interventions":8397},"NCT00983658","A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma",[90],"2011-01-05",[31],[8383],{"trials":8399,"activeCount":101},[],{"trials":8401,"activeCount":101},[],{"trials":8403,"activeCount":101},[],{"intervention":3707,"totalTrials":116,"cells":8405},{"EARLY_PHASE1":8406,"PHASE1":8408,"PHASE2":8410,"PHASE3":8416,"PHASE4":8418,"NA":8420},{"trials":8407,"activeCount":101},[],{"trials":8409,"activeCount":101},[],{"trials":8411,"activeCount":101},[8412],{"nctId":3701,"briefTitle":3702,"status":242,"phases":8413,"primaryCompletion":1088,"completion":1088,"start":1373,"enrollment":811,"conditions":8414,"interventions":8415},[90],[3705],[3691,3707,3708],{"trials":8417,"activeCount":101},[],{"trials":8419,"activeCount":101},[],{"trials":8421,"activeCount":101},[],{"intervention":1356,"totalTrials":116,"cells":8423},{"EARLY_PHASE1":8424,"PHASE1":8426,"PHASE2":8428,"PHASE3":8434,"PHASE4":8436,"NA":8438},{"trials":8425,"activeCount":101},[],{"trials":8427,"activeCount":101},[],{"trials":8429,"activeCount":101},[8430],{"nctId":1349,"briefTitle":1350,"status":242,"phases":8431,"primaryCompletion":1160,"completion":1160,"start":1310,"enrollment":1352,"conditions":8432,"interventions":8433},[90],[1133],[1355,520,1356,1339],{"trials":8435,"activeCount":101},[],{"trials":8437,"activeCount":101},[],{"trials":8439,"activeCount":101},[],{"intervention":8441,"totalTrials":116,"cells":8442},"Azithromycin",{"EARLY_PHASE1":8443,"PHASE1":8445,"PHASE2":8447,"PHASE3":8457,"PHASE4":8459,"NA":8461},{"trials":8444,"activeCount":101},[],{"trials":8446,"activeCount":101},[],{"trials":8448,"activeCount":101},[8449],{"nctId":8450,"briefTitle":8451,"status":325,"phases":8452,"primaryCompletion":8453,"completion":8453,"start":8454,"enrollment":654,"conditions":8455,"interventions":8456},"NCT04353661","A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications",[90],"2023-06-29","2021-11-16",[2283],[8441],{"trials":8458,"activeCount":101},[],{"trials":8460,"activeCount":101},[],{"trials":8462,"activeCount":101},[],{"intervention":8464,"totalTrials":116,"cells":8465},"MHAA549A",{"EARLY_PHASE1":8466,"PHASE1":8468,"PHASE2":8470,"PHASE3":8482,"PHASE4":8484,"NA":8486},{"trials":8467,"activeCount":101},[],{"trials":8469,"activeCount":101},[],{"trials":8471,"activeCount":101},[8472],{"nctId":8473,"briefTitle":8474,"status":242,"phases":8475,"primaryCompletion":8476,"completion":8476,"start":8477,"enrollment":8478,"conditions":8479,"interventions":8480},"NCT01980966","A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model",[90],"2014-06-19","2013-11-25",101,[15],[8464,8481],"oseltamivir [Tamiflu]",{"trials":8483,"activeCount":101},[],{"trials":8485,"activeCount":101},[],{"trials":8487,"activeCount":101},[],{"intervention":8481,"totalTrials":116,"cells":8489},{"EARLY_PHASE1":8490,"PHASE1":8492,"PHASE2":8494,"PHASE3":8500,"PHASE4":8502,"NA":8504},{"trials":8491,"activeCount":101},[],{"trials":8493,"activeCount":101},[],{"trials":8495,"activeCount":101},[8496],{"nctId":8473,"briefTitle":8474,"status":242,"phases":8497,"primaryCompletion":8476,"completion":8476,"start":8477,"enrollment":8478,"conditions":8498,"interventions":8499},[90],[15],[8464,8481],{"trials":8501,"activeCount":101},[],{"trials":8503,"activeCount":101},[],{"trials":8505,"activeCount":101},[],{"intervention":1465,"totalTrials":1131,"cells":8507},{"EARLY_PHASE1":8508,"PHASE1":8510,"PHASE2":8573,"PHASE3":8575,"PHASE4":8577,"NA":8579},{"trials":8509,"activeCount":101},[],{"trials":8511,"activeCount":101},[8512,8523,8527,8531,8541,8545,8549,8559,8563],{"nctId":8513,"briefTitle":8514,"status":242,"phases":8515,"primaryCompletion":8516,"completion":8516,"start":8517,"enrollment":1071,"conditions":8518,"interventions":8520},"NCT02655614","A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis",[89],"2020-03-16","2016-05-31",[8519],"Amyotrophic Lateral Sclerosis",[8521,1465,334,8522],"GDC-0134","Caffeine",{"nctId":3529,"briefTitle":3530,"status":242,"phases":8524,"primaryCompletion":1883,"completion":1883,"start":3532,"enrollment":3533,"conditions":8525,"interventions":8526},[89],[15],[3536,3537,3522,1465],{"nctId":5720,"briefTitle":5721,"status":242,"phases":8528,"primaryCompletion":5723,"completion":5723,"start":5724,"enrollment":5725,"conditions":8529,"interventions":8530},[89],[34],[3537,1465],{"nctId":8532,"briefTitle":8533,"status":242,"phases":8534,"primaryCompletion":416,"completion":416,"start":956,"enrollment":8535,"conditions":8536,"interventions":8537},"NCT01772290","A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib",[89],92,[15],[8538,8539,5549,8540],"fluconazole","itraconazole","vismodegib",{"nctId":1458,"briefTitle":1459,"status":242,"phases":8542,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":1021,"conditions":8543,"interventions":8544},[89],[15],[626,1465],{"nctId":5659,"briefTitle":5660,"status":242,"phases":8546,"primaryCompletion":5662,"completion":5662,"start":5663,"enrollment":1311,"conditions":8547,"interventions":8548},[89],[15],[347,347,347,347,347,347,5549],{"nctId":8550,"briefTitle":8551,"status":242,"phases":8552,"primaryCompletion":8553,"completion":8553,"start":8554,"enrollment":25,"conditions":8555,"interventions":8556},"NCT03237741","Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants",[89],"2017-12-14","2017-08-07",[8519],[8557,8558,5549],"Reference capsule GDC-0134","Prototype capsule GDC-0134",{"nctId":5543,"briefTitle":5544,"status":242,"phases":8560,"primaryCompletion":5546,"completion":5546,"start":3612,"enrollment":3533,"conditions":8561,"interventions":8562},[89],[34],[346,5549],{"nctId":8564,"briefTitle":8565,"status":242,"phases":8566,"primaryCompletion":8567,"completion":8567,"start":8568,"enrollment":488,"conditions":8569,"interventions":8570},"NCT07329972","A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants",[89],"2025-12-14","2025-11-21",[34],[8571,8572,1465],"ZN-A-1041 Formulation 1","ZN-A-1041 Formulation 2",{"trials":8574,"activeCount":101},[],{"trials":8576,"activeCount":101},[],{"trials":8578,"activeCount":101},[],{"trials":8580,"activeCount":101},[],{"intervention":1500,"totalTrials":2546,"cells":8582},{"EARLY_PHASE1":8583,"PHASE1":8585,"PHASE2":8613,"PHASE3":8615,"PHASE4":8617,"NA":8619},{"trials":8584,"activeCount":101},[],{"trials":8586,"activeCount":101},[8587,8591,8595,8601,8605,8609],{"nctId":8532,"briefTitle":8533,"status":242,"phases":8588,"primaryCompletion":416,"completion":416,"start":956,"enrollment":8535,"conditions":8589,"interventions":8590},[89],[15],[8538,8539,5549,8540],{"nctId":1930,"briefTitle":1931,"status":242,"phases":8592,"primaryCompletion":1933,"completion":1933,"start":1934,"enrollment":25,"conditions":8593,"interventions":8594},[89],[968],[783,1500],{"nctId":8596,"briefTitle":8597,"status":242,"phases":8598,"primaryCompletion":3748,"completion":3748,"start":1149,"enrollment":1884,"conditions":8599,"interventions":8600},"NCT01814709","A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers",[89],[15],[333,1500,1888],{"nctId":1879,"briefTitle":1880,"status":242,"phases":8602,"primaryCompletion":1882,"completion":1882,"start":1883,"enrollment":1884,"conditions":8603,"interventions":8604},[89],[1886],[1500,1888,627],{"nctId":1494,"briefTitle":1495,"status":242,"phases":8606,"primaryCompletion":1497,"completion":1497,"start":1415,"enrollment":1228,"conditions":8607,"interventions":8608},[89],[968],[626,1500],{"nctId":5737,"briefTitle":5738,"status":242,"phases":8610,"primaryCompletion":5740,"completion":5740,"start":5724,"enrollment":5725,"conditions":8611,"interventions":8612},[89],[968],[334,3537,5743,1946,5744,5745,5746,3537,1500,5747],{"trials":8614,"activeCount":101},[],{"trials":8616,"activeCount":101},[],{"trials":8618,"activeCount":101},[],{"trials":8620,"activeCount":101},[],{"intervention":333,"totalTrials":233,"cells":8622},{"EARLY_PHASE1":8623,"PHASE1":8625,"PHASE2":8654,"PHASE3":8656,"PHASE4":8658,"NA":8660},{"trials":8624,"activeCount":101},[],{"trials":8626,"activeCount":101},[8627,8633,8642,8646,8650],{"nctId":8628,"briefTitle":8629,"status":242,"phases":8630,"primaryCompletion":1386,"completion":1386,"start":1405,"enrollment":35,"conditions":8631,"interventions":8632},"NCT01967966","A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers",[89],[15],[333,333],{"nctId":8634,"briefTitle":8635,"status":242,"phases":8636,"primaryCompletion":8637,"completion":8637,"start":1405,"enrollment":8638,"conditions":8639,"interventions":8640},"NCT01980953","A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers",[89],"2014-07",76,[15],[8641,333,333],"GDC-0032 Phase III",{"nctId":1646,"briefTitle":1647,"status":242,"phases":8643,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":1651,"conditions":8644,"interventions":8645},[89],[1653],[711,333,525],{"nctId":8596,"briefTitle":8597,"status":242,"phases":8647,"primaryCompletion":3748,"completion":3748,"start":1149,"enrollment":1884,"conditions":8648,"interventions":8649},[89],[15],[333,1500,1888],{"nctId":323,"briefTitle":324,"status":325,"phases":8651,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":8652,"interventions":8653},[89],[24,331],[284,333,318,334],{"trials":8655,"activeCount":101},[],{"trials":8657,"activeCount":101},[],{"trials":8659,"activeCount":101},[],{"trials":8661,"activeCount":101},[],{"intervention":334,"totalTrials":793,"cells":8663},{"EARLY_PHASE1":8664,"PHASE1":8666,"PHASE2":8684,"PHASE3":8686,"PHASE4":8688,"NA":8690},{"trials":8665,"activeCount":101},[],{"trials":8667,"activeCount":101},[8668,8672,8676,8680],{"nctId":8513,"briefTitle":8514,"status":242,"phases":8669,"primaryCompletion":8516,"completion":8516,"start":8517,"enrollment":1071,"conditions":8670,"interventions":8671},[89],[8519],[8521,1465,334,8522],{"nctId":1448,"briefTitle":1449,"status":242,"phases":8673,"primaryCompletion":896,"completion":896,"start":1451,"enrollment":1452,"conditions":8674,"interventions":8675},[89],[316],[1446,1455,1456],{"nctId":323,"briefTitle":324,"status":325,"phases":8677,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":8678,"interventions":8679},[89],[24,331],[284,333,318,334],{"nctId":5737,"briefTitle":5738,"status":242,"phases":8681,"primaryCompletion":5740,"completion":5740,"start":5724,"enrollment":5725,"conditions":8682,"interventions":8683},[89],[968],[334,3537,5743,1946,5744,5745,5746,3537,1500,5747],{"trials":8685,"activeCount":101},[],{"trials":8687,"activeCount":101},[],{"trials":8689,"activeCount":101},[],{"trials":8691,"activeCount":101},[],{"intervention":8693,"totalTrials":793,"cells":8694},"GDC-0449",{"EARLY_PHASE1":8695,"PHASE1":8697,"PHASE2":8731,"PHASE3":8733,"PHASE4":8735,"NA":8737},{"trials":8696,"activeCount":101},[],{"trials":8698,"activeCount":101},[8699,8708,8715,8724],{"nctId":8700,"briefTitle":8701,"status":242,"phases":8702,"primaryCompletion":1254,"completion":1254,"start":4372,"enrollment":488,"conditions":8703,"interventions":8704},"NCT00991718","A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential",[89],[4124],[8705,8706,8707],"GDC-0449 oral","GDC-0449 IV","CDC-0449 oral suspension",{"nctId":8709,"briefTitle":8710,"status":242,"phases":8711,"primaryCompletion":8712,"completion":8712,"start":4372,"enrollment":622,"conditions":8713,"interventions":8714},"NCT00968981","A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists",[89],"2010-10",[24],[8693,8693,8693],{"nctId":8716,"briefTitle":8717,"status":242,"phases":8718,"primaryCompletion":8719,"completion":8719,"start":8720,"enrollment":3696,"conditions":8721,"interventions":8722},"NCT01173536","A Study to Investigate the Effect of GDC-0449 on the QT\u002FQTc Interval in Healthy Female Subjects",[89],"2011-03-18","2010-08-25",[15],[8693,8723],"moxifloxacin",{"nctId":8725,"briefTitle":8726,"status":242,"phases":8727,"primaryCompletion":1207,"completion":1207,"start":1416,"enrollment":7630,"conditions":8728,"interventions":8730},"NCT00607724","GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[89],[8729],"Unspecified Adult Solid Tumor, Protocol Specific",[8693],{"trials":8732,"activeCount":101},[],{"trials":8734,"activeCount":101},[],{"trials":8736,"activeCount":101},[],{"trials":8738,"activeCount":101},[],{"intervention":1888,"totalTrials":97,"cells":8740},{"EARLY_PHASE1":8741,"PHASE1":8743,"PHASE2":8757,"PHASE3":8759,"PHASE4":8761,"NA":8763},{"trials":8742,"activeCount":101},[],{"trials":8744,"activeCount":101},[8745,8749,8753],{"nctId":1948,"briefTitle":1949,"status":242,"phases":8746,"primaryCompletion":1951,"completion":1951,"start":1952,"enrollment":25,"conditions":8747,"interventions":8748},[89],[968],[783,1888],{"nctId":8596,"briefTitle":8597,"status":242,"phases":8750,"primaryCompletion":3748,"completion":3748,"start":1149,"enrollment":1884,"conditions":8751,"interventions":8752},[89],[15],[333,1500,1888],{"nctId":1879,"briefTitle":1880,"status":242,"phases":8754,"primaryCompletion":1882,"completion":1882,"start":1883,"enrollment":1884,"conditions":8755,"interventions":8756},[89],[1886],[1500,1888,627],{"trials":8758,"activeCount":101},[],{"trials":8760,"activeCount":101},[],{"trials":8762,"activeCount":101},[],{"trials":8764,"activeCount":101},[],{"intervention":8766,"totalTrials":200,"cells":8767},"DSTA4637S",{"EARLY_PHASE1":8768,"PHASE1":8770,"PHASE2":8790,"PHASE3":8792,"PHASE4":8794,"NA":8796},{"trials":8769,"activeCount":101},[],{"trials":8771,"activeCount":101},[8772,8780],{"nctId":8773,"briefTitle":8774,"status":242,"phases":8775,"primaryCompletion":8776,"completion":8776,"start":8777,"enrollment":770,"conditions":8778,"interventions":8779},"NCT02596399","A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers",[89],"2016-05-30","2015-11-29",[15],[8766],{"nctId":8781,"briefTitle":8782,"status":242,"phases":8783,"primaryCompletion":8784,"completion":8784,"start":8785,"enrollment":19,"conditions":8786,"interventions":8788},"NCT03162250","Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics",[89],"2020-01-15","2017-07-13",[8787],"Bacteremia",[8766,8789],"SOC",{"trials":8791,"activeCount":101},[],{"trials":8793,"activeCount":101},[],{"trials":8795,"activeCount":101},[],{"trials":8797,"activeCount":101},[],{"intervention":587,"totalTrials":200,"cells":8799},{"EARLY_PHASE1":8800,"PHASE1":8802,"PHASE2":8814,"PHASE3":8816,"PHASE4":8818,"NA":8820},{"trials":8801,"activeCount":101},[],{"trials":8803,"activeCount":101},[8804,8810],{"nctId":8805,"briefTitle":8806,"status":242,"phases":8807,"primaryCompletion":6600,"completion":6600,"start":896,"enrollment":5530,"conditions":8808,"interventions":8809},"NCT02048709","Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors",[89],[316],[587],{"nctId":579,"briefTitle":580,"status":242,"phases":8811,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":8812,"interventions":8813},[89],[316],[487,587],{"trials":8815,"activeCount":101},[],{"trials":8817,"activeCount":101},[],{"trials":8819,"activeCount":101},[],{"trials":8821,"activeCount":101},[],{"intervention":8823,"totalTrials":200,"cells":8824},"MFGR1877S",{"EARLY_PHASE1":8825,"PHASE1":8827,"PHASE2":8841,"PHASE3":8843,"PHASE4":8845,"NA":8847},{"trials":8826,"activeCount":101},[],{"trials":8828,"activeCount":101},[8829,8835],{"nctId":8830,"briefTitle":8831,"status":242,"phases":8832,"primaryCompletion":8353,"completion":8353,"start":3559,"enrollment":1425,"conditions":8833,"interventions":8834},"NCT01122875","A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma",[89],[502],[8823],{"nctId":8836,"briefTitle":8837,"status":242,"phases":8838,"primaryCompletion":5691,"completion":5691,"start":1217,"enrollment":488,"conditions":8839,"interventions":8840},"NCT01363024","Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors",[89],[316],[8823],{"trials":8842,"activeCount":101},[],{"trials":8844,"activeCount":101},[],{"trials":8846,"activeCount":101},[],{"trials":8848,"activeCount":101},[],{"intervention":8850,"totalTrials":200,"cells":8851},"GDC-0973 Oral",{"EARLY_PHASE1":8852,"PHASE1":8854,"PHASE2":8871,"PHASE3":8873,"PHASE4":8875,"NA":8877},{"trials":8853,"activeCount":101},[],{"trials":8855,"activeCount":101},[8856,8864],{"nctId":8857,"briefTitle":8858,"status":242,"phases":8859,"primaryCompletion":1462,"completion":1462,"start":3559,"enrollment":8860,"conditions":8861,"interventions":8862},"NCT01249118","An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)",[89],13,[34],[8863,8850],"GDC-0973 IV",{"nctId":8865,"briefTitle":8866,"status":242,"phases":8867,"primaryCompletion":1374,"completion":1374,"start":1374,"enrollment":2546,"conditions":8868,"interventions":8869},"NCT01711762","A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers",[89],[15],[8870],"GDC-0973",{"trials":8872,"activeCount":101},[],{"trials":8874,"activeCount":101},[],{"trials":8876,"activeCount":101},[],{"trials":8878,"activeCount":101},[],{"intervention":5533,"totalTrials":200,"cells":8880},{"EARLY_PHASE1":8881,"PHASE1":8883,"PHASE2":8893,"PHASE3":8895,"PHASE4":8897,"NA":8899},{"trials":8882,"activeCount":101},[],{"trials":8884,"activeCount":101},[8885,8889],{"nctId":5527,"briefTitle":5528,"status":242,"phases":8886,"primaryCompletion":1160,"completion":1160,"start":3559,"enrollment":5530,"conditions":8887,"interventions":8888},[89],[15],[346,346,5533],{"nctId":5679,"briefTitle":5680,"status":242,"phases":8890,"primaryCompletion":907,"completion":907,"start":1291,"enrollment":5530,"conditions":8891,"interventions":8892},[89],[15],[347,5684],{"trials":8894,"activeCount":101},[],{"trials":8896,"activeCount":101},[],{"trials":8898,"activeCount":101},[],{"trials":8900,"activeCount":101},[],{"intervention":1113,"totalTrials":200,"cells":8902},{"EARLY_PHASE1":8903,"PHASE1":8905,"PHASE2":8917,"PHASE3":8919,"PHASE4":8921,"NA":8923},{"trials":8904,"activeCount":101},[],{"trials":8906,"activeCount":101},[8907,8913],{"nctId":8908,"briefTitle":8909,"status":242,"phases":8910,"start":3628,"enrollment":16,"conditions":8911,"interventions":8912},"NCT00747734","A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors",[89],[24],[1113],{"nctId":1108,"briefTitle":1109,"status":242,"phases":8914,"primaryCompletion":907,"completion":907,"start":948,"enrollment":488,"conditions":8915,"interventions":8916},[89],[24],[1027,1113,998],{"trials":8918,"activeCount":101},[],{"trials":8920,"activeCount":101},[],{"trials":8922,"activeCount":101},[],{"trials":8924,"activeCount":101},[],{"intervention":1103,"totalTrials":200,"cells":8926},{"EARLY_PHASE1":8927,"PHASE1":8929,"PHASE2":8939,"PHASE3":8941,"PHASE4":8943,"NA":8945},{"trials":8928,"activeCount":101},[],{"trials":8930,"activeCount":101},[8931,8935],{"nctId":1095,"briefTitle":1096,"status":242,"phases":8932,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":1100,"conditions":8933,"interventions":8934},[89],[29],[1103,1027,1104,1105,1106],{"nctId":1115,"briefTitle":1116,"status":242,"phases":8936,"primaryCompletion":909,"completion":909,"start":1118,"enrollment":1021,"conditions":8937,"interventions":8938},[89],[29],[1027,1104,1103,1106,1121],{"trials":8940,"activeCount":101},[],{"trials":8942,"activeCount":101},[],{"trials":8944,"activeCount":101},[],{"trials":8946,"activeCount":101},[],{"intervention":1946,"totalTrials":200,"cells":8948},{"EARLY_PHASE1":8949,"PHASE1":8951,"PHASE2":8961,"PHASE3":8963,"PHASE4":8965,"NA":8967},{"trials":8950,"activeCount":101},[],{"trials":8952,"activeCount":101},[8953,8957],{"nctId":1938,"briefTitle":1939,"status":242,"phases":8954,"primaryCompletion":1941,"completion":1941,"start":1942,"enrollment":1335,"conditions":8955,"interventions":8956},[89],[968],[1945,783,1946],{"nctId":5737,"briefTitle":5738,"status":242,"phases":8958,"primaryCompletion":5740,"completion":5740,"start":5724,"enrollment":5725,"conditions":8959,"interventions":8960},[89],[968],[334,3537,5743,1946,5744,5745,5746,3537,1500,5747],{"trials":8962,"activeCount":101},[],{"trials":8964,"activeCount":101},[],{"trials":8966,"activeCount":101},[],{"trials":8968,"activeCount":101},[],{"intervention":8970,"totalTrials":200,"cells":8971},"MCAF5352A",{"EARLY_PHASE1":8972,"PHASE1":8974,"PHASE2":8988,"PHASE3":8990,"PHASE4":8992,"NA":8994},{"trials":8973,"activeCount":101},[],{"trials":8975,"activeCount":101},[8976,8982],{"nctId":8977,"briefTitle":8978,"status":242,"phases":8979,"primaryCompletion":1374,"completion":1374,"start":1098,"enrollment":1141,"conditions":8980,"interventions":8981},"NCT01540760","A Study of MCAF5352A in Healthy Volunteers",[89],[15],[8970],{"nctId":8983,"briefTitle":8984,"status":242,"phases":8985,"primaryCompletion":908,"completion":908,"start":907,"enrollment":1141,"conditions":8986,"interventions":8987},"NCT01480310","Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers",[89],[15],[8970],{"trials":8989,"activeCount":101},[],{"trials":8991,"activeCount":101},[],{"trials":8993,"activeCount":101},[],{"trials":8995,"activeCount":101},[],{"intervention":6877,"totalTrials":200,"cells":8997},{"EARLY_PHASE1":8998,"PHASE1":9000,"PHASE2":9012,"PHASE3":9014,"PHASE4":9016,"NA":9018},{"trials":8999,"activeCount":101},[],{"trials":9001,"activeCount":101},[9002,9008],{"nctId":9003,"briefTitle":9004,"status":242,"phases":9005,"primaryCompletion":3559,"completion":3559,"start":3855,"enrollment":5530,"conditions":9006,"interventions":9007},"NCT00556699","A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma",[89],[331],[3594,6877],{"nctId":6870,"briefTitle":6871,"status":242,"phases":9009,"primaryCompletion":6873,"completion":6873,"start":1310,"enrollment":25,"conditions":9010,"interventions":9011},[89],[502],[6876,6877],{"trials":9013,"activeCount":101},[],{"trials":9015,"activeCount":101},[],{"trials":9017,"activeCount":101},[],{"trials":9019,"activeCount":101},[],{"intervention":1510,"totalTrials":200,"cells":9021},{"EARLY_PHASE1":9022,"PHASE1":9024,"PHASE2":9037,"PHASE3":9039,"PHASE4":9041,"NA":9043},{"trials":9023,"activeCount":101},[],{"trials":9025,"activeCount":101},[9026,9030],{"nctId":1502,"briefTitle":1503,"status":242,"phases":9027,"primaryCompletion":1505,"completion":1505,"start":1506,"enrollment":488,"conditions":9028,"interventions":9029},[89],[1508],[626,1510],{"nctId":9031,"briefTitle":9032,"status":242,"phases":9033,"primaryCompletion":718,"completion":718,"start":9034,"enrollment":979,"conditions":9035,"interventions":9036},"NCT01875705","A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",[89],"2013-06-21",[316],[1510,1510],{"trials":9038,"activeCount":101},[],{"trials":9040,"activeCount":101},[],{"trials":9042,"activeCount":101},[],{"trials":9044,"activeCount":101},[],{"intervention":8521,"totalTrials":116,"cells":9046},{"EARLY_PHASE1":9047,"PHASE1":9049,"PHASE2":9055,"PHASE3":9057,"PHASE4":9059,"NA":9061},{"trials":9048,"activeCount":101},[],{"trials":9050,"activeCount":101},[9051],{"nctId":8513,"briefTitle":8514,"status":242,"phases":9052,"primaryCompletion":8516,"completion":8516,"start":8517,"enrollment":1071,"conditions":9053,"interventions":9054},[89],[8519],[8521,1465,334,8522],{"trials":9056,"activeCount":101},[],{"trials":9058,"activeCount":101},[],{"trials":9060,"activeCount":101},[],{"trials":9062,"activeCount":101},[],{"intervention":8522,"totalTrials":116,"cells":9064},{"EARLY_PHASE1":9065,"PHASE1":9067,"PHASE2":9073,"PHASE3":9075,"PHASE4":9077,"NA":9079},{"trials":9066,"activeCount":101},[],{"trials":9068,"activeCount":101},[9069],{"nctId":8513,"briefTitle":8514,"status":242,"phases":9070,"primaryCompletion":8516,"completion":8516,"start":8517,"enrollment":1071,"conditions":9071,"interventions":9072},[89],[8519],[8521,1465,334,8522],{"trials":9074,"activeCount":101},[],{"trials":9076,"activeCount":101},[],{"trials":9078,"activeCount":101},[],{"trials":9080,"activeCount":101},[],{"intervention":507,"totalTrials":116,"cells":9082},{"EARLY_PHASE1":9083,"PHASE1":9085,"PHASE2":9091,"PHASE3":9093,"PHASE4":9095,"NA":9097},{"trials":9084,"activeCount":101},[],{"trials":9086,"activeCount":101},[9087],{"nctId":495,"briefTitle":496,"status":325,"phases":9088,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":9089,"interventions":9090},[89],[502,503,504],[506,507,508,487],{"trials":9092,"activeCount":101},[],{"trials":9094,"activeCount":101},[],{"trials":9096,"activeCount":101},[],{"trials":9098,"activeCount":101},[],{"intervention":9100,"totalTrials":116,"cells":9101},"GDC-0917",{"EARLY_PHASE1":9102,"PHASE1":9104,"PHASE2":9112,"PHASE3":9114,"PHASE4":9116,"NA":9118},{"trials":9103,"activeCount":101},[],{"trials":9105,"activeCount":101},[9106],{"nctId":9107,"briefTitle":9108,"status":242,"phases":9109,"primaryCompletion":1374,"completion":1374,"start":8712,"enrollment":1100,"conditions":9110,"interventions":9111},"NCT01226277","A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma",[89],[24],[9100],{"trials":9113,"activeCount":101},[],{"trials":9115,"activeCount":101},[],{"trials":9117,"activeCount":101},[],{"trials":9119,"activeCount":101},[],{"intervention":8641,"totalTrials":116,"cells":9121},{"EARLY_PHASE1":9122,"PHASE1":9124,"PHASE2":9130,"PHASE3":9132,"PHASE4":9134,"NA":9136},{"trials":9123,"activeCount":101},[],{"trials":9125,"activeCount":101},[9126],{"nctId":8634,"briefTitle":8635,"status":242,"phases":9127,"primaryCompletion":8637,"completion":8637,"start":1405,"enrollment":8638,"conditions":9128,"interventions":9129},[89],[15],[8641,333,333],{"trials":9131,"activeCount":101},[],{"trials":9133,"activeCount":101},[],{"trials":9135,"activeCount":101},[],{"trials":9137,"activeCount":101},[],{"intervention":9139,"totalTrials":116,"cells":9140},"RO7303509",{"EARLY_PHASE1":9141,"PHASE1":9143,"PHASE2":9154,"PHASE3":9156,"PHASE4":9158,"NA":9160},{"trials":9142,"activeCount":101},[],{"trials":9144,"activeCount":101},[9145],{"nctId":9146,"briefTitle":9147,"status":242,"phases":9148,"primaryCompletion":9149,"completion":9149,"start":9150,"enrollment":1238,"conditions":9151,"interventions":9153},"NCT05462522","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis",[89],"2025-07-11","2023-01-16",[9152],"Systemic Sclerosis",[9139],{"trials":9155,"activeCount":101},[],{"trials":9157,"activeCount":101},[],{"trials":9159,"activeCount":101},[],{"trials":9161,"activeCount":101},[],{"intervention":9163,"totalTrials":116,"cells":9164},"GDC-0134 F09 Formulation",{"EARLY_PHASE1":9165,"PHASE1":9167,"PHASE2":9179,"PHASE3":9181,"PHASE4":9183,"NA":9185},{"trials":9166,"activeCount":101},[],{"trials":9168,"activeCount":101},[9169],{"nctId":9170,"briefTitle":9171,"status":242,"phases":9172,"primaryCompletion":9173,"completion":9173,"start":9174,"enrollment":5648,"conditions":9175,"interventions":9176},"NCT03807739","A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential",[89],"2019-05-30","2019-02-01",[34],[9163,9177,9178],"GDC-0134 F15 Formulation","GDC-0134 F16 Formulation",{"trials":9180,"activeCount":101},[],{"trials":9182,"activeCount":101},[],{"trials":9184,"activeCount":101},[],{"trials":9186,"activeCount":101},[],{"intervention":9177,"totalTrials":116,"cells":9188},{"EARLY_PHASE1":9189,"PHASE1":9191,"PHASE2":9197,"PHASE3":9199,"PHASE4":9201,"NA":9203},{"trials":9190,"activeCount":101},[],{"trials":9192,"activeCount":101},[9193],{"nctId":9170,"briefTitle":9171,"status":242,"phases":9194,"primaryCompletion":9173,"completion":9173,"start":9174,"enrollment":5648,"conditions":9195,"interventions":9196},[89],[34],[9163,9177,9178],{"trials":9198,"activeCount":101},[],{"trials":9200,"activeCount":101},[],{"trials":9202,"activeCount":101},[],{"trials":9204,"activeCount":101},[],{"intervention":9178,"totalTrials":116,"cells":9206},{"EARLY_PHASE1":9207,"PHASE1":9209,"PHASE2":9215,"PHASE3":9217,"PHASE4":9219,"NA":9221},{"trials":9208,"activeCount":101},[],{"trials":9210,"activeCount":101},[9211],{"nctId":9170,"briefTitle":9171,"status":242,"phases":9212,"primaryCompletion":9173,"completion":9173,"start":9174,"enrollment":5648,"conditions":9213,"interventions":9214},[89],[34],[9163,9177,9178],{"trials":9216,"activeCount":101},[],{"trials":9218,"activeCount":101},[],{"trials":9220,"activeCount":101},[],{"trials":9222,"activeCount":101},[],{"intervention":9224,"totalTrials":116,"cells":9225},"[14C]-GDC-0980",{"EARLY_PHASE1":9226,"PHASE1":9228,"PHASE2":9236,"PHASE3":9238,"PHASE4":9240,"NA":9242},{"trials":9227,"activeCount":101},[],{"trials":9229,"activeCount":101},[9230],{"nctId":9231,"briefTitle":9232,"status":242,"phases":9233,"primaryCompletion":2785,"completion":2785,"start":907,"enrollment":793,"conditions":9234,"interventions":9235},"NCT01487239","Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects",[89],[15],[9224],{"trials":9237,"activeCount":101},[],{"trials":9239,"activeCount":101},[],{"trials":9241,"activeCount":101},[],{"trials":9243,"activeCount":101},[],{"intervention":9245,"totalTrials":116,"cells":9246},"DEDN6526A",{"EARLY_PHASE1":9247,"PHASE1":9249,"PHASE2":9257,"PHASE3":9259,"PHASE4":9261,"NA":9263},{"trials":9248,"activeCount":101},[],{"trials":9250,"activeCount":101},[9251],{"nctId":9252,"briefTitle":9253,"status":242,"phases":9254,"primaryCompletion":1168,"completion":1168,"start":1098,"enrollment":1282,"conditions":9255,"interventions":9256},"NCT01522664","A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma",[89],[624],[9245],{"trials":9258,"activeCount":101},[],{"trials":9260,"activeCount":101},[],{"trials":9262,"activeCount":101},[],{"trials":9264,"activeCount":101},[],{"intervention":9266,"totalTrials":116,"cells":9267},"GDC-0623",{"EARLY_PHASE1":9268,"PHASE1":9270,"PHASE2":9278,"PHASE3":9280,"PHASE4":9282,"NA":9284},{"trials":9269,"activeCount":101},[],{"trials":9271,"activeCount":101},[9272],{"nctId":9273,"briefTitle":9274,"status":242,"phases":9275,"primaryCompletion":1069,"completion":1069,"start":4398,"enrollment":3696,"conditions":9276,"interventions":9277},"NCT01106599","A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors",[89],[24],[9266],{"trials":9279,"activeCount":101},[],{"trials":9281,"activeCount":101},[],{"trials":9283,"activeCount":101},[],{"trials":9285,"activeCount":101},[],{"intervention":9287,"totalTrials":116,"cells":9288},"GDC-0927",{"EARLY_PHASE1":9289,"PHASE1":9291,"PHASE2":9301,"PHASE3":9303,"PHASE4":9305,"NA":9307},{"trials":9290,"activeCount":101},[],{"trials":9292,"activeCount":101},[9293],{"nctId":9294,"briefTitle":9295,"status":242,"phases":9296,"primaryCompletion":9297,"completion":9297,"start":9298,"enrollment":1028,"conditions":9299,"interventions":9300},"NCT02316509","A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer",[89],"2020-01-10","2015-03-17",[18],[9287],{"trials":9302,"activeCount":101},[],{"trials":9304,"activeCount":101},[],{"trials":9306,"activeCount":101},[],{"trials":9308,"activeCount":101},[],{"intervention":835,"totalTrials":116,"cells":9310},{"EARLY_PHASE1":9311,"PHASE1":9313,"PHASE2":9319,"PHASE3":9321,"PHASE4":9323,"NA":9325},{"trials":9312,"activeCount":101},[],{"trials":9314,"activeCount":101},[9315],{"nctId":824,"briefTitle":825,"status":826,"phases":9316,"primaryCompletion":828,"completion":828,"start":829,"enrollment":101,"conditions":9317,"interventions":9318},[89],[831,832,833],[835,801],{"trials":9320,"activeCount":101},[],{"trials":9322,"activeCount":101},[],{"trials":9324,"activeCount":101},[],{"trials":9326,"activeCount":101},[],{"intervention":1644,"totalTrials":116,"cells":9328},{"EARLY_PHASE1":9329,"PHASE1":9331,"PHASE2":9337,"PHASE3":9339,"PHASE4":9341,"NA":9343},{"trials":9330,"activeCount":101},[],{"trials":9332,"activeCount":101},[9333],{"nctId":1636,"briefTitle":1637,"status":242,"phases":9334,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":9335,"interventions":9336},[89],[695],[519,711,1644,748,522,524,525],{"trials":9338,"activeCount":101},[],{"trials":9340,"activeCount":101},[],{"trials":9342,"activeCount":101},[],{"trials":9344,"activeCount":101},[],{"intervention":8863,"totalTrials":116,"cells":9346},{"EARLY_PHASE1":9347,"PHASE1":9349,"PHASE2":9355,"PHASE3":9357,"PHASE4":9359,"NA":9361},{"trials":9348,"activeCount":101},[],{"trials":9350,"activeCount":101},[9351],{"nctId":8857,"briefTitle":8858,"status":242,"phases":9352,"primaryCompletion":1462,"completion":1462,"start":3559,"enrollment":8860,"conditions":9353,"interventions":9354},[89],[34],[8863,8850],{"trials":9356,"activeCount":101},[],{"trials":9358,"activeCount":101},[],{"trials":9360,"activeCount":101},[],{"trials":9362,"activeCount":101},[],{"intervention":562,"totalTrials":116,"cells":9364},{"EARLY_PHASE1":9365,"PHASE1":9367,"PHASE2":9373,"PHASE3":9375,"PHASE4":9377,"NA":9379},{"trials":9366,"activeCount":101},[],{"trials":9368,"activeCount":101},[9369],{"nctId":552,"briefTitle":553,"status":242,"phases":9370,"primaryCompletion":555,"completion":555,"start":556,"enrollment":557,"conditions":9371,"interventions":9372},[89],[559],[487,506,521,561,526,525,562,563,520,564],{"trials":9374,"activeCount":101},[],{"trials":9376,"activeCount":101},[],{"trials":9378,"activeCount":101},[],{"trials":9380,"activeCount":101},[],{"intervention":8706,"totalTrials":116,"cells":9382},{"EARLY_PHASE1":9383,"PHASE1":9385,"PHASE2":9391,"PHASE3":9393,"PHASE4":9395,"NA":9397},{"trials":9384,"activeCount":101},[],{"trials":9386,"activeCount":101},[9387],{"nctId":8700,"briefTitle":8701,"status":242,"phases":9388,"primaryCompletion":1254,"completion":1254,"start":4372,"enrollment":488,"conditions":9389,"interventions":9390},[89],[4124],[8705,8706,8707],{"trials":9392,"activeCount":101},[],{"trials":9394,"activeCount":101},[],{"trials":9396,"activeCount":101},[],{"trials":9398,"activeCount":101},[],{"intervention":8707,"totalTrials":116,"cells":9400},{"EARLY_PHASE1":9401,"PHASE1":9403,"PHASE2":9409,"PHASE3":9411,"PHASE4":9413,"NA":9415},{"trials":9402,"activeCount":101},[],{"trials":9404,"activeCount":101},[9405],{"nctId":8700,"briefTitle":8701,"status":242,"phases":9406,"primaryCompletion":1254,"completion":1254,"start":4372,"enrollment":488,"conditions":9407,"interventions":9408},[89],[4124],[8705,8706,8707],{"trials":9410,"activeCount":101},[],{"trials":9412,"activeCount":101},[],{"trials":9414,"activeCount":101},[],{"trials":9416,"activeCount":101},[],{"intervention":9418,"totalTrials":116,"cells":9419},"PRO283698",{"EARLY_PHASE1":9420,"PHASE1":9422,"PHASE2":9430,"PHASE3":9432,"PHASE4":9434,"NA":9436},{"trials":9421,"activeCount":101},[],{"trials":9423,"activeCount":101},[9424],{"nctId":9425,"briefTitle":9426,"status":242,"phases":9427,"primaryCompletion":1070,"start":1130,"enrollment":1048,"conditions":9428,"interventions":9429},"NCT00888745","A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis",[89],[21],[9418],{"trials":9431,"activeCount":101},[],{"trials":9433,"activeCount":101},[],{"trials":9435,"activeCount":101},[],{"trials":9437,"activeCount":101},[],{"intervention":9439,"totalTrials":116,"cells":9440},"GDC-0810 Phase II",{"EARLY_PHASE1":9441,"PHASE1":9443,"PHASE2":9454,"PHASE3":9456,"PHASE4":9458,"NA":9460},{"trials":9442,"activeCount":101},[],{"trials":9444,"activeCount":101},[9445],{"nctId":9446,"briefTitle":9447,"status":242,"phases":9448,"primaryCompletion":9449,"completion":9449,"start":9450,"enrollment":8,"conditions":9451,"interventions":9452},"NCT02722018","Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810",[89],"2016-09-13","2016-01-06",[15],[9439,9453],"GDC-0810 Phase III Prototype",{"trials":9455,"activeCount":101},[],{"trials":9457,"activeCount":101},[],{"trials":9459,"activeCount":101},[],{"trials":9461,"activeCount":101},[],{"intervention":9453,"totalTrials":116,"cells":9463},{"EARLY_PHASE1":9464,"PHASE1":9466,"PHASE2":9472,"PHASE3":9474,"PHASE4":9476,"NA":9478},{"trials":9465,"activeCount":101},[],{"trials":9467,"activeCount":101},[9468],{"nctId":9446,"briefTitle":9447,"status":242,"phases":9469,"primaryCompletion":9449,"completion":9449,"start":9450,"enrollment":8,"conditions":9470,"interventions":9471},[89],[15],[9439,9453],{"trials":9473,"activeCount":101},[],{"trials":9475,"activeCount":101},[],{"trials":9477,"activeCount":101},[],{"trials":9479,"activeCount":101},[],{"intervention":9481,"totalTrials":116,"cells":9482},"GDC-0084",{"EARLY_PHASE1":9483,"PHASE1":9485,"PHASE2":9494,"PHASE3":9496,"PHASE4":9498,"NA":9500},{"trials":9484,"activeCount":101},[],{"trials":9486,"activeCount":101},[9487],{"nctId":9488,"briefTitle":9489,"status":242,"phases":9490,"primaryCompletion":1443,"completion":1443,"start":1515,"enrollment":5588,"conditions":9491,"interventions":9493},"NCT01547546","A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma",[89],[9492],"Glioblastoma, Glioma",[9481],{"trials":9495,"activeCount":101},[],{"trials":9497,"activeCount":101},[],{"trials":9499,"activeCount":101},[],{"trials":9501,"activeCount":101},[],{"intervention":9503,"totalTrials":116,"cells":9504},"MHAB5553A",{"EARLY_PHASE1":9505,"PHASE1":9507,"PHASE2":9517,"PHASE3":9519,"PHASE4":9521,"NA":9523},{"trials":9506,"activeCount":101},[],{"trials":9508,"activeCount":101},[9509],{"nctId":9510,"briefTitle":9511,"status":242,"phases":9512,"primaryCompletion":9513,"completion":9513,"start":9514,"enrollment":6799,"conditions":9515,"interventions":9516},"NCT02528903","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers",[89],"2016-01-26","2015-08-18",[15],[9503],{"trials":9518,"activeCount":101},[],{"trials":9520,"activeCount":101},[],{"trials":9522,"activeCount":101},[],{"trials":9524,"activeCount":101},[],{"intervention":9526,"totalTrials":116,"cells":9527},"[14C]-GDC-9545",{"EARLY_PHASE1":9528,"PHASE1":9530,"PHASE2":9543,"PHASE3":9545,"PHASE4":9547,"NA":9549},{"trials":9529,"activeCount":101},[],{"trials":9531,"activeCount":101},[9532],{"nctId":9533,"briefTitle":9534,"status":242,"phases":9535,"primaryCompletion":9536,"completion":9536,"start":9537,"enrollment":1228,"conditions":9538,"interventions":9539},"NCT04680273","Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential",[89],"2021-04-12","2021-01-07",[34],[9526,9540,9541,9542],"GDC-9545 Solution for","GDC-9545\u002FF12","GDC-9545\u002FF18",{"trials":9544,"activeCount":101},[],{"trials":9546,"activeCount":101},[],{"trials":9548,"activeCount":101},[],{"trials":9550,"activeCount":101},[],{"intervention":9540,"totalTrials":116,"cells":9552},{"EARLY_PHASE1":9553,"PHASE1":9555,"PHASE2":9561,"PHASE3":9563,"PHASE4":9565,"NA":9567},{"trials":9554,"activeCount":101},[],{"trials":9556,"activeCount":101},[9557],{"nctId":9533,"briefTitle":9534,"status":242,"phases":9558,"primaryCompletion":9536,"completion":9536,"start":9537,"enrollment":1228,"conditions":9559,"interventions":9560},[89],[34],[9526,9540,9541,9542],{"trials":9562,"activeCount":101},[],{"trials":9564,"activeCount":101},[],{"trials":9566,"activeCount":101},[],{"trials":9568,"activeCount":101},[],{"intervention":9541,"totalTrials":116,"cells":9570},{"EARLY_PHASE1":9571,"PHASE1":9573,"PHASE2":9579,"PHASE3":9581,"PHASE4":9583,"NA":9585},{"trials":9572,"activeCount":101},[],{"trials":9574,"activeCount":101},[9575],{"nctId":9533,"briefTitle":9534,"status":242,"phases":9576,"primaryCompletion":9536,"completion":9536,"start":9537,"enrollment":1228,"conditions":9577,"interventions":9578},[89],[34],[9526,9540,9541,9542],{"trials":9580,"activeCount":101},[],{"trials":9582,"activeCount":101},[],{"trials":9584,"activeCount":101},[],{"trials":9586,"activeCount":101},[],{"intervention":9542,"totalTrials":116,"cells":9588},{"EARLY_PHASE1":9589,"PHASE1":9591,"PHASE2":9597,"PHASE3":9599,"PHASE4":9601,"NA":9603},{"trials":9590,"activeCount":101},[],{"trials":9592,"activeCount":101},[9593],{"nctId":9533,"briefTitle":9534,"status":242,"phases":9594,"primaryCompletion":9536,"completion":9536,"start":9537,"enrollment":1228,"conditions":9595,"interventions":9596},[89],[34],[9526,9540,9541,9542],{"trials":9598,"activeCount":101},[],{"trials":9600,"activeCount":101},[],{"trials":9602,"activeCount":101},[],{"trials":9604,"activeCount":101},[],{"intervention":9606,"totalTrials":116,"cells":9607},"GDC-0349",{"EARLY_PHASE1":9608,"PHASE1":9610,"PHASE2":9619,"PHASE3":9621,"PHASE4":9623,"NA":9625},{"trials":9609,"activeCount":101},[],{"trials":9611,"activeCount":101},[9612],{"nctId":9613,"briefTitle":9614,"status":242,"phases":9615,"primaryCompletion":4205,"completion":4205,"start":1344,"enrollment":802,"conditions":9616,"interventions":9618},"NCT01356173","Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma",[89],[9617],"Non-Hodgkin's Lymphoma, Solid Tumor",[9606],{"trials":9620,"activeCount":101},[],{"trials":9622,"activeCount":101},[],{"trials":9624,"activeCount":101},[],{"trials":9626,"activeCount":101},[],{"intervention":9628,"totalTrials":116,"cells":9629},"GDC-0310",{"EARLY_PHASE1":9630,"PHASE1":9632,"PHASE2":9641,"PHASE3":9643,"PHASE4":9645,"NA":9647},{"trials":9631,"activeCount":101},[],{"trials":9633,"activeCount":101},[9634],{"nctId":9635,"briefTitle":9636,"status":242,"phases":9637,"primaryCompletion":9638,"completion":9638,"start":728,"enrollment":6526,"conditions":9639,"interventions":9640},"NCT02742779","A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers",[89],"2017-06-07",[15],[9628],{"trials":9642,"activeCount":101},[],{"trials":9644,"activeCount":101},[],{"trials":9646,"activeCount":101},[],{"trials":9648,"activeCount":101},[],{"intervention":6603,"totalTrials":116,"cells":9650},{"EARLY_PHASE1":9651,"PHASE1":9653,"PHASE2":9659,"PHASE3":9661,"PHASE4":9663,"NA":9665},{"trials":9652,"activeCount":101},[],{"trials":9654,"activeCount":101},[9655],{"nctId":6597,"briefTitle":6598,"status":242,"phases":9656,"primaryCompletion":6600,"completion":6600,"start":947,"enrollment":35,"conditions":9657,"interventions":9658},[89],[18],[356,6603],{"trials":9660,"activeCount":101},[],{"trials":9662,"activeCount":101},[],{"trials":9664,"activeCount":101},[],{"trials":9666,"activeCount":101},[],{"intervention":9668,"totalTrials":116,"cells":9669},"Entrectinib 600 mg",{"EARLY_PHASE1":9670,"PHASE1":9672,"PHASE2":9683,"PHASE3":9685,"PHASE4":9687,"NA":9689},{"trials":9671,"activeCount":101},[],{"trials":9673,"activeCount":101},[9674],{"nctId":9675,"briefTitle":9676,"status":242,"phases":9677,"primaryCompletion":9678,"completion":9678,"start":9679,"enrollment":1901,"conditions":9680,"interventions":9681},"NCT03961100","A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.",[89],"2019-08-09","2019-06-06",[316],[9668,9668,9682,9682],"Entrectinib 200 mg",{"trials":9684,"activeCount":101},[],{"trials":9686,"activeCount":101},[],{"trials":9688,"activeCount":101},[],{"trials":9690,"activeCount":101},[],{"intervention":9682,"totalTrials":116,"cells":9692},{"EARLY_PHASE1":9693,"PHASE1":9695,"PHASE2":9701,"PHASE3":9703,"PHASE4":9705,"NA":9707},{"trials":9694,"activeCount":101},[],{"trials":9696,"activeCount":101},[9697],{"nctId":9675,"briefTitle":9676,"status":242,"phases":9698,"primaryCompletion":9678,"completion":9678,"start":9679,"enrollment":1901,"conditions":9699,"interventions":9700},[89],[316],[9668,9668,9682,9682],{"trials":9702,"activeCount":101},[],{"trials":9704,"activeCount":101},[],{"trials":9706,"activeCount":101},[],{"trials":9708,"activeCount":101},[],{"intervention":9710,"totalTrials":116,"cells":9711},"GDC-9545 Tablet, Fasted: Treatment A",{"EARLY_PHASE1":9712,"PHASE1":9714,"PHASE2":9726,"PHASE3":9728,"PHASE4":9730,"NA":9732},{"trials":9713,"activeCount":101},[],{"trials":9715,"activeCount":101},[9716],{"nctId":9717,"briefTitle":9718,"status":242,"phases":9719,"primaryCompletion":9720,"completion":9720,"start":9721,"enrollment":25,"conditions":9722,"interventions":9723},"NCT04274075","Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential",[89],"2020-04-16","2020-03-06",[34],[9710,9724,9725],"GDC-9545 Capsule, Fasted: Treatment B","GDC-9545 Capsule, Fed: Treatment C",{"trials":9727,"activeCount":101},[],{"trials":9729,"activeCount":101},[],{"trials":9731,"activeCount":101},[],{"trials":9733,"activeCount":101},[],{"intervention":9724,"totalTrials":116,"cells":9735},{"EARLY_PHASE1":9736,"PHASE1":9738,"PHASE2":9744,"PHASE3":9746,"PHASE4":9748,"NA":9750},{"trials":9737,"activeCount":101},[],{"trials":9739,"activeCount":101},[9740],{"nctId":9717,"briefTitle":9718,"status":242,"phases":9741,"primaryCompletion":9720,"completion":9720,"start":9721,"enrollment":25,"conditions":9742,"interventions":9743},[89],[34],[9710,9724,9725],{"trials":9745,"activeCount":101},[],{"trials":9747,"activeCount":101},[],{"trials":9749,"activeCount":101},[],{"trials":9751,"activeCount":101},[],{"intervention":9725,"totalTrials":116,"cells":9753},{"EARLY_PHASE1":9754,"PHASE1":9756,"PHASE2":9762,"PHASE3":9764,"PHASE4":9766,"NA":9768},{"trials":9755,"activeCount":101},[],{"trials":9757,"activeCount":101},[9758],{"nctId":9717,"briefTitle":9718,"status":242,"phases":9759,"primaryCompletion":9720,"completion":9720,"start":9721,"enrollment":25,"conditions":9760,"interventions":9761},[89],[34],[9710,9724,9725],{"trials":9763,"activeCount":101},[],{"trials":9765,"activeCount":101},[],{"trials":9767,"activeCount":101},[],{"trials":9769,"activeCount":101},[],{"intervention":9771,"totalTrials":116,"cells":9772},"DCLL9718S",{"EARLY_PHASE1":9773,"PHASE1":9775,"PHASE2":9786,"PHASE3":9788,"PHASE4":9790,"NA":9792},{"trials":9774,"activeCount":101},[],{"trials":9776,"activeCount":101},[9777],{"nctId":9778,"briefTitle":9779,"status":242,"phases":9780,"primaryCompletion":5763,"completion":5763,"start":9781,"enrollment":1335,"conditions":9782,"interventions":9784},"NCT03298516","A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy",[89],"2017-11-15",[9783],"Leukemia, Myeloid, Acute",[9771,9785],"Azacitidine",{"trials":9787,"activeCount":101},[],{"trials":9789,"activeCount":101},[],{"trials":9791,"activeCount":101},[],{"trials":9793,"activeCount":101},[],{"intervention":9785,"totalTrials":116,"cells":9795},{"EARLY_PHASE1":9796,"PHASE1":9798,"PHASE2":9804,"PHASE3":9806,"PHASE4":9808,"NA":9810},{"trials":9797,"activeCount":101},[],{"trials":9799,"activeCount":101},[9800],{"nctId":9778,"briefTitle":9779,"status":242,"phases":9801,"primaryCompletion":5763,"completion":5763,"start":9781,"enrollment":1335,"conditions":9802,"interventions":9803},[89],[9783],[9771,9785],{"trials":9805,"activeCount":101},[],{"trials":9807,"activeCount":101},[],{"trials":9809,"activeCount":101},[],{"trials":9811,"activeCount":101},[],{"intervention":1074,"totalTrials":116,"cells":9813},{"EARLY_PHASE1":9814,"PHASE1":9816,"PHASE2":9822,"PHASE3":9824,"PHASE4":9826,"NA":9828},{"trials":9815,"activeCount":101},[],{"trials":9817,"activeCount":101},[9818],{"nctId":1066,"briefTitle":1067,"status":242,"phases":9819,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":1071,"conditions":9820,"interventions":9821},[89],[24],[1074,1027],{"trials":9823,"activeCount":101},[],{"trials":9825,"activeCount":101},[],{"trials":9827,"activeCount":101},[],{"trials":9829,"activeCount":101},[],{"intervention":9831,"totalTrials":116,"cells":9832},"CD4-IgG",{"EARLY_PHASE1":9833,"PHASE1":9835,"PHASE2":9845,"PHASE3":9847,"PHASE4":9849,"NA":9851},{"trials":9834,"activeCount":101},[],{"trials":9836,"activeCount":101},[9837],{"nctId":9838,"briefTitle":9839,"status":242,"phases":9840,"conditions":9841,"interventions":9844},"NCT00002250","A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura",[89],[9842,9843],"Immune Thrombocytopenic Purpura ( ITP )","HIV Infections",[9831],{"trials":9846,"activeCount":101},[],{"trials":9848,"activeCount":101},[],{"trials":9850,"activeCount":101},[],{"trials":9852,"activeCount":101},[],{"intervention":1455,"totalTrials":116,"cells":9854},{"EARLY_PHASE1":9855,"PHASE1":9857,"PHASE2":9863,"PHASE3":9865,"PHASE4":9867,"NA":9869},{"trials":9856,"activeCount":101},[],{"trials":9858,"activeCount":101},[9859],{"nctId":1448,"briefTitle":1449,"status":242,"phases":9860,"primaryCompletion":896,"completion":896,"start":1451,"enrollment":1452,"conditions":9861,"interventions":9862},[89],[316],[1446,1455,1456],{"trials":9864,"activeCount":101},[],{"trials":9866,"activeCount":101},[],{"trials":9868,"activeCount":101},[],{"trials":9870,"activeCount":101},[],{"intervention":9872,"totalTrials":116,"cells":9873},"RO7105705",{"EARLY_PHASE1":9874,"PHASE1":9876,"PHASE2":9887,"PHASE3":9889,"PHASE4":9891,"NA":9893},{"trials":9875,"activeCount":101},[],{"trials":9877,"activeCount":101},[9878],{"nctId":9879,"briefTitle":9880,"status":242,"phases":9881,"primaryCompletion":9882,"completion":9882,"start":9883,"enrollment":9884,"conditions":9885,"interventions":9886},"NCT02820896","A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease",[89],"2017-06-26","2016-06-29",74,[6227],[9872],{"trials":9888,"activeCount":101},[],{"trials":9890,"activeCount":101},[],{"trials":9892,"activeCount":101},[],{"trials":9894,"activeCount":101},[],{"intervention":8538,"totalTrials":116,"cells":9896},{"EARLY_PHASE1":9897,"PHASE1":9899,"PHASE2":9905,"PHASE3":9907,"PHASE4":9909,"NA":9911},{"trials":9898,"activeCount":101},[],{"trials":9900,"activeCount":101},[9901],{"nctId":8532,"briefTitle":8533,"status":242,"phases":9902,"primaryCompletion":416,"completion":416,"start":956,"enrollment":8535,"conditions":9903,"interventions":9904},[89],[15],[8538,8539,5549,8540],{"trials":9906,"activeCount":101},[],{"trials":9908,"activeCount":101},[],{"trials":9910,"activeCount":101},[],{"trials":9912,"activeCount":101},[],{"intervention":9914,"totalTrials":116,"cells":9915},"D4064A",{"EARLY_PHASE1":9916,"PHASE1":9918,"PHASE2":9927,"PHASE3":9929,"PHASE4":9931,"NA":9933},{"trials":9917,"activeCount":101},[],{"trials":9919,"activeCount":101},[9920],{"nctId":9921,"briefTitle":9922,"status":9923,"phases":9924,"start":3628,"enrollment":1238,"conditions":9925,"interventions":9926},"NCT00753480","A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","SUSPENDED",[89],[1574,1284,1573],[9914],{"trials":9928,"activeCount":101},[],{"trials":9930,"activeCount":101},[],{"trials":9932,"activeCount":101},[],{"trials":9934,"activeCount":101},[],{"intervention":9936,"totalTrials":116,"cells":9937},"RG7667",{"EARLY_PHASE1":9938,"PHASE1":9940,"PHASE2":9948,"PHASE3":9950,"PHASE4":9952,"NA":9954},{"trials":9939,"activeCount":101},[],{"trials":9941,"activeCount":101},[9942],{"nctId":9943,"briefTitle":9944,"status":242,"phases":9945,"primaryCompletion":2575,"completion":2575,"start":2785,"enrollment":8188,"conditions":9946,"interventions":9947},"NCT01496755","A Study of RG7667 in Healthy Volunteers",[89],[15],[9936],{"trials":9949,"activeCount":101},[],{"trials":9951,"activeCount":101},[],{"trials":9953,"activeCount":101},[],{"trials":9955,"activeCount":101},[],{"intervention":9957,"totalTrials":116,"cells":9958},"GDC-0152",{"EARLY_PHASE1":9959,"PHASE1":9961,"PHASE2":9969,"PHASE3":9971,"PHASE4":9973,"NA":9975},{"trials":9960,"activeCount":101},[],{"trials":9962,"activeCount":101},[9963],{"nctId":9964,"briefTitle":9965,"status":325,"phases":9966,"primaryCompletion":1207,"completion":1207,"start":1208,"enrollment":979,"conditions":9967,"interventions":9968},"NCT00977067","A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies",[89],[24],[9957],{"trials":9970,"activeCount":101},[],{"trials":9972,"activeCount":101},[],{"trials":9974,"activeCount":101},[],{"trials":9976,"activeCount":101},[],{"intervention":9978,"totalTrials":116,"cells":9979},"GDC-0068",{"EARLY_PHASE1":9980,"PHASE1":9982,"PHASE2":9991,"PHASE3":9993,"PHASE4":9995,"NA":9997},{"trials":9981,"activeCount":101},[],{"trials":9983,"activeCount":101},[9984],{"nctId":9985,"briefTitle":9986,"status":242,"phases":9987,"primaryCompletion":9988,"completion":9988,"start":7824,"enrollment":1161,"conditions":9989,"interventions":9990},"NCT01090960","A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors",[89],"2015-02",[24],[9978],{"trials":9992,"activeCount":101},[],{"trials":9994,"activeCount":101},[],{"trials":9996,"activeCount":101},[],{"trials":9998,"activeCount":101},[],{"intervention":10000,"totalTrials":116,"cells":10001},"GDC-0334",{"EARLY_PHASE1":10002,"PHASE1":10004,"PHASE2":10014,"PHASE3":10016,"PHASE4":10018,"NA":10020},{"trials":10003,"activeCount":101},[],{"trials":10005,"activeCount":101},[10006],{"nctId":10007,"briefTitle":10008,"status":325,"phases":10009,"primaryCompletion":10010,"completion":10010,"start":10011,"enrollment":5967,"conditions":10012,"interventions":10013},"NCT03381144","A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants",[89],"2019-04-29","2017-12-08",[34],[10000],{"trials":10015,"activeCount":101},[],{"trials":10017,"activeCount":101},[],{"trials":10019,"activeCount":101},[],{"trials":10021,"activeCount":101},[],{"intervention":10023,"totalTrials":116,"cells":10024},"DMUC4064A",{"EARLY_PHASE1":10025,"PHASE1":10027,"PHASE2":10039,"PHASE3":10041,"PHASE4":10043,"NA":10045},{"trials":10026,"activeCount":101},[],{"trials":10028,"activeCount":101},[10029],{"nctId":10030,"briefTitle":10031,"status":242,"phases":10032,"primaryCompletion":10033,"completion":10033,"start":10034,"enrollment":16,"conditions":10035,"interventions":10038},"NCT02146313","A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer",[89],"2018-06-18","2014-06-22",[10036,10037],"Pancreatic Neoplasms","Ovarian Neoplasms",[10023],{"trials":10040,"activeCount":101},[],{"trials":10042,"activeCount":101},[],{"trials":10044,"activeCount":101},[],{"trials":10046,"activeCount":101},[],{"intervention":10048,"totalTrials":116,"cells":10049},"DMOT4039A",{"EARLY_PHASE1":10050,"PHASE1":10052,"PHASE2":10060,"PHASE3":10062,"PHASE4":10064,"NA":10066},{"trials":10051,"activeCount":101},[],{"trials":10053,"activeCount":101},[10054],{"nctId":10055,"briefTitle":10056,"status":242,"phases":10057,"primaryCompletion":947,"completion":947,"start":1291,"enrollment":9,"conditions":10058,"interventions":10059},"NCT01469793","A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer",[89],[1284],[10048],{"trials":10061,"activeCount":101},[],{"trials":10063,"activeCount":101},[],{"trials":10065,"activeCount":101},[],{"trials":10067,"activeCount":101},[],{"intervention":8723,"totalTrials":116,"cells":10069},{"EARLY_PHASE1":10070,"PHASE1":10072,"PHASE2":10078,"PHASE3":10080,"PHASE4":10082,"NA":10084},{"trials":10071,"activeCount":101},[],{"trials":10073,"activeCount":101},[10074],{"nctId":8716,"briefTitle":8717,"status":242,"phases":10075,"primaryCompletion":8719,"completion":8719,"start":8720,"enrollment":3696,"conditions":10076,"interventions":10077},[89],[15],[8693,8723],{"trials":10079,"activeCount":101},[],{"trials":10081,"activeCount":101},[],{"trials":10083,"activeCount":101},[],{"trials":10085,"activeCount":101},[],{"intervention":10087,"totalTrials":116,"cells":10088},"BITS7201A",{"EARLY_PHASE1":10089,"PHASE1":10091,"PHASE2":10102,"PHASE3":10104,"PHASE4":10106,"NA":10108},{"trials":10090,"activeCount":101},[],{"trials":10092,"activeCount":101},[10093],{"nctId":10094,"briefTitle":10095,"status":242,"phases":10096,"primaryCompletion":10097,"completion":10097,"start":10098,"enrollment":622,"conditions":10099,"interventions":10101},"NCT02748642","A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma",[89],"2017-06-14","2016-04-07",[10100],"Mild Atopic Asthma",[10087],{"trials":10103,"activeCount":101},[],{"trials":10105,"activeCount":101},[],{"trials":10107,"activeCount":101},[],{"trials":10109,"activeCount":101},[],{"intervention":10111,"totalTrials":116,"cells":10112},"GDC-0276",{"EARLY_PHASE1":10113,"PHASE1":10115,"PHASE2":10124,"PHASE3":10126,"PHASE4":10128,"NA":10130},{"trials":10114,"activeCount":101},[],{"trials":10116,"activeCount":101},[10117],{"nctId":10118,"briefTitle":10119,"status":826,"phases":10120,"primaryCompletion":10121,"completion":10121,"start":6379,"enrollment":101,"conditions":10122,"interventions":10123},"NCT02856152","A Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy Participants",[89],"2016-11",[15],[10111,10111],{"trials":10125,"activeCount":101},[],{"trials":10127,"activeCount":101},[],{"trials":10129,"activeCount":101},[],{"trials":10131,"activeCount":101},[],{"intervention":10133,"totalTrials":116,"cells":10134},"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody",{"EARLY_PHASE1":10135,"PHASE1":10137,"PHASE2":10149,"PHASE3":10151,"PHASE4":10153,"NA":10155},{"trials":10136,"activeCount":101},[],{"trials":10138,"activeCount":101},[10139],{"nctId":10140,"briefTitle":10141,"status":242,"phases":10142,"primaryCompletion":10143,"completion":10143,"start":10144,"enrollment":10145,"conditions":10146,"interventions":10147},"NCT02410512","A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors",[89],"2019-11-22","2015-04-24",610,[695],[10133,10148],"MOXR0916, a humanized agonist anti-OX40 monoclonal antibody",{"trials":10150,"activeCount":101},[],{"trials":10152,"activeCount":101},[],{"trials":10154,"activeCount":101},[],{"trials":10156,"activeCount":101},[],{"intervention":10148,"totalTrials":116,"cells":10158},{"EARLY_PHASE1":10159,"PHASE1":10161,"PHASE2":10167,"PHASE3":10169,"PHASE4":10171,"NA":10173},{"trials":10160,"activeCount":101},[],{"trials":10162,"activeCount":101},[10163],{"nctId":10140,"briefTitle":10141,"status":242,"phases":10164,"primaryCompletion":10143,"completion":10143,"start":10144,"enrollment":10145,"conditions":10165,"interventions":10166},[89],[695],[10133,10148],{"trials":10168,"activeCount":101},[],{"trials":10170,"activeCount":101},[],{"trials":10172,"activeCount":101},[],{"trials":10174,"activeCount":101},[],{"intervention":10176,"totalTrials":116,"cells":10177},"BLYG8824A",{"EARLY_PHASE1":10178,"PHASE1":10180,"PHASE2":10190,"PHASE3":10192,"PHASE4":10194,"NA":10196},{"trials":10179,"activeCount":101},[],{"trials":10181,"activeCount":101},[10182],{"nctId":10183,"briefTitle":10184,"status":242,"phases":10185,"primaryCompletion":10186,"completion":10186,"start":10187,"enrollment":1311,"conditions":10188,"interventions":10189},"NCT04468607","A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer",[89],"2024-10-16","2020-08-31",[29],[10176],{"trials":10191,"activeCount":101},[],{"trials":10193,"activeCount":101},[],{"trials":10195,"activeCount":101},[],{"trials":10197,"activeCount":101},[],{"intervention":10199,"totalTrials":116,"cells":10200},"GDC-3280",{"EARLY_PHASE1":10201,"PHASE1":10203,"PHASE2":10212,"PHASE3":10214,"PHASE4":10216,"NA":10218},{"trials":10202,"activeCount":101},[],{"trials":10204,"activeCount":101},[10205],{"nctId":10206,"briefTitle":10207,"status":242,"phases":10208,"primaryCompletion":947,"completion":947,"start":1168,"enrollment":10209,"conditions":10210,"interventions":10211},"NCT02471859","A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants",[89],8,[15],[10199],{"trials":10213,"activeCount":101},[],{"trials":10215,"activeCount":101},[],{"trials":10217,"activeCount":101},[],{"trials":10219,"activeCount":101},[],{"intervention":10221,"totalTrials":116,"cells":10222},"rgp120\u002FHIV-1IIIB",{"EARLY_PHASE1":10223,"PHASE1":10225,"PHASE2":10233,"PHASE3":10235,"PHASE4":10237,"NA":10239},{"trials":10224,"activeCount":101},[],{"trials":10226,"activeCount":101},[10227],{"nctId":10228,"briefTitle":10229,"status":242,"phases":10230,"conditions":10231,"interventions":10232},"NCT00001992","A Phase I Study of the Safety and Immunogenicity of Rgp 120\u002FHIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers",[89],[9843],[10221],{"trials":10234,"activeCount":101},[],{"trials":10236,"activeCount":101},[],{"trials":10238,"activeCount":101},[],{"trials":10240,"activeCount":101},[],{"intervention":10242,"totalTrials":116,"cells":10243},"rhuMAb IFNalpha",{"EARLY_PHASE1":10244,"PHASE1":10246,"PHASE2":10254,"PHASE3":10256,"PHASE4":10258,"NA":10260},{"trials":10245,"activeCount":101},[],{"trials":10247,"activeCount":101},[10248],{"nctId":10249,"briefTitle":10250,"status":242,"phases":10251,"start":1246,"enrollment":2231,"conditions":10252,"interventions":10253},"NCT00541749","A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus",[89],[2568],[10242],{"trials":10255,"activeCount":101},[],{"trials":10257,"activeCount":101},[],{"trials":10259,"activeCount":101},[],{"trials":10261,"activeCount":101},[],{"intervention":10263,"totalTrials":116,"cells":10264},"ZN-A-1041",{"EARLY_PHASE1":10265,"PHASE1":10267,"PHASE2":10277,"PHASE3":10279,"PHASE4":10281,"NA":10283},{"trials":10266,"activeCount":101},[],{"trials":10268,"activeCount":101},[10269],{"nctId":10270,"briefTitle":10271,"status":242,"phases":10272,"primaryCompletion":10273,"completion":10273,"start":10274,"enrollment":25,"conditions":10275,"interventions":10276},"NCT07051993","A Study to Evaluate the Relative Bioavailability of Two Tablet Formulations Compared to Capsule Formulation and the Effect of Food and Proton Pump Inhibitor on ZN-A-1041 Tablet(s) in Healthy Participants",[89],"2025-07-12","2025-06-27",[968],[10263],{"trials":10278,"activeCount":101},[],{"trials":10280,"activeCount":101},[],{"trials":10282,"activeCount":101},[],{"trials":10284,"activeCount":101},[],{"intervention":1945,"totalTrials":116,"cells":10286},{"EARLY_PHASE1":10287,"PHASE1":10289,"PHASE2":10295,"PHASE3":10297,"PHASE4":10299,"NA":10301},{"trials":10288,"activeCount":101},[],{"trials":10290,"activeCount":101},[10291],{"nctId":1938,"briefTitle":1939,"status":242,"phases":10292,"primaryCompletion":1941,"completion":1941,"start":1942,"enrollment":1335,"conditions":10293,"interventions":10294},[89],[968],[1945,783,1946],{"trials":10296,"activeCount":101},[],{"trials":10298,"activeCount":101},[],{"trials":10300,"activeCount":101},[],{"trials":10302,"activeCount":101},[],{"intervention":2808,"totalTrials":116,"cells":10304},{"EARLY_PHASE1":10305,"PHASE1":10307,"PHASE2":10313,"PHASE3":10315,"PHASE4":10317,"NA":10319},{"trials":10306,"activeCount":101},[],{"trials":10308,"activeCount":101},[10309],{"nctId":2800,"briefTitle":2801,"status":242,"phases":10310,"primaryCompletion":2803,"completion":2803,"start":2804,"enrollment":1345,"conditions":10311,"interventions":10312},[89],[2806],[2808,647],{"trials":10314,"activeCount":101},[],{"trials":10316,"activeCount":101},[],{"trials":10318,"activeCount":101},[],{"trials":10320,"activeCount":101},[],{"intervention":10322,"totalTrials":116,"cells":10323},"DLYE5953A",{"EARLY_PHASE1":10324,"PHASE1":10326,"PHASE2":10336,"PHASE3":10338,"PHASE4":10340,"NA":10342},{"trials":10325,"activeCount":101},[],{"trials":10327,"activeCount":101},[10328],{"nctId":10329,"briefTitle":10330,"status":242,"phases":10331,"primaryCompletion":10332,"completion":10332,"start":10333,"enrollment":1100,"conditions":10334,"interventions":10335},"NCT02092792","A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors",[89],"2017-07-10","2014-04-01",[695],[10322,10322],{"trials":10337,"activeCount":101},[],{"trials":10339,"activeCount":101},[],{"trials":10341,"activeCount":101},[],{"trials":10343,"activeCount":101},[],{"intervention":10345,"totalTrials":116,"cells":10346},"anti-Abeta",{"EARLY_PHASE1":10347,"PHASE1":10349,"PHASE2":10357,"PHASE3":10359,"PHASE4":10361,"NA":10363},{"trials":10348,"activeCount":101},[],{"trials":10350,"activeCount":101},[10351],{"nctId":10352,"briefTitle":10353,"status":242,"phases":10354,"primaryCompletion":3749,"start":4122,"enrollment":1238,"conditions":10355,"interventions":10356},"NCT00736775","A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease",[89],[6227],[10345],{"trials":10358,"activeCount":101},[],{"trials":10360,"activeCount":101},[],{"trials":10362,"activeCount":101},[],{"trials":10364,"activeCount":101},[],{"intervention":10366,"totalTrials":116,"cells":10367},"Entrectinib Test Formulation",{"EARLY_PHASE1":10368,"PHASE1":10370,"PHASE2":10381,"PHASE3":10383,"PHASE4":10385,"NA":10387},{"trials":10369,"activeCount":101},[],{"trials":10371,"activeCount":101},[10372],{"nctId":10373,"briefTitle":10374,"status":242,"phases":10375,"primaryCompletion":10376,"completion":10376,"start":10377,"enrollment":1425,"conditions":10378,"interventions":10379},"NCT03796260","A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants",[89],"2019-02-04","2019-01-09",[34],[10366,10380],"Entrectinib Reference Formulation",{"trials":10382,"activeCount":101},[],{"trials":10384,"activeCount":101},[],{"trials":10386,"activeCount":101},[],{"trials":10388,"activeCount":101},[],{"intervention":10380,"totalTrials":116,"cells":10390},{"EARLY_PHASE1":10391,"PHASE1":10393,"PHASE2":10399,"PHASE3":10401,"PHASE4":10403,"NA":10405},{"trials":10392,"activeCount":101},[],{"trials":10394,"activeCount":101},[10395],{"nctId":10373,"briefTitle":10374,"status":242,"phases":10396,"primaryCompletion":10376,"completion":10376,"start":10377,"enrollment":1425,"conditions":10397,"interventions":10398},[89],[34],[10366,10380],{"trials":10400,"activeCount":101},[],{"trials":10402,"activeCount":101},[],{"trials":10404,"activeCount":101},[],{"trials":10406,"activeCount":101},[],{"intervention":10408,"totalTrials":116,"cells":10409},"MTRX1011A",{"EARLY_PHASE1":10410,"PHASE1":10412,"PHASE2":10420,"PHASE3":10422,"PHASE4":10424,"NA":10426},{"trials":10411,"activeCount":101},[],{"trials":10413,"activeCount":101},[10414],{"nctId":10415,"briefTitle":10416,"status":325,"phases":10417,"primaryCompletion":4928,"start":1385,"enrollment":5967,"conditions":10418,"interventions":10419},"NCT00718588","A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis",[89],[21],[10408],{"trials":10421,"activeCount":101},[],{"trials":10423,"activeCount":101},[],{"trials":10425,"activeCount":101},[],{"trials":10427,"activeCount":101},[],{"intervention":8557,"totalTrials":116,"cells":10429},{"EARLY_PHASE1":10430,"PHASE1":10432,"PHASE2":10438,"PHASE3":10440,"PHASE4":10442,"NA":10444},{"trials":10431,"activeCount":101},[],{"trials":10433,"activeCount":101},[10434],{"nctId":8550,"briefTitle":8551,"status":242,"phases":10435,"primaryCompletion":8553,"completion":8553,"start":8554,"enrollment":25,"conditions":10436,"interventions":10437},[89],[8519],[8557,8558,5549],{"trials":10439,"activeCount":101},[],{"trials":10441,"activeCount":101},[],{"trials":10443,"activeCount":101},[],{"trials":10445,"activeCount":101},[],{"intervention":8558,"totalTrials":116,"cells":10447},{"EARLY_PHASE1":10448,"PHASE1":10450,"PHASE2":10456,"PHASE3":10458,"PHASE4":10460,"NA":10462},{"trials":10449,"activeCount":101},[],{"trials":10451,"activeCount":101},[10452],{"nctId":8550,"briefTitle":8551,"status":242,"phases":10453,"primaryCompletion":8553,"completion":8553,"start":8554,"enrollment":25,"conditions":10454,"interventions":10455},[89],[8519],[8557,8558,5549],{"trials":10457,"activeCount":101},[],{"trials":10459,"activeCount":101},[],{"trials":10461,"activeCount":101},[],{"trials":10463,"activeCount":101},[],{"intervention":658,"totalTrials":116,"cells":10465},{"EARLY_PHASE1":10466,"PHASE1":10468,"PHASE2":10474,"PHASE3":10476,"PHASE4":10478,"NA":10480},{"trials":10467,"activeCount":101},[],{"trials":10469,"activeCount":101},[10470],{"nctId":649,"briefTitle":650,"status":325,"phases":10471,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":10472,"interventions":10473},[89],[656],[658,487],{"trials":10475,"activeCount":101},[],{"trials":10477,"activeCount":101},[],{"trials":10479,"activeCount":101},[],{"trials":10481,"activeCount":101},[],{"intervention":6238,"totalTrials":116,"cells":10483},{"EARLY_PHASE1":10484,"PHASE1":10486,"PHASE2":10492,"PHASE3":10494,"PHASE4":10496,"NA":10498},{"trials":10485,"activeCount":101},[],{"trials":10487,"activeCount":101},[10488],{"nctId":6230,"briefTitle":6231,"status":242,"phases":10489,"primaryCompletion":6233,"completion":6233,"start":6234,"enrollment":979,"conditions":10490,"interventions":10491},[89],[6236],[6214,6238,6239],{"trials":10493,"activeCount":101},[],{"trials":10495,"activeCount":101},[],{"trials":10497,"activeCount":101},[],{"trials":10499,"activeCount":101},[],{"intervention":6239,"totalTrials":116,"cells":10501},{"EARLY_PHASE1":10502,"PHASE1":10504,"PHASE2":10510,"PHASE3":10512,"PHASE4":10514,"NA":10516},{"trials":10503,"activeCount":101},[],{"trials":10505,"activeCount":101},[10506],{"nctId":6230,"briefTitle":6231,"status":242,"phases":10507,"primaryCompletion":6233,"completion":6233,"start":6234,"enrollment":979,"conditions":10508,"interventions":10509},[89],[6236],[6214,6238,6239],{"trials":10511,"activeCount":101},[],{"trials":10513,"activeCount":101},[],{"trials":10515,"activeCount":101},[],{"trials":10517,"activeCount":101},[],{"intervention":10519,"totalTrials":116,"cells":10520},"Period 1 treatment",{"EARLY_PHASE1":10521,"PHASE1":10523,"PHASE2":10532,"PHASE3":10534,"PHASE4":10536,"NA":10538},{"trials":10522,"activeCount":101},[],{"trials":10524,"activeCount":101},[10525],{"nctId":10526,"briefTitle":10527,"status":242,"phases":10528,"primaryCompletion":6417,"completion":6417,"start":1046,"enrollment":10209,"conditions":10529,"interventions":10530},"NCT02390492","A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects",[89],[15],[10519,10531],"Period 2 treatment",{"trials":10533,"activeCount":101},[],{"trials":10535,"activeCount":101},[],{"trials":10537,"activeCount":101},[],{"trials":10539,"activeCount":101},[],{"intervention":10531,"totalTrials":116,"cells":10541},{"EARLY_PHASE1":10542,"PHASE1":10544,"PHASE2":10550,"PHASE3":10552,"PHASE4":10554,"NA":10556},{"trials":10543,"activeCount":101},[],{"trials":10545,"activeCount":101},[10546],{"nctId":10526,"briefTitle":10527,"status":242,"phases":10547,"primaryCompletion":6417,"completion":6417,"start":1046,"enrollment":10209,"conditions":10548,"interventions":10549},[89],[15],[10519,10531],{"trials":10551,"activeCount":101},[],{"trials":10553,"activeCount":101},[],{"trials":10555,"activeCount":101},[],{"trials":10557,"activeCount":101},[],{"intervention":2820,"totalTrials":116,"cells":10559},{"EARLY_PHASE1":10560,"PHASE1":10562,"PHASE2":10568,"PHASE3":10570,"PHASE4":10572,"NA":10574},{"trials":10561,"activeCount":101},[],{"trials":10563,"activeCount":101},[10564],{"nctId":2814,"briefTitle":2815,"status":242,"phases":10565,"primaryCompletion":2817,"completion":2817,"start":1640,"enrollment":979,"conditions":10566,"interventions":10567},[89],[316],[2820,2821],{"trials":10569,"activeCount":101},[],{"trials":10571,"activeCount":101},[],{"trials":10573,"activeCount":101},[],{"trials":10575,"activeCount":101},[],{"intervention":2941,"totalTrials":116,"cells":10577},{"EARLY_PHASE1":10578,"PHASE1":10580,"PHASE2":10586,"PHASE3":10588,"PHASE4":10590,"NA":10592},{"trials":10579,"activeCount":101},[],{"trials":10581,"activeCount":101},[10582],{"nctId":2934,"briefTitle":2935,"status":242,"phases":10583,"primaryCompletion":2937,"completion":2937,"start":2938,"enrollment":802,"conditions":10584,"interventions":10585},[89],[29,27],[577,2941,575],{"trials":10587,"activeCount":101},[],{"trials":10589,"activeCount":101},[],{"trials":10591,"activeCount":101},[],{"trials":10593,"activeCount":101},[],{"intervention":10595,"totalTrials":116,"cells":10596},"Rosiglitazone",{"EARLY_PHASE1":10597,"PHASE1":10599,"PHASE2":10608,"PHASE3":10610,"PHASE4":10612,"NA":10614},{"trials":10598,"activeCount":101},[],{"trials":10600,"activeCount":101},[10601],{"nctId":10602,"briefTitle":10603,"status":242,"phases":10604,"primaryCompletion":1098,"completion":1098,"start":3559,"enrollment":1161,"conditions":10605,"interventions":10606},"NCT01209143","A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists",[89],[24],[699,10595,10607],"Norethindrone\u002Fethinyl estradiol",{"trials":10609,"activeCount":101},[],{"trials":10611,"activeCount":101},[],{"trials":10613,"activeCount":101},[],{"trials":10615,"activeCount":101},[],{"intervention":10607,"totalTrials":116,"cells":10617},{"EARLY_PHASE1":10618,"PHASE1":10620,"PHASE2":10626,"PHASE3":10628,"PHASE4":10630,"NA":10632},{"trials":10619,"activeCount":101},[],{"trials":10621,"activeCount":101},[10622],{"nctId":10602,"briefTitle":10603,"status":242,"phases":10623,"primaryCompletion":1098,"completion":1098,"start":3559,"enrollment":1161,"conditions":10624,"interventions":10625},[89],[24],[699,10595,10607],{"trials":10627,"activeCount":101},[],{"trials":10629,"activeCount":101},[],{"trials":10631,"activeCount":101},[],{"trials":10633,"activeCount":101},[],{"intervention":10635,"totalTrials":116,"cells":10636},"DSTP3086S",{"EARLY_PHASE1":10637,"PHASE1":10639,"PHASE2":10647,"PHASE3":10649,"PHASE4":10651,"NA":10653},{"trials":10638,"activeCount":101},[],{"trials":10640,"activeCount":101},[10641],{"nctId":10642,"briefTitle":10643,"status":242,"phases":10644,"primaryCompletion":1522,"completion":1522,"start":1196,"enrollment":2044,"conditions":10645,"interventions":10646},"NCT01283373","A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer",[89],[4567],[10635,10635],{"trials":10648,"activeCount":101},[],{"trials":10650,"activeCount":101},[],{"trials":10652,"activeCount":101},[],{"trials":10654,"activeCount":101},[],{"intervention":10656,"totalTrials":116,"cells":10657},"DCDT2980S",{"EARLY_PHASE1":10658,"PHASE1":10660,"PHASE2":10669,"PHASE3":10671,"PHASE4":10673,"NA":10675},{"trials":10659,"activeCount":101},[],{"trials":10661,"activeCount":101},[10662],{"nctId":10663,"briefTitle":10664,"status":242,"phases":10665,"primaryCompletion":1046,"completion":1046,"start":8712,"enrollment":910,"conditions":10666,"interventions":10668},"NCT01209130","A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma",[89],[10667],"Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia",[10656,3594],{"trials":10670,"activeCount":101},[],{"trials":10672,"activeCount":101},[],{"trials":10674,"activeCount":101},[],{"trials":10676,"activeCount":101},[],{"intervention":1173,"totalTrials":116,"cells":10678},{"EARLY_PHASE1":10679,"PHASE1":10681,"PHASE2":10687,"PHASE3":10689,"PHASE4":10691,"NA":10693},{"trials":10680,"activeCount":101},[],{"trials":10682,"activeCount":101},[10683],{"nctId":1165,"briefTitle":1166,"status":242,"phases":10684,"primaryCompletion":1168,"completion":1168,"start":1169,"enrollment":500,"conditions":10685,"interventions":10686},[89],[24],[347,1027,1172,1173],{"trials":10688,"activeCount":101},[],{"trials":10690,"activeCount":101},[],{"trials":10692,"activeCount":101},[],{"trials":10694,"activeCount":101},[],{"intervention":10696,"totalTrials":116,"cells":10697},"Efmarodocokin Alfa",{"EARLY_PHASE1":10698,"PHASE1":10700,"PHASE2":10710,"PHASE3":10712,"PHASE4":10714,"NA":10716},{"trials":10699,"activeCount":101},[],{"trials":10701,"activeCount":101},[10702],{"nctId":10703,"briefTitle":10704,"status":242,"phases":10705,"primaryCompletion":10706,"completion":10706,"start":10707,"enrollment":25,"conditions":10708,"interventions":10709},"NCT04539470","Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",[89],"2023-02-24","2020-11-19",[7313],[10696],{"trials":10711,"activeCount":101},[],{"trials":10713,"activeCount":101},[],{"trials":10715,"activeCount":101},[],{"trials":10717,"activeCount":101},[],{"intervention":8789,"totalTrials":116,"cells":10719},{"EARLY_PHASE1":10720,"PHASE1":10722,"PHASE2":10728,"PHASE3":10730,"PHASE4":10732,"NA":10734},{"trials":10721,"activeCount":101},[],{"trials":10723,"activeCount":101},[10724],{"nctId":8781,"briefTitle":8782,"status":242,"phases":10725,"primaryCompletion":8784,"completion":8784,"start":8785,"enrollment":19,"conditions":10726,"interventions":10727},[89],[8787],[8766,8789],{"trials":10729,"activeCount":101},[],{"trials":10731,"activeCount":101},[],{"trials":10733,"activeCount":101},[],{"trials":10735,"activeCount":101},[],{"intervention":10737,"totalTrials":116,"cells":10738},"INO-1001",{"EARLY_PHASE1":10739,"PHASE1":10741,"PHASE2":10751,"PHASE3":10753,"PHASE4":10755,"NA":10757},{"trials":10740,"activeCount":101},[],{"trials":10742,"activeCount":101},[10743],{"nctId":10744,"briefTitle":10745,"status":325,"phases":10746,"start":3648,"enrollment":10747,"conditions":10748,"interventions":10749},"NCT00272415","A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma",[89],39,[599],[10737,10750],"temozolomide",{"trials":10752,"activeCount":101},[],{"trials":10754,"activeCount":101},[],{"trials":10756,"activeCount":101},[],{"trials":10758,"activeCount":101},[],{"intervention":10750,"totalTrials":116,"cells":10760},{"EARLY_PHASE1":10761,"PHASE1":10763,"PHASE2":10769,"PHASE3":10771,"PHASE4":10773,"NA":10775},{"trials":10762,"activeCount":101},[],{"trials":10764,"activeCount":101},[10765],{"nctId":10744,"briefTitle":10745,"status":325,"phases":10766,"start":3648,"enrollment":10747,"conditions":10767,"interventions":10768},[89],[599],[10737,10750],{"trials":10770,"activeCount":101},[],{"trials":10772,"activeCount":101},[],{"trials":10774,"activeCount":101},[],{"trials":10776,"activeCount":101},[],{"intervention":10778,"totalTrials":116,"cells":10779},"RO7171009",{"EARLY_PHASE1":10780,"PHASE1":10782,"PHASE2":10792,"PHASE3":10794,"PHASE4":10796,"NA":10798},{"trials":10781,"activeCount":101},[],{"trials":10783,"activeCount":101},[10784],{"nctId":10785,"briefTitle":10786,"status":242,"phases":10787,"primaryCompletion":10788,"completion":10788,"start":10789,"enrollment":12,"conditions":10790,"interventions":10791},"NCT03295877","Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)",[89],"2018-11-20","2017-09-21",[2233],[10778],{"trials":10793,"activeCount":101},[],{"trials":10795,"activeCount":101},[],{"trials":10797,"activeCount":101},[],{"trials":10799,"activeCount":101},[],{"intervention":10801,"totalTrials":116,"cells":10802},"Entrectinib Form A",{"EARLY_PHASE1":10803,"PHASE1":10805,"PHASE2":10815,"PHASE3":10817,"PHASE4":10819,"NA":10821},{"trials":10804,"activeCount":101},[],{"trials":10806,"activeCount":101},[10807],{"nctId":10808,"briefTitle":10809,"status":242,"phases":10810,"primaryCompletion":4341,"completion":4341,"start":10811,"enrollment":12,"conditions":10812,"interventions":10813},"NCT03796013","A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects",[89],"2019-01-10",[34],[10801,10814],"Entrectinib Form C",{"trials":10816,"activeCount":101},[],{"trials":10818,"activeCount":101},[],{"trials":10820,"activeCount":101},[],{"trials":10822,"activeCount":101},[],{"intervention":10814,"totalTrials":116,"cells":10824},{"EARLY_PHASE1":10825,"PHASE1":10827,"PHASE2":10833,"PHASE3":10835,"PHASE4":10837,"NA":10839},{"trials":10826,"activeCount":101},[],{"trials":10828,"activeCount":101},[10829],{"nctId":10808,"briefTitle":10809,"status":242,"phases":10830,"primaryCompletion":4341,"completion":4341,"start":10811,"enrollment":12,"conditions":10831,"interventions":10832},[89],[34],[10801,10814],{"trials":10834,"activeCount":101},[],{"trials":10836,"activeCount":101},[],{"trials":10838,"activeCount":101},[],{"trials":10840,"activeCount":101},[],{"intervention":10842,"totalTrials":116,"cells":10843},"[14C]-GDC-0810",{"EARLY_PHASE1":10844,"PHASE1":10846,"PHASE2":10855,"PHASE3":10857,"PHASE4":10859,"NA":10861},{"trials":10845,"activeCount":101},[],{"trials":10847,"activeCount":101},[10848],{"nctId":10849,"briefTitle":10850,"status":242,"phases":10851,"primaryCompletion":6379,"completion":6379,"start":10852,"enrollment":3791,"conditions":10853,"interventions":10854},"NCT02802670","A Pharmacokinetic Study of [14C]-GDC-0810 After Single Oral Administration in Healthy Female Participants",[89],"2016-05",[34],[10842],{"trials":10856,"activeCount":101},[],{"trials":10858,"activeCount":101},[],{"trials":10860,"activeCount":101},[],{"trials":10862,"activeCount":101},[],{"intervention":10864,"totalTrials":116,"cells":10865},"DHES0815A",{"EARLY_PHASE1":10866,"PHASE1":10868,"PHASE2":10878,"PHASE3":10880,"PHASE4":10882,"NA":10884},{"trials":10867,"activeCount":101},[],{"trials":10869,"activeCount":101},[10870],{"nctId":10871,"briefTitle":10872,"status":242,"phases":10873,"primaryCompletion":10874,"completion":10874,"start":10875,"enrollment":1425,"conditions":10876,"interventions":10877},"NCT03451162","Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer",[89],"2021-07-16","2018-04-17",[18],[10864],{"trials":10879,"activeCount":101},[],{"trials":10881,"activeCount":101},[],{"trials":10883,"activeCount":101},[],{"trials":10885,"activeCount":101},[],{"intervention":10887,"totalTrials":116,"cells":10888},"DMUC5754A",{"EARLY_PHASE1":10889,"PHASE1":10891,"PHASE2":10901,"PHASE3":10903,"PHASE4":10905,"NA":10907},{"trials":10890,"activeCount":101},[],{"trials":10892,"activeCount":101},[10893],{"nctId":10894,"briefTitle":10895,"status":242,"phases":10896,"primaryCompletion":1290,"completion":1290,"start":6310,"enrollment":10897,"conditions":10898,"interventions":10900},"NCT01335958","Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer",[89],77,[10899],"Ovarian Cancer, Pancreatic Cancer",[10887],{"trials":10902,"activeCount":101},[],{"trials":10904,"activeCount":101},[],{"trials":10906,"activeCount":101},[],{"trials":10908,"activeCount":101},[],{"intervention":10910,"totalTrials":116,"cells":10911},"Immunoglobulin G",{"EARLY_PHASE1":10912,"PHASE1":10914,"PHASE2":10925,"PHASE3":10927,"PHASE4":10929,"NA":10931},{"trials":10913,"activeCount":101},[],{"trials":10915,"activeCount":101},[10916],{"nctId":10917,"briefTitle":10918,"status":242,"phases":10919,"primaryCompletion":10920,"completion":10921,"start":10922,"enrollment":2033,"conditions":10923,"interventions":10924},"NCT07025577","A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions",[89],"2025-08-08","2025-09-03","2025-06-02",[968],[10910],{"trials":10926,"activeCount":101},[],{"trials":10928,"activeCount":101},[],{"trials":10930,"activeCount":101},[],{"trials":10932,"activeCount":101},[],{"intervention":10934,"totalTrials":116,"cells":10935},"RO7297089",{"EARLY_PHASE1":10936,"PHASE1":10938,"PHASE2":10950,"PHASE3":10952,"PHASE4":10954,"NA":10956},{"trials":10937,"activeCount":101},[],{"trials":10939,"activeCount":101},[10940],{"nctId":10941,"briefTitle":10942,"status":242,"phases":10943,"primaryCompletion":10944,"completion":10944,"start":10945,"enrollment":19,"conditions":10946,"interventions":10949},"NCT04434469","A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma",[89],"2022-02-23","2020-07-08",[10947,10948],"Refractory Multiple Myeloma","Relapsed Multiple Myeloma",[10934],{"trials":10951,"activeCount":101},[],{"trials":10953,"activeCount":101},[],{"trials":10955,"activeCount":101},[],{"trials":10957,"activeCount":101},[],{"intervention":8571,"totalTrials":116,"cells":10959},{"EARLY_PHASE1":10960,"PHASE1":10962,"PHASE2":10968,"PHASE3":10970,"PHASE4":10972,"NA":10974},{"trials":10961,"activeCount":101},[],{"trials":10963,"activeCount":101},[10964],{"nctId":8564,"briefTitle":8565,"status":242,"phases":10965,"primaryCompletion":8567,"completion":8567,"start":8568,"enrollment":488,"conditions":10966,"interventions":10967},[89],[34],[8571,8572,1465],{"trials":10969,"activeCount":101},[],{"trials":10971,"activeCount":101},[],{"trials":10973,"activeCount":101},[],{"trials":10975,"activeCount":101},[],{"intervention":8572,"totalTrials":116,"cells":10977},{"EARLY_PHASE1":10978,"PHASE1":10980,"PHASE2":10986,"PHASE3":10988,"PHASE4":10990,"NA":10992},{"trials":10979,"activeCount":101},[],{"trials":10981,"activeCount":101},[10982],{"nctId":8564,"briefTitle":8565,"status":242,"phases":10983,"primaryCompletion":8567,"completion":8567,"start":8568,"enrollment":488,"conditions":10984,"interventions":10985},[89],[34],[8571,8572,1465],{"trials":10987,"activeCount":101},[],{"trials":10989,"activeCount":101},[],{"trials":10991,"activeCount":101},[],{"trials":10993,"activeCount":101},[],{"intervention":10995,"totalTrials":116,"cells":10996},"Crenezumab dose level 1",{"EARLY_PHASE1":10997,"PHASE1":10999,"PHASE2":11012,"PHASE3":11014,"PHASE4":11016,"NA":11018},{"trials":10998,"activeCount":101},[],{"trials":11000,"activeCount":101},[11001],{"nctId":11002,"briefTitle":11003,"status":242,"phases":11004,"primaryCompletion":5800,"completion":11005,"start":11006,"enrollment":10897,"conditions":11007,"interventions":11009},"NCT02353598","A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease",[89],"2019-03-26","2015-02-26",[11008],"Alzheimer Disease",[10995,11010,11011],"Crenezumab dose level 2","Crenezumb dose level 3",{"trials":11013,"activeCount":101},[],{"trials":11015,"activeCount":101},[],{"trials":11017,"activeCount":101},[],{"trials":11019,"activeCount":101},[],{"intervention":11010,"totalTrials":116,"cells":11021},{"EARLY_PHASE1":11022,"PHASE1":11024,"PHASE2":11030,"PHASE3":11032,"PHASE4":11034,"NA":11036},{"trials":11023,"activeCount":101},[],{"trials":11025,"activeCount":101},[11026],{"nctId":11002,"briefTitle":11003,"status":242,"phases":11027,"primaryCompletion":5800,"completion":11005,"start":11006,"enrollment":10897,"conditions":11028,"interventions":11029},[89],[11008],[10995,11010,11011],{"trials":11031,"activeCount":101},[],{"trials":11033,"activeCount":101},[],{"trials":11035,"activeCount":101},[],{"trials":11037,"activeCount":101},[],{"intervention":11011,"totalTrials":116,"cells":11039},{"EARLY_PHASE1":11040,"PHASE1":11042,"PHASE2":11048,"PHASE3":11050,"PHASE4":11052,"NA":11054},{"trials":11041,"activeCount":101},[],{"trials":11043,"activeCount":101},[11044],{"nctId":11002,"briefTitle":11003,"status":242,"phases":11045,"primaryCompletion":5800,"completion":11005,"start":11006,"enrollment":10897,"conditions":11046,"interventions":11047},[89],[11008],[10995,11010,11011],{"trials":11049,"activeCount":101},[],{"trials":11051,"activeCount":101},[],{"trials":11053,"activeCount":101},[],{"trials":11055,"activeCount":101},[],{"intervention":5743,"totalTrials":116,"cells":11057},{"EARLY_PHASE1":11058,"PHASE1":11060,"PHASE2":11066,"PHASE3":11068,"PHASE4":11070,"NA":11072},{"trials":11059,"activeCount":101},[],{"trials":11061,"activeCount":101},[11062],{"nctId":5737,"briefTitle":5738,"status":242,"phases":11063,"primaryCompletion":5740,"completion":5740,"start":5724,"enrollment":5725,"conditions":11064,"interventions":11065},[89],[968],[334,3537,5743,1946,5744,5745,5746,3537,1500,5747],{"trials":11067,"activeCount":101},[],{"trials":11069,"activeCount":101},[],{"trials":11071,"activeCount":101},[],{"trials":11073,"activeCount":101},[],{"intervention":5744,"totalTrials":116,"cells":11075},{"EARLY_PHASE1":11076,"PHASE1":11078,"PHASE2":11084,"PHASE3":11086,"PHASE4":11088,"NA":11090},{"trials":11077,"activeCount":101},[],{"trials":11079,"activeCount":101},[11080],{"nctId":5737,"briefTitle":5738,"status":242,"phases":11081,"primaryCompletion":5740,"completion":5740,"start":5724,"enrollment":5725,"conditions":11082,"interventions":11083},[89],[968],[334,3537,5743,1946,5744,5745,5746,3537,1500,5747],{"trials":11085,"activeCount":101},[],{"trials":11087,"activeCount":101},[],{"trials":11089,"activeCount":101},[],{"trials":11091,"activeCount":101},[],{"intervention":5745,"totalTrials":116,"cells":11093},{"EARLY_PHASE1":11094,"PHASE1":11096,"PHASE2":11102,"PHASE3":11104,"PHASE4":11106,"NA":11108},{"trials":11095,"activeCount":101},[],{"trials":11097,"activeCount":101},[11098],{"nctId":5737,"briefTitle":5738,"status":242,"phases":11099,"primaryCompletion":5740,"completion":5740,"start":5724,"enrollment":5725,"conditions":11100,"interventions":11101},[89],[968],[334,3537,5743,1946,5744,5745,5746,3537,1500,5747],{"trials":11103,"activeCount":101},[],{"trials":11105,"activeCount":101},[],{"trials":11107,"activeCount":101},[],{"trials":11109,"activeCount":101},[],{"intervention":5746,"totalTrials":116,"cells":11111},{"EARLY_PHASE1":11112,"PHASE1":11114,"PHASE2":11120,"PHASE3":11122,"PHASE4":11124,"NA":11126},{"trials":11113,"activeCount":101},[],{"trials":11115,"activeCount":101},[11116],{"nctId":5737,"briefTitle":5738,"status":242,"phases":11117,"primaryCompletion":5740,"completion":5740,"start":5724,"enrollment":5725,"conditions":11118,"interventions":11119},[89],[968],[334,3537,5743,1946,5744,5745,5746,3537,1500,5747],{"trials":11121,"activeCount":101},[],{"trials":11123,"activeCount":101},[],{"trials":11125,"activeCount":101},[],{"trials":11127,"activeCount":101},[],{"intervention":5747,"totalTrials":116,"cells":11129},{"EARLY_PHASE1":11130,"PHASE1":11132,"PHASE2":11138,"PHASE3":11140,"PHASE4":11142,"NA":11144},{"trials":11131,"activeCount":101},[],{"trials":11133,"activeCount":101},[11134],{"nctId":5737,"briefTitle":5738,"status":242,"phases":11135,"primaryCompletion":5740,"completion":5740,"start":5724,"enrollment":5725,"conditions":11136,"interventions":11137},[89],[968],[334,3537,5743,1946,5744,5745,5746,3537,1500,5747],{"trials":11139,"activeCount":101},[],{"trials":11141,"activeCount":101},[],{"trials":11143,"activeCount":101},[],{"trials":11145,"activeCount":101},[],{"intervention":11147,"totalTrials":116,"cells":11148},"DFRF4539A",{"EARLY_PHASE1":11149,"PHASE1":11151,"PHASE2":11159,"PHASE3":11161,"PHASE4":11163,"NA":11165},{"trials":11150,"activeCount":101},[],{"trials":11152,"activeCount":101},[11153],{"nctId":11154,"briefTitle":11155,"status":242,"phases":11156,"primaryCompletion":896,"completion":896,"start":1178,"enrollment":10747,"conditions":11157,"interventions":11158},"NCT01432353","A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma",[89],[502],[11147],{"trials":11160,"activeCount":101},[],{"trials":11162,"activeCount":101},[],{"trials":11164,"activeCount":101},[],{"trials":11166,"activeCount":101},[],{"intervention":508,"totalTrials":6799,"cells":11168},{"EARLY_PHASE1":11169,"PHASE1":11171,"PHASE2":11193,"PHASE3":11238,"PHASE4":11286,"NA":11288},{"trials":11170,"activeCount":101},[],{"trials":11172,"activeCount":101},[11173,11177,11181,11185,11189],{"nctId":495,"briefTitle":496,"status":325,"phases":11174,"primaryCompletion":498,"completion":498,"start":499,"enrollment":500,"conditions":11175,"interventions":11176},[89],[502,503,504],[506,507,508,487],{"nctId":2038,"briefTitle":2039,"status":242,"phases":11178,"primaryCompletion":2041,"completion":2042,"start":2043,"enrollment":2044,"conditions":11179,"interventions":11180},[89],[2046],[2048,2036,508,71],{"nctId":6520,"briefTitle":6521,"status":242,"phases":11182,"primaryCompletion":6523,"completion":6524,"start":6525,"enrollment":6526,"conditions":11183,"interventions":11184},[89],[6528,2046],[2590,508],{"nctId":10663,"briefTitle":10664,"status":242,"phases":11186,"primaryCompletion":1046,"completion":1046,"start":8712,"enrollment":910,"conditions":11187,"interventions":11188},[89],[10667],[10656,3594],{"nctId":9003,"briefTitle":9004,"status":242,"phases":11190,"primaryCompletion":3559,"completion":3559,"start":3855,"enrollment":5530,"conditions":11191,"interventions":11192},[89],[331],[3594,6877],{"trials":11194,"activeCount":101},[11195,11199,11203,11207,11211,11215,11219,11223,11227,11231],{"nctId":6008,"briefTitle":6009,"status":242,"phases":11196,"primaryCompletion":4928,"completion":4928,"start":5506,"enrollment":6011,"conditions":11197,"interventions":11198},[90],[331],[1121,3594],{"nctId":7419,"briefTitle":7420,"status":242,"phases":11200,"primaryCompletion":908,"completion":908,"start":1254,"enrollment":2055,"conditions":11201,"interventions":11202},[90],[2046],[7410,3594],{"nctId":3541,"briefTitle":3542,"status":242,"phases":11204,"primaryCompletion":3544,"completion":3545,"start":3546,"enrollment":3547,"conditions":11205,"interventions":11206},[90],[21],[508,3522,3550,3551,3552,3553,3554],{"nctId":6463,"briefTitle":6464,"status":325,"phases":11208,"primaryCompletion":3749,"start":6466,"enrollment":6080,"conditions":11209,"interventions":11210},[89,90],[331],[6469,508],{"nctId":2582,"briefTitle":2583,"status":242,"phases":11212,"primaryCompletion":2585,"completion":2585,"start":2586,"enrollment":418,"conditions":11213,"interventions":11214},[89,90],[732],[2545,2589,2036,2590,2591,2592,508],{"nctId":4305,"briefTitle":4306,"status":242,"phases":11216,"primaryCompletion":4308,"completion":4309,"start":4310,"enrollment":4311,"conditions":11217,"interventions":11218},[89,90],[4313,4314],[2036,4316,2590,508],{"nctId":3577,"briefTitle":3578,"status":242,"phases":11220,"primaryCompletion":1271,"completion":1271,"start":3580,"enrollment":1100,"conditions":11221,"interventions":11222},[90],[21],[3583,914,3584,508],{"nctId":4705,"briefTitle":4706,"status":826,"phases":11224,"primaryCompletion":1290,"completion":1290,"start":342,"enrollment":101,"conditions":11225,"interventions":11226},[90],[4314],[4710,4711,3594],{"nctId":3586,"briefTitle":3587,"status":242,"phases":11228,"primaryCompletion":3589,"completion":1169,"start":3590,"enrollment":3591,"conditions":11229,"interventions":11230},[90],[21],[914,3594,3595],{"nctId":11232,"briefTitle":11233,"status":242,"phases":11234,"completion":4400,"start":11235,"enrollment":1345,"conditions":11236,"interventions":11237},"NCT00097188","A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis",[90],"2004-12",[168],[3594],{"trials":11239,"activeCount":101},[11240,11244,11248,11252,11260,11264,11268,11272,11276,11282],{"nctId":5130,"briefTitle":5131,"status":242,"phases":11241,"primaryCompletion":2576,"completion":956,"start":5133,"enrollment":5134,"conditions":11242,"interventions":11243},[91],[21],[508,5119],{"nctId":4578,"briefTitle":4445,"status":242,"phases":11245,"primaryCompletion":4580,"completion":4580,"start":4581,"enrollment":4582,"conditions":11246,"interventions":11247},[90,91],[4451],[508,2592,4453,3708],{"nctId":4444,"briefTitle":4445,"status":325,"phases":11249,"primaryCompletion":4447,"completion":4448,"start":4449,"enrollment":1901,"conditions":11250,"interventions":11251},[91],[4451],[508,3575,4453,3708],{"nctId":11253,"briefTitle":11254,"status":242,"phases":11255,"primaryCompletion":1118,"start":11256,"enrollment":11257,"conditions":11258,"interventions":11259},"NCT00087529","A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis",[90,91],"2004-06",439,[168],[3594],{"nctId":3618,"briefTitle":3619,"status":242,"phases":11261,"primaryCompletion":1118,"start":1364,"enrollment":3621,"conditions":11262,"interventions":11263},[91],[21],[3594,914,3583],{"nctId":4465,"briefTitle":4466,"status":242,"phases":11265,"primaryCompletion":4022,"completion":2575,"start":1364,"enrollment":4468,"conditions":11266,"interventions":11267},[91],[2619],[508,4471,3575,3708,4453,2592],{"nctId":3625,"briefTitle":3626,"status":242,"phases":11269,"primaryCompletion":3628,"completion":1415,"start":1364,"enrollment":3629,"conditions":11270,"interventions":11271},[91],[21],[3583,914,3584,3594],{"nctId":3644,"briefTitle":3645,"status":242,"phases":11273,"primaryCompletion":3647,"completion":1415,"start":3648,"enrollment":3649,"conditions":11274,"interventions":11275},[91],[21],[3652,3522,3575,508],{"nctId":11277,"briefTitle":11278,"status":826,"phases":11279,"enrollment":101,"conditions":11280,"interventions":11281},"NCT00404157","A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g",[91],[2619],[508],{"nctId":5448,"briefTitle":5449,"status":242,"phases":11283,"primaryCompletion":2576,"completion":2576,"start":1385,"enrollment":5451,"conditions":11284,"interventions":11285},[91],[331],[508,5437,5454,5455],{"trials":11287,"activeCount":101},[],{"trials":11289,"activeCount":101},[11290],{"nctId":11291,"briefTitle":11292,"status":242,"phases":11293,"primaryCompletion":11294,"completion":11295,"start":11296,"enrollment":166,"conditions":11297,"interventions":11300},"NCT01613599","An Observational Study of The Safety of MabThera\u002FRituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis",[],"2015-07-13","2017-04-28","2012-06-20",[11298,11299],"Granulomatosis With Polyangiitis","Microscopic Polyangiitis",[508],{"intervention":2623,"totalTrials":8860,"cells":11302},{"EARLY_PHASE1":11303,"PHASE1":11305,"PHASE2":11307,"PHASE3":11324,"PHASE4":11363,"NA":11376},{"trials":11304,"activeCount":101},[],{"trials":11306,"activeCount":101},[],{"trials":11308,"activeCount":101},[11309,11313,11317],{"nctId":3567,"briefTitle":3568,"status":325,"phases":11310,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":12,"conditions":11311,"interventions":11312},[90],[21],[3574,3522,3575,2623],{"nctId":8047,"briefTitle":8048,"status":242,"phases":11314,"primaryCompletion":8050,"completion":8051,"start":8052,"enrollment":8053,"conditions":11315,"interventions":11316},[90],[8055],[2623,8038],{"nctId":11318,"briefTitle":11319,"status":242,"phases":11320,"completion":4400,"start":3829,"enrollment":11321,"conditions":11322,"interventions":11323},"NCT00077870","A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis",[89,90],237,[21],[3663],{"trials":11325,"activeCount":101},[11326,11330,11334,11338,11342,11346,11350,11359],{"nctId":3599,"briefTitle":3600,"status":325,"phases":11327,"primaryCompletion":3602,"completion":3603,"start":3604,"enrollment":3605,"conditions":11328,"interventions":11329},[91],[21],[3522,2623],{"nctId":5232,"briefTitle":5233,"status":242,"phases":11331,"primaryCompletion":5235,"completion":5235,"start":5236,"enrollment":1571,"conditions":11332,"interventions":11333},[91],[5238,5239],[2623,5221,5241],{"nctId":3609,"briefTitle":3610,"status":325,"phases":11335,"primaryCompletion":3612,"completion":3612,"start":3613,"enrollment":3614,"conditions":11336,"interventions":11337},[91],[21],[3522,2623],{"nctId":4455,"briefTitle":4456,"status":325,"phases":11339,"primaryCompletion":4458,"completion":4458,"start":4459,"enrollment":4460,"conditions":11340,"interventions":11341},[91],[2568],[2592,4463,3575,2623],{"nctId":3633,"briefTitle":3634,"status":325,"phases":11343,"primaryCompletion":3636,"completion":3637,"start":3638,"enrollment":3639,"conditions":11344,"interventions":11345},[91],[21],[3642,3522,2623,2623],{"nctId":2611,"briefTitle":2612,"status":325,"phases":11347,"primaryCompletion":2614,"completion":2615,"start":2616,"enrollment":2617,"conditions":11348,"interventions":11349},[91],[2619,2568],[2621,2545,2622,2623,2624],{"nctId":11351,"briefTitle":11352,"status":242,"phases":11353,"primaryCompletion":11354,"completion":11354,"start":11355,"enrollment":11356,"conditions":11357,"interventions":11358},"NCT02637856","A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)",[91],"2019-05-03","2016-02-11",608,[8055],[2623,2623],{"nctId":3654,"briefTitle":3655,"status":325,"phases":11360,"primaryCompletion":3657,"completion":3658,"start":3659,"enrollment":3660,"conditions":11361,"interventions":11362},[91],[21],[3522,3663],{"trials":11364,"activeCount":101},[11365],{"nctId":11366,"briefTitle":11367,"status":242,"phases":11368,"primaryCompletion":11369,"completion":11370,"start":11371,"enrollment":11372,"conditions":11373,"interventions":11375},"NCT04377555","Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab",[92],"2022-12-15","2025-11-11","2020-07-30",179,[11374],"Multiple Sclerosis, Relapsing",[2623],{"trials":11377,"activeCount":101},[11378],{"nctId":11379,"briefTitle":11380,"status":2478,"phases":11381,"conditions":11382,"interventions":11383},"NCT02807285","Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis",[],[168],[2623],{"intervention":11385,"totalTrials":3791,"cells":11386},"Pirfenidone",{"EARLY_PHASE1":11387,"PHASE1":11389,"PHASE2":11391,"PHASE3":11407,"PHASE4":11441,"NA":11443},{"trials":11388,"activeCount":101},[],{"trials":11390,"activeCount":101},[],{"trials":11392,"activeCount":101},[11393,11401],{"nctId":11394,"briefTitle":11395,"status":242,"phases":11396,"primaryCompletion":1899,"completion":1899,"start":11397,"enrollment":11,"conditions":11398,"interventions":11400},"NCT00080223","Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis\u002FIdiopathic Pulmonary Fibrosis",[90],"2003-08-31",[2011,11399],"Pulmonary Fibrosis",[11385],{"nctId":11402,"briefTitle":11403,"status":242,"phases":11404,"primaryCompletion":4371,"completion":4371,"start":1497,"enrollment":5725,"conditions":11405,"interventions":11406},"NCT01933334","Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)",[90],[9152],[11385],{"trials":11408,"activeCount":101},[11409,11416,11425,11433],{"nctId":11410,"briefTitle":11411,"status":242,"phases":11412,"primaryCompletion":1290,"completion":1290,"start":1344,"enrollment":11413,"conditions":11414,"interventions":11415},"NCT01366209","Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)",[91],555,[2011],[11385],{"nctId":11417,"briefTitle":11418,"status":242,"phases":11419,"primaryCompletion":11420,"completion":11420,"start":11421,"enrollment":11422,"conditions":11423,"interventions":11424},"NCT00287716","Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis",[91],"2008-11-10","2006-07-14",435,[2011],[11385],{"nctId":11426,"briefTitle":11427,"status":242,"phases":11428,"primaryCompletion":6600,"completion":6600,"start":4122,"enrollment":11429,"conditions":11430,"interventions":11431},"NCT00662038","Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)",[91],1058,[2011],[11432],"pirfenidone",{"nctId":11434,"briefTitle":11435,"status":242,"phases":11436,"primaryCompletion":4082,"completion":4082,"start":11437,"enrollment":11438,"conditions":11439,"interventions":11440},"NCT00287729","Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis",[91],"2006-04",344,[2011],[11385],{"trials":11442,"activeCount":101},[],{"trials":11444,"activeCount":101},[11445],{"nctId":11446,"briefTitle":11447,"status":227,"phases":11448,"conditions":11449,"interventions":11450},"NCT02141087","Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone",[],[2011],[11385],{"intervention":699,"totalTrials":3791,"cells":11452},{"EARLY_PHASE1":11453,"PHASE1":11455,"PHASE2":11471,"PHASE3":11487,"PHASE4":11489,"NA":11491},{"trials":11454,"activeCount":101},[],{"trials":11456,"activeCount":101},[11457,11461,11467],{"nctId":8532,"briefTitle":8533,"status":242,"phases":11458,"primaryCompletion":416,"completion":416,"start":956,"enrollment":8535,"conditions":11459,"interventions":11460},[89],[15],[8538,8539,5549,8540],{"nctId":11462,"briefTitle":11463,"status":242,"phases":11464,"primaryCompletion":896,"completion":896,"start":1098,"enrollment":1901,"conditions":11465,"interventions":11466},"NCT01546519","A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function",[89],[517],[699],{"nctId":10602,"briefTitle":10603,"status":242,"phases":11468,"primaryCompletion":1098,"completion":1098,"start":3559,"enrollment":1161,"conditions":11469,"interventions":11470},[89],[24],[699,10595,10607],{"trials":11472,"activeCount":101},[11473,11477,11483],{"nctId":688,"briefTitle":689,"status":242,"phases":11474,"primaryCompletion":691,"completion":691,"start":692,"enrollment":693,"conditions":11475,"interventions":11476},[90],[695,614,696,697,667],[61,321,576,627,626,699,86,487],{"nctId":11478,"briefTitle":11479,"status":242,"phases":11480,"primaryCompletion":416,"completion":416,"start":8712,"enrollment":9884,"conditions":11481,"interventions":11482},"NCT01201915","A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma",[90],[1337],[699],{"nctId":1330,"briefTitle":1331,"status":242,"phases":11484,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":11485,"interventions":11486},[90],[1284,1337,1133],[699,1135,1339,520],{"trials":11488,"activeCount":101},[],{"trials":11490,"activeCount":101},[],{"trials":11492,"activeCount":101},[11493],{"nctId":11494,"briefTitle":11495,"status":227,"phases":11496,"primaryCompletion":1515,"completion":1515,"start":5842,"conditions":11497,"interventions":11498},"NCT01160250","A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma",[],[1337],[8540],{"intervention":11500,"totalTrials":233,"cells":11501},"Xolair",{"EARLY_PHASE1":11502,"PHASE1":11504,"PHASE2":11506,"PHASE3":11515,"PHASE4":11539,"NA":11541},{"trials":11503,"activeCount":101},[],{"trials":11505,"activeCount":101},[],{"trials":11507,"activeCount":101},[11508],{"nctId":11509,"briefTitle":11510,"status":325,"phases":11511,"completion":11437,"start":11256,"enrollment":4614,"conditions":11512,"interventions":11514},"NCT00086606","A Safety and Efficacy Study of Xolair in Peanut Allergy",[90],[11513],"Allergy",[11500],{"trials":11516,"activeCount":101},[11517,11524,11533],{"nctId":11518,"briefTitle":11519,"status":242,"phases":11520,"completion":3839,"start":11521,"enrollment":101,"conditions":11522,"interventions":11523},"NCT00109187","An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g",[91],"2002-06",[31],[11500],{"nctId":11525,"briefTitle":11526,"status":242,"phases":11527,"completion":11528,"start":11529,"enrollment":11530,"conditions":11531,"interventions":11532},"NCT00401596","A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)",[91],"2002-07","2000-07",1899,[31],[11500],{"nctId":11534,"briefTitle":11535,"status":242,"phases":11536,"completion":3821,"start":1604,"conditions":11537,"interventions":11538},"NCT00109200","A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma",[91],[31],[11500],{"trials":11540,"activeCount":101},[],{"trials":11542,"activeCount":101},[11543],{"nctId":11544,"briefTitle":11545,"status":242,"phases":11546,"primaryCompletion":937,"completion":937,"start":1373,"enrollment":2055,"conditions":11547,"interventions":11548},"NCT00813748","Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing",[],[3698],[11500],{"intervention":11550,"totalTrials":97,"cells":11551},"Somatropin",{"EARLY_PHASE1":11552,"PHASE1":11554,"PHASE2":11556,"PHASE3":11558,"PHASE4":11560,"NA":11569},{"trials":11553,"activeCount":101},[],{"trials":11555,"activeCount":101},[],{"trials":11557,"activeCount":101},[],{"trials":11559,"activeCount":101},[],{"trials":11561,"activeCount":101},[11562],{"nctId":11563,"briefTitle":11564,"status":242,"phases":11565,"primaryCompletion":6996,"completion":6996,"start":4342,"enrollment":2033,"conditions":11566,"interventions":11568},"NCT02311894","A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency",[92],[11567],"Growth Hormone Deficiency",[11550],{"trials":11570,"activeCount":101},[11571,11577],{"nctId":11572,"briefTitle":11573,"status":325,"phases":11574,"primaryCompletion":1217,"completion":1217,"start":3559,"enrollment":25,"conditions":11575,"interventions":11576},"NCT01243892","A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device",[],[11567],[11550],{"nctId":11578,"briefTitle":11579,"status":242,"phases":11580,"primaryCompletion":1070,"completion":1070,"start":11581,"enrollment":11582,"conditions":11583,"interventions":11585},"NCT00097539","National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin",[],"1985-10",65205,[11584],"Growth Disorders",[11586,11550],"Somatrem",{"intervention":942,"totalTrials":97,"cells":11588},{"EARLY_PHASE1":11589,"PHASE1":11591,"PHASE2":11603,"PHASE3":11605,"PHASE4":11607,"NA":11609},{"trials":11590,"activeCount":101},[],{"trials":11592,"activeCount":101},[11593,11599],{"nctId":11594,"briefTitle":11595,"status":242,"phases":11596,"primaryCompletion":1272,"completion":1272,"start":11437,"enrollment":1071,"conditions":11597,"interventions":11598},"NCT00932373","A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen",[89],[940],[942],{"nctId":934,"briefTitle":935,"status":242,"phases":11600,"primaryCompletion":937,"completion":937,"start":938,"enrollment":634,"conditions":11601,"interventions":11602},[89],[940],[346,61,942],{"trials":11604,"activeCount":101},[],{"trials":11606,"activeCount":101},[],{"trials":11608,"activeCount":101},[],{"trials":11610,"activeCount":101},[11611],{"nctId":11612,"briefTitle":11613,"status":2478,"phases":11614,"start":3749,"conditions":11615,"interventions":11616},"NCT01120561","A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer",[],[940],[942],{"intervention":11618,"totalTrials":200,"cells":11619},"Ranibizumab 0.5 mg",{"EARLY_PHASE1":11620,"PHASE1":11622,"PHASE2":11624,"PHASE3":11626,"PHASE4":11628,"NA":11630},{"trials":11621,"activeCount":101},[],{"trials":11623,"activeCount":101},[],{"trials":11625,"activeCount":101},[],{"trials":11627,"activeCount":101},[],{"trials":11629,"activeCount":101},[],{"trials":11631,"activeCount":101},[11632,11638],{"nctId":11633,"briefTitle":11634,"status":242,"phases":11635,"primaryCompletion":5842,"completion":5842,"start":1385,"enrollment":11356,"conditions":11636,"interventions":11637},"NCT01442064","An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)",[93],[3898,4912],[11618],{"nctId":11639,"briefTitle":11640,"status":242,"phases":11641,"primaryCompletion":3628,"completion":3628,"start":1586,"enrollment":11642,"conditions":11643,"interventions":11645},"NCT00379795","An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO",[93],853,[11644],"Choroidal Neovascularization, Age-related Macular Degeneration",[11618],{"intervention":11647,"totalTrials":200,"cells":11648},"Emicizumab",{"EARLY_PHASE1":11649,"PHASE1":11651,"PHASE2":11653,"PHASE3":11655,"PHASE4":11657,"NA":11667},{"trials":11650,"activeCount":101},[],{"trials":11652,"activeCount":101},[],{"trials":11654,"activeCount":101},[],{"trials":11656,"activeCount":101},[],{"trials":11658,"activeCount":101},[11659],{"nctId":11660,"briefTitle":11661,"status":325,"phases":11662,"primaryCompletion":389,"completion":389,"start":11663,"enrollment":1425,"conditions":11664,"interventions":11666},"NCT03361137","Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures",[92],"2018-06-28",[11665],"Hemophilia A",[11647],{"trials":11668,"activeCount":101},[11669],{"nctId":11670,"briefTitle":11671,"status":227,"phases":11672,"conditions":11673,"interventions":11674},"NCT03154437","An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors",[],[11665],[11647],{"intervention":11676,"totalTrials":200,"cells":11677},"CD4 Antigens",{"EARLY_PHASE1":11678,"PHASE1":11680,"PHASE2":11688,"PHASE3":11690,"PHASE4":11692,"NA":11694},{"trials":11679,"activeCount":101},[],{"trials":11681,"activeCount":101},[11682],{"nctId":11683,"briefTitle":11684,"status":242,"phases":11685,"conditions":11686,"interventions":11687},"NCT00002004","A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex",[89],[9843],[11676],{"trials":11689,"activeCount":101},[],{"trials":11691,"activeCount":101},[],{"trials":11693,"activeCount":101},[],{"trials":11695,"activeCount":101},[11696],{"nctId":11697,"briefTitle":11698,"status":242,"phases":11699,"conditions":11700,"interventions":11701},"NCT00002005","A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex",[93],[9843],[11676],{"intervention":11586,"totalTrials":116,"cells":11703},{"EARLY_PHASE1":11704,"PHASE1":11706,"PHASE2":11708,"PHASE3":11710,"PHASE4":11712,"NA":11714},{"trials":11705,"activeCount":101},[],{"trials":11707,"activeCount":101},[],{"trials":11709,"activeCount":101},[],{"trials":11711,"activeCount":101},[],{"trials":11713,"activeCount":101},[],{"trials":11715,"activeCount":101},[11716],{"nctId":11578,"briefTitle":11579,"status":242,"phases":11717,"primaryCompletion":1070,"completion":1070,"start":11581,"enrollment":11582,"conditions":11718,"interventions":11719},[],[11584],[11586,11550],{"intervention":11721,"totalTrials":116,"cells":11722},"Atezolizumab [TECENTRIQ]",{"EARLY_PHASE1":11723,"PHASE1":11725,"PHASE2":11727,"PHASE3":11729,"PHASE4":11731,"NA":11733},{"trials":11724,"activeCount":101},[],{"trials":11726,"activeCount":101},[],{"trials":11728,"activeCount":101},[],{"trials":11730,"activeCount":101},[],{"trials":11732,"activeCount":101},[],{"trials":11734,"activeCount":101},[11735],{"nctId":11736,"briefTitle":11737,"status":227,"phases":11738,"primaryCompletion":11739,"completion":11739,"start":1796,"conditions":11740,"interventions":11741},"NCT02589717","An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy",[],"2016-08",[604],[11721],{"intervention":11743,"totalTrials":116,"cells":11744},"Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration",{"EARLY_PHASE1":11745,"PHASE1":11747,"PHASE2":11749,"PHASE3":11751,"PHASE4":11753,"NA":11755},{"trials":11746,"activeCount":101},[],{"trials":11748,"activeCount":101},[],{"trials":11750,"activeCount":101},[],{"trials":11752,"activeCount":101},[],{"trials":11754,"activeCount":101},[],{"trials":11756,"activeCount":101},[11757],{"nctId":11758,"briefTitle":11759,"status":227,"phases":11760,"conditions":11761,"interventions":11763},"NCT04395508","An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic",[],[11762],"HER2-positive Breast Cancer",[11743],{"intervention":1025,"totalTrials":116,"cells":11765},{"EARLY_PHASE1":11766,"PHASE1":11768,"PHASE2":11770,"PHASE3":11772,"PHASE4":11774,"NA":11776},{"trials":11767,"activeCount":101},[],{"trials":11769,"activeCount":101},[],{"trials":11771,"activeCount":101},[],{"trials":11773,"activeCount":101},[],{"trials":11775,"activeCount":101},[],{"trials":11777,"activeCount":101},[11778],{"nctId":1016,"briefTitle":1017,"status":242,"phases":11779,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":1021,"conditions":11780,"interventions":11781},[],[18,1023],[61,321,1025],{"intervention":11783,"totalTrials":116,"cells":11784},"Xolair®",{"EARLY_PHASE1":11785,"PHASE1":11787,"PHASE2":11789,"PHASE3":11791,"PHASE4":11793,"NA":11795},{"trials":11786,"activeCount":101},[],{"trials":11788,"activeCount":101},[],{"trials":11790,"activeCount":101},[],{"trials":11792,"activeCount":101},[],{"trials":11794,"activeCount":101},[],{"trials":11796,"activeCount":101},[11797],{"nctId":11798,"briefTitle":11799,"status":242,"phases":11800,"primaryCompletion":11801,"completion":11802,"start":11803,"enrollment":11804,"conditions":11805,"interventions":11806},"NCT00373061","An Observational Study of the Use and Safety of Xolair® During Pregnancy",[],"2017-12-11","2018-01-05","2006-10-20",309,[31],[11783]]